Understanding the Early Events of Human Papillomavirus Lesion Formation by Pagliarulo, E
1	  	  
	  
Understanding	  the	  Early	  Events	  of	  
Human	  Papillomavirus	  Lesion	  
Formation	  
	  
	   Thesis	  submitted	  for	  the	  Degree	  of	  Doctor	  of	  Philosophy	  in	  accordance	  with	  the	  requirements	  of	  the	  	  
University	  College	  of	  London,	  UCL	  	  	  	  	  	  
Emilio	  Pagliarulo	  	   Student	  No.	  1015472	  	   	  	  	  Division	  of	  Virology	  MRC	  National	  Institute	  for	  Medical	  Research	  The	  Ridgeway,	  Mill	  Hill	  	  London	  NW7	  1AA	  
2	  	  
	  
Statement	  of	  declaration	  
	  I,	  Emilio	  Pagliarulo,	  confirm	  that	  the	  work	  presented	  in	  this	  thesis	  is	  my	  own.	  Where	  information	  has	  been	  derived	  from	  other	  sources,	  I	  confirm	  that	  this	  has	  been	  indicated	  in	  the	  thesis.	  	   	  	  


















	  The	  events	  during	  papillomavirus	  lesion-­‐formation	  are	  not	  well	  understood,	  but	   are	   likely	   to	   differ	   between	   high	   and	   low	   risk	   HPV	   types,	   which	   have	  different	   effects	   on	   the	   infected	   basal	   layer.	   These	   differences	   most	   likely	  reflect	   differences	   in	   protein	   function	   and	   gene	   expression	   patterns	   that	  have	   evolved	   to	   support	   the	   different	   biologies	   of	   the	   two	   virus	   groups.	  While	  high-­‐risk	  types	  such	  asHPV16	  or	  18	  can	  drive	  cell	  proliferation	  in	  the	  basal	  and	  suprabasal	  layers,	  low-­‐risk	  types	  such	  as	  HPV	  6	  and	  11	  appear	  not	  to	  require	  this	  function.	  	  In	  order	  to	  compare	  the	  two	  virus	  groups	  we	  have	  introduced	  the	  different	  HPV	   genomes	   into	   a	   genetically	   identical	   keratinocyte	   background	   and	  examined	   their	   effect	   on	   functions	   required	   for	   lesion	   formation	   following	  epithelial	   trauma.	   The	   non-­‐immortal	   keratinocyte	   cells	   have	   normal	  differentiation	   properties,	   are	   near-­‐diploid	   and	   are	   sensitive	   to	   contact	  inhibition.	  They	  are	  currently	  used	   in	   the	  clinic	   to	  prepare	  skin	  substitutes	  for	  burns	  victims.	  	  In	  this	  model,	  high-­‐risk	  HPV	  types	   increase	  cell	  growth	  (but	  not	  migration)	  rate	   when	   cells	   have	   space	   to	   grow,	   such	   as	   would	   occur	   during	   wound	  healing.	   They	   can	   also	   overcome	   normal	   cell-­‐cell	   contact	   inhibition	   as	   the	  cells	  pack-­‐up,	  and	  this	  is	  manifest	  in	  organotypic	  rafts	  as	  an	  increase	  in	  basal	  and	   parabasal	   cell	   division	   similar	   to	   that	   seen	   in	   neoplasia.	   This	   growth	  advantage	   would	   allow	   a	   single	   infected	   cell	   to	   outgrow	   its	   uninfected	  neighbours	   following	   infection	   or	   during	   lesion	   expansion	   after	  wounding.	  Interestingly,	   the	   low-­‐risk	   HPV	   types	   appear	   to	   have	   negative	   effect	   on	  growth	   rate,	   allowing	   the	   more	   rapidly	   dividing	   uninfected	   cells	   to	  predominate.	   This	   suggests	   a	   fundamental	   difference	   in	   the	   biology	   of	   the	  two	   HPV	   groups,	   and	   supports	   the	   idea	   that	   low-­‐risk	   types	  may	   reside	   in	  long-­‐lived	   slow-­‐cycling	   cell	   such	   as	   stem	   cell.	   For	   the	   high-­‐risk	   types	   this	  model	   may	   not	   hold	   true,	   with	   lesion-­‐formation	   being	   directed	   actively	  through	  functional	  changes	  in	  the	  infected	  basal	  layer	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  ng	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  nanogram	  NGS	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  normal	  goat	  serum	  	  nm	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  nanometer	  nM	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  nanomolar	  NP40	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  nonyl	  phenoxylpolyethoxylethanol	  ORF	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  open	  reading	  frame	  PAGE	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  polyacrylamide	  gel	  electrophoresis	  PBS	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  phosphate	  buffered	  saline	  PCNA	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  proliferating	  cell	  nuclear	  antigen	  PCR	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  polymerase	  chain	  reaction	  PDZ	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  structural	  domain	  acronym	  of	  PSD95,	  Dlg1	  and	  ZO-­‐1	  	  pen/strep	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  penicillin/streptomycin	  solution	  poly(A)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  polyadenylation	  PV	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  papillomavirus	  PVDF	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  polyvinylidene	  fluoride	  	  qPCR	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  quantitative	  PCR	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ROPV	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  rabbit	  oral	  papillomavirus	  	  rpm	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  revolutions	  per	  minute	  RRP	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  recurrent	  respiratory	  papillomatosis	  RT-­‐qPCR	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  real-­‐time	  qPCR	  SDS	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  sodium	  dodecyl	  sulphate	  TAE	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  tris-­‐acetate	  EDTA	  	  TBS	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  tris-­‐buffered	  saline	  TGF	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  transforming	  growth	  factor	  v/v	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  volume/volume	  VLP	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  virus-­‐like	  particle	  	  w/v	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  weight/volume	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1.1	  Human	  Papillomavirus	  and	  Cancer	  	  
1.1.1	  Incidence	  of	  Human	  Papillomavirus	  Associated	  Cancers	  
	  Human	  variants	  of	  Papillomaviruses	  (HPV)	  cause	  various	  diseases	  such	  as	  visible	  papillomas,	   respiratory	   papillomas,	   verrucas	   and	   even	   cancer.	   Papillomas	  occurring	   at	   oral	   or	   genital	   sites	   can	   be	   persistent	   and	   often	   require	   surgical	  treatment	   (Hsueh,	  2009).	  However,	   approximately	  one-­‐third	  of	   individuals	  who	  present	   for	   treatment	   with	   genital	   warts	   will	   still	   have	   their	   lesions	   3	   months	  later,	  with	   recurrence	   after	   treatment	   being	   a	   significant	   problem	   (Lacey	   et	   al.,	  2006).	   The	   HPV	   types	   that	   cause	   such	   lesions	   are	   also	   implicated	   in	   the	  development	   of	   recurrent	   respiratory	   papillomatosis	   (RRP)(Major	   et	   al.,	   2005).	  RRP	  is	  a	  rare	  disease	  as	  affect	  0.004%	  of	  children	  population	  (Donne	  and	  Clarke,	  2010;	  Gerein	  et	  al.,	  2005)	  but	  is	  a	  serious	  condition	  that	  can	  only	  be	  managed	  by	  repeated	   surgery,	   and	   can	   progress	   to	   cancer	   in	   a	   small	   percentage	  (approximately	   5%)	   of	   persistently	   infected	   individuals	   where	   the	   infection	  spreads	  to	  the	  lung	  (Derkay,	  1995).	  Other	  HPV	  types	  are	  known	  to	  cause	  cancer	  when	  infect	  epithelial	  sites,	  such	  as	  the	  anus,	  the	  endocervix,	  the	  penis	  (Silva	  et	  al.,	  2011;	  Wikstrom	  et	  al.,	  2012)	  and	  the	  oropharynx	  (Syrjanen	  et	  al.,	  2011;	  Szentirmay	  et	  al.,	  2005).	  The	  mucosal	  HPV	  types	  that	  cause	  infections	  of	  the	  ectocervix	  and	  the	  cervical	  transformation	  zone	  are	  well	  studied	  because	  of	  their	  association	  with	  development	  of	  cervical	  cancers	  (zur	  Hausen,	  2009).	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Cervical	   cancer	   is	   the	   second	   highest	   cause	   of	   cancer-­‐associated	   deaths	   in	  developing	  countries	  and	  is	  the	  third	  most	  diagnosed	  form	  of	  cancer	  in	  the	  female	  population	   worldwide.	   There	   is	   a	   significant	   difference	   in	   terms	   of	   cancer	  incidence	  between	  developed	   and	  developing	   regions	   of	   the	  world,	   presumably	  due	   to	   the	   existence	   of	   screening	   programs	   established	   in	   the	   developed	  countries.	   In	   2008,	   about	   530,000	  women	  were	   diagnosed	  with	   cervical	   cancer	  resulting	   in	   roughly	   275,000	   deaths	   worldwide,	   with	   the	   developing	   world	  accounting	  for	  85%	  of	  this	  burden	  (Figure	  1.1)	  (Ferlay	  et	  al.,	  2012).	  Although	  the	  mortality	   rate	   among	   women	   diagnosed	   with	   cervical	   cancers	   is	   consistent	  throughout	   the	  world,	   the	   incidence	   of	   diagnosed	   cancer	   lesions	   is	   significantly	  lower	  in	  the	  developed	  countries.	  This	  lower	  incidence	  confirms	  the	  importance	  of	  active	  screening	  programs	  that	  should	  be	  implemented	  in	  all	  areas	  of	  the	  globe.	  However,	  most	  developing	  countries	  cannot	  afford	  these	  screening	  programs,	  and	  therefore	  there	  is	  still	  an	  urgent	  need	  to	  develop	  a	  specific	  therapy	  for	  this	  form	  of	  cancer.	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Figure	   1.1	   Age-­‐standardized	   incidence	   rates	   for	   cervical	   cancer.	   The	   color	  scale	  bar	  indicates	  the	  incidence	  rates	  per	  100,000	  women.	  Adapted	  from	  (Ferlay	  et	  al.,	  2010).	  .	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1.1.2	  Development	  of	  cervical	  neoplasia	  and	  cancer	  	  About	   85%	   of	   cervical	   cancers	   diagnosed	   in	   both	   developing	   and	   developed	  countries	   are	   squamous	   cell	   carcinomas	   (SCCs).	   The	   remaining	   cancers	   are	  equally	   divided	   into	   adenocarcinomas	   and	   adenosquamous	   carcinomas.	   The	  neoplastic	   progression	   of	   ‘cervical	   cancer’	   or	   ‘cervical	   carcinoma’	   is	   a	  multistep	  process	   grading	   from	   the	   mild	   form	   of	   disease,	   called	   low-­‐grade	   squamous	  intraepithelial	   lesion	   (L-­‐SIL),	   to	   the	   more	   severe	   and	   aggressive	   high-­‐grade	  squamous	   intraepithelial	   lesion	   (H-­‐SIL),	   and	   eventually	   progressing	   to	   the	  invasive	  form	  described	  as	  cervical	  carcinoma	  (Doorbar	  et	  al.,	  2012).	  	  	  A	   number	   of	   studies	   have	   demonstrated	   that	   infection	   with	   high-­‐risk	   Human	  Papillomaviruses	   (HR-­‐HPVs)	   is	   a	   prerequisite	   for	   the	   development	   of	   cervical	  lesions	   in	   more	   than	   99%	   of	   cases	   (Bosch	   and	   Munoz,	   2002).	   Furthermore,	  infection	  with	  a	  subset	  of	  genital	  HR-­‐HPVs,	  including	  mainly	  HPV16	  and	  HPV18,	  is	  largely	   responsible	  of	   the	  development	  of	   cervical	   lesions,	   as	  HR-­‐HPV	  DNA	  was	  found	  in	  ~99.75%	  of	  cervical	  carcinomas	  (Bosch	  and	  Munoz,	  2002;	  Stanley,	  2001;	  Walboomers	  et	  al.,	  1999).	  However,	  transient	  infection	  with	  HR-­‐HPVs	  alone	  is	  not	  sufficient	  to	  induce	  carcinogenic	  cervical	  lesions;	  in	  fact,	   less	  than	  1%	  of	  women	  that	  become	  infected	  with	  HR-­‐HPV	  will	  develop	  cervical	  cancer,	  as	  most	  women	  will	   clear	   the	   infection	   within	   2	   years.	   Of	   the	   women	   who	   have	   a	   cervical	  neoplastic	  lesion	  resulting	  from	  a	  persistent	  infection	  with	  HR-­‐HPV,	  a	  number	  of	  risk	   factors	   contribute	   to	   the	   progression	   towards	   malignancy.	   The	   most	  important	   risk	   factor	   is	   the	   deregulation	   of	   the	   HR-­‐HPV	   oncogenes	   E6	   and	   E7,	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resulting	   in	   high	   and	   uncontrolled	   expression	   of	   these	   genes,	   often	   caused	   by	  integration	  of	  HR-­‐HPV	  genomes	  into	  host	  chromosomes	  (Stanley,	  2001).	  	  
	  
1.1.3	  Physiology	  of	  the	  uterine	  cervix	  and	  HPV	  infection	  
	  HPVs	   infect	   almost	   every	   tissue	   in	   the	   female	   lower	   genital	   tract.	   Usually,	  infections	  are	  asymptomatic	  and	  transient,	  as	   they	  are	  cleared	  within	  1-­‐2	  years.	  The	  rare	   infections	   that	  progress	   to	  cancer	  usually	  occur	  at	   the	  cervical	   tract	  of	  the	   uterus.	   Understanding	   of	   the	   physiology	   of	   the	   uterus	   and	   the	   cervix	   is	  necessary	   to	  understand	  why	   this	  particular	  anatomical	  site	   is	   so	  susceptible	   to	  HPV-­‐associated	  disease.	  	  Most	  HPV	  infections	  occur	  at	  cervix	  because	  of	  its	  anatomy.	  A	  schematic	  diagram	  of	  the	  female	  anatomy,	  highlighting	  the	  cervix,	  is	  shown	  in	  Figure	  1.2.	  The	  cervix	  is	  considered	  part	  of	  the	  lower	  uterus,	  and	  connects	  the	  uterus	  to	  the	  vagina	  via	  the	   internal	   opening	   of	   the	   cervix	   (OS)	   and	   external	   OS,	   respectively.	   The	  endocervical	   canal	   lies	   at	   the	   centre	   of	   the	   cervix	   and	   is	   comprised	   of	   mucus-­‐secreting	   columnar	   epithelial	   cells,	   which	   form	   the	   endocervical	   columnar	  epithelium.	  The	  vaginal	   side	  of	   the	  cervix,	   called	   the	  ectocervix,	   is	   comprised	  of	  non-­‐keratinising	   stratified	   epithelial	   cells	   that	   form	   the	   ectocervical	   squamous	  epithelium,	   a	   tissue	   with	   similar	   characteristics	   to	   the	   vaginal	   epithelium	  (Buckley,	   1994).	   This	   endocervical	   columnar	   epithelium	  meets	   the	   ectocervical	  squamous	   epithelium	   at	   the	   squamous-­‐columnar	   junction	   (SCJ).	   Hormonal	  changes	  caused	  by	  puberty,	  pregnancy,	  and	  oral	  contraceptives	  can	  cause	  cervical	  ectopy,	   an	   elongation	   of	   the	   cervix	   that	   exposes	   the	   SCJ	   to	   the	   vaginal	   canal.	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During	   cervical	   ectopy,	   the	   squamous	   epithelium	   replaces	   the	   columnar	  epithelium	   at	   the	   ‘transformation	   zone’	   in	   a	   metaplastic	   process.	   This	  ‘transformation	  zone’	  is	  particularly	  susceptible	  to	  HPV	  infection,	  and	  it	  is	  where	  the	  majority	  of	  lesions	  are	  diagnosed	  (Arends	  et	  al.,	  1998;	  Herfs	  et	  al.,	  2012).	  	  	  
	  
Figure	   1.2.	   Anatomy	   of	   the	   cervix.	   The	   diagram	   shows	   the	   location	   of	   the	  transformation	  zone	  and	  the	  endocervical	  canal.	  The	  other	  features	  of	  the	  cervix	  are	  also	  detailed	  (see	  text	  for	  details).	  	  
1.1.4	  Classification	  of	  cervical	  intraepithelial	  lesions	  	  In	  order	  to	  understand	  the	  physiology	  of	  cervical	  cancer	  it	  is	  necessary	  to	  classify	  cervical	  lesions	  so	  that	  pathological	  events	  are	  clearly	  identified.	  Cervical	  cancer	  in	   fact	   develops	   from	   a	   pre-­‐malignant	   neoplastic	   transformation	   that	   presents	  diverse	  degrees	  of	   severity	  during	   its	  pathological	   evolution.	  Two	  main	  grading	  systems,	   one	   based	   on	   histology	   and	   the	   other	   based	   on	   cytology	   of	   cervical	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specimens,	  have	  been	  created	  to	  define	   these	  events	  and	  describe	   the	  degree	  of	  cell	  atypia	  (Richart,	  1973;	  Solomon,	  1990).	  	  	  The	   histology-­‐based	   system	   has	   been	   used	   since	   1960	   and	   defines	   cervical	  intraepithelial	   neoplasia	   (CIN)	   at	   three	   different	   stages	   (Figure	   1.3).	   By	   this	  system,	  cervical	  dysplasia	  is	  diagnosed	  according	  to	  the	  proportion	  of	  cells	  in	  the	  cervical	   epithelium	   displaying	   dysplastic	   characteristics	   or	   cell	   atypia,	   such	   as	  multiple	  enlarged	  nuclei	   typical	  of	  koilocytes.	  CIN1	  and	  CIN2	   lesions	   show	  one-­‐third	   and	   two-­‐thirds	   of	   the	   epithelium	   thickness	   presenting	   cell	   atypia,	  respectively.	   Furthermore,	   squamous	  maturation	  occurs	  only	   in	   the	  middle	   and	  upper	  third	  of	  the	  epithelium,	  and	  koilocytes	  are	  observed	  here	  due	  to	  cytopathic	  virus	  activity.	  CIN3	  lesions	  show	  cell	  atypia	  throughout	  the	  entire	  thickness	  of	  the	  epithelium.	   Because	   invasive	   cells	   are	   not	   identified	   by	   this	  method,	   squamous	  cell	   carcinomas	   are	   outside	   this	   classification	   range	   (Doorbar,	   2006;	   Richart,	  1973).	   This	   histology-­‐based	   classification	   system	   presents	   some	   limitations,	   as	  the	  classification	  does	  not	  precisely	  correlate	  with	  the	  biological	  behaviour	  of	  the	  lesion.	  There	  is	  also	  no	  indication	  of	  putative	  regressing	  lesions.	  	  	  In	   recent	   years	   a	   new	   methodology	   to	   classify	   lesions	   based	   on	   cytology	   of	  cervical	   specimens,	   called	   the	   Bethesda	   grading	   system,	   has	   been	   adapted	   to	  overcome	   these	   limitations.	  This	   system	  adopts	  only	   two	  grades	  which	   indicate	  the	   risk	   of	   progression	   to	  malignancy:	   the	   low-­‐grade	   squamous	   intra-­‐epithelial	  lesions	   (L-­‐SIL	   corresponding	   to	   CIN1)	   and	   the	   high-­‐grade	   squamous	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intraepithelial	   lesions	   (H-­‐SIL	   corresponding	   to	   CIN2	   and	   CIN3	   of	   the	   histology-­‐based	  classification	  system)	  (Solomon,	  1990).	  	  	  
	  
Figure	   1.3.	   Cervical	   neoplastic	   progression	   and	   pathological	   changes	   in	  
lesions	   with	   LSIL	   and	   HSIL	   (adapted	   from	   (Branca	   et	   al.,	   2004).	   Top,	   left	  panel:	  In	  the	  normal	  cervix,	  the	  basal	  layer	  of	  the	  epithelium	  is	  comprised	  of	  small	  and	  uniform	  cells,	  and	  squamous	  maturation	  occurs	  in	  the	  layers	  directly	  above.	  	  Top,	   right	   panel:	   An	   L-­‐SIL	   lesion	   (CIN1),	   however,	   contains	   dysplastic	   cells	   in	  about	   half	   of	   the	   thickness	   of	   the	   epithelium.	   The	   dysplastic	   cells	   present	  pleomorphic	   nuclei	   and	   exhibit	   a	   loss	   of	   polarity.	   Bottom	   panels:	   H-­‐SIL	   lesions	  (CIN2	  and	  CIN3)	   show	  dysplastic	   cells	   in	   the	   entire	   thickness	  of	   the	   epithelium	  and	  squamous	  maturation	  occurs	  only	  in	  the	  upper-­‐most	  layers.	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1.1.5	  Clinical	  management	  of	  lesions	  caused	  by	  HPV	  
	  The	  pathologies	  caused	  by	  HPV	  infections	  have	  an	  enormous	  impact	  on	  people’s	  lives	   in	  both	  populations	  of	   the	  developed	  and	  developing	  countries.	  To	  date,	   in	  order	  to	  limit	  the	  loss	  of	  lives,	  HPV	  diseases	  have	  been	  tackled	  using	  three	  major	  tools:	   prevention,	   diagnosis	   and	   treatment.	   In	   the	   recent	   years,	   the	   prevention	  and	   diagnosis	   have	   been	   considered	   fundamental	   to	   limit	   the	   spread	   of	   HPV	  infection	   and	   decrease	   the	   number	   of	   people	   in	   need	   of	   surgical	   treatment.	  Diagnostic	   and	   screening	   programs	   however,	   are	   mainly	   implemented	   only	   in	  developed	   countries.	   Moreover,	   the	   recently	   developed	   prophylactic	   vaccine	  (Hanna	   and	   Bachmann,	   2006;	   Szarewski,	   2007)	   is	   most	   useful	   when	   used	   in	  specific	   categories	   of	   people,	   depending	   on	   sex	   and	   age	   group.	   Although	   their	  utility	   has	   been	   demonstrated,	   the	   vaccine	   and	   the	   screening	   programs	   do	   not	  guarantee	  the	  maximal	  efficacy	  in	  preventing	  cervical	  cancer	  or	  in	  detecting	  pre-­‐neoplastic	   lesions.	   Furthermore	   the	   high	   costs	   associated	   with	   clinical	  management	   of	   the	   lesions	   caused	   by	   HPV,	   including	   screening	   programs	   and	  vaccination	  limit	  enormously	  their	  use	  in	  the	  developing	  countries.	  Therefore,	   it	  is	   necessary	   to	   develop	   cost	   effective	   screening	   tools	   and	   to	   understand	   the	  biological	  mechanisms	  leading	  to	  the	  formation	  of	  HPV	  associated	  lesions.	  
	  
1.1.6	  The	  prevention	  of	  HPV:	  the	  prophylactic	  vaccine	  
	  Since	  the	  discovery	  that	  HPV	  is	  a	  necessary	  cause	  of	  cervical	  cancer,	  development	  of	  a	  vaccine	  has	  been	  researched.	  The	  presence	  of	  specific	  antibodies	  against	  the	  coat	   proteins	   of	  HPV	   in	   subjects	   infected	  with	   viruses	   suggested	   the	   possibility	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that	  immunization	  may	  be	  protective	  against	  infection.	  In	  fact,	  studies	  on	  animal	  models	   have	   demonstrated	   that	   antibodies	   against	   HPV,	   produced	   in	   infected	  animals,	   were	   able	   to	   produce	   an	   efficient	   response	   when	   injected	   in	   naïve	  animals	   (Ghim	   et	   al.,	   2000).	   The	   development	   of	   a	   prophylactic	   vaccine	   was	  allowed	  by	   the	   singular	   feature	  of	   the	  L1	  proteins	   given	  by	   their	   ability	   to	   self-­‐assemble	   and	   form	   virus	   like	   particles	   (VLPs)	   (Galloway,	   2003;	   Salunke	   et	   al.,	  1986).	   These	   VLPs	   were	   produced	   by	   cloning	   the	   L1	   fragment	   in	   competent	  organisms	  and	  the	  resulting	  empty	  shells	  were	  used	  to	  test	  their	  immunogenicity.	  Clinical	   trials	   demonstrated	   that	   VLPs	   containing	   L1	   from	   HPV16	   and	   HPV18	  were	   able	   to	   produce	   a	   consistent	   protection	   against	   future	   infections.	   This	  strategy	   opened	   the	   possibility	   to	   use	   such	   particles	   in	   the	   vaccine	   production	  (Stanley	  et	  al.,	  2012).	  Since	   the	   introduction	   of	   licensed	  products	   containing	  VLPs,	   two	   vaccines	   from	  two	   companies	   have	   been	   commercialized:	   Cervarix	   (GlaxoSmithKline	  Biologicals)	   and	   Gardasil	   (Merck	   &	   Co.	   Inc.).	   Both	   products	   offer	   protection	  against	  the	  high-­‐risk	  HPV16	  and	  HPV18,	  with	  an	  extended	  protection	  of	  Gardasil	  against	   two	   low-­‐risk	  HPV	   types	   (HPV6	   and	  HPV11).	   Therefore	  Gardasil	   has	   the	  ability	   to	   protect	   from	   HPV6	   and	   HPV11	   infections	   causing	   warts-­‐like	   lesions.	  After	  few	  years	  from	  their	  release	  in	  the	  market,	  the	  efficacy	  of	  these	  vaccines	  was	  demonstrated,	  with	  Gardasil	  scoring	  a	  remarkable	  100%	  of	  efficacy	  (Dyson	  et	  al.,	  1989;	   Gage	   et	   al.,	   1990).	   Such	   vaccines	   have	   now	   been	   licensed	   in	   over	   100	  countries	  worldwide.	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A	  vaccination	  campaign	  of	  young	  women	  is	  currently	  ongoing	   in	  the	  majority	  of	  the	   developed	   countries.	   The	   extension	   of	   the	   vaccination	   program	   to	   the	  men	  population	  is	  currently	  debated	  (Stanley	  et	  al.,	  2012).	  Despite	   the	   proven	   efficacy	   of	   the	   recently	   introduced	   vaccines,	   it	   will	   still	   be	  necessary	  to	  sustain	  an	  active	  screening	  program.	  In	  fact,	  both	  vaccines	  cannot	  be	  used	  as	  therapy	  for	  people	  with	  current	  disease.	  Furthermore,	  there	  are	  a	  number	  of	  HPV	  types	  outside	  the	  protection	  range	  of	  the	  two	  vaccines,	  which	  may	  cause	  a	  number	  of	   pathologies	   including	   cervical	   cancer.	   It	   has	  been	   estimated	   that	   the	  protection	  gained	  with	  a	  vaccination	  program	  covering	  the	  entire	  young-­‐women	  population,	  would	   reduce	   the	   number	   of	  women	   developing	   cervical	   cancer	   by	  70%	   (Stanley	   et	   al.,	   2012).	   Moreover,	   a	   reduction	   in	   the	   mortality	   rates	   from	  cervical	   cancer	   might	   only	   be	   detected	   after	   several	   years	   because	   the	  progression	   of	   the	   HPV	   infection	   to	   cervical	   cancer	   is	   not	   rapid	   (Stanley	   et	   al.,	  2012).	   Thus,	   the	   necessity	   to	   continue	   and	   improve	   the	   current	   screening	  program	  for	  pre-­‐neoplastic	  lesions	  is	  evident.	  
	  
1.1.7	  Diagnosis	  of	  HPV	  lesions	  	  HPVs	  usually	  cause	  benign	  epithelial	   lesions	  known	  as	  warts	  typically	  located	  at	  the	  ano-­‐genital	  areas.	  Some	  strains	  produce	  also	  verrucas	  and	  others	  are	  able	  to	  cause	   RRP.	   Only	   in	   rare	   cases	   infections	   from	   HR-­‐HPVs	   cause	   pre-­‐neoplastic	  lesions	  that	  necessarily	  need	  treatment.	  As	  discussed	  earlier,	  pre-­‐malignant	  lesions	  range	  from	  LSIL	  to	  HSIL	  according	  to	  the	   severity	   status	   of	   the	   disease.	   Such	   a	   difference	   in	   their	   grade	   allows	   an	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efficient	  management	  of	  the	  pre-­‐cancerous	  lesions.	  In	  fact,	  LSIL	  can	  be	  monitored	  whereas	  HSIL	  infections	  can	  be	  removed	  before	  reaching	  invasivity.	  	  George	  Papanicolaou	  in	  1941	  introduced	  a	  methodology	  commonly	  used	  to	  detect	  morphological	  abnormalities	  in	  the	  cervical	  cells.	  The	  method,	  known	  as	  Pap	  test	  or	  Pap	  smear,	  consists	  of	  the	  screening	  for	  neoplastic	  change	  of	  cells	  taken	  from	  the	   cervical	   surface.	   The	   Pap	   test	   is	   not	   100%	   accurate,	   but	   it	   has	   indeed	  demonstrated	   to	   contribute	   to	   the	   reduction	   of	   the	   fatalities	   caused	   by	   HPV	  (Vizcaino	  et	  al.,	  2000).	  A	  comparative	  study	  has	  shown	  that	  the	  number	  of	  women	  diagnosed	   with	   cervical	   cancer	   have	   significantly	   decreased	   since	   the	  introduction	   of	   the	   screening	   program	   in	   the	   developed	   countries.	   The	   current	  cervical	  cancer	  incidence	  in	  developing	  countries,	  where	  screening	  programs	  are	  not	   established,	   is	   comparable	   to	   that	   of	   the	   developed	   countries	   before	   the	  screening	  introduction.	  	  As	  mentioned	  earlier,	  the	  Pap	  test	  is	  not	  completely	  efficient	  (Sasieni	  et	  al.,	  1996).	  Both	   specificity	   and	   sensitivity	   of	   the	   test	   are	   considered	   low,	   with	   Pap	   test	  negatives	  in	  86-­‐100%	  of	  disease-­‐negative	  cases,	  and	  Pap	  test	  positives	  in	  30-­‐87%	  of	  disease	  positive	   cases	   (Nanda	  et	   al.,	   2000).	  The	  Pap	   test	   results	  depend	  on	  a	  cytopathologists	   judgement	   and	   so	   it	   is	   subjective.	   Although	   not	   completely	  reliable,	   the	   Pap	   test	   remains	   a	   useful	   tool	   in	   the	   cervical	   cancer	   diagnosis.	   In	  addition	  the	  test	  is	  too	  expensive	  to	  be	  implemented	  in	  developing	  regions	  due	  to	  the	  need	  of	  a	  pathologists	  in	  performing	  the	  test.	  In	   the	  recent	  years,	  many	  studies	  have	  been	  dedicated	   to	   the	  research	  of	  better	  diagnostic	  tools,	  in	  particular	  to	  implement	  the	  detection	  of	  neoplastic	  lesions	  at	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the	   earliest	   stages,	   and	   new	   methods	   have	   been	   proposed	   to	   improve	   the	  reliability	   of	   the	   cervical	   screenings,	   but	   not	   yet	   implemented	   (Baldwin	   et	   al.,	  2003).	   One	   example	   is	   the	   detection	   of	   biomarkers,	   host	   genes	   that	   become	  deregulated	   during	   cervical	   neoplastic	   progression,	   through	   a	   combination	   of	  microscope	  and	  liquid	  phase	  techniques.	  	  




1.2.1	  Classification	  of	  papillomaviruses	  
	  Papillomaviruses	  (PVs)	  are	  a	  member	  of	  the	  family	  Papillomaviridae,	  an	  ancient	  family	  of	  viruses	  estimated	  to	  date	  beyond	  the	  origin	  of	  Homo	  sapiens	  (Bernard	  et	  al.,	  1994;	  Ho	  et	  al.,	  1993).	  PVs	  are	  non-­‐enveloped	  viruses,	  approximately	  55	  nm	  in	  diameter,	   containing	   a	   double-­‐stranded	   circular	   DNA	   genome	   of	   about	   7.9kb	  (Howley,	  1982).	  PVs	  are	  highly	  species	  and	  tissue	  tropic,	  and	  have	  evolved	  with	  an	  estimated	  mutation	  rate	  similar	  to	  that	  of	  its	  host	  germ	  line	  (Chan	  et	  al.,	  1997).	  	  PVs	  are	  known	  to	  infect	  most	  animal	  species,	  as	  well	  as	  reptiles	  and	  cetaceans	  (de	  Villiers	  et	  al.,	  2004a).	  Due	  to	  the	  diversity	  of	  species	  with	  which	  PVs	  co-­‐evolved	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and	   their	   strict	   species	   tropism,	   these	   viruses	   have	   become	   genetically	   distinct	  from	  one	  another.	  	  	  Despite	   their	   genetic	   divergence,	   PVs	   share	   fundamental	   biological	   features	   as	  they	   infect	  exclusively	  epithelial	  cells	  and	  use	   the	  entire	  epithelium	  to	  complete	  their	   life	   cycle.	   PVs	   are	  well	   adapted	   to	   their	   hosts,	   as	   they	   complete	   their	   life	  cycle	   and	   are	  maintained	   in	   the	   population	   usually	   without	   causing	   significant	  harm	   to	   their	   hosts.	   This	   characteristic	   highlights	   a	   conserved	   virus-­‐host	  interaction	   that,	   over	   time,	   has	   lead	   to	   a	   fine	  balance	  between	  virus	   replication	  and	   host	   immune	   surveillance	   (Woolhouse	   and	   Gaunt,	   2007).	   	   It	   is	   widely	  established	  however	  that	  a	  single	  PV	  type	  can	  cause	  a	  clinical	  spectrum	  of	  disease	  among	  individual	  hosts	  (Doorbar	  et	  al.	  2012).	  	  PVs	   are	   organized	   into	   genera,	   species,	   and	   types	   based	   on	   the	   nucleotide	  sequence	   of	   their	   L1	   capsid	   ORF;	   PVs	   within	   a	   genera	   share	   at	   least	   40%	   L1	  sequence	   identity,	   species	   share	   at	   least	   60%,	   and	   types	   share	  more	   than	   90%	  (Barnard	   and	   McMillan,	   1999;	   de	   Villiers	   et	   al.,	   2004b).	   Most	   host	   species	   are	  infected	   by	   only	   one	   PV	   genera.	   HPVs	   represent	   only	   a	   small	   group	   of	   PVs,	   of	  which	  more	   than	  150	   types	  have	  been	   completely	   sequenced	   to	  date.	  HPVs	  are	  divided	   into	   five	   genera:	   Alpha-­‐,	   Beta-­‐,	   Gamma-­‐,	   Mu-­‐,	   and	   Nu-­‐papillomaviruses	  (Doorbar	   et	   al.,	   2012).	  The	  most	  well	   studied	  group	   is	   the	  Alpha-­‐PV	  because	  of	  their	  ability	  to	  cause	  benign	  genital	  lesions	  and	  cervical,	  anogenital,	  and	  head	  and	  neck	  cancers.	  The	  Alpha	  group	  is	  subsequently	  divided	  into	  two	  sub-­‐groups	  based	  on	  their	  oncogenic	  potential:	  ‘low-­‐risk’	  types	  (LR-­‐HPVs,	  including	  type	  6	  and	  11)	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mostly	  cause	  benign	  lesions	  known	  as	  papillomas	  or	  warts,	  and	  ‘high-­‐risk’	  types	  (HR-­‐HPVs,	  such	  as	  type	  16,	  18,	  31,	  33,	  45)	  cause	  an	  array	  of	  cancers.	  Papillomas	  caused	   by	   LR-­‐HPVs	   frequently	   require	   surgical	   treatment	   when	   they	   occur	   in	  genital	  areas	  or	  oral	  sites.	  The	  LR-­‐HPVs	  are	  also	  responsible	  for	  the	  development	  of	   respiratory	  papillomatosis,	  which	   requires	   surgical	   treatment	   as	  well,	   and	   in	  rare	  cases	  can	  progress	  to	  cancer	  (Derkay,	  1995;	  Donne	  and	  Clarke,	  2010;	  Major	  et	  al.,	  2005).	   	  The	  variety	  of	  epithelial	  disease	  caused	  by	  HPVs	  may	  be	  related	  to	  different	  transmission	  strategies	  as	  well	  as	  their	  diverse	  interaction	  with	  the	  host	  immune	   system	   (Doorbar,	   2005).	   This	   broad	   range	   of	   pathological	   disease	   has	  formed	  a	  large	  basis	  for	  the	  study	  of	  different	  HPV	  types.	  
	  
1.2.2	  HPV	  genome	  organization	   	  
	  As	   mentioned	   previously,	   HPVs	   are	   small,	   non-­‐enveloped	   viruses	   containing	   a	  circular	   double-­‐stranded	   DNA	   genome	   of	   around	   7.9kb	   (Howley,	   1982).	   HPV	  genomes	  contain	  three	  main	  domains:	  the	  non-­‐coding	  long	  control	  region	  (LCR),	  the	   ‘early’	   region,	   and	   the	   ‘late’	   region	   (Figure	   1.4).	   The	   LCR	   contains	   the	   viral	  origin	  of	  replication,	  which	  is	  ~1kb.	  The	  names	  ‘early’	  and	  ‘late’	  correspond	  to	  the	  position	   of	   the	   ORFs	   in	   the	   genome	   and	   the	   kinetics	   of	   expression	   during	  vegetative	   viral	   replication,	   and	   the	   numbers	   indicate	   the	   relative	   size	   of	   the	  corresponding	  ORF	  (Duensing	  and	  Munger,	  2004).	  The	  early	  region	  is	  ~4kb	  and	  contains	   the	   non-­‐structural	   genes.	   These	   are	   E6	   and	   E7,	  which	   are	   involved	   in	  host	  cell	  immortalization,	  and	  E1,	  E2,	  E8^E6,	  E1^E4,	  and	  E5,	  which	  are	  primarily	  involved	  in	  virus	  replication	  and	  regulation	  of	  viral	  gene	  transcription.	   	  The	  late	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region	   is	  ~3kb	   and	   contains	   the	   structural	   genes,	   L1	   and	  L2,	  which	   encode	   the	  major	  and	  minor	  capsid	  proteins,	  respectively.	  	  The	   two	   major	   promoters	   that	   regulate	   the	   viral	   gene	   expression	   in	   the	  epithelium	   are	   the	   ‘early’	   p97	   promoter	   and	   the	   ‘late’	   p670	   differentiation-­‐dependent	  promoter.	  The	  p97	  promoter	  controls	  the	  expression	  of	  early	  genes	  E6	  and	   E7,	   and	   the	   p670	   promoter,	   located	   within	   the	   E7	   ORF,	   controls	   the	  expression	  of	  several	  early	  genes	  including	  E1,	  E2,	  E4	  and	  E5	  as	  well	  as	  late	  genes	  L1	  and	  L2	  (Grassmann	  et	  al.,	  1996;	  Smotkin	  and	  Wettstein,	  1986).	  Transcription	  from	  the	  late	  promoter	  must	  bypass	  the	  early	  polyadenylation	  site	  (early	  poly-­‐A)	  to	  allow	  gene	  expression	  from	  the	  late	  region	  (Zheng	  and	  Baker,	  2006).	  The	  long	  control	  region	  (LCR)	  is	  located	  immediately	  upstream	  of	  the	  E6	  ORF	  in	  proximity	   of	   the	   p97	   promoter.	   This	   region	   contains	   cis-­‐acting	   regulatory	  promoter	   sequences,	   which	   are	   fundamental	   for	   virus	   replication	   and	   viral	  transcription.	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Figure	   1.4.	   Schematic	   representation	   of	   the	   double-­‐stranded	   circular	  
genome	  of	  HPV16.	  The	  early	  (E)	  and	   late	  (L)	  genes	  as	  well	  as	   the	   long	  control	  region	  (LCR)	  are	  shown.	  The	  early	  and	  late	  polyadenylation	  sites	  are	  indicated	  as	  AE	  and	  AL.	  P97	  and	  P670	  indicate	  the	  position	  of	  the	  early	  and	  late	  promoters.	  	  
	  
1.2.3	  HPV	  gene	  expression	  
	  
1.2.3.1	  HPV	  gene	  transcription	  
	  HPV	  gene	  transcription	  has	  been	  characterised	  studying	  mainly	  the	  HPV16	  type.	  The	  HPV16	  early	  promoter,	  p97,	  is	  responsible	  for	  early	  gene	  expression	  whereas	  the	   late	   genes	   are	   transcribed	   from	   the	   late	   promoter,	   p670.	   However	   several	  other	   promoters	   have	   been	   identified	   within	   the	   LCR	   and	   within	   the	   E4	   ORF	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(Doorbar	   et	   al.,	   1990;	   Milligan	   et	   al.,	   2007).	   Binding	   of	   specific	   cellular	  transcription	  factors	  such	  as	  Sp-­‐1,	  AP-­‐1,	  Oct-­‐1	  and	  YY1	  within	  the	  LCR	  can	  have	  both	   positive	   and	   negative	   effects	   on	   viral	   transcription	   (Lace	   et	   al.,	   2009).	  Furthermore,	  the	  LCR	  contains	  sites	  responsive	  to	  glucocorticoid	  binding	  (Todaro	  and	   Green,	   1963),	   which	   enhance	   virus	   replication	   (Piccini	   et	   al.,	   1997).	  Interestingly,	  the	  HPV16	  E2	  protein	  is	  a	  known	  regulator	  of	  early	  transcription,	  as	  the	  HPV16	  LCR	  also	   contains	   four	  binding	  sites	   for	   the	  E2	  protein	   (E2BS	   (1-­‐4))	  that	   are	   located	   in	   the	   proximity	   of	   the	   cellular	   transcription	   factor	   sites	  (Androphy	   et	   al.,	   1987).	   Binding	   of	   E2	   to	   E2BS-­‐2	   and	   -­‐4	   sites	   within	   the	   LCR	  impedes	  access	  to	  cellular	  transcription	  factors,	  thereby	  repressing	  p97	  promoter	  activity	  (Sousa	  et	  al.,	  1990).	  	  The	  transcription	  starting	  points	  within	  HPV	  genomes	  is	  variable	  and	  strictly	  HPV	  type-­‐dependent.	   Interestingly,	   transcription	   occurs	   only	   from	   one	   of	   the	   viral	  DNA	  strands	  in	  clockwise	  direction	  as	  shown	  in	  Figure	  1.5.	  During	  many	  years	  of	  evolution,	  PVs	  have	  made	  extraordinary	  use	  of	  alternative	  splicing	  mechanisms	  to	  diversify	   the	   proteins	   encoded	   by	   the	   viral	   genome.	   Transcription	   of	   the	   virus	  genome	  produces	  a	  number	  of	  polycistronic	  mRNAs	  from	  both	  the	  early	  and	  late	  promoters	   that	   undergo	   a	   series	   of	   post-­‐transcriptional	   splicing	   and	   are	  polyadenylated	  at	  either	  an	  early	  (AE)	  or	  late	  (AL)	  poly-­‐A	  site	  (Zheng	  and	  Baker,	  2006).	   Splicing	   is	   intricately	   regulated	   by	   both	   viral	   cis-­‐elements	   and	   cellular	  splicing	   factors	   (Zheng	   and	  Baker,	   2006).	   The	   splice	   transcripts	   produced	   from	  the	  early	  promoter	  include	  many	  combinations	  of	  E1,	  E2,	  E4,	  E5,	  E6	  and	  E7	  poly-­‐	  and	  bi-­‐cistronic	  mRNAs	  (Figure	  1.5)	  (Doorbar	  et	  al.,	  1990).	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Referring	   to	   HPV	   E6/E7	   splicing,	   selection	   of	   the	   first	   5’-­‐alternative	   splice	   site	  gives	   rise	   to	   a	   new	  ORF	   termed	   E6*	   (which	   has	   so	   far	   only	   been	   described	   for	  high-­‐risk	   but	   not	   for	   low-­‐risk	   HPVs	   (Schneider-­‐Gadicke	   and	   Schwarz,	   1986).	  Alternative	  splicing	  of	  HPV16	  E6	  and	  E7	  oncogenes,	  which	  are	  mainly	  transcribed	  by	  the	  p97	  promoter,	  result	  in	  multiple	  products	  which	  are	  functionally	  distinct.	  The	  E6	  mRNA	  contains	  one	  intron,	  which	  when	  spliced	  at	  3’	  site,	  produces	  three	  transcripts:	  E6*I,	  E6*II	  and	  E6^E7	  (Figure	  1.5)	  (Doorbar	  et	  al.,	  1990;	  Zheng	  and	  Baker,	  2006).	  E6*I	  is	  the	  most	  abundant	  E6	  transcript	  detected	  in	  cervical	  cancer	  cell	  lines	  and	  may	  have	  functional	  importance	  in	  the	  virus	  life	  cycle	  (Cornelissen	  et	   al.,	   1990).	   Interestingly,	   splicing	   of	   E6	   is	   thought	   to	   promote	   E7	   translation	  (Tang	   et	   al.,	   2006).	   However,	   it	   is	   important	   to	   mention	   that	   full-­‐length	   E6	   is	  always	  transcribed	  alongside	  full-­‐length	  E7.	  The	  mRNA	  products	  derived	  from	  the	  differentiation-­‐dependent	   late	  promoter,	  p670,	   include	  a	  combination	  of	  E1,	  E2,	  E5,	  E1^E4,	  and	  the	  structural	  genes	  L1	  and	  L2	  (Milligan	  et	  al.,	  2007).	  E1^E4	  and	  L1	   transcripts	   were	   originally	   identified	   in	   the	   suprabasal	   differentiating	   cells	  (Doorbar,	   2005;	   Doorbar	   et	   al.,	   1997;	   Middleton	   et	   al.,	   2003),	   however	   non-­‐functional	   L1	   transcripts	   lacking	   a	   poly-­‐A	   tail	   have	   recently	   been	   found	   in	  undifferentiated	   cells	   also	   (Milligan	   et	   al.,	   2007).	   This	   demonstrates	   that	  transcription	   of	   late	   genes	   can	   occur	   during	   early	   stages	   of	   the	   virus	   life	   cycle,	  however	   the	  post-­‐transcriptional	  modifications	  necessary	   to	  produce	   functional	  transcripts	  occur	  in	  a	  differentiation-­‐dependent	  manner.	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Figure	   1.5.	   Schematic	   representation	   of	   the	   HPV16	   transcript	   map.	   The	  boxes	  indicate	  the	  HPV16	  genome	  ORFs	  situated	  on	  three	  levels	  representing	  the	  coding	   frames.	   The	   position	   of	   the	   early	   (P97)	   and	   late	   (P670)	   promoters	   is	  shown	  underneath	   the	  boxes,	   the	  arrows	   indicate	   the	  direction	  of	   transcription.	  The	   early	   (AE)	   and	   late	   (AL)	   polyadenylation	   sites	   are	   identified	   at	   nucleotides	  4215	  and	  7321,	  respectively.	  The	  mRNA	  species	  are	  indicated	  as	  splicing	  variants.	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1.2.3.2	  Translation	  in	  HPV	  mRNAs	  	  Translation	   of	   HPV	   transcripts	   generally	   occurs	   with	   low	   efficiency	   relative	   to	  translation	   of	   host	   cellular	   transcripts,	   which	   occurs	   constitutively	   (Zheng	   and	  Baker,	   2006).	   Furthermore,	   HPV	   transcripts	   are	   bi-­‐	   and	   poly-­‐cistronic,	   while	  cellular	   transcripts	   are	   typically	   monocistronic	   (Firth	   and	   Brierley,	   2012).	   One	  explanation	   for	   the	   observed	   slow	   translation	   rate	   of	   viral	   transcripts	   is	   the	  requirement	  for	  rare	  codons	  used	  for	  translation	  of	  HPV	  mRNAs	  (Zhao	  and	  Chen,	  2011).	  Instability	  of	  viral	  mRNAs	  and	  complex	  translation	  initiation	  control	  may	  also	   be	   contributing	   factors	   to	   the	   low	   translation	   efficiency	   of	  HPV	   transcripts	  (Zheng	   and	   Baker,	   2006).	   Translation	   initiation	   control	   mechanisms,	   such	   as	  through	  translation	  re-­‐initiation,	   leaky	  scanning,	  ribosome	   jumping	  and	   internal	  ribosome	   entry	   not	   only	   explain	   the	   low	   translation	   efficiency	   but	   also	   how	  downstream	  ORFs	  in	  a	  polycistronic	  transcript	  are	  translated	  (Remm	  et	  al.,	  1999;	  Stacey	   et	   al.,	   2000;	   Tang	   et	   al.,	   2006).	   All	   the	   above	   mechanisms	   have	   limited	  experiment	  evidence	  except	  for	  the	  internal	  ribosome	  entry	  as	  the	  HPV16	  has	  no	  internal	  ribosome	  entry	  sites	  (IRES)	  (Stacey	  et	  al.,	  2000).	  	  	  
1.2.4	  The	  HPV	  life	  cycle	  
	  During	   transient	   infections,	   the	   HPV	   life	   cycle	   is	   controlled	   to	   limit	   the	   host	  immune	   response,	   and	   does	   not	   increase	   proliferation	   of	   the	   infected	   cells.	  However,	  persistent	  infection	  with	  HR-­‐HPVs	  results	  in	  an	  abortive	  viral	  life	  cycle,	  which	  can	  cause	  the	  infected	  cells	  to	  progress	  to	  malignancy.	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1.2.4.1	   Early	   events	   in	   the	   HPV16	   life	   cycle:	   Virion	   Binding	   and	  
Internalization	  
	  The	  initial	  events	  of	  HPV	  infection	  are	  thought	  to	  happen	  in	  the	  basal	  cells	  of	  the	  stratified	   squamous	   epithelium.	   In	   the	   normal	   epithelium,	   the	   undifferentiated	  basal	   keratinocytes	   are	   the	   only	   cells,	   which	   are	   proliferating	   and	   thus	  undergoing	  mitosis,	  a	  necessary	  feature	  to	  support	  the	  establishment	  of	  the	  viral	  infection	   in	  vivo	  (Pyeon	  et	  al.,	  2009;	  Stanley	  et	  al.,	  2007).	  Recent	  studies	  carried	  out	  using	  animal	  models	   showed	   that	  HPV	   infection	  requires	  gentle	  abrasion	  of	  the	  genital	  epithelium	  (Roberts	  et	  al.,	  2007).	  Further	  investigations	  demonstrated	  that	   these	  abrasions	  exposed	   the	  basement	  membrane	  of	   the	  epithelium,	  where	  initial	   attachment	   of	   virions	   occurs.	   The	   binding	   of	   virions	   to	   the	   basement	  membrane	   is	   followed	  by	  binding	  and	   internalization	  of	   the	  virions	   in	   the	  basal	  keratinocytes,	  as	  these	  cells	  continuously	  move	  towards	  the	  site	  of	  the	  abrasion	  in	  order	   to	   repair	   the	   damaged	   epithelium	   (Roberts	   et	   al.,	   2007).	   Therefore,	  abrasion	   of	   the	   epithelium	   allowing	   virion	   binding	   to	   basement	   membrane	  ensures	   access	   to	   the	   basal	   cells,	   which	   are	   permissive	   to	   HPV	   infection.	  Moreover,	   wound-­‐healing	   responses	   promote	   proliferation	   of	   the	   basal	  keratinocytes,	  thereby	  further	  contributing	  to	  the	  establishment	  of	  virus	  infection	  (Pyeon	  et	  al.,	  2009;	  Schiller	  et	  al.,	  2010).	  Wound-­‐healing	  stimulated	  cell	  divisions	  are,	   in	   fact,	   necessary	   for	   viral	   entry	   into	   nucleus	   and	   thus	   productive	   HPV	  infection	  (Pyeon	  et	  al.,	  2009).	  The	  initial	  binding	  of	  the	  major	  capsid	  protein,	  L1,	  to	  the	  basement	  membrane	  is	  mediated	   through	   interactions	  with	  heparin	   sulphate	  proteoglycans	   exposed	  by	  injury	   to	   the	   epithelium	   (Johnson	   et	   al.,	   2009).	   Binding	   to	   the	   basement	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membrane	   triggers	   a	   conformational	   change	   in	   L1,	   which	   allows	   for	   furin	  cleavage	   of	   the	   L2	  minor	   capsid	   protein	   at	   the	   N-­‐terminus,	   thereby	   exposing	   a	  portion	  of	  the	  L1	  that	  was	  previously	  hidden.	  Exposure	  of	  this	  hidden	  epitope	  of	  L1	   by	   furin	   cleavage	   of	   L2	   is	   required	   for	   binding	   to	   the	   basal	   keratinocytes	  (Schiller	   et	   al.,	   2010).	   Internalization	   of	   virions	   of	   many	   HPV	   types	   including	  HPV16	  was	  originally	  suggested	  to	  occur	  through	  clathrin-­‐dependent	  endocytosis	  (Schiller	   et	   al.,	   2010).	   However,	   more	   recent	   data	   suggests	   that	   HPV16	  internalization	  is	  clathrin-­‐independent	  and	  instead	  requires	  tetraspanin-­‐enriched	  microdomains	   (Spoden	   et	   al.,	   2008).	   Furthermore,	   internalization	   mechanisms	  among	  HPV	  types	  does	  not	  appear	  to	  be	  conserved,	  as	  HPV31	  virions	  have	  been	  shown	  to	  enter	  via	  caveolin-­‐dependent	  endocytosis	  (Smith	  et	  al.,	  2008).	  All	  HPV	  types,	   however,	   require	   transit	   through	   low-­‐pH	   compartments	   such	   as	   late	  endosomes	  and	  lysosomes,	  where	  uncoating	  occurs	  prior	  to	  transport	  of	  the	  viral	  genome	  to	  the	  nucleus	  via	  microtubules	  (Kamper	  et	  al.,	  2006).	  	  
1.2.4.2	  Control	  of	  viral	  genome	  expression	  in	  productive	  infections	  	  Upon	   successful	   entry,	   the	   L1	   capsid	   protein	   remains	   in	   late	   endosomal/	  lysosomal	  compartments	  and	  the	  L2/DNA	  complex	  enters	  the	  host	  cell’s	  nucleus,	  a	  process	  which	  requires	  mitosis	  (Day	  et	  al.,	  2003;	  Pyeon	  et	  al.,	  2009).	  The	  viral	  genome	   is	   then	   established	   as	   an	   episome	   in	   the	   host	   nucleus	   (Schiller	   et	   al.,	  2010).	   As	   discussed	   above,	   the	   HPV	   life	   cycle	   is	   tightly	   linked	   to	   the	  differentiation	  state	  of	  the	  host	  cells,	  whereby	  infection	  of	  basal	  keratinocytes	  is	  followed	  by	  timely	  controlled	  expression	  of	  viral	  genes	  throughout	  the	  thickness	  of	   the	   epithelium	   (Figure	   1.6).	   During	   the	   initial	   phase	   of	   infection,	   the	   viral	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genome	  is	  replicated	  to	  around	  200	  copies	  (De	  Geest	  et	  al.,	  1993;	  Doorbar	  et	  al.,	  2012).	   Expression	   of	   E1	   and	   E2	   from	   the	   early	   promoter	   facilitates	   the	   initial	  replication	   of	   the	   virus.	   The	  E1	   protein	   serves	   as	   a	   viral	   helicase	   and	   is	   loaded	  onto	  the	  origin	  of	  replication	  by	  the	  E2	  protein	  (Masterson	  et	  al.,	  1998).	  E2	  also	  attaches	  viral	  episomes	  to	  mitotic	  chromosomes,	  leading	  to	  correct	  viral	  genome	  segregation	  during	  mitosis	  (You	  et	  al.,	  2004).	  In	   the	   uninfected	   epithelium,	   basal	   cells	   proliferate	   actively	   pushing	   daughter	  cells	  upwards	   to	   the	  suprabasal	   layers.	  Upon	  reaching	   the	  differentiating	  strata,	  these	  cells	  exit	  the	  cell	  cycle	  and	  initiate	  terminal	  differentiation.	  In	  a	  productive	  HPV	   infection,	   viral	   gene	   expression	   is	   tightly	   regulated	   and	   low	   copies	   of	   viral	  DNA	  are	  produced	  alongside	  the	  host	  DNA	  during	  basal	  cell	  divisions.	  Following	  the	  movement	  of	  the	  proliferating	  basal	  and	  suprabasal	  cells	  to	  the	  differentiating	  strata,	  viral	  gene	  expression	  from	  the	  early	  P97	  promoter	  is	  up-­‐regulated	  (Stanley	  et	  al.,	  2007).	  Importantly,	  expression	  of	  the	  two	  viral	  oncogenes	  E6	  and	  E7	  from	  the	   early	   P97	   promoter	   extends	   the	   S-­‐phase	   of	   the	   cycling	   cells	   thereby	  prolonging	   cell	   cycle	   arrest	   and	   terminal	   differentiation	   (Cheng	   et	   al.,	   1995;	  Middleton	   et	   al.,	   2003).	   Once	   the	   infected	   cells	   reach	   the	   upper	   layer	   of	   the	  epithelium,	   the	   late	   P670	   promoter	   is	   up-­‐regulated	   and	   the	   cells	   undergo	  differentiation.	  The	  up-­‐regulation	  of	  the	  late	  P670	  promoter	  allows	  expression	  of	  structural	   viral	   genes	   L1	   and	   L2	   as	   well	   as	   further	   amplification	   of	   the	   viral	  genome	  to	  around	  1000	  copies	  per	  cell	  (Hebner	  and	  Laimins,	  2006;	  Stanley	  et	  al.,	  2007).	   The	   viruses	   are	   packaged	  with	   the	   newly	   formed	   capsid	   proteins	   in	   the	  upper	   layer	   of	   the	   differentiating	   epithelium,	   which	   naturally	   sloughs	   off,	  releasing	  fully	  functional	  virions	  without	  cytolysis.	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Figure	   1.6.	   HPV16	   gene	   expression	   pattern	   during	   productive	   infection.	  
(Adapted	   from	   Doorbar	   2006).	   Viruses	   gain	   access	   to	   the	   basal	   layer	   of	   the	  epithelium	   through	   a	   micro-­‐wound.	   As	   the	   HPV	   infected	   cells	   divide	   they	   are	  pushed	  up	  into	  the	  suprabasal	  layers	  where	  the	  terminal	  differentiation	  program	  begins	  The	  HPV-­‐16	  p97	  early	  promoter	  activation	  results	  in	  the	  expression	  of	  the	  E1	  and	  E2	  replication	  proteins	  as	  well	  as	  the	  E6	  and	  E7	  oncogenes	  (cells	  with	  red	  nuclei/arrow).	  The	  E7	  oncogene	  is	  necessary	  for	  S-­‐phase	  entry.	  In	  addition	  to	  E1	  and	  E2,	   E6	   and	  E7	   are	   necessary	   for	   episomal	   replication.	   As	   the	   keratinocytes	  differentiate,	   the	   (late)	   promoter	   p670	   is	   upregulated.	   This	   leads	   to	   increased	  levels	  of	  E1,	  E2,	  E5	  and	  E4	  (green	  cells/arrows).	  The	  start	  of	  late	  gene	  expression	  also	  coincides	  with	  a	  brief	  overlap	  of	  early	  genes	  and	  late	  genes.	  Cells	  that	  contain	  both	  (early)	  E7	  and	  (late)	  E4	  are	  thought	  to	  be	  the	  site	  of	  viral	  DNA	  amplification	  (blue	  nuclei).	  	  In	  the	  upper-­‐layer	  cells	  the	  early	  genes	  are	  no	  longer	  expressed	  and	  high	   levels	   of	   E4	   are	   expressed	   from	   the	   late	   promoter.	   A	   large	   number	   of	   E4	  positive	   cells	   also	   contain	  amplified	  genomes	   (green	  cells	  with	  blue	  nuclei)	   and	  later	   L1/L2	   capsid	   proteins	   (green	   cells	  with	   yellow	  dots).	  Mature	   capsids	   that	  contain	  amplified	  genomes	  (yellow	  dots)	  are	  released	  as	  cells	  are	  shed	  from	  the	  top	  layers.	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1.2.4.3.	  The	  functions	  of	  the	  viral	  proteins	  E1	  and	  E2	  	  The	   major	   role	   of	   E1	   and	   E2	   proteins	   is	   in	   HPV	   genome	   replication	   and	  transcription.	  In	  particular,	  E2	  facilitates	  the	  docking	  of	  viral	  episomes	  to	  mitotic	  chromosomes,	  ensuring	  stable	  maintenance	  of	  viral	  copies	  in	  replicating	  cells.	  E1,	  an	  ATP-­‐dependent	  helicase,	  and	  E2	  act	  together	  to	  assemble	  the	  viral	  replication	  complex	  with	  host	  replication	  machinery	  at	  the	  origin	  of	  replication	  (Boyer	  et	  al.,	  1996;	  Cripe	  et	  al.,	  1987;	  Hebner	  and	  Laimins,	  2006).	  	  E2	  also	  acts	  as	  a	  transcription	  factor	  as	  well	  as	  a	  repressor,	  as	  it	  binds	  to	  specific	  palindromic	  sequences	   (ACCN6GGT)	  within	   the	  viral	  genome	  and	  regulates	  HPV	  gene	  transcription.	  In	  HR-­‐HPVs,	  three	  E2	  binding	  sites	  are	  located	  near	  the	  origin	  of	  replication	  in	  the	  LCR,	  and	  a	  fourth	  is	  situated	  in	  the	  proximity	  of	  the	  L1	  ORF	  (Hebner	  and	  Laimins,	  2006).	  E2	  binding	  at	  these	  sites	  has	  either	  a	  repressive	  or	  a	  stimulative	  effect	  on	  viral	  gene	  transcription	  depending	  on	  the	  HR-­‐HPV	  type	  and	  E2	  concentration.	  This	  is	  caused	  by	  the	  misplacement	  of	  two	  transcription	  factors,	  SP1	   and	   TFIID	   (Bechtold	   et	   al.,	   2003;	   Hamid	   et	   al.,	   2009).	   Recent	   evidence	  suggests	   that	   E2	  might	   have	   a	   role	   in	   enhancing	   the	   viral	   transcription	   of	   late	  genes	   by	   inhibiting	   early	   polyadenylation	   (Johansson	   et	   al.,	   2012).	   Importantly,	  E2	   regulates	   the	   transcription	   of	   host	   cancer-­‐associated	   genes	   hTERT	   and	   p21	  (Lee	  et	  al.,	  2002b;	  Steger	  et	  al.,	  2002).	  Because	  of	  these	  characteristics,	  the	  roles	  of	   E2	   are	   considered	   critical	   in	   regulating	   viral	   gene	   expression	   and	   neoplastic	  progression.	  	  HPV16	  E2	  promotes	  virus	  replication,	  as	  it	  recruits	  the	  helicase	  protein	  E1	  (Berg	  and	  Stenlund,	  1997).	  E1	  serves	  as	   the	  viral	  helicase,	  which	   is	   transferred	   to	   the	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origin	  of	  replication	  by	  the	  E2	  protein	  (Hughes	  and	  Romanos,	  1993;	  Masterson	  et	  al.,	  1998).	  	  
	  
1.2.4.4	  The	  functions	  of	  the	  viral	  protein	  E1^E4	  
	  The	  E1^E4	  protein,	  commonly	  referred	  as	  E4	  protein,	  is	  the	  most	  abundant	  HPV	  protein	  expressed	  in	  the	  normal	  HPV	  life	  cycle.	  E1^E4	  gene	  expression	  is	  limited	  in	   the	  undifferentiated	  basal	   cells	   and	   increases	   as	   cells	   differentiate.	   The	  main	  role	  of	  E1^E4	  is	  to	  facilitate	  virion	  release	  through	  interference	  with	  cytokeratin	  networks	  (Khan	  et	  al.,	  2011;	  McIntosh	  et	  al.,	  2010).	  Another	  function	  of	  E1^E4	  is	  to	   induce	   G2	   arrest,	  which	  may	   collaborate	  with	   E7	   to	   allow	   for	  more	   efficient	  viral	  replication	  before	  the	  cells	  enter	  the	  M	  phase	  (Chow	  et	  al.,	  2009;	  Davy	  et	  al.,	  2002).	  	  
1.2.4.5.	  The	  functions	  of	  the	  viral	  protein	  E8^E2	  	  	  The	   E8^E2	   protein	   is	   produced	   from	   splicing	   of	   the	   E8	   transcript	   to	   the	   E2	  transcript.	   Presently,	   only	   HPV16	   and	   HPV31	   are	   known	   to	   transcribe	   this	  protein.	  E8^E2	   is	   important	   for	  viral	  episome	  maintenance	   in	  HPV31	  and	   it	  has	  repressive	   effects	   on	   viral	   transcription	   and	   replication	   in	   both	   HPV16	   and	  HPV31	   (Lace	   et	   al.,	   2008;	   Stubenrauch	   et	   al.,	   2000).	   Interestingly,	   E8^E2	  transcription	   is	   unique,	   as	   it	   does	   not	   require	   activation	   of	   the	   early	   P97	  promoter.	  Rather,	  E8^E2	  transcription	  is	  regulated	  by	  conserved	  cis	  elements	  in	  the	  LCR	  (Lace	  et	  al.,	  2008).	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1.2.4.6.	  The	  functions	  of	  the	  viral	  protein	  E5	  
	  The	  HR-­‐HPV	  E5	  protein	  primarily	  functions	  as	  a	  mild	  oncogene.	  E5	  can	  contribute	  to	   cellular	   transformation,	   modulate	   the	   levels	   of	   growth	   factor	   receptors	   and	  alter	  the	  immune	  response	  in	  the	  proximity	  of	  infected	  cells	  (Venuti	  et	  al.,	  2011).	  As	   the	   E5	   gene	   is	   frequently	   deleted	   upon	  HPV	   genome	   integration	   during	   late	  progression	   to	  malignant	   disease,	   it	   is	   thought	   to	   play	   a	   role	   only	   in	   the	   early	  stages	   of	   carcinogenesis	   (Kim	   et	   al.,	   2010).	   Recent	   data,	   however,	   indicates	   E5	  expression	   during	   cervical	   neoplastic	   progression	   is	   more	   common	   and	   may	  contribute	  to	  cervical	  carcinogenesis	  (Chang	  et	  al.,	  2001;	  Lorenzon	  et	  al.,	  2011).	  	  	  Due	   to	   its	   hydrophobic	   characteristics,	   the	   E5	   protein	   associates	   with	   cellular	  membranes,	   including	   the	   Golgi,	   endoplasmic	   reticulum	   (ER),	   and	   endosome	  membranes	   (Hu	   and	   Ceresa,	   2009).	   It	   performs	   its	   transforming	   effect	   mainly	  through	  interaction	  with	  the	  Epidermal	  Growth	  Factor	  Receptor	  (EGFR)	  signaling	  pathway	  (Genther	  Williams	  et	  al.,	  2005;	  Straight	  et	  al.,	  1993).	  Activation	  of	  EGFR	  regulates	  host	  gene	  transcription	  and	  modulates	  several	  biological	  processes	  such	  as	   cell	   proliferation,	   apoptosis,	   angiogenesis,	   tumour	   invasion	   and	   metastasis	  through	  the	  Ras-­‐Raf-­‐Map	  kinase	  pathway	  and	  the	  PI3-­‐Akt	  pathway	  (Crusius	  et	  al.,	  2000).	   E5	   increases	   the	   number	   of	   EGFR	  molecules	   present	   on	   the	   cell	   surface	  through	  binding	  and	  inhibition	  of	  vacuolar	  ATPase,	  which	  is	  necessary	  for	  EGFR	  degradation	   (DiMaio	   and	   Mattoon,	   2001).	   Plasma	   membrane-­‐associated	   E5	  proteins	  exhibit	  weak	  oncogenic	  properties	  by	  further	   increasing	  the	  number	  of	  EGFR	   molecules	   on	   the	   cell	   surface	   and	   by	   inhibiting	   the	   expression	   of	   Major	  Histocompatibility	  Complex	  class	  I	  and	  II	  (MHC-­‐I	  and	  MHC-­‐II)	  (Venuti	  et	  al.,	  2011;	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zur	   Hausen,	   2002).	   A	   number	   of	   E5	   functions	   can	   be	   related	   to	   the	   specific	  membrane	   locations:	   ER-­‐localised	   E5	   inhibits	   endosomal	   acidification	   (Disbrow	  et	  al.,	  2005)	  and	  possibly	   is	   involved	   in	  altering	   the	   trafficking	  of	  growth	   factor	  receptors	  as	  well	  as	  molecules	   involved	  in	   immune	  control	  (Venuti	  et	  al.,	  2011).	  HPV16	  E5	  has	  recently	  been	  described	  as	  an	  oligomeric	  channel-­‐forming	  protein	  with	   viro-­‐porin	   functions	   in	   vitro,	  which	   makes	   it	   a	   potential	   target	   for	   future	  drug	   treatments	   (Wetherill	   et	   al.,	   2012).	   Lastly,	   E5	   has	   recently	   been	   shown	   to	  cause	  cell-­‐cell	   fusion	  and	  to	   inhibit	   the	   induction	  of	  apoptosis	   in	  vitro	   (Lagunas-­‐Martinez	  et	  al.,	  2010).	  	  
1.2.4.7.	  The	  functions	  of	  the	  viral	  proteins	  E6	  and	  E7	  
	  The	  E6	  and	  E7	  proteins	  of	  HR-­‐HPV	  types	  have	  major	  roles	  in	  immortalization	  of	  human	   keratinocytes	   in	   vitro	   and	   are	   required	   for	   carcinogenesis	   in	   vivo	  (Doorbar,	   2006).	   Deregulated	   expression	   of	   E6	   and	   E7	   oncogenes	   in	   basal	   and	  parabasal	   cells	   initiates	   transformation,	   and	   in	   fact,	   immunization	   of	  mice	  with	  recombinant	   E7	   proteins	   results	   in	   regression	   of	   HPV16-­‐associated	   neoplastic	  lesions	   through	   generation	   of	   E7	   antibodies	   (Gerard	   et	   al.,	   2001).	   High-­‐risk	   E6	  and	  E7	  proteins	  drive	  proliferation	  of	  infected	  non-­‐cycling	  cells	  primarily	  through	  inactivation	  of	  p53	  and	  retinoblastoma	  (pRb)	   tumour	  suppressors,	   respectively,	  thereby	  interfering	  with	  cell-­‐cycle	  checkpoints	  and	  cell	  death	  signals.	  The	  E6	  and	  E7	  proteins	  together	  are	  critical	   for	  the	  viral	   life	  cycle	  as	  they	  force	  the	  infected	  cells	  to	  remain	  in	  a	  replication-­‐competent	  state,	  and	  control	  cell-­‐death	  pathways	  to	  favour	  viral	  persistence.	  However,	  when	  high-­‐risk	  E6	  and	  E7	  gene	  expression	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is	   not	   controlled,	   their	   dramatic	   effects	   on	   cellular	   homeostasis	   often	   lead	   to	  deleterious	  transformation	  events	  (Doorbar	  et	  al.,	  2012).	  	  	  The	  main	   difference	   in	   transforming	   capacity	   between	   low-­‐	   and	   high-­‐risk	   HPV	  types	   lies	   in	   the	   features	   of	   E6	   and	   E7.	   For	   example,	   one	   important	   way	   E6	  contributes	   to	   transformation	   is	   through	   interaction	   with	   proteins	   containing	  PDZ-­‐binding	  motifs.	  While	  high-­‐risk	  E6	  proteins	  bind	  PDZ	  motifs	  very	  efficiently,	  the	  low-­‐risk	  E6	  proteins	  have	  only	  a	  weak	  affinity	  for	  the	  PDZ	  motifs,	  and	  thus	  do	  not	   have	   a	   significant	   effect	   on	   the	  proteins	   containing	   them.	   In	   the	   case	   of	   E7,	  high-­‐risk	  E7	  proteins	  have	  a	  high	  affinity	   for	  Rb	  pocket	  proteins,	  and	  binding	  to	  these	   proteins	   results	   in	   activation	   of	   E2F-­‐driven	   gene	   expression	   and	   cell	  proliferation.	  The	   low-­‐risk	  E7	  proteins,	  however,	  have	  a	  much	   lower	  affinity	   for	  pocket	   proteins	   and	   therefore	   do	   not	   significantly	   induce	   expression	   of	   E2F-­‐driven	  genes	  and	  cell	  proliferation	  (Oh	  et	  al.,	  2004).	  	  	  The	  High-­‐risk	  E6	  protein	  weighs	  18kDa	  and	  contains	  two	  zinc	   finger-­‐like	  motifs	  (Cole	   and	   Danos,	   1987).	   Specific	   mass	   spectrometry-­‐based	   studies	   have	   been	  used	  to	  identify	  the	  interactions	  between	  human	  papillomavirus	  and	  host	  cellular	  proteins.	   These	   studies	   reported	   153	   cellular	   proteins,	   including	   several	  previously	   reported	   HPV	   E6	   interactors	   such	   as	   p53,	   E6AP,	   MAML1,	   and	  p300/CBP	  and	  proteins	  containing	  PDZ	  domains	  (White	  et	  al.,	  2012).	  	  Thus,	   E6	   interacts	   with	   a	   wide	   range	   of	   host	   proteins	   that	   are	   involved	   in	   1)	  transcription	   and	   DNA	   replication;	   2)	   apoptosis	   and	   immune	   evasion;	   3)	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epithelial	   organization	   and	   differentiation;	   4)	   cell-­‐cell	   adhesion,	   polarity	   and	  proliferation	  control;	  and	  5)	  DNA	  repair.	  	  Many	   of	   these	   interactions	   occur	   through	   PDZ-­‐binding	   motifs	   within	   the	   host	  proteins,	   of	   which	   high-­‐risk	   E6	   proteins	   efficiently	   bind.	   One	   of	   the	   most	  important	   functions	   of	   high-­‐risk	   E6	   in	   cellular	   transformation	   is	   its	   ability	   to	  interfere	  with	  the	  tumour	  suppressor	  p53	  in	  order	  to	  prevent	  cell	  cycle	  arrest	  and	  apoptosis.	   High-­‐risk	   E6	   interferes	   with	   p53	   in	   several	   different	   ways.	   First,	   it	  forms	   a	   complex	   with	   the	   cellular	   ubiquitin	   ligase	   E6AP	   to	   target	   p53	   for	  proteasomal	   degradation	   (Tomaic	   et	   al.,	   2009).	  However,	   E6	   also	  mediates	   p53	  degradation	   via	   a	   ubiquitin-­‐independent	   mechanism	   (Camus	   et	   al.,	   2007).	  Furthermore,	  E6	  acts	  as	  a	  repressor	  of	  p53	  transcription	  through	  inactivation	  of	  the	  transcriptional	  coactivator	  hADA3	  (Kumar	  et	  al.,	  2002).	  Aside	  from	  interfering	  with	   p53,	   another	   important	   function	   of	   high-­‐risk	   E6	   proteins	   is	   to	   induce	  telomerase	  activity	  by	  inducing	  hTERT	  expression	  (Yugawa	  and	  Kiyono,	  2009).	  It	  does	   this	   through	   ubiquitination	   of	   the	   hTERT	   repressor	   NFX1-­‐91	   (Xu	   et	   al.,	  2008),	   and	   transactivation	   of	   the	   hTERT	   promoter	   in	   an	   E6,	   E6AP	   and	   c-­‐myc	  complex	  (Katzenellenbogen	  et	  al.,	  2009;	  Liu	  et	  al.,	  2005;	  Veldman	  et	  al.,	  2003).	  	  	  The	   high-­‐risk	   E7	   protein	   has	   a	   molecular	   weight	   of	   approximately	   19kDa,	   and	  consists	   of	   three	   regions:	  CR1,	  CR2	  and	  CR3	   (Barbosa	   et	   al.,	   1990;	  Dyson	  et	   al.,	  1992).	  The	  primary	  function	  of	  E7	  is	  to	  drive	  cells	  into	  S-­‐phase	  in	  order	  to	  enable	  viral	   DNA	   replication	   and	   transcription.	   While	   E7	   interferes	   with	   several	   host	  proteins	  involved	  in	  cell	  cycle	  regulation,	  one	  of	  its	  most	  important	  functions	  is	  to	  interfere	   with	   the	   pRB	   tumour	   suppressor.	   pRB	   is	   a	   pocket	   protein	   which
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interacts	  with	  and	   sequesters	  E2F	   transcription	   factors,	   thereby	   inhibiting	  E2F-­‐driven	  genes,	  of	  which	  many	  have	   important	   roles	   in	  cell	   cycle	  progression	  and	  proliferation	   (Zerfass	   et	   al.,	   1995).	   Similar	   to	   E6’s	   multifaceted	   approach	   to	  interfere	  with	  p53,	   E7	   interferes	  with	  pRB	   in	  multiple	  ways.	   First,	   the	  CR1	  and	  CR2	  regions	  of	  E7	  bind	  directly	  to	  pRB	  resulting	  in	  release	  of	  E2F	  and	  subsequent	  activation	  of	  E2F-­‐driven	  gene	   transcription.	   Interaction	  of	   the	  CR1	  domain	  with	  pRB	   also	   results	   in	   proteasome-­‐dependent	   degradation	   of	   pRB	   (Hebner	   and	  Laimins,	   2006).	   Finally,	   it	   has	   been	   suggested	   that	   E7	   interacts	   with	   cyclins	   to	  promote	  cyclin	  A	  and	  cyclin	  E	  complex	  formation	  with	  Cyclin-­‐dependent	  kinase-­‐2	  (CDK2),	  which	  facilitate	  phosphorylation	  and	  subsequent	  degradation	  of	  pRB	  (He	  et	  al.,	  2003).	  	  	  	  Aside	   from	   interfering	  with	  pRB,	  E7	  also	  binds	   the	  other	  pocket	  proteins,	  p107	  and	   p130,	   and	   targets	   them	   for	   degradation.	   Similar	   to	   pRB,	   these	   proteins	  sequester	   and	   thus	   inhibit	   E2F	   transcription	   factors,	   however	   they	   are	   also	  inhibitors	  of	  CDK2/cyclin	  A	  and	  CDK2/cyclin	  E	  complex	  formation.	  Therefore,	  by	  interfering	  with	  pocket	  proteins	  p107	  and	  p130,	  E2F-­‐driven	  gene	   expression	   is	  further	   induced	  by	  release	  from	  p107	  and	  p130,	  as	  well	  as	  by	  release	  from	  pRB	  upon	   cyclin-­‐dependent	   phosphorylation	   and	   degradation	   (Barrow-­‐Laing	   et	   al.,	  2010).	   E7’s	   ability	   to	   interfere	   with	   pRB	   function	   both	   directly	   and	   indirectly	  results	   in	   release	   of	   E2F	   transcription	   factors,	   thereby	   driving	   cell	   cycle	  progression	  through	  the	  S-­‐phase.	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The	  low-­‐risk	  E7	  has	  lower	  affinity	  for	  p105	  and	  p107	  but	  can	  interact	  with	  p130	  in	   the	   supra-­‐basal	   layers	   of	   the	   epithelia	   sustaining	   cell	   cycle	  maintenance	   and	  creating	   the	   condition	   for	   viral	   genome	   amplification	   (Klingelhutz	   and	   Roman,	  2012).	  
	  
1.2.4.8.	  The	  functions	  of	  the	  viral	  proteins	  L1	  and	  L2	  
	  The	  viral	   life	  cycle	   is	  completed	  in	  the	  upper	  layers	  of	  the	  epithelium	  where	  the	  structural	  proteins	  L1	  and	  L2	  are	  uniquely	  expressed	  (Ozbun	  and	  Meyers,	  1997).	  L1	  and	  L2	  proteins	   form	  the	  shell	  of	   the	  new	  virions	  by	  self-­‐assembling	   into	  an	  icosahedral	  capsid	  comprised	  of	  72-­‐capsomeres	  of	   five	  L1	  molecules	  per	  one	  L2	  molecule	  (Belnap	  et	  al.,	  1996;	  Chen	  et	  al.,	  2000).	  The	  assembled	  mature	  capsids	  are	   incredibly	   stable	   and	   resistant	   to	   proteolysis	   (Buck	   et	   al.,	   2005).	   Newly	  formed	  virions	  are	  released	  from	  the	  uppermost	  layers	  of	  the	  epithelium	  as	  cells	  naturally	  exfoliate.	  
	  
1.3	  Oncogene	  deregulation	  in	  high-­‐risk	  HPVs	  
	  As	   mentioned	   in	   sections	   1.1.3	   and	   1.2.4.1,	   high-­‐risk	   HPV	   infections	   can	   cause	  lesions	  ranging	  from	  low-­‐	  to	  high-­‐grade	  neoplasia,	  also	  classified	  as	  LSIL	  and	  HSIL	  (Figure	   1.6).	   The	   main	   reason	   for	   progression	   to	   high-­‐grade	   neoplasia	   is	   the	  continue	   persistence	   of	   high-­‐risk	   HPVs	   that	   are	   not	   cleared	   by	   the	   immune	  system.	   Low-­‐risk	  HPVs,	   instead,	   cause	   essentially	   benign	   lesions,	   and,	   except	   in	  rare	   cases,	   are	   not	   associated	   with	   invasive	   tumours.	   As	   discussed	   earlier,	   the	  main	  reason	  relies	  on	  the	  different	  effects	  that	  the	  early	  proteins	  E6	  and	  E7	  exert	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on	   infected	   cells:	   with	   high-­‐risk	   E6	   and	   E7	   featuring	   the	   greater	   transforming	  capacity	  (Figure	  1.7)	  (Pim	  and	  Banks,	  2010).	  In	  tissues	  infected	  by	  HR-­‐HPVs	  the	  mechanism	  that	  leads	  to	  cancer	  starts	  with	  the	  deregulation	   of	   the	   E6	   and	   E7	   expression.	   The	   deregulation	   of	   the	   early	  oncogenes	   causes	   the	   maintenance	   of	   the	   cell	   cycling	   state	   that	   in	   the	   HSIL	  classified	  lesions	  involves	  the	  whole	  thickness	  of	  the	  epithelium.	  When	  infections	  are	  not	  cleared	  by	  the	  immune	  system,	  the	  increased	  cell	  cycling	  activity	  leads	  to	  a	   continuous	   auto-­‐selective	   competitive	   state,	   where	   infected	   keratinocytes	  actively	   select	   their	   polyclonal	   populations.	   The	   keratinocyte	   outgrowth	  mechanism	  of	  selection	  selects	  for	  clones	  with	  specific	  characteristics	  resulting	  in	  a	   monoclonal	   cancerous	   population	   (Dall	   et	   al.,	   2008;	   Doorbar	   et	   al.,	   2012;	  Isaacson	   Wechsler	   et	   al.,	   2012).	   The	   deregulated	   expression	   of	   E6	   and	   E7	   is	  thought	  to	  play	  a	  critical	  role	  in	  the	  malignant	  progression;	  it	  was	  in	  fact	  shown	  that	  their	  expression	  quantitatively	  increases	  in	  the	  compartment	  addressed	  to	  a	  more	  invasive	  cell	  phenotype	  both	   in	  vivo	  (Durst	  et	  al.,	  1992;	  Stoler	  et	  al.,	  1992)	  and	  in	  vitro	  (Gray	  et	  al.,	  2010;	  Isaacson	  Wechsler	  et	  al.,	  2012).	  Thus,	  deregulated	  expression	  of	  early	  oncogenes	  in	  HR-­‐HPVs	  infections	  are	  of	  considerable	  interest	  in	  the	  study	  of	  the	  mechanisms	  for	  infections	  management	  and	  control.	  	  To	   date,	   the	   events	   that	   lead	   to	   a	   deregulated	   expression	   of	   E6	   and	  E7	   are	   not	  fully	  understood.	  HR-­‐HPVs	  early	  gene	  deregulation	  can	   follow	   two	  main	   routes.	  The	  most	  common	  of	   the	   two	  potential	  mechanisms	  relies	  on	   the	   integration	  of	  the	  LCR,	  E6	  and	  E7	  parts	  of	  the	  viral	  genome	  in	  the	  host	  DNA,	  which	  is	  estimated	  to	  occur	  in	  85%	  of	  cervical	  cancers	  (Choo	  et	  al.,	  1987;	  Klaes	  et	  al.,	  1999).	  E6	  and	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E7	   expression	   from	   integrated	   genome,	   however,	   can	   be	   repressed	   by	   E2	  expressed	   from	   episomes.	   However,	   until	   the	   episomes	   are	   completely	   lost	   the	  effects	  of	  integrated	  E6	  an	  E7	  are	  not	  at	  their	  best.	  Thus,	  episome	  loss,	  E6	  and	  E7	  integration	  confer	  advantageous	  growth	  characteristics	  to	  the	  infected	  cells	  (Dall	  et	  al.,	  2008).	  Another	  mechanism	  by	  which	  E6	  and	  E7	  can	  be	  deregulated	  is	  by	  maintaining	  the	  integrity	  of	  the	  physical	  state	  of	  the	  viral	  episomal	  genome.	  In	  fact,	  it	  is	  estimated	  that	   at	   least	   15%	  of	   the	   cervical	   cancers	   still	   retain	   viral	   genomes	   as	   episomes	  (Klaes	  et	  al.,	  1999).	  Furthermore,	  it	  was	  shown	  that	  episomal	  HPVs	  were	  able	  to	  cause	   serious	   disease,	   such	   as	   head	   and	   neck	   cell	   squamous	   cancers	   (HNSCCs),	  underlining	  the	  possibility	  that	  E6	  and	  E7	  deregulation	  can	  happen	  in	  regions	  of	  the	   infected	   epithelium	   not	   containing	   integrants	   (Joseph	   and	   D'Souza,	   2012;	  Theelen	  et	  al.,	  2010).	  The	  exact	  mechanism	  behind	  the	  deregulation	  of	  E6	  and	  E7	  has	   not	   been	   completely	   elucidated.	   It	   is	   suggested	   that	   changes	   in	   acetylation	  status	   of	   the	   viral	   chromatin	   may	   cause	   expression	   instability	   and	   oncogene	  deregulation.	   Furthermore,	   in	   vitro	   studies	   have	   shown	   that	   differential	  expression	   of	   E6	   and	   E7	   oncogenes	   causes	   a	   broad	   range	   of	   cell	   phenotypes,	  ranging	   from	   LSIL	   to	   HSIL,	   in	   HR-­‐HPVs	   episome-­‐containing	   cell	   lines	   (Isaacson	  Wechsler	  et	  al.,	  2012).	  The	  maintenance	  of	  the	  episomal	  physical	  state	  requires	  immune	  system	  escape.	  As	   stated	   earlier	  E6	   and	  E7	  oncogenes	   are	   able	   to	   interfere	  with	   the	   interferon	  (INF)	   pathway,	   which	   is	   sustained	   by	   evidence	   from	   studies	   on	   episome-­‐contained	  neoplastic	  progression	  model	  systems	  (Gray	  et	  al.,	  2010).	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Figure	   1.7	  HPV	   expression	   patterns	   during	   neoplastic	   progression.	  The	  E6	  and	   E7	   oncogenes	   are	   expressed	   in	   the	   suprabasal	   and	   upper	   layers	   of	   the	  epithelium	  during	  neoplastic	  progression.	  Lesions	  classified	  as	  low-­‐grade	  present	  expression	  of	   early	  oncogenes	   limited	  at	  basal-­‐suprabasal	   layers	  of	   the	   infected	  epithelium.	  High-­‐grade	  squamous	  intraepithelial	   lesion	  (HSIL)	  present	  oncogene	  expression	   throughout	   the	   thickness	   of	   the	   epithelium.	   In	   HSIL	   lesions	   the	  keratinocytes	  are	  maintained	  in	  S-­‐Phase	  state	  by	  the	  action	  of	  oncogenes	  E6	  and	  E7	  instead	  of	  differentiating.	  Misregulation	  of	  oncogene	  expression	  causes	  lesions	  to	  persist	  for	  a	  long	  time	  and	  in	  some	  cases	  to	  progress	  to	  cancer	  (adapted	  from	  (Doorbar,	  2005).	  	  	  
1.4	  HPV	  and	  the	  Host	  Immune	  System	  
	  There	   is	  no	  evidence	  of	   an	   immune	  response	  during	  HPV	  DNA	  amplification,	   as	  the	  virus	   is	  only	  poorly	  visible	   to	   the	  host	   immune	  system,	   replicating	  with	   the	  host	   DNA	   and	   not	   causing	   any	   cytopathology	   in	   the	   host	   cells	   (Stanley,	   2004).	  Furthermore,	   during	   HPV	   infections,	   there	   is	   very	   little	   release	   of	   pro-­‐inflammatory	   cytokines	   that	   are	   important	   for	   Antigen-­‐Presenting	   Cell	   (APC)	  activation	   and	   migration	   towards	   the	   sites	   of	   infection,	   resulting	   in	   a	   lack	   of	  immune	  recognition	  response	  (Stanley	  et	  al.,	  2007).	  HPV,	  like	  other	  viruses,	  have	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developed	  mechanisms	  to	  interfere	  with	  the	  production	  of	  certain	  cytokines	  that	  are	  necessary	  for	  immune	  defense	  (Stanley	  et	  al.,	  2012).	  In	  particular,	  the	  E6	  and	  E7	   proteins	   from	  HR-­‐HPVs	   interact	   directly	  with	   components	   of	   the	   interferon	  (IFN)–signalling	  pathway	  (Barnard	  and	  McMillan,	  1999;	  Lace	  et	  al.,	  2009).	  	  	  To	   date,	   it	   is	   not	   clear	   whether	   persistent	   HPV	   infections	   with	   chronically	  reappearing	   lesions	   are	   due	   to	   exposure	   to	   new	   exogenous	   HPVs	   or	   due	   to	  reactivation	  of	  undetected	  latent	  viruses.	  HPV	  latency	  is	  not	  well	  understood,	  but	  there	  is	  evidence	  that	  lesions	  tend	  to	  reappear	  in	  treated	  areas,	  and	  reactivation	  of	   previous	   infections	   in	   immunosuppressed	   patients	   is	   very	   common	   (Penn,	  1986;	   Sillman	   et	   al.,	   1984).	   Furthermore,	   it	   has	   been	   suggested	   that	   the	   viral	  episome	   may	   persist	   for	   a	   long	   time	   in	   slow-­‐cycling	   epithelial	   cells	   without	  causing	   apparent	   disease	   (Maglennon	   and	   Doorbar,	   2012).	   These	   observations	  suggest	  that	  the	  host	   immune	  system	  is	  unable	  to	  fully	  clear	  HPV	  virions,	  which	  could	  explain	  recurrent	  lesions.	  	  Paradoxically,	   establishment	   of	   HPV	   infections	   requires	   wounding	   of	   the	  epithelium	  in	  order	   for	  virions	   to	  physically	  reach	  the	  basement	  membrane,	  yet	  any	   potential	   inflammatory	   response	   invoked	   during	   wound	   healing	   does	   not	  clear	  these	  infections.	  It	  is	  yet	  unclear	  whether	  wound	  healing	  does	  not	  induce	  a	  strong	  inflammatory	  response	  or	  whether	  HPV	  has	  evolved	  a	  mechanism	  to	  evade	  this	   response.	   Thus,	   elucidation	  of	   the	  phases	   of	  wound	  healing	   is	   necessary	   to	  understand	  the	  mechanism	  of	  lesion	  formation	  following	  HPV	  infection.	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1.5	  Wound	  healing	  process	  	  
	  In	   order	   to	   understand	   the	   environmental	   conditions	   in	   which	   HPV	   infections	  occur,	   it	   is	   useful	   to	   characterize	   the	  phases	  of	   the	  wound	  healing	  process.	  The	  primary	   purposes	   of	   the	   healing	   process	   is	   to	   fill	   the	   gap	   created	   by	   tissue	  destruction	   and	   restore	   the	   structural	   continuity	   of	   the	   injured	   parts.	   Wound	  healing	   is	   commonly	   divided	   into	   three	   phases:	   the	   inflammatory	   phase,	   the	  proliferative	  phase,	  and	  the	  remodeling	  phase.	  The	  inflammatory	  stage	  primarily	  serves	  to	  remove	  the	  injury-­‐causing	  agent	  and	  prepare	  the	  wounded	  environment	  for	   healing	   (Eming	   et	   al.,	   2007).	   During	   this	   stage	   there	   is	   a	   release	   of	   growth	  factors	   and	   cytokines,	   which	   attract	   surrounding	   fibroblasts,	   including	   basic	  fibroblast	   growth	   factors	   (bFGF),	   interleukin-­‐6	   (IL-­‐6),	   and	   transforming	   growth	  factor	  beta-­‐1	  (TGFβ-­‐1).	  	  	  The	   arrival	   of	   fibroblasts	   marks	   the	   beginning	   of	   a	   second	   phase	   of	   wound	  healing,	  the	  proliferative	  phase.	  The	  purpose	  of	  the	  proliferative	  phase	  is	  to	  build	  new	  tissue	  to	  fill	  the	  wound	  space.	  The	  recruited	  fibroblasts,	  which	  are	  connective	  tissue	  cells,	  synthesize	  and	  secrete	  collagen.	  They	  also	  secrete	  growth	  factors	  that	  induce	   the	  growth	  of	  blood	  vessels	   in	  a	  process	  called	  angiogenesis,	  which	   then	  promotes	   endothelial	   cell	   proliferation	   and	   migration.	   The	   fibroblasts	   and	  endothelial	  cells	  together	  form	  granulation	  tissue	  that	  serves	  as	  a	  foundation	  for	  scar	   tissue	   development.	   The	   final	   process	   of	   the	   proliferative	   stage	   is	  epithelialization,	   which	   involves	   regeneration,	   migration,	   proliferation	   and	  differentiation	   of	   epithelial	   cells	   at	   the	   wound’s	   edge	   in	   order	   to	   form	   a	   new	  surface	  area	  similar	  to	  that	  destroyed	  by	  the	  injury.	  By	  the	  end	  of	  the	  proliferative	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phase,	  white	  blood	  cells	  leave	  the	  wound	  site	  and	  the	  newly	  formed	  small	  blood	  vessels	  eventually	  degenerate.	  	  	  The	   third	   phase	   of	   wound	   healing	   is	   the	   remodeling	   phase,	   which	   begins	   at	  variable	   times,	   typically	   weeks	   after	   the	   injury,	   continues	   for	   six	   months	   or	  longer.	   During	   this	   final	   stage,	   scar	   tissue	   is	   formed	   by	   simultaneous	   synthesis	  and	   lysis	   of	   collagen.	   At	   this	   stage	   the	   scar	   tissue	   becomes	   avascular	   and	  may	  achieve	  70-­‐80%	  of	  tensile	  strength	  after	  three	  months	  (Clark	  et	  al.,	  1996;	  Werner	  et	  al.,	  2007).	  	  
1.5.1	  Establishment	  of	  HPV	  Infection	  During	  Tissue	  Injury	  	  HPVs	  require	  wounding	  of	  the	  epithelium	  in	  order	  to	  expose	  basal	  cells	  for	  virus	  entry.	  Generally,	   a	  micro-­‐trauma	  exfoliates	   the	  primary	   layer	   of	   the	   epithelium,	  exposing	   the	   basal	   cells	   and	   basement	   membrane	   without	   causing	   a	   strong	  inflammatory	  or	   immune	  response	  (Kines	  et	  al.,	  2009).	  Thus,	   it	   is	  plausible	   that	  HPV	   infection	   and	   viral	   genome	   replication	   occur	   during	   the	   early	   phase	   of	  wound	  healing	  known	  as	   the	  proliferative	  phase.	  To	  date,	   it	   is	   unclear	  whether	  the	  increased	  cell	  proliferation	  observed	  during	  early	  HPV	  infections	  is	  caused	  by	  viral	  oncogene	  expression	  or	  by	  the	  proliferative	  responses	  in	  the	  would	  healing	  environment.	  The	  phases	  of	  wound	  healing	  in	  the	  context	  of	  an	  HPV	  infection	  can	  be	  studied	  in	  vitro	  using	  keratinocytes	  cultured	  in	  monolayer.	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1.5.2	  Growth	  factors	  in	  wound	  healing	  	  
	  It	  was	  recently	  documented	  that	  wound	  healing	  might	  increase	  the	  efficiency	  with	  which	   the	   HPV	   DNA	   becomes	   established	   as	   a	   nuclear	   plasmid	   in	   basal	   cells,	  because	  the	  basal	  cells	  are	  then	  in	  a	  hyperproliferative	  state	  (Pyeon	  et	  al.,	  2009;	  Werner	   et	   al.,	   2007).	   The	   hyperproliferative	   state	   of	   basal	   cells	   is	   due	   to	   the	  augmented	   concentration	   of	   growth	   factors	   during	   wound	   healing	   (Shirakata,	  2010).	  Growth	   factors	   and	   cytokines	   are	   produced	   from	   a	   variety	   of	   epithelial	   and	  immune	  cells	  during	  wound	  healing.	  They	  are	  important	  during	  the	  proliferative	  phase	   to	   attract	   surrounding	   cells	   to	   fill	   in	   the	   damaged	   area	   and	   to	   induce	  cellular	  proliferation	  and/or	  differentiation	  in	  the	  recruited	  cells.	  Growth	  factors	  in	  particular	  are	  secreted	  by	  keratinocytes	  and	  fibroblasts	  and	  bind	  to	  receptors	  on	   the	   cell	   surface	   to	   produce	   new	   epithelia.	  Many	   of	   these	   growth	   factors	   are	  quite	   versatile,	   stimulating	   cellular	   division	   in	   numerous	   different	   cell	   types,	  whereas	  others	  are	  more	  specific,	  imparting	  their	  functions	  in	  only	  one	  particular	  cell	   type.	   The	  main	   keratinocyte-­‐derived	   growth	   factors	   are:	   Epidermal	  Growth	  Factor	  (EGF),	  Transforming	  Growth	  Factor	  -­‐	  α	   	  (TGF-­‐α),	  Platelet	  Derived	  Growth	  Factor	   (PDGF),	   Transforming	   Growth	   Factor	   – β	   (TGF-­‐β),	   and	   Keratinocyte	  Growth	  Factor	  (KGF).	  Fibroblasts	  also	  produce	  growth	  factors	  to	   induce	  cellular	  proliferation,	  and	  the	  most	   important	  are	  the	  18	  members	  of	  Fibroblast	  Growth	  Factor	  family	  (FGF-­‐1	  -­‐	  FGF-­‐18),	  and	  TGF-­‐β	  (Goodsell,	  2003).	  	  The	   role	   of	   EGF	   has	   been	   extensively	   investigated	   in	   normal	   and	   pathological	  wound	  healing.	  Since	  the	  discovery	  of	  EGF,	  the	  first	  growth	  factor	  to	  be	  isolated,	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over	  50	  years	  ago,	  growth	  factor	  therapy	  has	  progressed	  into	  clinical	  practice	  in	  the	  treatment	  of	  wounds	  (Weltman,	  1987).	  	  EGF,	  like	  all	  growth	  factors,	  binds	  to	  specific	  high-­‐affinity,	  low-­‐capacity	  receptors	  on	  the	  surface	  of	  responsive	  cells	  to	  induce	  signal	  transduction	  cascades	  resulting	  primarily	  in	  DNA	  synthesis	  and	  proliferation.	  Binding	  of	  EGF	  to	  the	  EGF	  receptor	  (EGFR)	   stimulates	   its	   intrinsic	   tyrosine	   kinase	   activity,	   which	   then	   results	   in	  autophosphorylation	   and	   subsequent	   binding	   to	   proteins	   containing	   SH2	  domains.	   EGF	   has	   proliferative	   effects	   on	   cells	   of	   both	   mesodermal	   and	  ectodermal	   origin,	   and	   particularly	   on	   keratinocytes	   and	   fibroblasts.	   Growth-­‐related	  responses	  to	  EGF	  include	  the	  induction	  of	  MAPK,	  Akt,	  and	  JNK	  pathways	  and	   nuclear	   proto-­‐oncogene	   expression,	   such	   as	   fos,	   jun	   and	   myc	   (Carpenter,	  2000).	  	  
1.6	  Rational	  and	  Aims	  of	  this	  Study	  
	  The	  general	   aim	  of	  my	   thesis	   study	   is	   to	   further	   the	  understanding	  of	   the	  early	  phases	  of	  HPV	  lesion	  formation.	  The	  formation	  of	  a	  lesion	  is	  a	  complex	  and	  not	  yet	  well-­‐understood	  process	  that	  implicates	   several	   protagonists.	   Current	   hypotheses	   suggest	   that	   in	  many	   cases	  HPV	   infection	   of	   the	   basal	   layer	   happens	   through	   an	   epithelial	   micro-­‐wound	  (Kines	  et	  al.,	  2009).	  Recent	  work	  also	  suggests	  that	  a	  wound	  healing	  environment	  and	   the	   presence	   of	   growth	   factors	   can	   facilitate	   infection	   of	   basal	   cells	  (Surviladze	   et	   al.,	   2012).	   According	   to	   clinical	   biopsy	   studies,	   the	   HPV	   genome	  expression	  in	  the	  basal	  layer	  can	  vary	  between	  HPV	  types	  (Fig.	  1.8).	  For	  example,	  low	   risk	  HPV	   do	   not	   produce	   an	   increase	   in	   cell	   proliferation	  markers	   in	   basal	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cells,	   whereas	   high	   risk	   HPV	   have	   the	   ability	   to	   drive	   basal	   cell	   proliferation,	  possibly	  because	  of	   the	  expression	  of	   the	  early	  oncogenes	  E6	  and	  E7.	  To	  date	   it	  remains	   unclear	  why	   the	   phenotypic	   differences	   between	   the	   two	   groups	   have	  evolved,	  and	  how	  low-­‐	  and	  high-­‐risk	  viruses	  produce	  such	  lesions.	  	  	  
	  
Figure	  1.8.	  Immunostaining	  of	  HPV11	  and	  HPV16	  caused	  lesions.	  Sections	  of	  human	   lesions	   caused	  by	   low-­‐risk	  and	  high-­‐risk	  HPVs	  were	   stained	  using	  a	   cell	  proliferation	  marker	   (mcm,	   in	   red)	   and	   E4	   (in	   green)	   antibodies.	   Dapi	   staining	  (blue)	  was	  used	  to	  visualize	  cell	  nuclei.	  The	  white	  dots	  indicate	  the	  position	  of	  the	  basal	  layer	  (Adapted	  from	  Doorbar	  et	  al.,	  2012).	  	  
Hypotheses:	  	  1. We	   hypothesize	   that	   during	   infection	   with	   high-­‐risk	   HPV,	   wound-­‐healing	  responses	   lead	   to	  up-­‐regulation	  of	  viral	  E6/E7	  expression.	  This	   in	   turn	   leads	   to	  increased	   cell	   growth,	   with	   infected	   cells	   out-­‐growing	   their	   uninfected	  neighbours.	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2. We	   hypothesize	   that	   low-­‐risk	   viruses	   also	   elevate	   their	   E6/E7	   expression	   in	  response	  to	  wound	  healing	  but	  that	  the	  low-­‐risk	  E6/E7	  proteins	  are	  not	  capable	  of	  increasing	  growth	  of	  the	  infected	  cells.	  3. We	  hypothesize	  that	  the	  wound	  healing	  response	  facilitates	  establishment	  of	  HPV	  genomes.	  	  	  
Objectives:	  
	  1. Develop	  an	  in	  vitro	  model	  system	  that	  recreates	  the	  conditions	  of	  wound	  healing.	  2. Study	  the	  effects	  of	  the	  presence	  of	  growth	  factors	  on	  viral	  genome	  expression	  in	  ‘infected’	  cells.	  3. Compare	  the	  effect	  of	  wound	  healing	  responses	  between	  low-­‐	  and	  high-­‐	  risk	  HPV	  types.	  4. Investigate	   the	   differences	   between	   low-­‐	   and	   high-­‐risk	   types	   in	   terms	   of	   cell	  proliferation	  in	  vitro.	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2.	  Materials	  and	  Methods	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2.1	  Suppliers	  of	  chemicals	  and	  reagents	  The	  chemicals	  used,	  unless	  otherwise	  stated,	  were	  purchased	  from	  Sigma-­‐Aldrich	  (Boukamp	   et	   al.),	   BDH	   Laboratory	   Supplies	   (Boukamp	   et	   al.),	   Fisher	   Scientific	  (Boukamp	  et	  al.)	  or	  VWR	   International	   Ltd.	  (Boukamp	  et	  al.).	  	  
2.1.1	  Commonly	  used	  buffers	  and	  reagents	  Table	   2.1	   shows	   the	   commonly	   used	   buffers	   and	   reagents.	   The	   buffers	   listed	  were	  prepared	  by	  the	  NIMR	  media	  facility.	  	  
Table	  2.1:	  Buffers	  and	  reagents	   	  
Name	   Components	  Penicillin/Streptomycin	  (for	  cell	  culture)	   0.6	  %	  (v/v)	  penicillin,	  1	  %	  (v/v)	  streptomycin	  Trypsin-­‐versene	  (for	  cell	  culture)	   0.8	  %	  NaCl,	  0.02	  %	  KCl,	  0.12	  %	  Na2HPO4,	  0.02	  %	  KH2PO4,	  0.01	  %	  EDTA,	  0.13	  %	   trypsin,	  0.001	  %	  phenol	  red	  1X	  Phosphate	  buffered	  Saline	  (PBS)	   1	  %	  NaCl,	  0.025	  %	  KCl,	  0.14	  %	  Na2HPO,	  0.025	  %	  KH2PO4	  1X	  Tris-­‐buffered	  saline	  (TBS)	   2.42	  g	  Tris	  base,	  8	  g	  NaCl;	  pH	  7.6	  (for	  1L)	  Luria-­‐Bertani	  (LB)	  medium	   1	  %	  Tryptone,	  0.5	  %	  yeast	  extract,	  1	  %	  NaCl	  
LB	  agar	   LB	  medium	  plus	  2	  %	  Bacto	  agar	  
50X	  Tris	  acetate	  EDTA	  (TAE)	   242	  g	  Tris	  base,	  57.1	  ml	  glacial	  acetic	  acid,	  18.6	  g	  EDTA	  (for	  1L)	  SDS	  electrophoresis	  buffer	   25	  mM	  Tris	  base,	  200	  mM	  glycine,	  0.1	  %	  sodium	  dodecyl	  sulphate	  (SDS);	  pH	  8.3	  Transfer	  buffers	   (Western	   blots)	   25	   mM	   Tris-­‐HCl,	   200	   mM	  glycine,	  20	  %	  (v/v)	  methanol;	  pH	  8.3;	  	  (Southern	  blots)	  Saline-­‐sodium	  citrate	  20x	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2.2	  Keratinocyte	  and	  fibroblast	  monolayer	  cell	  culture	  method	  
	  
2.2.1	  Cell	  lines	  
	  
2.2.1.1	  Normal	  immortalized	  Human	  Keratinocytes	  (NIKS)	  NIKS,	   a	   cutaneous	   foreskin	   keratinocyte	   cell	   line,	  were	  used	   as	   host	   cell	   and	   as	  negative	   control	   with	   all	   HPV16	   and	   HPV11	   experiments.	   NIKS	   are	   a	  spontaneously	  immortalized	  HPV-­‐negative	  human	  foreskin	  keratinocyte	  cell	  line.	  	  These	   cells	   arose	   originally	   from	   their	   parental	   BC-­‐1-­‐Ep	   cell	   line,	   isolated	   from	  neonatal	  foreskin,	  through	  serial	  passaging	  (Allen-­‐Hoffmann	  et	  al.,	  2000).	  	  	  
2.2.1.2	  J2-­‐3T3	  mouse	  fibroblasts	  J2-­‐3T3	  are	  an	   immortalized	   fibroblast	   cell	   line	   that	  was	  originally	   isolated	   from	  Swiss	   albino	   mouse	   embryos	   (Todaro	   and	   Green,	   1963).	   J2-­‐3T3	   cells	   were	   γ-­‐irradiated	  and	  used	  as	  ‘feeder	  layer’	  to	  support	  the	  growth	  of	  NIKS	  cells.	  	  
2.2.1.3	  NIKS	  HPV16-­‐positive	  cells	  HPV16	   clonal	   cell	   lines	   were	   established	   from	   two	   independent	   transfections	  (made	  by	  Kenneth	  Raj;	  NIMR,	   London,	  UK	  and	  Qian	  Wang;	  NIMR,	   London,	  UK).	  NIKS	  were	  co-­‐transfected	  with	  re-­‐circularized	  replication	  competent	  HPV16	  wild	  type	   	   (WI2)	   genomes	   and	   a	   pcDNA6	   vector	   containing	   a	   Blasticidin	   resistance	  gene.	  Clonal	  cell	  lines	  were	  recovered	  after	  selection	  with	  6	  µg/ml	  of	  Blasticidin.	  After	  individual	  colonies	  became	  visible,	  cells	  were	  first	  cultured	  in	  single	  wells	  of	  60	  mm	  6-­‐well	  plates	  (Thermo	  	  	  Scientific;	  140675)	  and	  subsequently	  expanded	  to	  make	  cell	  stock.	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2.2.1.4	  NIKS	  HPV11-­‐positive	  cells	  NIKS-­‐HPV11	   cell	   populations	   were	   prepared	   co-­‐transfecting	   NIKS	   with	   re-­‐circularized	   replication	   competent	   HPV11	   wild	   type	   (Hershey)	   genomes	   and	   a	  pcDNA6	   vector	   containing	   a	   Blasticidin	   resistance	   gene.	   Cell	   populations	   were	  recovered	   after	   short	   selection	  with	   6	   µg/ml	   of	   Blasticidin.	   The	   cell	   population	  were	  separated	  and	  kept	  growing	  in	  single	  wells	  of	  60	  mm	  6-­‐well	  plates	  (Thermo	  Scientific;	  140675).	  After	  Blasticidin	  selection	  the	  NIKS-­‐HPV11	  populations	  were	  assessed	  for	  the	  presence	  of	  HPV11	  genome.	  	  
2.2.1.5	  NIKS	  GFP	  positive	  cells	  NIKS-­‐GFP	  positive	  cells	  were	  produced	  transfecting	  NIKS	  cells	  with	  the	  ZsGreen1	  Fluorescent	  Protein	   transforming	  vectors	   (#632473;	  Clontech	  Laboratories,	   Inc.	  USA).	   The	   bright	   green	   fluorescent	   protein-­‐encoding	   gene	   derived	   from	   a	  
Zoanthus	  sp.	  reef	  coral.	  We	  find	  that	  the	  protein	  is	  stable	  and	  non-­‐toxic	   in	  NIKS,	  and	  can	  be	  easily	  visualized	  in	  living	  and	  fixed	  specimen.	  	  
2.2.2	  Media	  and	  Supplements	  The	  following	  media	  were	  used	  for	  culturing	  the	  cell	  lines	  as	  well	  as	  for	  freezing	  of	  cells	  for	  long-­‐term	  storage	  are	  described	  in	  Table	  2.2.	  The	  supplements	  used	  in	  the	   FI	   medium	   for	   NIKS	   were	   prepared	   either	   as	   100	   or	   1000X	   stock,	   filter	  sterilized	   using	   a	   0.2	   µM	   membrane	   filter	   unit	   (Sartorius;	   16534).	   All	  supplements	  were	  stored	  as	  5	  ml	  aliquots	  at	  -­‐20	  °C.	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Table	  2.2	  Cell	  Culture	  and	  Freeze	  Media	  
Cell	  type	   Medium	  type	   Medium	  components	  
NIKS,	  HPV16,	  clones	  and	  and	  other	  NIKS-­‐derived	  cell	  populations	  
F-­‐Medium	  Incomplete	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (FI)	   500	   ml	   F	   Medium	   (3	   part	   F12-­‐Hams	  +	  1	  part	  high	  glucose	  DMEM)	  (PAA;	   T15-­‐355),	   5	   %	   (v/v)	   FBS	  (Biosera;	   S1900-­‐500),	   24	   µg/ml	  adenine	   (Sigma-­‐Aldrich;	   A2786),	  8.4	   ng/ml	   cholera	   toxin	   (Sigma-­‐Aldrich;	   C8052),	   0.4	   µg/ml	  hydrocortisone	   (Calbiochem;	   CAS	  50-­‐23-­‐7),	   5	   µg/ml	   insulin	   (Sigma-­‐Aldrich;	   I4011)	   and	   1	   %	   (v/v)	  pen/strep	  NIKS,	  HPV16	  clones	  and	  other	  NIKS-­‐derived	  cell	  populations	   F-­‐Medium	  Complete	  (FC)	   FI	  medium	  with	  Epidermal	  Growth	  Factor	  (EGF)	  added	  prior	  to	  use	  at	  a	   concentration	  of	  10	  ng/ml	   (R&D	  Systems;	  236-­‐EG)	  NIKS,	  HPV16	  clones	  and	  other	  NIKS-­‐derived	  cell	  populations	   NIKS	  freezing	  Medium	   90	  %	  (v/v)	  FBS,	  10	  %	  (v/v)	  DMSO	  (Sigma-­‐Aldrich;	  D2650)	  	  J2-­‐3T3	   DMEM	  complete	   500	   ml	   high	   glucose	   DMEM	  (Sigma-­‐Aldrich;	  D6429),	  	  10	  %	  (v/v)	  FBS	  and	  1	  %	  (v/v)	  	  pen/strep	  J2-­‐3T3	  	   J2-­‐3T3	  	  Freezing	  Medium	   95	  %	  (v/v)	  FBS,	  5	  %	  (v/v)	  DMSO	  	  
2.2.3	  Maintenance	  of	  monolayer	  cells	  	  
2.2.3.1	  J2	  3T3	  	  J2-­‐3T3	  fibroblasts	  cells	  were	  cultured	  in	  10	  ml	  of	  DMEM	  complete	  medium	  in	  T75	  flasks	   (Fisher	   Scientific;	   TKV-­‐123-­‐013L)	   at	   37	   °C	   and	   5	  %	   CO2.	   The	   fibroblasts	  were	  grown	  until	  they	  were	  80%	  confluent	  and	  were	  then	  split	  between	  1:10	  and	  1:40	   as	   required.	   To	   harvest,	   cells	  were	  washed	  with	   5-­‐10	  ml	   of	   PBS	   and	   then	  incubated	  with	  1	  ml	  of	  trypsin-­‐versene	  for	  2	  minutes	  at	  37	  °C.	  Thereafter,	  9-­‐12	  ml	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of	  DMEM	  Complete	  Medium	  were	  added	  to	  the	  fibroblasts	  flask.	  A	  small	  aliquot	  of	  the	  suspended	  cells	  was	  then	  added	  to	  anew	  flask	  for	  further	  culturing.	  Cells	  were	  given	   fresh	  medium	   every	   3-­‐4	   days.	   For	   long-­‐term	   storage,	   a	   confluent	   flask	   of	  low	   passage	   cells	  was	   harvested,	   spun	   down	   at	   1500	   rpm	   using	   a	  MSE	  Mistral	  1000	  centrifuge	  for	  5	  minutes,	  re-­‐suspended	  in	  2	  ml	  of	  J2-­‐3T3	  freezing	  medium,	  transferred	  to	  2	  Cryovials	  (Thermo	  Scientific;	  5000-­‐1012)	  and	  froze	  down	  at	  -­‐80°	  C	   or	   in	   liquid	   nitrogen.	   J2	   3T3	   cells	   above	   passage	   20	   were	   not	   used	   for	  experimental	  purposes.	  	  
2.2.3.2	  NIKS,	  NIKS	  HPV16	  clones	  and	  other	  NIKS-­‐derived	  cell	  populations	  NIKS,	  and	  NIKS-­‐HPVs	  cells,	  were	  cultured	  on	  a	  layer	  of	  γ-­‐irradiated	  J2-­‐3T3	  cells.	  J2-­‐3T3	   cells	   were	   irradiated	   at	   a	   dosage	   of	   60	   Gy	   using	   a	   Caesium	   source.	  Approximately	  1.8x106	  feeders	  were	  seeded	  in	  a	  T75	  flask	  in	  10	  ml	  of	  FI	  medium	  and	  left	  to	  attach	  for	  1.5-­‐	  2	  hours	  prior	  to	  plating	  NIKS	  cells.	  NIKS	  were	  cultured	  to	  a	  maximum	  of	  80%	  confluence	  and	  split	  approximately	  once	  a	  week	  between	  1:5	  and	  1:30,	  depending	  on	  the	  growth	  rate	  of	  the	  cells.	  NIKS	  cells	  above	  passage	  15	  were	  not	  used	  for	  experimental	  purposes.	  To	  harvest	  the	  NIKS,	  the	  cells	  were	  washed	  with	  8-­‐10	  ml	  of	  PBS	  and	  then	  incubated	  with	  1	  ml	  of	  trypsin-­‐versene	  for	  2-­‐4	  minutes	   at	   37	   °C,	   in	   order	   to	   remove	   the	   fibroblast	   layer.	  After	   tapping	   the	  flask	  few	  times	  to	  completely	  dislocate	  the	  fibroblasts,	  trypsin	  was	  aspirated,	  and	  cells	  washed	  with	  8-­‐10	  ml	  of	  PBS.	  Keratinocytes	  were	  then	  incubated	  in	  2	  ml	  of	  fresh	   trypsin-­‐versene	   at	   37	   °C	   for	   about	   10-­‐15	   minutes.	   When	   all	   cells	   had	  dislodged	  from	  the	  flask,	  8	  ml	  of	  FI	  medium	  was	  added,	  cells	  were	  collected	  into	  a	  single	   cell	   suspension	   and	   transferred	   to	   a	   flask	   of	   γ-­‐irradiated	   fibroblast	   for	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further	  culturing.	  Cells	  were	  provided	  with	  fresh	  FI	  or	  FC	  medium	  every	  second	  day.	  For	  long-­‐term	  storage,	  a	  flask	  of	  low	  passage	  cells	  was	  harvested,	  spun	  down	  at	  1500	  rpm	  for	  5	  minutes.	  Approximately	  2-­‐3x106	  cells	  were	  re-­‐suspended	  in	  1	  ml	  of	  NIKS	  freezing	  medium,	  transferred	  to	  a	  cryovial	  and	  stored	  at	  -­‐80	  °C.	  	  
2.2.4	   Cell	   counts	   of	   NIKS,	   NIKS	   HPV16	   clones	   and	   other	   NIKS-­‐derived	   cell	  
populations	  For	   all	   experiments	   involving	   NIKS,	   cells	   were	   counted	   using	   a	   Z1Coulter®	  Particle	  Counter	   (Beckman	  Coulter;	  UK).	  After	   cell	  harvest,	   as	  described	  earlier,	  0.5	   ml	   of	   the	   cell	   suspension	   was	   re-­‐suspended	   in	   9.5	   ml	   of	   Isoton	   II	   diluent	  (Beckman	   Coulter;	   8546733)	   in	   a	   coulter	   counter	   cuvette	   (VWR	   International	  Ltd.;	   720-­‐0812).	   The	   coulter	   counter	   was	   optimized	   to	   NIKS	   cells	   size.	   As	  previously	  established	  the	  majority	  of	  cells	  fell	  within	  a	  peak	  range	  of	  11-­‐20	  µm	  in	  size	   (Erin	   Isaacson;	   NIMR,	   London,	   UK).	   In	   order	   to	   account	   for	   cells	   that	   are	  slightly	   larger,	   the	   coulter	   counter	  parameters	  were	   set	   to	   count	   all	   cells	   above	  the	  lower	  limit	  tL=11	  µm.	  	  
2.2.5	  Transfection	  of	  NIKS	  and	  NIKS	  HPV11/16-­‐positive	  cells	  For	   transfections,	  NIKS	   and	   varieties	   thereof,	  were	   harvested	   and	   plated	   on	   60	  mm	  6-­‐well	  plates	  at	  a	  density	  of	  5x105	  cells	  per	  well	  on	  a	  layer	  of	  1x105	  feeders	  and	   left	   to	   grow	  overnight	   in	   FC	  medium.	  Transfections	  were	   carried	  out	  using	  the	   Effectene®	   Transfection	   Reagent	   Kit	   (Qiagen;	   301425)	   following	   the	  manufacturer’s	   instructions.	  Cells	  were	   transfected	  with	  up	   to	  a	   total	  of	  1	  µg	  of	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circular	  or	  linearized	  DNA,	  which	  was	  purified	  from	  bacterial	  cultures.	  Six	  hours	  after	  transfection	  cells	  were	  given	  fresh	  FC	  medium.	  
	  
2.2.6	  Electroporation	  Alternatively	   to	   Effectene®	   transfection	   reagent	   we	   have	   performed	   the	  transfection	  of	  the	  NIKS	  and	  NIKS-­‐derived	  cells	  by	  electroporation.	  NIKS,	   NIKS-­‐derived	   cells	   were	   harvested,	   washed	   twice	  with	   PBS,	   counted	   and	  divided	   into	   aliquots	   of	   2.0x106	   cells	   in	   individual	  micro	   centrifuge	   tubes.	   Cells	  were	  electroporated	  using	  the	  4D	  Nucleofector®	  X	  Unit	  from	  Lonza	  (Boukamp	  et	  al.)	  and	  the	  Amaxa™	  SE	  Cell	  Line	  4D-­‐Nucleofector™	  X	  Kit	  L	  (Lonza;	  V4XC-­‐1024),	  according	   to	   the	   manufacturer’s	   instructions.	   The	   specific	   program	   used	   was	  previously	   optimized	   for	   NIKS	   cells	   according	   to	   manufacturer’s	   instructions	  (Figure	  2.1).	   Subsequently	   cells	  were	   seeded	   into	  6-­‐well	   plates	   on	   top	  of	   1x105	  feeder	  cells	  in	  FC	  medium	  and	  given	  fresh	  FC	  medium	  after	  24	  hours.	  
	  
Figure	   2.1	   Fluorescence	   microscopy	   digital	   image	   of	   NIKS	   transfection	  
optimization.	  GFP	  expressing	  plasmid	  was	  used	  to	  optimize	  the	  electroporation	  protocol	   for	  NIKS	   transfection.	  48	  hours	  post	   transfection	  60-­‐70%	  of	  NIKS	  cells	  were	  GFP	  positive.	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2.3	  Growth	   assays	   of	  NIKS,	  NIKS	  HPV16	   clones	   and	   other	  NIKS-­‐
derived	  cell	  populations	  To	  determine	  the	  proliferation	  patterns	  of	  NIKS,	  NIKS-­‐HPV	  clones	  and	  NIKS-­‐HPV	  populations,	   1x105	   keratinocytes	  were	   seeded	   on	   top	   of	   a	   layer	   of	   0.8-­‐1x105	   γ-­‐irradiated	  J2-­‐3T3	  fibroblasts	  per	  well	  of	  a	  6-­‐well	  plate.	  Triplicate	  wells	  were	  set-­‐up	  for	  each	  cell	  type	  and	  time-­‐point.	  The	  day	  of	  seeding	  was	  denoted	  as	  day	  0.	  The	  seeded	  cells	  were	   left	   to	  grow	  overnight	   in	  3	  ml	  of	  FI	  medium.	  On	  the	  following	  day	   (day	   1)	   cells	   were	   counted	   to	   determine	   the	   seeding	   efficiency.	   For	   most	  experiments	  cells	  were	  grown	  for	  a	  total	  of	  7	  days	  and	  counted	  at	  days	  1,	  3,	  5,	  and	  7.	  On	  day	  1	  and	  every	  other	  day	  thereafter	  (days	  3,	  5,	  and	  7)	  cells	  were	  fed	  with	  3	  ml	  of	  FC	  medium.	  For	  harvesting,	   cells	  were	  washed	  with	  3	  ml	  of	  PBS	  and	   then	  incubated	   for	  2-­‐4	  minutes	  with	  1	  ml	  of	   trypsin-­‐versene	  at	  37	  °C	   to	  dislodge	   the	  fibroblasts.	   After	   tapping	   the	   plate	   few	   times	   to	   completely	   separate	   the	  fibroblasts,	   trypsin	  was	  aspirated.	  To	  remove	  the	  keratinocytes,	  1	  ml	  of	  trypsin-­‐versene	  was	  added	   to	  each	  well	  and	  cells	  were	   incubated	  at	  37	   °C	   for	  about	  10	  minutes.	  When	   all	   cells	   had	   detached	   from	   the	   bottom	   of	   the	  wells,	   4	  ml	   of	   FI	  medium	  was	  added,	  cells	  collected	  into	  a	  single	  cell	  suspension	  and	  0.5	  ml	  of	  the	  mix	   used	   for	   counting.	   Cells	   remaining	   from	   counting	   at	   each	   time-­‐point	   were	  collected	  in	  cell	  pellets	  and	  stored	  at	  -­‐80	  °C	  for	  protein	  and/or	  transcript	  analysis.	  	  
2.4	   Short	   growth	   assays	   of	   NIKS,	   NIKS	  HPV16	   clones	   and	   other	  
NIKS-­‐derived	  cell	  populations	  This	   growth	  assay	   format	  was	  developed	   to	  assess	   the	  proliferation	  patterns	  of	  NIKS	  and	  NIKS-­‐HPV16	  clones	  during	  a	  shorter	  time	  frame.	  1.0x105	  keratinocytes	  were	   seeded	   on	   top	   of	   a	   layer	   of	   1x105	   feeders	   per	  well	   of	   a	   6-­‐well	   plate	   in	   FI	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medium.	  Triplicate	  wells	  were	  set-­‐up	  for	  each	  cell	  type	  and	  time-­‐point.	  The	  day	  of	  seeding	  was	  denoted	  as	  day	  0.	  On	  the	  following	  day	  (day	  1)	  cells	  were	  given	  fresh	  FI	   medium	   and	   counted	   as	   described	   in	   Section	   2.3	   to	   assess	   the	   seeding	  efficiency	  of	  cells.	  On	  the	   following	  12,	  24,	  36,	  and	  72	  hours,	  cells	  were	  counted	  and	   all	   remaining	   cells	   fed	  with	   3	  ml	   of	   FC	  medium.	   The	   cells	   remaining	   from	  counting	  at	  each	  time-­‐point	  were	  pelleted	  and	  frozen	  at	  -­‐80	  °C.	  
	  
2.5	  Wound	  healing	  scratch	  assay	  In	   both	  migration	   and	   invasion	   assay,	   100µl	   of	   NIKS	   or	  NIKS	   derived	   cell	   lines	  (106	  cells	  per	  ml)	  in	  FI	  Medium	  were	  seeded	  onto	  a	  γ-­‐irradiated	  fibroblast	  layer	  in	  35	  mm	  Glass	  Bottom	  Dishes	  (P35GC-­‐1.5-­‐14-­‐C;	  MatTek	  Co.,	  USA).	  The	  dishes	  were	  incubated	  at	  37˚C	  and	  24	  hours	  after	  seeding	  the	  Medium	  was	  changed	  with	  3ml	  of	  fresh	  FC	  Medium.	  The	  cells	  were	  grown	  to	  confluence	  and	  scratch	  wounds	  then	  created	  using	  a	  pipet	  tip.	  The	  wound	  site	  was	  photographed	  digitally	  at	  two-­‐hours	  intervals.	  Image-­‐J®	  software	  was	  then	  used	  to	  calculate	  the	  cell-­‐free	  area,	  and	  the	  cell	  migration	  rate	  was	  calculated	  using	  the	  changes	  in	  this	  area.	  A	  reproducibility	  test	   showed	   that	   repeated	   annotation	   of	   the	   same	   image	   area	   produced	   an	  average	  difference	  of	  1.4%	  of	  the	  total	  image	  area	  between	  replicates	  and	  that	  the	  difference	  never	  exceeded	  4.2%.	  	  
2.5.1	  Calculation	  of	  the	  migration	  rate	  The	  cell	  migration	  rate	  was	  calculated	  as	  the	  area	  conquered	  in	  the	  free-­‐cell	  area	  by	  the	  cells	  over	  time.	  The	  measurement	  were	  taken	  using	  the	  Image-­‐J® software	  and	   using	   the	   free	   cell	   area	   measured	   at	   the	   specified	   time-­‐point	   we	   have	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calculated	   the	   area	   cover	   by	   the	   movement	   of	   the	   two	   fronts	   in	   the	   vertical	  direction.	   Results	   were	   obtained	   from	   at	   least	   three	   independent	   experiments	  with	  using	  different	  sets	  of	  NIKS	  and	  NISK-­‐derived	  cell	  lines.	  Data	  collected	  were	  presented	   as	   means	   ±	   Standard	   Deviations	   (SDs)	   of	   triplicates	   from	   a	  representative	  experiment.	  	  
2.6	  Immunocytology	  and	  Immunohistochemistry	  
	  
2.6.1	  Immunocytology	  of	  NIKS,	  NIKS	  HPV16	  clones	  and	  other	  NIKS-­‐derived	  
cell	  populations	  To	  harvest	  monolayer	  keratinocytes	  for	  immunocytology,	  round	  coverslips	  	  (VWR	  International	  Ltd.;	  631-­‐0713)	  were	  sterilized	  using	  70	  %	  ethanol	  and	  placed	  into	  60	  mm	  6-­‐well	  plates.	  Irradiated	  fibroblasts	  and	  keratinocytes	  were	  seeded	  on	  top	  as	  described	  in	  Section	  2.3.	  
	  
2.6.2	  Fixation	  of	  coverslips	  The	   cells	   on	   coverslips	  were	   fixed	  with	   5%	  paraformaldehyde	   for	   5	  minutes	   at	  room	  temperature.	  To	  do	  this,	  growth	  medium	  was	  aspirated	  from	  the	  wells	  and	  the	  coverslips	  washed	  twice	  with	  1x	  PBS.	  After	  the	  incubation	  period,	  cells	  were	  washed	  twice	  with	  PBS	  and	  stored	  in	  0.01%	  sodium	  azide	  in	  PBS	  at	  4	  °C.	  
	  
2.6.2.1	  Immunocytology	  and	  mounting	  monolayer	  coverslips	  The	  PBS/azide	  solution	  in	  each	  well	  with	  the	  coverslips	  was	  aspirated.	  The	  cells	  were	  blocked	  in	  5	  %	  normal	  goat	  serum	  (NGS)	  (Cell	  Signaling	  Technology;	  5425)	  in	  PBS	  for	  1	  hour	  at	  room	  temperature.	  After	  blocking,	  the	  primary	  antibody	  (Cell	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Signaling	  Technology;	  9733)	  was	  made	  up	  in	  5	  %	  NGS	  in	  PBS	  at	  a	  1:200	  dilution,	  applied	   to	   the	  coverslips	  and	   left	   for	  1	  hour	  at	  room	  temperature.	  Thereafter,	  5	  quick	  rinses	  of	   the	  coverslips	  (within	   the	  wells)	  were	  done	  using	  PBS.	  Next,	   the	  secondary	  antibody	  was	  applied	  as	  a	  secondary	  antibody	  in	  5	  %	  NGS	  in	  PBS	  and	  left	   for	  1	  hour	  at	   room	   temperature.	  DAPI	  was	  added	  as	  a	  nuclear	   counterstain	  alongside	   the	   secondary	   antibody	   at	   a	   1:1000	   dilution.	   Subsequently,	   the	  coverslips	   (within	   the	   wells)	   were	   rinsed	   5	   times	   using	   PBS.	   Coverslips	   were	  rinsed	  once	  in	  dH2O,	  lifted	  out	  of	  the	  wells	  carefully	  and	  dried	  gently.	  Then	  10-­‐20	  µl	   of	   Citifluor®	   reagent	   was	   dropped	   onto	   a	   Superfrost-­‐plus	   slide	   and	   the	  coverslip	  inverted	  on	  top,	  taking	  great	  care	  to	  ensure	  no	  air	  bubbles	  were	  trapped	  underneath.	  Slides	  were	  stored	  in	  a	  folder	  at	  4	  °C.	  	  
2.6.2.2	  Primary	  antibody	  signal	  amplification	  In	   cases	   where	   an	   amplified	   signal	   of	   the	   primary	   antibody	   was	   needed,	  secondary	  biotinylated	  antibodies	  were	  applied	  to	  the	  raft	  sections,	  according	  to	  Table	   2.5.	   	   Approximately	   30	   minutes	   through	   this	   incubation,	   Strep	   A/B	  (avidin/biotin)	   complexes	   were	   assembled	   using	   the	   ABC	   (peroxidase)	   kit	  according	  to	  Table	  2.6	  and	  the	  manufacturer’s	  instructions.	  The	  complexes	  were	  removed	  using	  the	  same	  PBS-­‐Tween	  0.05	  %	  wash	  regimen.	   	   	  In	  order	  to	  quench	  endogenous	  human	  peroxidases,	  3	  %	  hydrogen	  peroxide/PBS	  (v/v)	  was	  applied	  to	   the	   section	   for	  15	  min.	   at	  RT,	   following	   the	   removal	   of	  ABC	   complexes.	   	   The	  hydrogen	  peroxide	  was	  removed	  by	  rinsing	  the	  sections	  several	  times	  in	  PBS.	  	  To	  complete	   the	   amplification	   process,	   the	   fluorochrome	   labeled	   Tyramide	  (rhodamine)	   was	   applied	   to	   the	   sections	   according	   to	   Table	   2.6	   and	   the	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manufacturer’s	   instructions.	   	  The	  rhodamine	  was	  removed	  using	   the	  same	  PBS-­‐Tween	  0.05	  %	  wash	  regimen.	  	  	  	  
Table	  2.3	  Primary	  Antibodies	  Target	   Species	   Clone	   Dilution	   Incubation	   Supplier	  K10	   Mouse	   DE-­‐K10	   1:200	   1	  hr.	  RT	   Neomarkers	  H3P	   Rabbit	   LYS-­‐27	   1:250	   1	  hr.	  RT	   Cell	  Signaling	  	  
	  
Table	  2.4	  Secondary	  Antibodies	  Target	   Species	  
raised	  




Table	  2.5	  Chemical	  Reagents	  
Reagent	   Dilution/Diluent	   Incubation	   Supplier	  
DAPI	  	   1:1000	  /	  5%	  NGS	   1	  hr.	   	  
Strep	  A/B	  (avidin/biotin)	  (peroxidase)	  complex	  
1:400	  50mM	  Tris/HCL	  pH	  7.6	   30	  min.	   Vector	  Labs	  
Tyramide	  (rhodamine)	   1:100	  Amplification	  diluent	   8	  min.	   NEN	  Life	  Science	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2.6.3	  Microscopy	  and	  imaging	  software	  All	   fluorescently	   stained	   cells	  were	   viewed	   on	   a	   Zeiss	   A1	  microscope	   equipped	  with	   fluorescent	   filters.	   Fluorescent	   images	   were	   captured	   using	   a	   Carl	   Zeiss	  Microscopy	  AxioCam	  MRm	  camera	  and	  images	  viewed	  using	  Axiovision	  software.	  
	  
2.7	  Molecular	  biology	  techniques	  
	  
2.7.1	  Transformation	  of	  E.	  coli	  with	  DNA	  Plasmid	   DNA	   was	   mixed	   with	   50	   µl	   of	   competent	   XL10-­‐Gold®	   Ultracompetent	  cells	   (Stratagene;	   200314)	   and	   incubated	   on	   ice	   for	   30	   minutes.	   The	   mix	   was	  heat-­‐pulsed	  in	  a	  water	  bath	  at	  42	  °C	  for	  30	  seconds	  and	  then	  cooled	  on	  ice	  for	  2	  minutes.	   Subsequently,	   800	   µl	   of	   SOC	   medium	   (Life	   Technologies;	   15544-­‐034)	  was	  added	  and	  cells	  were	  incubated	  at	  37	  °C	  for	  45	  minutes	  at	  constant	  shaking	  (220	   rpm).	   Cells	   were	   plated	   on	   LB	   agar	   plates	   containing	   ampicillin	   (Sigma	  Aldrich;	  A5454)	  at	  100	  µg/ml.	  All	  plates	  were	  left	  incubate	  at	  37	  °C	  overnight.	  	  
2.7.2	  Plasmid	  purification	  To	   extract	   plasmid	   DNA	   from	   bacteria,	   three	   commercial	   kits	   were	   used	  depending	   on	   the	   amount	   and	   purity	   of	   plasmid	   required.	   The	   QIAprep®	   Spin	  Miniprep	   Kit	   (Qiagen;	   27106)	   was	   used	   for	   small-­‐scale	   preps,	   from	   2-­‐5	   ml	  overnight	  bacterial	  cultures.	  The	  QIAGEN®	  Plasmid	  Midi	  Kit	  (QIAGEN;	  12143)	  and	  the	  QIAGEN®	  Plasmid	  Maxi	  Kit	  (QIAGEN;	  12162)	  were	  used	  for	  larger-­‐scale	  preps,	  from	  100	  ml	  up	  to	  500	  ml	  cultures,	  respectively.	  The	  purification	  was	  carried	  out	  following	  the	  manufacturer’s	  instructions.	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2.7.3	  Extraction	  of	  total	  genomic	  DNA	  from	  NIKS	  and	  other	  NIKS-­‐derived	  cell	  
lines	  Prior	  to	  extracting	  the	  DNA,	  the	  cells	  were	  washed	  with	  PBS	  and	  pelleted	  at	  a	  low	  speed	  (3000rpm)	  in	  a	  microcentrifuge	  for	  5	  minutes.	  	  The	  cells	  were	  immediately	  put	   on	   ice	   and	   the	   pellets	  were	   prepared	   for	   the	   removal	   of	   RNA.	   	   In	   order	   to	  remove	  RNA	  from	  the	  cells,	  the	  pellet	  was	  resuspended	  in	  140	  µl	  of	  PBS	  and	  40	  µl	  of	   (10mg/mL)	   RNase	   A	   (Invitrogen;	   UK).	   	   The	   cells	   were	   incubated	   in	   a	   37ºC	  water	  bath	  for	  20	  minutes	  and	  the	  DNA	  extraction	  protocol	  immediately	  followed.	  The	  extraction	  of	  total	  genomic	  DNA,	  including	  HPV	  genomic	  DNA,	  from	  NIKS	  or	  HPV-­‐16	   cell	   lines	   was	   performed	   using	   the	   QIAamp®	   DNA	   Blood	   Mini	   kit	  (protocol	  for	  small	  volumes	  of	  blood)	  (Qiagen;	  UK).	   	  The	  complete	  set	  of	  buffers	  and	  reagents	  required	  to	  extract	  the	  DNA	  were	  contained	  in	  the	  Qiagen	  kit.	  	  	  	  
2.7.4	  Quantification	  of	  plasmid	  DNA	  Plasmid	  DNA	  was	  quantified	  using	  a	  Nanodrop®	  ND-­‐1000	  Spectrophotometer.	  	  
2.7.5	  Restriction	  enzyme	  plasmid	  digestion	  To	  allow	  for	  the	  transfection	  of	  cells	  with	  linearized	  DNA	  (as	  outlined	  in	  Section	  2.2.5),	  wt-­‐HPV11	  (Hershey),	  wt-­‐HPV16	  (W12)	  and	  pcDNA6	  vectors	  were	  digested	  using	  restriction	  enzymes	  BamH1	  (New	  England	  Biolabs;	  R0136).	  A	  total	  of	  20	  µg	  of	  plasmid	  DNA	  was	  used	  in	  the	  reaction	  for	  each	  of	  the	  vectors	  and	  digested	  with	  20	  units	  of	  the	  enzyme.	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2.7.6	  Vector	  re-­‐ligation	  Vector	  re-­‐ligation	  was	  carried	  out	  using	  T4-­‐Ligase	  kit	  (New	  England	  Biolabs,	  UK)	  according	  to	  manufacture’s	  instructions.	  	  
2.7.7	  Agarose	  gel	  electrophoresis	  To	   assess	   the	   presence	   and	   quality	   of	   plasmid	   DNA	   or	   for	   subsequent	   gel	  extraction,	  DNA	  was	  separated	  on	  a	  1	  %	  (w/v)	  agarose	  (NBS	  Biologicals,	  UK)	  gel	  in	  1x	  TAE	  containing	  0.5	  µg/ml	  Ethidium	  Bromide	  (Bio-­‐Rad;	  161-­‐0433)	  at	  120	  V	  for	  up	  to	  45	  minutes.	  	  
2.8	  Quantitative	  RT-­‐PCR	  (qPCR)	  Quantitative	   real-­‐time	   (RT)	   polymerase	   chain	   reaction	   (PCR)	   was	   carried	   out	  using	  cDNA	  as	  a	  template.	  Forward	  and	  reverse	  primers	  (Table	  2.7)	  were	  used	  to	  assess	   the	   levels	   of	   HPV16	   E6,	   p21,	   EGFR,	   Akt,	   Cyclin	   D1,	   p53,	   Caspase	   3	   and	  GAPDH	   transcripts	   in	   NIKS-­‐HPV11	   and	   NIKS-­‐HPV16	   cell	   populations.	   GAPDH	  primers	  were	  used	  as	  endogenous	  controls.	  	  
2.8.1	  Extraction	  of	  total	  RNA	  To	   perform	   the	   extraction	   of	   the	   total	   RNA,	   cells	  were	   harvested,	  washed	  with	  PBS	   and	   then	   placed	   on	   ice.	   Total	   RNA	   extraction	   was	   carried	   out	   using	   the	  RNeasy®	   Mini	   Kit	   (Qiagen;	   74104)	   and	   QIAshredder®	   kit	   (QIAGEN;	   79654)	  according	   to	   the	   manufacturer’s	   protocol.	   RNA	   was	   stored	   at	   -­‐80	   °C.	   If	   RNA	  extraction	   was	   not	   carried	   out	   immediately	   after	   harvest	   of	   cells,	   pellets	   were	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resuspended	   in	   RNAprotect®	   Cell	   Reagent	   (QIAGEN;	   76526)	   following	   the	  manufacturer’s	  instructions	  and	  stored	  at	  -­‐80	  °C	  indefinitely.	  	  
2.8.2	  DNase	  digestion	  and	  reverse	  transcription	  Prior	  to	  making	  cDNA,	  genomic	  DNA	  was	  removed	  from	  2	  µg	  of	  total	  RNA	  using	  the	  DNA-­‐free™	  kit	   (Ambion;	  AM1906)	  according	   to	   the	  manufacturer’s	  protocol.	  The	   reverse	   transcription	   was	   done	   using	   the	   SuperScript™	   III	   First-­‐Strand	  Synthesis	  Kit	  (Life	  Technologies;	  18080-­‐051).	  A	  volume	  of	  16	  µl	  (approximately	  0.5	  µg)	  of	  clean	  RNA	  was	  added	  to	  a	  tube	  along	  with	  2	  µl	  oligo	  (dT)20	  primers	  and	  2	  µl	  dNTPs.	  The	  mixture	  was	  incubated	  at	  65	  °C	  for	  5	  minutes	  and	  then	  placed	  on	  ice	  for	  at	  least	  1	  minute.	  Subsequently	  4	  µl	  of	  10X	  RT	  Buffer,	  8	  µl	  of	  MgCl2,	  4	  µl	  of	  DTT,	  2	  µl	  RNase	  OUT™	  and	  2	  µl	  SuperScript™	  III	  reverse	  transcriptase	  was	  added	  to	   each	   tube	   before	   incubating	   at	   50	   °C	   for	   1	   hour.	   To	   stop	   the	   reaction,	   tubes	  were	  placed	  at	  85	  °C	  for	  5	  minutes.	  Thereafter,	  cDNA	  was	  stored	  at	  -­‐80	  °C	  or	  used	  for	  qPCR.	  An	  additional	   tube	  was	  prepared	  using	  2	  µl	  of	  nuclease-­‐free	  H2O	  (Life	  Technologies;	  AM9935)	  instead	  of	  the	  enzyme.	  The	  reaction	  without	  enzyme	  was	  used	  as	  control.	  The	  cDNA	  was	  generally	  diluted	  40-­‐	  fold	  with	  nuclease-­‐free	  H2O	  prior	  to	  doing	  qPCR.	  	  
Table	  2.6	  Primers	  used	  for	  RT-­‐PCR	  
E6/E6*	  primers	   Forward:	  5’-­‐TCAGGACACAGTGGCTTTT-­‐3’	  Reverse:	  5’-­‐	  ACTGCAATGTTTCAGGACCCA-­‐3’	  
GAPDH	  primers	   Forward:	  5’-­‐TGGATATTGTTGCCATCAATGACC-­‐3’	  Reverse:	  5’-­‐GATGGCATGGACTGTGGTCATG-­‐3’	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2.8.3	  qPCR	  primer	  design	  and	  primer	  sequences	  Caspase	   3,	   Akt-­‐1,	   Cyclin	  D1,	   p21,	   p53,	   EGFR,	  HPV11	  E4,	  HPV16	  E6	   and	  GAPDH	  primers	   were	   designed	   using	   Primer	   Select	   software	   and	   ordered	   from	   Sigma	  Aldrich	   (Boukamp	  et	   al.).	   A	   list	   of	   the	  primers	   and	   their	   sequences	   is	   shown	   in	  Table	  2.7	  	  
Table	  2.7	  Primers	  used	  for	  qPCR	  	  
p21	  primers	   Forward:	  5’-­‐CTCTCCAATTCCCTCCTTCC-­‐3’	  Reverse:	  5’-­‐AGAAGCACCTGGAGCACCTA-­‐3’	  
p53	  primers	   Forward:	  5’-­‐GCTGGCTTCCATGAGACTTC-­‐3’	  Reverse:	  5’-­‐AGGGTGTGATGGGATGGATA-­‐3’	  
Cyclin	  D1	  primers	   Forward:	  5’-­‐TCGCTGGAGCCCGTGAAA-­‐3’	  Reverse:	  5’-­‐GCGTGTGAGGCGGTAGTAGTAGGA-­‐3’	  
EGFR	  primers	   Forward:	  5’-­‐ATGCCCG-­‐CATTAGCTCTTAG-­‐3’	  Reverse:	  5’-­‐GCAACTTCCCAAAATGTGCC-­‐3’	  
HPV16	  E6	  primers	   Forward:	  5’-­‐TGTTTCAGGACCCACAGGAGC-­‐3’	  Reverse:	  5’-­‐CGCAGTAACTGTTGCTTGCAG-­‐3’	  
GAPDH	  primers	   Forward:	  5’-­‐CCTCCCGCTTCGCTCTCT-­‐3’	  Reverse:	  5’-­‐CTGGCGACGCAAAAGAAGA-­‐3’	  
Caspase	  3	  primers	   Forward:	  5’-­‐TTTTTCAGAGGGGATCGTTG-­‐3’	  Reverse:	  5’-­‐TCAAGCTTGTCGGCATACTG-­‐3’	  
Akt-­‐1	  primers	   Forward:	  5’-­‐GGCAGCGGCAGCGTGT-­‐3’	  Reverse:	  5’-­‐GGCCCACACACTCACCGAGAA-­‐3’	  
HPV11	  E4	  primers	   Forward:	  5’-­‐ACATTAGATCCGTGGACAGTACAATC-­‐3’	  Reverse:	  5’-­‐TTCCTTCTTTGGTGCTTGTTGTAA-­‐3’	  
	  
	  
2.8.4	  qPCR	  reagent	  cocktails	  Power	  SYBR®	  Green	  PCR	  Master-­‐Mix	  (Applied	  Biosystems;	  4367659)	  was	  used	  to	  amplify	   and	   detect	   cDNA	   in	   96-­‐well	   PCR	   plates	   (Thermo	   Scientific;	   TUL-­‐962-­‐
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011N)	  using	  an	  ABI	  -­‐7500	  Real-­‐Time	  PCR	  System.	  A	  fresh	  master	  mix	  of	  reagents	  was	  prepared	  for	  each	  primer	  set	  (see	  Table	  2.7)	  immediately	  prior	  to	  loading	  the	  plate.	  The	  final	  volume	  in	  each	  well	  was	  25	  µl.	  	  	   	  
	  
	  
2.8.5	  qPCR	  plating	  scheme	  and	  cycle	  parameters	  Samples	  were	  run	  in	  triplicate	  wells	  (for	  each	  primer	  set).	  To	  set	  up	  the	  reaction,	  19-­‐22	  µl	  of	  the	  master	  mix	  was	  pipetted	  into	  each	  well,	  followed	  by	  3-­‐6	  µl	  of	  cDNA	  pipetted	  separately.	  Table	  2.9a	  outlines	  the	  qPCR	  cycle	  parameters.	  They	  include	  a	   dissociation	   curve	   at	   the	   end	   of	   the	   amplification	   steps.	   This	   was	   included	  because	  SYBR	  Green	  can	  bind	  to	  unspecific	  double	  stranded	  DNA,	  such	  as	  primer-­‐dimers,	  which	  can	  interfere	  with	  results.	  The	  dissociation	  curve	  shows	  whether	  a	  single	   or	   multiple	   PCR	   products	   have	   been	   amplified.	   Table	   2.9b	   outlines	   the	  parameters	  for	  the	  dissociation	  program.	  	  
Table	  2.9a:	  PCR	  cycle	  parameters	  
Step	   Number	  of	  cycles	   Time	  per	  cycle	   Temperature	  1	   1	   2	  minutes	   50	  °C	  2	   1	   15	  minutes	   95	  °C	  3	   40	   15	  seconds	   95	  °C	  
Table	  2.8	  qPCR	  cocktail	  
	   Cocktail	  Mix	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   (µl)	  	  per	  reaction	  (well)	  
*Primer	  Forward	  	   1.75	  µl	  
*Primer	  Reverse	  	   1.75	  µl	  
SYBR	  Green	   12.5	  µl	  
H2O	   8	  µl	  	   x	  number	  of	  reactions	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4	   1	   1	  minute	   60	  °C	  
Table	  2.9b:	  Dissociation	  parameters	  
Step	   Number	  of	  cycles	   Time	  per	  cycle	   Temperature	  1	   1	   15	  seconds	   95	  °C	  2	   1	   20	  seconds	   60	  °C	  3	   1	   95	  seconds	   95	  °C	  	  
	  
2.8.6	  Standard	  curves	  for	  primers	  A	  standard	  curve	  and	  linear	  equation	  was	  generated	  for	  each	  primer	  set	  used	  in	  order	  to	  establish	  their	  efficiency	  and	  sensitivity.	  To	  generate	  the	  standard	  curve,	  a	   DNA	   plasmid	   containing	   the	   sequence	   that	   is	   amplified	   by	   the	   primers	   was	  chosen	  as	  a	  template.	  To	  establish	  a	  linear	  relationship,	  six	  10-­‐fold	  serial	  dilutions	  of	  the	  template	  were	  prepared	  which	  corresponded	  to	  a	  known	  number	  of	  copies	  of	  the	  template,	  from	  1	  to	  1x106,	  and	  served	  as	  a	  template	  for	  the	  qPCR	  reaction.	  To	   generate	   the	   standard	   equation,	   the	   logarithms	   of	   the	   values	   of	   the	   known	  copy	  numbers	  in	  each	  dilution	  (either	  1,	  10,	  100,	  1000,	  10000	  or	  1000000)	  were	  plotted	  on	  a	  graph	  along	  the	  x-­‐axis	  against	  the	  Ct	  (cycle	  threshold)	  value	  given	  by	  the	   qPCR	   machine	   for	   each	   dilution	   along	   the	   y-­‐axis,	   and	   an	   equation	   was	  obtained	   in	   the	   form	  of	  y	  =	  mx	  +	  c.	  The	  slope	  (m)	  refers	   to	   the	  efficiency	  of	   the	  primer	  pairs,	  where	  a	  slope	  of	  -­‐3.33	  shows	  a	  perfect	  linear	  relationship	  between	  DNA	   copy	  number	   and	  Ct	   value	   and	   corresponds	   to	   an	   increase	   of	   3.33	   Cts	   for	  every	  10-­‐fold	  dilution	  of	  sample.	  The	  y-­‐value	  in	  this	  equation	  is	  the	  Ct	  value	  that	  the	  qPCR	  measures,	  which	  refers	  to	  the	  number	  of	  cycles,	  needed	  to	  amplify	  one	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copy	  of	  DNA.	  The	  following	  table	  shows	  the	  standard	  curve	  equation	  for	  HPV16-­‐E6,	  HPV11-­‐E4	  and	  GAPDH.	  
Table	  2.10:	  Standard	  curves	  for	  primers	  used	  for	  qPCR	  
Standard	  curve	  equation	  HPV16-­‐E6:	  	   y	  =	  -­‐3.362x	  +	  34.18	  
Standard	  curve	  equation	  HPV11-­‐E4:	   y	  =	  -­‐3.395x	  +	  38.16	  
Standard	  curve	  equation	  GAPDH:	   y	  =	  -­‐3.316x	  +	  36.23	  	  	  
2.8.7	  Copy	  number	  determination	  The	  standard	  curves	  for	  the	  primer	  sets	  were	  used	  to	  calculate	  the	  copy	  numbers	  of	   the	   transcripts	  of	   interest	   in	  each	  sample.	  Each	   triplicate	  set	  of	  Ct	  values	  per	  sample	  and	  primer	  set	  was	  averaged.	  To	  account	  for	  pipetting	  error	  the	  software	  calculated	   the	   standard	   deviation	   for	   each	   set,	   with	   those	   above	   0.5	   indicating	  excessive	  variation.	  Reactions	  were	  repeated	  if	  standard	  deviations	  exceeded	  0.5.	  Acceptable	   Ct	   averages	   were	   used	   to	   calculate	   copy	   number.	   To	   do	   so,	   the	  standard	  curve	  equation	  was	  solved	  for	  x.	  The	  number	  of	  copies	  is	  the	  inverse	  log	  of	  x	   i.e.	  10x.	  When	  transcript	  numbers	  had	  been	  established	  for	  all	  primer	  pairs,	  the	  values	  of	  HPV16-­‐E6	  and	  HPV11-­‐E4	  were	  divided	  by	  the	  values	  of	  GAPDH	  to	  normalize	   the	   results.	   In	   order	   to	   establish	   the	   total	   number	   of	   cells	   in	   each	  reaction,	  the	  GAPDH	  copy	  numbers	  were	  divided	  by	  four.	  This	  was	  due	  to	  the	  fact	  that	   previous	   work	   with	   these	   GAPDH	   primers	   had	   identified	   two	   additional	  GAPDH	   pseudogene	   sequences	   within	   the	   NIKS	   genome.	   To	   complete	   the	   HPV	  copy	  number/cell	   calculation	   for	   each	   cell	   line,	   the	   total	   number	   of	  HPV	   copies	  were	  divided	  by	  the	  total	  number	  of	  cells.	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2.8.8	  Analysis	  of	  Relative	  Gene	  Expression	  using	  the	  ΔΔCt	  method	  The	  Ct	   values	   provided	   from	   real-­‐time	  qPCR	  were	   imported	   into	   a	   spreadsheet	  program	   such	   as	  Microsoft	   Excel®.	   The	   relative	   variation	  between	   samples	  was	  established	  following	  the	  protocol	  as	  described	  in	  (Livak	  and	  Schmittgen,	  2001).	  The	  GAPDH	  primers	  were	  used	  to	  assess	  the	  calibrator	  gene	  GAPDH.	  	  
2.9	   Amplification	   of	   Papillomavirus	   Oncogene	   Transcripts	  
(APOT)	  analysis	  
	  2x106	   sub-­‐confluent	   NIKS-­‐HPV16	   cell	   lines	   were	   first	   harvested	   for	   total	   RNA	  extraction.	   	   Total	   RNA	   extraction	  was	   carried	   out	   using	   the	   Qiagen	   RNeasy	   kit	  (Qiagen;	  UK).	  APOT	  analysis	  of	  HPV-­‐16	  extracted	  RNA	  was	  carried	  out	  using	  the	  exact	   primers	   and	   protocol	   as	   described	   in	   (Klaes	   et	   al.,	   1999).	   The	   basic	  principles	   of	   the	   APOT	   assay	   for	   the	   integrated	   and	   episomal	   transcripts	   are	  shown	   in	   Figure	   2.2.	   The	   reserve	   transcription	   reaction	   is	   performed	   using	   an	  adaptor	  linked	  oligo	  dT	  primer	  (dT	  P3).	  Subsequently,	  two	  PCR	  reaction	  steps	  are	  performed	  using	  oligo	  dT	  or	  Adaptor	  primers	  and	  HPV	  E7	  specific	  primers.	  The	  amplification	  products	  are	  hybridized	   to	  HPV	  E7	  and	  HPV	  E4	  specific	  probes	   to	  discriminate	   episomal	   from	   integrated-­‐derived	   transcripts	   (Figure	   2.2).	   The	  cycling	  conditions	  and	  the	  primers	  sequences	  are	   listed	   in	  Table	  2.12	  and	  Table	  2.13.	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Figure	  2.2	  APOT	  diagram,	  transcription	  and	  amplification.	  The	  arrows	  show	  the	  primer	  binding	  sites.	  P1	  and	  P2	  are	  HPV	  specific	  forward	  primers	  for	  1st	  and	  2nd	  PCR.	  dT-­‐P3	  is	  a	  Oligo	  dT	  primer.	  H1	  and	  H2	  are	  the	  probes	  designed	  to	  bind	  at	  E7	   and	   E4	   respectively.	   Transcript	   schemes	   are	   shown	   on	   the	   left	   side.	   The	  corresponding	  amplification	  products	  are	  depicted	  on	  the	  right	  side.	  	  	  
Table	  2.11:	  Cycling	  conditions	  and	  primers	  for	  the	  1st	  APOT	  PCR	  
30	  Cycles	   HPV16	  
Initial	  denaturation	   94	  ˚	  C	  	  	  3	  min	  
Denaturation	   94	  ˚	  C	  	  	  45	  sec	  
Annealing	   59	  ˚	  C	  	  	  30	  sec	  
Extension	   72	  ˚	  C	  	  	  4	  min	  
Final	  Extension	   94	  ˚	  C	  	  	  7	  min	  
P1-­‐	  sequence	   5’-­‐	  CGGACAGAGCCCATTACAAT	  -­‐3’	  
P3	  -­‐	  sequence	   5’-­‐	  GACTCGAGTCGACATCG	  -­‐3’	  	  	  
Table	  2.12:	  Cycling	  conditions	  and	  primers	  for	  the	  2st	  APOT	  PCR	  
30	  Cycles	   HPV16	  
Initial	  denaturation	   94	  ˚	  C	  	  	  3	  min	  
Denaturation	   94	  ˚	  C	  	  	  40	  sec	  
Annealing	   67	  ˚	  C	  	  	  30	  sec	  
Extension	   72	  ˚	  C	  	  	  4	  min	  
Final	  Extension	   94	  ˚	  C	  	  	  7	  min	  
P2-­‐	  sequence	   5’-­‐	  CCTTTTGTTGCAAGTGTGACTCTACG-­‐3’	  
(dT)17-­‐P3	  -­‐	  sequence	   5’-­‐	  GACTCGAGTCGACATCGATTTTTTTTTTTTTTTTT-­‐3’	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The	   PCR	   products	   are	   electrophoresed	   in	   1.0%	   agarose	   gels,	   blotted	   on	   nylon	  membranes	   (Hybond	  N+,	  Amersham	  Life	  Science,	  Buckinghamshire,	  England)	  as	  shown	  in	  Figure	  2.3.	  The	  membrane	  is	  then	  hybridized	  with	  an	  E7-­‐specific	  probe	  (H1,	  Table	  2.13)	  at	  55	  ˚C.	  A	  second	  membrane	  is	  hybridized	  with	  the	  E4-­‐specific	  probe	   (H2,	   Table	   2.13)	   at	   55	   ˚C.	   The	   labeling	   and	   detection	   of	   the	   probe	   was	  performed	   using	   the	   ECL	   oligo-­‐labeling	   and	   detection	   kit	   (GE	   Healthcare,	   USA)	  following	   manufacture’s	   instructions.	   The	   amplified	   products	   that	   did	   not	  hybridize	   with	   the	   E4-­‐specific	   probe	   were	   suspected	   to	   be	   derived	   from	  integrated	  HPV	  genomes.	  	  
	  
Figure	  2.3	  Schematic	  representation	  of	  the	  capillary	  blotting.	  Transfer	  buffer	  is	  drawn	  up	   the	  wick,	   through	   the	  gel	  and	  membrane,	  and	   into	   the	  dry	  stack	  of	  towels.	  The	  flow	  of	  buffer	  elutes	  the	  nucleic	  acid	  molecules	  from	  the	  gel	  onto	  the	  membrane,	  preserving	  the	  band	  pattern.	  	  	  	  
Table	  2.13:	  H1	  and	  H2	  specific	  probe	  sequence	  
H1	  E7-­‐specific	  probe	   5’-­‐	  TCGTACTTTGGAAGACCTGTTAATG	  -­‐3’	  
H2	  E4-­‐specific	  probe	   5’-­‐	  GAAGAAACACAGACGACTATATCCAG	  -­‐3’	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2.10	  Protein	  Analysis	  
2.10.1	  Cell	  lysis	  for	  western	  blot	  analysis	  Monolayer	  HPV-­‐16	  cell	   lines	  were	  grown	   in	  60cm	  dishes.	   	  Approximately	  2x106	  NIKS	   or	   HPV-­‐16	   cell	   lines	   were	   harvested	   and	   pelleted	   for	   lysis.	   	   Pellets	   were	  washed	  with	  1	  X	  PBS	  and	  were	  then	  were	  resuspended	  in	  100-­‐200	  µl	  lysis	  buffer	  (50	  mM	  Tris	   [pH	  7.4],	   150	  ml	  NaCl,	   1	  mM	  EDTA	  +	  4µl	   of	  1x	   complete	  protease	  inhibitor	  solution	  (Roche;	  UK)),	  The	  lysates	  were	  held	  on	  ice	  for	  30	  minutes	  and	  then	   were	   spun	   at	   14000	   rpm	   for	   30	   minutes.	   	   The	   soluble	   supernatant	   was	  removed	   and	   stored	   separately	   at	   -­‐70	   °C	   until	   further	   analysis.	   	   The	   insoluble	  pellet	  was	  then	  resuspended	  in	  100	  µl	  3x	  Laemmli	  Sample	  buffer	  (New	  England	  Biolabs;	  UK)	  and	  was	  spun	  at	  14000	  rpm	  for	  15	  minutes	  at	  room	  temperature.	  	  	  	  
2.10.2	  Protein	  quantification	  The	   protein	   quantification	   of	   soluble	   lysates	  was	   carried	   out	   using	   the	  Bio-­‐Rad	  RCDC	   kit	   (Bio-­‐Rad;	   UK).	   	   Quantification	   was	   carried	   out	   according	   to	   the	  manufacturers	   instructions.	   BSA	   standards,	   prepared	   in	   0.5	   mg/ml	   increments	  ranging	   from	   0	   mg/ml	   to	   up	   to	   10	   mg/ml,	   were	   used	   to	   create	   a	   standard	  absorbance	  curve.	  	  
2.10.3	  SDS	  PAGE	  	  
2.10.3.1	  Gel	  electrophoresis	  for	  E7	  protein	  analysis	  The	   separation	   of	   E7	   proteins	   was	   carried	   out	   using	   15	   %	   Tris/	   Glycine	  polyacrylamide	  gels.	   	  Table	  2.14	  contains	  the	  gel	  composition	  for	  both	  the	  stack	  and	  resolving	  gel.	  	  	  7.5	  mL	  of	  the	  resolving	  gel	  mixture	  was	  first	  poured	  and	  set	  at	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room	  temperature	  for	  30	  minutes.	   	  2	  mL	  of	  the	  stack	  gel	  was	  overlaid	  on	  top	  of	  the	  resolving	  gel	  and	  was	   left	   to	  polymerize	  for	  30	  minutes.	  20-­‐40	  µg	  of	  soluble	  lysate	   was	   loaded	   into	   each	   well.	   Each	   gel	   was	   submerged	   in	   500	   mL	   of	   SDS	  Running	   buffer	   (25mM	   Tris	   pH	   8.3,	   200mM	   glycine,	   0.1%	   SDS)	   in	   Bio-­‐Rad	   gel	  tanks.	  	  The	  separation	  of	  E7	  proteins	  was	  carried	  out	  at	  80	  V	  for	  30	  minutes	  and	  then	  at	  160	  V	  for	  1	  hour.	  	  
2.10.3.2	  Gel	  electrophoresis	  for	  cellular	  proteins	  The	   separation	   of	   various	   cellular	   proteins	   was	   carried	   out	   using	   8	  %	   or	   10%	  Tris-­‐Glycine	  polyacrylamide	  gels.	   	  Proteins	  greater	   than	  80	  kDa	  were	   separated	  on	   an	   8%	   gel.	   	   Table	   2.14	   contains	   the	   gel	   composition	   for	   both	   the	   stack	   and	  resolving	   gel.	   	   	   7.5	  mL	   of	   the	   resolving	   gel	  mixture	  was	   first	   poured	   and	   set	   at	  room	  temperature	  for	  30	  minutes.	   	  2	  mL	  of	  the	  stack	  gel	  was	  overlaid	  on	  top	  of	  the	  resolving	  gel	  and	  was	  left	  to	  polymerize	  for	  30	  minutes.	   	  15-­‐30	  µg	  of	  soluble	  lysate	   was	   loaded	   into	   each	   well.	   	   Each	   gel	   was	   submerged	   in	   500	  mL	   of	   SDS	  running	   buffer	   in	   Bio-­‐Rad	   gel	   tanks.	   The	   separation	   of	   cellular	   proteins	   was	  carried	  out	  at	  80	  V	   for	  30	  minutes	  and	   then	  at	  160	  V	   for	  40	  minutes	   to	  1	  hour	  depending	  on	  the	  protein	  size.	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Table	  2.14:	  Composition	  of	  6,	  10	  and	  15%	  Tris-­‐glycine	  SDS-­‐
polyacrylamide	  Resolving	  gels	  and	  5%	  Stacking	  gel	  
Resolving	  gel	  (for	  10	  ml)	  
Reagent	   6	  %	   10	  %	   15	  %	  dH20	   5.3	  ml	   4	  ml	   2.3	  ml	  30	  %	  acrylamide	  mix	   2	  ml	   3.3	  ml	   5	  ml	  1.5	  M	  Tris	  (pH	  8.8)	   2.5	  ml	   2.5	  ml	   2.5	  ml	  10	  %	  SDS	   0.1	  ml	   0.1	  ml	   0.1	  ml	  10%	  ammonium	  persulphate	   0.1	  ml	   0.1	  ml	   0.1	  ml	  TEMED	   8	  µl	   4	  µl	   4	  µl	  
Stacking	  gel	  (2	  ml)	  dH20	   1.4	  ml	  30	  %	  acrylamide	  mix	   0.33	  ml	  1	  M	  Tris	  (pH	  6.8)	   0.25	  ml	  10	  %	  SDS	   20	  µl	  10	  %	  ammonium	  persulphate	   20	  µl	  TEMED	   2	  µl	  
	  
2.10.3.3	  Membrane	  transfer	  for	  Western	  blot	  The	  15%	  gels	  were	  transferred	  onto	  0.2	  µm	  Immuno-­‐Blot	  PVDF	  membranes	  (Bio-­‐Rad;	  162-­‐0176).	  All	  other	  gels	  were	  transferred	  onto	  0.45	  µm	  PVDF	  membranes	  (Millipore;	   IPVH00010).	   Before	   use,	   membranes	   were	   submerged	   in	   methanol,	  and	   left	   to	   soak	   in	   transfer	   buffer	   until	   mounting	   on	   the	   protein-­‐transfer	  equipment.	  All	  transfers	  were	  done	  using	  500	  ml	  of	  Transfer	  buffer	  per	  Bio-­‐Rad	  Mini	  Trans-­‐Blot®	  Cell	  tank	  (containing	  up	  to	  2	  gels)	  at	  4	  °C	  overnight	  at	  50V.	  	  
2.10.3.4	  Blocking,	  antibody	  incubations	  and	  washing	  Following	  protein	  transfer,	  the	  membranes	  were	  incubated	  under	  light	  shaking	  in	  0.1	  %	  PBS/Tween	  containing	  5%	  of	  milk	  powder	  (Oxoid;	  LP0031)	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room	   temperature	   or	   overnight	   at	   4	   °C.	   Subsequently,	   the	   membranes	   were	  incubated	  with	  primary	  antibody	  for	  1-­‐2	  hours	  at	  room	  temperature	  or	  overnight	  at	   4	   °C.	   Commonly,	   the	  membranes	  were	   cut	   into	   several	   smaller	   strips	   before	  applying	  antibody	   to	  allow	   incubation	  with	   several	  different	  antibodies	  at	  once.	  The	  antibodies	  were	  diluted	  in	  5	  ml	  of	  5	  %	  milk	  in	  0.1	  %	  PBS/Tween.	  Table	  2.15	  lists	   all	   the	   primary	   antibodies	   used	   for	   protein	   analysis	   and	   their	   respective	  dilutions.	   Following	   the	   incubation	   with	   the	   primary	   antibody,	   all	   membrane	  pieces	  were	  washed	  in	  0.1	  %	  PBS/Tween	  at	  room	  temperature	  for	  30	  minutes	  to	  up	  to	  1	  hour	  with	  a	  change	  in	  wash	  buffer	  every	  10-­‐15	  minutes.	  The	  membranes	  were	  then	  incubated	  with	  secondary	  antibody,	  listed	  in	  Table	  2.16,	  in	  5	  ml	  of	  5	  %	  milk	  in	  0.1	  %	  PBS/	  Tween	  for	  1	  hour	  at	  room	  temperature.	  The	  incubation	  with	  secondary	   antibody	   was	   followed	   by	   a	   second	   round	   of	   washing	   with	   0.1	   %	  PBS/Tween	   at	   room	   temperature,	   lasting	   up	   to	   2	   hours	  with	   a	   change	   in	  wash	  buffer	  every	  20-­‐30	  minutes	  	  
Table	  2.15.	  Primary	  Antibodies	  for	  Western	  Blot	  
Antibody	   Clone	   Dilution	   Supplier	  
E7*	   ED17	  and	  8C9	  	   1:500	  /	  1:500	   Santa	  Cruz/	  Invitrogen	  (Zymed)	  
EGFR	   Sc-­‐71034	   1:1000	   Santa	  Cruz	  
GAPDH	   MAB374	   1:4000	   Chemicon	  
Rb	   G3-­‐245	   1:1000	   Pharmingen	  
P53	   D0-­‐1	   1:1000	   Santa	  Cruz	  *	  The	  E7	  antibodies	  were	  together	  used	  as	  cocktail	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Table	  2.16	  Secondary	  Antibodies	  for	  Western	  Blot	  
Antibody	   Clone	   Dilution	   Supplier	  
Anti-­‐Mouse	  	  
IgG-­‐HRP	  	  
NA931V	  	  	   1:10000	  	  	   GE	  Healthcare	  	  
	  
2.10.3.5	  Signal	  detection	  The	   proteins	   on	   membranes	   were	   detected	   using	   2	   different	   kits,	   partly	  depending	   on	   the	   level	   of	   sensitivity	   needed.	   	   The	   Amersham™	   ECL	   Western	  Blotting	  Detection	  kit	   	   (GE	  Healthcare;	  RPN2106)	  was	  used	   for	  highly	  abundant	  proteins	  while	  the	  Amersham™	  ECL	  Advance	  kit	  (GE	  Healthcare;	  RPN2135)	  was	  used	  to	  detect	  low	  level	  proteins.	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3.	  The	  analysis	  of	  monolayer	  LSIL-­‐like	  and	  HSIL-­‐
like	  HPV16	  cell	  lines	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3.1	  Introduction	  As	   demonstrated	   in	   previous	   studies,	   the	   viral	   gene	   expression	   patterns	   and	  pathological	  features	  of	  HSIL-­‐like	  raft	  cultures	  are	  similar	  to	  those	  of	  high-­‐grade	  cervical	   lesions	   (Isaacson	   Wechsler	   et	   al.,	   2012).	   This	   discovery	   has	   been	  important	   in	   the	   development	   of	   a	   HPV-­‐16	   raft	  model	   system	   that	   reflects	   the	  LSIL	  and	  HSIL	  phenotypes	  seen	   in	  vivo,	  and	   to	   further	  study	   the	  viral	  molecular	  basis	  of	  HPV-­‐associated	  neoplasia.	  	  	  	  Our	  understanding	  of	   the	  viral	  mechanisms	   that	   lead	   to	  HPV-­‐induced	  neoplasia	  and	  HPV-­‐related	  cancers	  proposed	  in	  the	  past	  is	  primary	  based	  on	  the	  E6	  and	  E7	  oncogenes	   (Duensing	   et	   al.,	   2000).	   In	   fact,	   both	   E6	   and	   E7	   have	   been	  demonstrated	   to	   have	   transforming	   capabilities	   for	   the	   cell	   (Galloway	   and	  McDougall,	   1996).	   The	   integration	  of	   E6	   and	  E7	   genes	   into	   a	   host	   chromosome	  often	  correlate	  with	  precancerous	  high-­‐grade	  neoplasia	  and	  cancer	  (Klaes	  et	  al.,	  1999).	   Although	   previous	   investigations	   suggested	   that	   both	   E6	   and	   E7	  transcripts	  are	  more	  expressed	  following	  viral	  integration,	  presumably	  due	  to	  the	  loss	   of	   viral	   negative	   regulatory	   elements	   during	   integration,	   it	   has	   been	  more	  recently	   shown	   that	   85%	   of	   precancerous	   high-­‐grade	   lesions	   and	   15%	   of	   HPV	  related	   cancers	   contain	   only	   viral	   episomes	   (Hafner	   et	   al.,	   2008;	   Klaes	   et	   al.,	  1999).	  For	   this	  reason,	  considering	   that	   integration	   is	   likely	   to	  occur	  during	   the	  final	   stages	   of	   neoplastic	   progression	   and	   less	   frequently	   in	   the	   precancerous	  stages	   of	   neoplasia,	   E6	   and	   E7	   expressed	   essentially	   from	   episomes	   might	   be	  important	   during	   the	   phases	   of	   lesion	   formation.	   This	  would	   therefore	   suggest	  that	   a	   deregulation	   of	   E6	   and	   E7	   expression	   could	   occur	   from	   intact	   viral	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episomes	  and	   that	   their	  expression	  might	  be	  an	   important	  driving	   force	   for	   the	  formation	  of	  the	  HR-­‐HPV	  lesions.	  	  Several	   studies	   using	   E6	   and	   E7	   transgenic	   mouse	   models	   have	   shown	   that	  persistent	   E6	   and	  E7	   expression	   is	   important	   for	   the	   development	   of	   neoplasia	  and	  cancer	  (Griep	  et	  al.,	  1993).	  However,	  although	  this	  was	  seen	  in	  models	  where	  E6	  and	  E7	  were	  expressed,	  this	  was	  not	  seen	  in	  systems	  that	  express	  endogenous	  levels	  of	  E6	  and	  E7	  from	  a	  full	  intact	  HPV-­‐16	  genome	  (Brake	  and	  Lambert,	  2005;	  Shai	  et	  al.,	  2007).	  Other	  studies	  showed	  that	  E6	  and	  E7	  from	  HR-­‐HPVs	  are	  able	  to	  enhance	  cell	  proliferation	  of	  wounded	  epithelia	  when	  expressed	   in	  mice	  models	  (Davies	  et	  al.,	  1993).	  Furthermore,	  it	  has	  been	  suggested	  from	  studies	  on	  clinical	  material	   that	   early	   oncogene	   expression	   might	   drive	   cell	   proliferation	   at	   basal	  sites	   	   (Zhonglin	  Wu,	  NIMR).	   However,	   there	   is	   not	   evidence	   that	   correlates	   the	  expression	  of	  E6	  and	  E7	  genes	  with	  the	  very	  early	  stages	  of	  the	  lesion	  formation	  process.	  Other	   interesting	  questions	  are	  how	  gene	  expression	  differs	  between	  HPV	  types	  and	   whether	   the	   environment	   in	   which	   basal	   cells	   proliferate	   after	   wounding	  might	  influence	  their	  proliferation	  after	  HPV	  infection.	  	  Here	   we	   hypothesize	   that	   early	   genes	   from	   HR-­‐HPVs	   are	   able	   to	   drive	   cell	  proliferation	  and	  are	  important	  in	  early	  stages	  of	  lesion	  formation.	  LR-­‐HPVs	  may,	  however,	  not	  have	  evolved	   this	   feature	  and	  possibly	  have	  developed	  a	  different	  strategy	   to	   form	  a	   lesion,	   perhaps	   exploiting	   the	   local	  microenvironment	  of	   the	  epithelia.	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A	  well-­‐known	   role	   of	   high-­‐risk	  E7	   is	   its	   ability	   to	  bind	  Rb,	   p107	  and	  p130,	   and	  target	  them	  for	  proteasomal	  degradation	  (Boyer	  et	  al.,	  1996;	  Davies	  et	  al.,	  1993;	  Dyson	  et	  al.,	  1989).	  	  E7	  from	  low-­‐risk	  viruses	  can	  also	  bind	  to	  Rb,	  but	  with	  a	  lower	  affinity	  than	  high-­‐risk	   E7.	   This	  may	   explain	   the	   inability	   of	   low-­‐risk	   E7	   to	   induce	   transformation	  (Gage	   et	   al.,	   1990).	   However,	   low-­‐risk	   E7	   can	   cause	   hyper-­‐proliferation	   in	   the	  suprabasal	   layers	   of	   the	   epithelium(Heck	   et	   al.,	   1992).	   Another	   difference	  between	  low-­‐	  and	  high-­‐risk	  E7	  proteins	  relies	  in	  the	  ability	  to	  degrade	  RB,	  p107	  and	  p130.	  Low-­‐risk	  E7	  can	   in	   fact	  only	  degrade	  p130	  (Zhang	  et	  al.,	  2006).	  Both	  p107	  and	  p130	  share	  the	  role	  of	  Rb	  to	  modulate	  E2F	  levels.	  The	  degradation	  of	  Rb	  by	  E7	  is	  commonly	  efficient	  in	  basal	  and	  suprabasal	  cells,	  while	  p130	  degradation	  has	  been	  found	  mainly	  in	  differentiating	  cells	  (Collins	  et	  al.,	  2005;	  Klingelhutz	  and	  Roman,	  2012).	  This	  suggests	   that	  an	   inefficient	  Rb	  degradation	   in	   favor	  of	  p130	  destabilization	  may	  contribute	  to	  the	  lack	  of	  transformation	  potential	  of	  low-­‐risk	  E7.	  The	   E6	   protein	   from	   low-­‐risk	   and	   high-­‐risk	   HPV	   types	   also	   present	   different	  functions	   (Klingelhutz	   and	   Roman,	   2012).	   In	   particular	   E6	   from	   low-­‐risk	   types	  lack	  the	  ability	  to	  bind	  and	  degrade	  p53	  (Doorbar,	  2006).	  Contrary	  to	  high-­‐risk	  E6	  the	  low-­‐risk	  E6	  lack	  binding	  to	  PDZ-­‐domain	  proteins	  and	  have	  weak	  inhibition	  of	  interferon	  responses.	  Furthermore,	   it	   is	   important	   to	  notice	   that	  high-­‐	  and	   low-­‐risk	  HPV	  types	  have	  significant	  differences	  in	  promoter	  positioning	  and	  promoter	  regulation,	  as	  well	  as	  in	  patterns	  of	  mRNA	  splicing,	  which	  affect	  expression	  of	  E6	  and	  E7	  genes	  (Doorbar,	  2003,	  2006,	  Roman).	  Current	  hypotheses	  suggest	  that	  the	  differential	  expression	  of	  viral	  genes	  and	  the	  differences	  in	  the	  protein	  functions	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in	  the	  various	  compartments	  of	   the	  epithelium	  play	  a	  major	  role	   in	  determining	  disease	  phenotype	  following	  infection.	  	  In	   this	   Chapter	   we	   aim	   to	   characterize	   a	   monolayer	   culture	   system	   NIKS	   to	  perform	  experiments	  oriented	  to	  further	  the	  understanding	  in	  the	  biology	  of	  the	  high-­‐	  and	  low-­‐HPV	  types,	  and	  in	  particular	  to	  consider	  the	  behaviour	  of	  the	  NIKS-­‐HPVs	   cells	   in	   a	   wound	   healing	   like	   environment.	  We	   address	   important	   issues	  relating	   to	   the	   development	   of	   a	   suitable	   wound-­‐healing	   model	   system	   used	  subsequently	   to	   study	   the	   episomal	   NIKS-­‐HPV16	   cell	   lines.	   Early	   passage	  monolayer	   cultures	   were	   used	   for	   these	   experiments,	   as	   they	   approximate	   the	  pre-­‐differentiated	  basal	   layer	  of	   raft	   cultures	  where	  early	  viral	  events	   (e.g.	  viral	  replication	  and	  viral	  oncogene	  expression)	  are	   likely	   to	  begin.	  Using	  monolayer	  LSIL-­‐like	   and	  HSIL-­‐like	   cultures,	  we	   investigated	   the	   early	   E6	   and	  E7	   oncogene	  expression	   and	   cellular	   growth	   characteristics.	   In	   addition,	   we	   investigated	  whether	   the	   E7	   oncogene	   expression	   in	   HPV-­‐16	   cell	   lines	   was	   mainly	   derived	  from	  episomal	   forms	  of	   the	  viral	  genome.	  Furthermore,	  as	  NIKS	  cells	  were	  used	  regularly	   throughout	   the	   various	   phases	   of	   the	   project,	   we	   checked	   that	   no	  appreciable	   differences	   in	   the	   cell	   background	   were	   present	   in	   parental	   NIKS	  clones.	  The	  evaluation	  of	  the	  keratinocyte	  differentiation	  state	  in	  our	  monolayer	  system	  was	  also	  considered.	  	  In	  this	  study,	  we	  support	  the	  hypothesis	  that	  early	  viral	  episomal	  establishment	  in	  the	  basal	  layer	  can	  lead	  to	  phenotypic	  differences	  in	  terms	  of	  cell	  proliferation,	  which	   are	   not	   however	   significant	   at	   early	   stages	   of	   cell	   proliferation	   in	  monolayer.	  LSIL-­‐like	  and	  HSIL-­‐like	  phenotypes	  are	  instead	  always	  manifest	  when	  cells	  are	  cultured	  for	  an	  extensive	  length	  of	  time	  (Figure	  3.1).	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Figure	  3.1	  Growth	  characteristics	  of	  LSIL-­‐like	  and	  HSIL-­‐like	  NIKS-­‐HPV16	  cell	  
lines.	  Monolayer	  culture	  of	  NIKS	  and	  LSIL	  and	  HSIL	  NIKS-­‐HPV16	  cell	  lines	  were	  counted	  in	  triplicate	  over	  seven	  days	  time	  period.	  The	  average	  cell	  number	  from	  triplicate	  counts	  for	  each	  cell	   line	  was	  plotted	  against	  days	  of	  growth.	  The	  error	  bars	  represent	  the	  standard	  deviation	  of	  the	  triplicate	  counts.	  	  
3.1.1	  The	  use	  of	  NIKS®	  (Normal	  Immortal	  KeratinocyteS)	  as	  a	  host	  
keratinocyte	  cell	  line	  	  To	   develop	   a	   model	   system	   I	   have	   established	   NIKS	   clonal	   cell	   lines	   and	  populations	  that	  maintain	  episomal	  forms	  of	  the	  HPV-­‐16	  and	  HPV-­‐11	  genomes.	  	  We	  specifically	  chose	  the	  high-­‐risk	  type	  HPV-­‐16	  and	  the	  low-­‐risk	  type	  HPV-­‐11	  as	  models	  with	  an	  interest	  in	  evaluating	  the	  biology	  of	  both	  HPV	  groups.	  HPV-­‐16	  and	  HPV-­‐11	  present	  substantial	  genetic	  differences	  and	  have	  very	  different	  oncogenic	  potentials.	   HPV-­‐16	   alone	   has	   been	   shown	   to	   cause	   over	   50%	   of	   total	   cervical	  cancers,	  whereas	  HPV11	  commonly	  associates	  with	  benign	  lesions.	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The	  experiments	  describe	  the	  establishment	  of	  a	  monolayer	  model	  system	  useful	  for	   the	   study	   of	   the	   effects	   that	   wound	   healing	   responses	   might	   have	   on	   a	  productive	  HPV16	  or	  HPV11	  infection.	  	  	  Normal	  Immortalized	  Human	  Keratinocytes	  (NIKS)	  were	  chosen	  as	  a	  host	  cell	  line	  for	   our	  model	   system	   due	   to	   their	   known	   ability	   to	   successfully	  maintain	   HPV	  viral	   episomes	   (Nicolaides	   et	   al.,	   2011).	   NIKS	   raft	   cultures	   (which	   are	   used	  extensively	  in	  our	  laboratory	  as	  a	  system	  to	  support	  the	  life	  cycle	  of	  several	  HPV	  types)	  were	   preferred	   over	   the	   use	   of	   primary	   foreskin	   keratinocytes.	   Primary	  Normal	  Human	  Epidermal	  Keratinocytes	  (NHEK),	   in	   fact,	  are	  generally	  available	  from	   single	   or	   from	   pooled	   donors	  isolated	   from	   the	   epidermis	   of	   juvenile	  foreskin	   or	   adult	   skin	   from	   different	   locations	   like	   the	   face,	   the	   breasts,	   the	  abdomen,	   and	   the	   thighs.	  NIKS	   cells	  however,	   result	   from	  expansion	  of	   a	   single	  colony	   (Allen-­‐Hoffmann	   et	   al.,	   2000).	   In	   addition	   to	   the	   clonal	   characteristics,	  NIKS	  are	  also	  immortalized	  cell	  lines,	  whereas	  primary	  cell	  lines	  typically	  contain	  an	   assortment	   of	   stem	   cells	   and	   transit	   amplifying	   cells.	   Therefore,	   in	   order	   to	  make	   a	   HPV	   cell	   line	   or	   population	   we	   chose	   a	   clonal	   recipient	   instead	   of	   a	  heterogeneous	  population	  of	  cells.	  	  	  	  The	  NIKS	  cells	  were	  isolated	  and	  characterized	  as	  a	  spontaneously	  immortalized	  human	  keratinocyte	   cell	   line,	   and	  were	  derived	   from	  a	  normal	   human	  neonatal	  foreskin	  keratinocytes	  strain,	  BC-­‐1-­‐Ep.	  However,	  the	  NIKS	  population	  presented	  a	  specific	  abnormality	  following	  karyotyping	  studies	  (Allen-­‐Hoffmann	  et	  al.,	  2000).	  In	   fact,	   all	   of	   the	  NIKS	   had	   acquired	   an	   additional	   copy	   of	   chromosome	   8.	   This	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abnormality	   did	   not	   compromise	   their	   ability	   to	   be	   employed	   as	  HPV	   recipient	  and	  to	  produce	  a	  fully	  differentiated	  epithelium.	  Further	  investigation	  confirmed	  that	  NIKS	  cells	  were	  free	  from	  HPV	  as	  no	  detectable	  level	  of	  viral	  DNA	  was	  found.	  NIKS	  maintained	  normal	  growth	  characteristics	  compared	  to	  the	  parental	  cell	  line	  The	  studies	  on	  the	  autocrine	  expression	  levels	  of	  the	  growth	  factors	  and	  markers	  such	   as	   the	   Transforming	   growth	   factor	   (TGF),	   TGF-­‐ß1	   (a	   keratinocyte	   growth	  inhibitor),	   the	   Epidermal	   growth	   factor	   (EGF),	   the	   oncogene	   c-­‐myc	   and	   keratin	  K14,	   showed	  no	  differences	  with	   the	  original	  population	   (Allen-­‐Hoffmann	  et	  al.,	  2000).	  Moreover,	   NIKS	   have	   been	   shown	   to	   be	   non-­‐tumorigenic	  when	   injected	  into	  mice,	  which	  indicates	  that	  they	  are	  not	  a	  transformed	  line.	  Our	  studies	  show	  that,	  NIKS	  cells	  grow,	  differentiate,	  and	  develop	  into	  skin	  tissue	  in	  a	  similar	  manner	  to	  the	  normal	  human	  keratinocytes,	  exhibiting	  characteristic	  physical,	  chemical,	  and	  histological	  properties	  of	  the	  skin	  (Figure	  3.2)	  (Boukamp	  et	  al.,	  1988;	  GIbson,	  2007;	  Isaacson	  Wechsler	  et	  al.,	  2012;	  Middleton	  et	  al.,	  2003).	  	  We	  also	  further	  developed	  the	  analysis	  on	  NIKS	  background	  to	  make	  sure	  that	  no	  genetic	  variations	  were	  present	  in	  transfected	  NIKS	  cells	  that	  may	  alter	  the	  HPV	  cell	  lines	  produced.	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Figure	   3.2	   Pathology	   of	   cervical	   LSIL	   HPV16	   lesion	   and	   NIKS-­‐HPV16	   raft	  
culture	  with	  LSIL-­‐like	  phenotype.	  	  Haematoxylin	  and	  eosin	  (H&E)	  were	  applied	  to	  raft	  culture	  sections	  of	  NIKS	  (HPV-­‐negative)	  and	  NIKS-­‐HPV16	  LSIL-­‐like	  clone.	  The	   anatomy	  of	   the	   tissue	  was	   compared	  with	  H&E	   stained	   cervical	   sections	  of	  HPV16	   LSIL	   grade	   lesion.	   The	   anatomy	   of	   the	   raft	   culture	   obtained	   from	   NIKS	  cells	   shows	   normal	   characteristics	   with	   small	   size	   nuclei	   in	   the	   basal	   and	  suprabasal	   strata	   (MS).	   Normal	   stratification	   and	   cytoplasmic	   maturation	   is	  evident	  at	  upper	  layers	  of	  the	  section.	  A	  thin	  cornified	  layer	  (CL)	  is	  present	  in	  the	  uppermost	  region.	  In	  both	  NIKS-­‐HPV16	  LSIL	  raft	  and	  HPV16	  LSIL	  cervical	  lesion	  the	  cells	  at	  basal	  compartment	  present	  a	  mild	  dysplasia	  (Doorbar	  et	  al.).	  Normal	  stratification	   and	   cellular	  maturation	   occur	   in	   the	  middle	   and	   final-­‐third	   of	   the	  epithelium.	   NIKS-­‐HPV16	   raft	   culture	   present	   a	   cornfied	   layer	   (CL)	   in	   the	  uppermost	  region	  of	  the	  section.	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3.2.	  LSIL-­‐like	  and	  HSIL-­‐like	  monolayer	  episomal	  HPV-­‐16	  cell	  lines	  
proliferate	  faster	  than	  NIKS	  HPV-­‐negative	  cells.	  	  Isaacson	   et	   al.	   (Isaacson	  Wechsler	   et	   al.,	   2012)	   showed	   in	   raft	   culture	   that	   the	  HSIL-­‐like	  cell	   lines	  maintained	  proliferating	  cells	   throughout	   the	  majority	  of	   the	  epithelium,	  and	  that	  this	  coincided	  with	  a	  delay	  in	  cellular	  differentiation	  and	  late	  viral	  gene	  expression.	  Such	  proliferating	  cells	  were	  only	  detected	  in	  the	  first	  few	  layers	   of	   raft	   epithelium	   formed	   by	   NIKS-­‐HPV16	   LSIL,	   which	   coincided	   with	   a	  more	  normal	  onset	  of	  cellular	  terminal	  differentiation	  and	  an	  earlier	  onset	  of	  late	  viral	   gene	   expression.	   	   It	   was	   reported	   that	   the	   HSIL	   and	   LSIL	   related	  characteristics	   were	   consistent	   phenotypes	   deriving	   from	   NIKS-­‐HPV16	   clonal	  cells	   and	   this	  was	   exclusively	   supported	  by	  my	  experience	  with	   these	   cell	   lines	  (Figure	  3.1;	  3.3A).	  In	  addition,	  it	  was	  demonstrated	  that	  these	  cell	  lines	  retained	  these	  characteristics	  in	  monolayer	  culture	  as	  well.	  In	  fact,	  HSIL-­‐like	  cells	  cultured	  in	   monolayer	   dishes	   were	   able	   to	   overcome	   the	   cell-­‐to-­‐cell	   contact	   inhibition	  stimuli	   and	   proliferated	   beyond	   the	   confluence	   point.	   The	   LSIL-­‐like	   cell	   lines,	  however,	   were	   not	   able	   to	   grow	   well	   beyond	   the	   usual	   confluence	   point,	   and	  generated	  a	  low	  number	  of	  cells	  than	  HSIL	  cells	  grown	  for	  the	  same	  time.	  In	  this	  study	  the	  phenotypical	  characteristics	  of	  the	  HSIL-­‐like	  and	  LSIL-­‐like	  cells	  were	   investigated	   (in	   particular	   at	   the	   early	   phases	   of	   cell	   proliferation	   in	  monolayer)	   as	   in	   this	   phase	   the	   cells	   have	   space	   to	   proliferate	   as	  would	   occur	  during	  the	  proliferative	  phase	  of	  wound	  healing.	  	  In	  order	  to	  understand	  the	  dynamics	  of	   infected	  cells	  during	  wound	  healing,	  we	  considered	   low-­‐density	   monolayer	   culture	   as	   a	   model	   to	   measure	   the	  proliferation	  rate	  of	  cells	  that	  have	  limited	  contact	  with	  their	  neighbouring	  cells.	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These	  conditions	  are	  similar	   to	   those	  expected	  during	  the	  proliferative	  phase	  of	  wound	  healing.	  We	  considered	  the	  72	  hour	   time	   frame	   following	  cell	  plating	   to	  be	   important	   to	  understand	  whether	  the	  HPV16	  genome	  contained	  in	  the	  NIKS	  cells	  is	  able	  to	  give	  infected	   cells	   a	   proliferative	   advantage	   in	   comparison	   with	   NIKS	   HPV-­‐negative	  cells.	  We	   aimed	   to	   evaluate	   if	   LSIL-­‐like	   and	  HSIL-­‐like	   cell	   lines	   have	   a	   higher	   growth	  potential	  than	  NIKS	  HPV-­‐negative	  cells.	  In	  order	  to	  compare	  the	  growth	  potentials	  of	  LSIL-­‐like,	  HSIL-­‐like	  and	  NIKS	  cell	   lines,	  we	  seeded	  the	  NIKS,	  the	  LSIL-­‐like	  and	  the	  HSIL-­‐like	  cell	  lines	  at	  1	  x	  105	  cells	  per	  well	  in	  6-­‐well	  plates.	  Each	  cell	  line	  was	  harvested	  and	  counted	  in	  triplicate	  over	  a	  72	  hour	  time	  course	  in	  which	  the	  cells	  maintain	  a	  sub-­‐confluent	  growth	  density	  (Figure	  3.3B).	  Both	  LSIL-­‐like	  and	  HSIL-­‐like	  cell	   lines	  maintained	  a	  growth	  advantage	  over	   the	  HPV-­‐negative	  NIKS.	  This	  was	  expected	  since	   the	  viral	  oncogenes	   lead	   to	  higher	   levels	  of	  proliferation.	  At	  the	   end	  of	   the	   72	  hours	   LSIL-­‐like	   and	  HSIL-­‐like	   cell	   lines	   reached	   a	   similar	   cell	  numbers.	  We	   reported	  no	   significant	  difference	   in	   the	  growth	   rate	  between	   the	  two	   NIKS-­‐HPV16	   cell	   lines	   in	   the	   72	   hours	   following	   cell	   plating.	   This	   is	  interesting	   because,	   in	   absence	   of	   cell-­‐to-­‐cell	   contact,	   the	   proliferation	   rate	   of	  LSIL-­‐like	  and	  HSIL-­‐like	  cells	  was	  consistently	  comparable	  (Figure	  3.3B).	  	  Furthermore,	   we	   considered	   the	   possibility	   that	   the	   presence	   of	   the	   HPV16	  genome	  enhanced	  the	  cell	  cycling	  pace,	  often	  referred	  to	  as	  doubling	  time.	  The	  study	  of	   the	  doubling	   time,	  which	  considers	   the	  number	  of	   replicating	  cells	  during	   the	   24	   hours	   post-­‐seeding,	   demonstrated	   that	   cells	   containing	   the	   viral	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genome	  were	   cycling	   considerably	   faster	   than	   NIKS	   HPV-­‐negative	   cells	   (Figure	  3.3C).	  Interestingly	  we	  noticed	  that,	  although	  the	  LSIL-­‐like	  cells	  presented	  an	  enhanced	  cycling	   speed	   during	   the	   initial	   24	   hours,	   proliferating	   at	   a	   similar	   rate	   to	   the	  HSIL-­‐like	   cells,	   they	   retained	   their	   characteristic	   phenotype	   (growth	   beyond	  confluence	  point)	  at	  later	  stages	  of	  proliferation.	  	  We	  further	  speculate	  that	  this	  might	  be	  the	  case	  for	  the	  low-­‐risk	  HPV	  infection,	  as	  it	   is	  thought	  that	  the	  early	  E6	  and	  E7	  genes	  from	  these	  HPV	  types	  do	  not	  confer	  growth	  advantages	  to	  the	  infected	  cells	  (Roman,	  2006).	  The	  analysis	  of	  the	  genome	  copy	  number	  maintenance	  and	  the	  putative	  influence	  that	  growth	  factors	  have	  on	  viral	  oncogenes	  expression	  will	  be	  considered	  in	  the	  following	  chapters.	  	  
Figure	   3.3.	   Growth	   characteristics	   of	   LSIL	   and	   HSIL	   HPV-­‐16	   cell	   lines.	   (A)	  Monolayer	   cultures	   of	   LSIL	   and	   HSIL	   cell	   lines	   were	   counted	   in	   triplicate	   over	  seven	  day	  time	  frame.	  The	  mean	  total	  cell	  numbers	  from	  triplicate	  counts	  for	  each	  cell	  line	  were	  plotted	  against	  days	  of	  growth.	  (B)	  Monolayer	  cultures	  of	  LSIL	  and	  HSIL	  cell	  lines	  were	  counted	  in	  triplicate	  over	  72	  hour	  time	  frame.	  The	  mean	  total	  cell	  numbers	  from	  triplicate	  counts	  for	  each	  cell	  line	  were	  plotted	  against	  the	  time	  points	  of	  growth.	  The	  error	  bars	  represent	  the	  standard	  deviation	  of	  the	  triplicate	  counts.	   	   (C)	   The	   doubling	   time	   was	   estimated	   in	   hour	   units	   for	   each	   cell	   line	  during	  the	  24	  hours	  following	  cell	  plating.	  Six	  measurements	  were	  taken	  for	  each	  cell	  lines	  from	  two	  independent	  experiments	  and	  the	  results	  were	  averaged.	  The	  absolute	  mean,	  maximum,	  and	  minimum	  values	  are	  shown	  in	  the	  table	  below	  the	  chart.	   The	   error	   bars	   represent	   the	   standard	   deviation	   of	   the	   triplicate	   counts.	  There	   was	   significant	   difference	   between	   NIKS-­‐HPV16	   (H-­‐SIL	   and	   L-­‐SIL)	   and	  NIKS	  (p	  <	  0.05).	  The	  experiment	  was	  repeated	  three	  times.	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3.3.	  Cellular	  p53	  and	  pRb	  expression	  levels	  are	  reduced	  in	  both	  
LSIL-­‐like	  and	  HSIL-­‐like	  cell	  lines	  cultured	  in	  monolayer	  	  So	  far	  I	  have	  shown	  that	  the	  LSIL-­‐like	  and	  the	  HSIL-­‐like	  cell	  lines	  have	  increased	  proliferation	   rates	   compared	   to	   NIKS	   HPV-­‐negative	   cells.	   	   A	   molecular	  explanation	   for	   this	   phenomenon	   is	   that	   the	   E6	   and	   E7	   proteins	   expressed	   in	  these	  NIKS	  HPV16	  clones	  act	  on	  cellular	  pathways.	  The	  main	  E6	  and	  E7	  cellular	  targets	  are	  the	  p53	  and	  the	  pRb	  proteins	  respectively.	  E7	  can	  bind	  to	  Rb	  protein	  and	   induce	   its	   degradation	   (Gonzalez	   et	   al.,	   2001;	   Munger	   et	   al.,	   1989).	   Such	  process	  is	  important	  as	  the	  Rb	  protein	  allows	  for	  the	  transcription	  factor	  E2F	  to	  remain	   in	   an	   active	   state	   as	   the	   binding	   of	   Rb	   to	   the	   E2F-­‐2	   peptide	   conceals	  several	   conserved	   residues	   that	   are	   crucial	   for	   transcription	   activation	   of	   E2F	  (Lee	  et	  al.,	  2002a).	  This	  promotes	  entry	   into	  S-­‐phase	   from	  G1.	   It	   is	   thought	   that	  that	  E7	  expression	  can	   lead	   to	  Rb	  protein	  degradation,	  activation	  of	  E2F,	  which	  then	   increases	   cellular	   proteins	   such	   as	   MCM-­‐7,	   which	   are	   involved	   in	   cell	  proliferation.	  Another	  cellular	  protein	  marker	  that	  is	  altered	  after	  HPV	  infection	  is	  the	  tumour	  suppressor	  protein	  p53.	  In	  fact,	  the	  continuous	  Rb	  protein	  degradation	  and	  MCM-­‐7	  induction	  by	  viral	  E7	  in	  cells	  expressing	  only	  E7	  results	  in	  the	  up-­‐regulation	  of	  p53	  levels	  (Demers	  et	  al.,	  1994;	  Laurson	  et	  al.,	  2010).	  The	  main	  role	  of	  p53	  is	  to	  play	  as	  a	  G1	  to	  S-­‐phase	  checkpoint	  protein	  (Agarwal	  et	  al.,	  1995).	  This	  prevents	  the	  cell	  from	  proceeding	  through	  S-­‐phase.	  In	  a	  separate	  pathway,	  p53	   can	  also	   encourage	   cellular	   apoptosis	   (Demers	   et	   al.,	   1994;	  Ozaki	  and	  Nakagawara,	  2011).	  Furthermore,	  activation	  of	  p53-­‐mediated	  transcription	  is	  a	   critical	   cellular	   response	   to	   DNA	   damage	   (Lakin	   and	   Jackson,	   1999).	   p53	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stability	   and	   site-­‐specific	   DNA-­‐binding	   activity	   and,	   therefore,	   transcriptional	  activity,	   are	   modulated	   by	   post-­‐translational	   modifications	   including	  phosphorylation	  and	  acetylation	  (Sakaguchi	  K.	  et	  al.,	  1998)	  .	  	  HR-­‐HPVs	   have	   evolved	   to	   exploit	   these	   pathways	   and	   to	   counteract	   the	   p53	  functions.	   These	   viruses	   have,	   in	   fact,	   developed	   a	   way	   to	   degrade	   p53	   by	   the	  action	   of	   protein	  E6.	   This	   happens	   through	   the	   ubiquitination	   and	  proteosomal	  degradation	  of	  p53	  (Scheffner	  et	  al.,	  1993).	  	  	  According	  to	  the	  described	  biological	  functions,	  p53	  and	  Rb	  loss	  have	  been	  used	  as	   surrogate	   markers	   for	   E6	   and	   E7,	   respectively.	   However,	   due	   to	   their	  interdependent	  relationship,	  it	  is	  not	  certain	  whether	  the	  levels	  of	  the	  p53	  protein	  and	  pRb	  degradation	  exactly	  correlate	  with	  the	  levels	  of	  the	  E6	  and	  E7	  proteins.	  Taking	   this	   into	   consideration,	   we	   anticipate	   that	   NIKS-­‐HPV16	   cells,	   actively	  expressing	  E6	  and	  E7	  proteins,	  have	  reduced	  expression	  levels	  compared	  to	  p53	  and	  pRb	  seen	  in	  the	  parental	  NIKS	  line.	  Such	  a	  relationship	  was	  also	  supported	  in	  my	   previous	   studies	   using	   the	   NIKS-­‐HPV16	   systems	   (Isaacson	  Wechsler	   et	   al.,	  2012).	  	  In	  order	  to	  evaluate	  whether	  the	  LSIL	  and	  HSIL	  cell	  lines	  express	  viral	  oncogenes	  from	  the	  very	  early	  stages	   following	  cell	  plating,	  a	  western	  blot	  analysis	  of	  p53,	  pRb	  and	  GAPDH	  was	  performed	  on	  lysates	  obtained	  from	  cells	  harvested	  on	  day:	  one,	  three,	  five,	  six	  and	  seven,	  from	  cells	  cultured	  in	  monolayer	  (Figure	  3.4A).	  	  Furthermore,	  we	  used	  anti	  HPV16-­‐E7	  specific	  antibodies	  on	  the	  same	  cell	  lysates	  in	   order	   to	   compare	   the	   levels	   of	   expression	   of	   pRb	   to	   the	   levels	   of	   E7	   protein	  (figure	  3.4B).	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The	  western	  blot	  analysis	  showed	  that	   in	  both	  LSIL	  and	  HSIL	  cell	   lines	  p53	  and	  pRb	   were	   undetectable	   indicating	   their	   effective	   degradation	   for	   all	   the	   time	  points	   analysed	   (Figure	   3.4A).	   NIKS	  HPV-­‐negative	   cells	  were	   used	   alongside	   as	  positive	  controls,	  and	  presented	  visible	  bands	  at	  all	  stages.	  The	  expression	  levels	  of	   the	   p53	   and	   pRb	   proteins	   in	   NIKS	   HPV-­‐negative	   cells	   were	   considered	  physiological	   and	   the	   differences	   in	   expression	   found	   in	   the	   NIKS-­‐HPV16	  transfected	  cells	  were	  then	  implicated	  in	  the	  expression	  of	  the	  oncogenes	  E6	  and	  E7.	  Specific	  antibodies	  against	  GAPDH	  were	  used	  as	  loading	  control	  (Figure	  3.4A).	  E7	   expression	  was	   investigated	   using	   HPV16-­‐E7	   specific	   antibodies	   and	   it	   was	  found	  to	  be	  persistent	  in	  all	  lysates	  (Figure	  3.4B).	  The	  analysis	  of	  the	  early	  phases	  of	  cell	  proliferation	  (day	  1	  to	  3)	  showed	  an	  increase	  in	  the	  expression	  level	  of	  the	  E7	  protein	   in	  both	  LSIL-­‐like	  and	  HSIL-­‐like	  cell	   lines.	  However,	  as	  the	  expression	  levels	  of	   the	  Rb	  protein	  was	  drastically	   reduced	   in	   the	  analysed	  cell	   lysates,	  we	  concluded	  that	  the	  E7	  expression	  level	  could	  not	  be	  correlated	  precisely	  with	  the	  expression	  of	  pRb.	  Although	  previous	   investigations	   employed	   successfully	  E6	  antibodies	  on	  NIKS-­‐HPV16	  cell	  extracts	  (Isaacson	  Wechsler	  et	  al.,	  2012),	  in	  the	  recent	  time	  the	  levels	  of	   E6	   expression	   could	   not	   be	   further	   investigated	   as	   effective	   anti	   HPV-­‐16	   E6	  antibodies	   showed	   irregular	   reliability.	   Nonetheless,	   we	   conclude	   that	   the	  drastically	   reduced	   p53	   levels	   in	   LSIL-­‐like	   and	   HSIL-­‐like	   cell	   lines	   were	   likely	  caused	  by	  the	  action	  of	  the	  viral	  E6	  protein.	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Figure	  3.4.	  Western	  blot	  analysis	  of	  p53,	  pRb	  and	  E7	  proteins	   in	  HSIL-­‐like	  
and	  LSIL-­‐like	  cells.	  (A)	  Cell	  Lysates	  of	  NIKS	  and	  NIKS-­‐HPV16	  cell	  lines	  (HSIL	  and	  LSIL)	  were	  collected	  at	  day	  1,	  2,	  3,	  5	  and	  7	  after	  plating	  and	  the	  levels	  of	  p53	  and	  pRb	  proteins	  determined	  by	  western	  blotting.	   	  The	  expression	  levels	  of	  p53	  and	  pRb	   in	   NIKS	   lysates	   were	   used	   as	   comparative	   control.	   GAPDH	   was	   used	   as	  loading	  control.	  (B)	  Cell	  lysates	  of	  HSIL-­‐like	  and	  LSIL-­‐like	  cells	  were	  also	  used	  to	  determine	   the	   expression	   levels	   of	   the	   E7	   protein.	   NIKS	   lysates	   were	   used	   as	  negative	  control	  and	  GAPDH	  as	  protein	  loading	  control.	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In	   summary,	   the	   data	   suggest	   that	   the	   continuous	   expression	   of	   E6	   and	   E7	  allowed	  the	  reduction	  of	  both	  p53	  and	  pRb	  proteins	  in	  both	  cell	  lines.	  The	  result	  of	  the	  expression	  of	  viral	  oncogenes,	  contributed	  to	  the	  phenotypic	  change	  and	  to	  the	   consequential	   increase	   of	   the	   observed	   proliferation	   rate	   (Untersperger	   C.	  PhD	   Thesis,	   2013).	   The	   expression	   of	   these	   genes	  might	   thus	   confer	   to	   the	  HR	  HPVs	   infected	   cell	   an	   obvious	   growth	   advantage	   in	   a	   competitive	   environment	  immediately	  post	  infection.	  My	  aim	  is	  to	  further	  understand	  these	  characteristics	  by	  artificially	  recreating	  competitive-­‐like	  conditions,	  such	  as	  occurs	  in	  the	  wound	  healing-­‐like	  proliferative	  environment.	  Additional	  aim	  was	  to	  investigate	  whether	  exogenous	   growth	   factors	   contribute	   to	   the	   proliferation	   rate	   of	   infected	   cells	  facilitating	  the	  formation	  of	  HPVs	  caused	  lesions.	  
	  
3.4	   The	   NIKS-­‐HPV16	   genome-­‐containing	   cells,	   HSIL	   and	   LSIL,	  
express	  their	  oncogenes	  from	  an	  episomal	  form	  of	  the	  HPV16.	  	  E6	  and	  E7	  viral	   integrants	  versus	   intact	  8kb	  episome	  have	  been	  detected	   in	   the	  majority	   of	   HPV-­‐related	   cancers	   and	   also	   in	   about	   15%	   of	   pre-­‐cancerous	   HPV-­‐induced	  high-­‐grade	  lesions	  (Klaes	  et	  al.,	  1999).	   In	  addition,	  the	  expression	  of	  E6	  and	   E7,	   following	   integration,	   can	   lead	   to	   chromosomal	   abnormalities,	   pushing	  cells	   towards	   transformation.	   Thus,	   in	   order	   to	   simulate	   a	   post-­‐infection/basal-­‐like	  environment	  we	  preferred	  to	  perform	  the	  experiments	  exclusively	  using	  cells	  that	  did	  not	  contain	  viral	  integrant.	  A	   specific	   molecular	   assay,	   the	   Amplification	   of	   Papillomavirus	   Oncogene	  Transcripts	  (APOT),	  was	  used	  to	  determine	  whether	  our	  cells	  contained	  episomal	  genomes	  or	  oncogene	  integrants.	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This	  method	  has	  been	  successfully	  used	  in	  the	  past	  to	  understand	  if	  E7	  transcripts	  were	  produced	  from	  episomal	  or	   integrated	  forms	  of	  the	  viral	  genome	  (Klaes	  et	  al.,	  1999).	  Results	  from	  studies	  using	  the	  APOT	  method	  surprisingly	  show	  that	  the	  majority	   of	   HPV-­‐induced	   high-­‐grade	   lesions	   contain	   E7	   transcripts	   that	   are	  produced	   only	   from	   the	   episomal	   form	   of	   the	   virus	   (Klaes	   et	   al.,	   1999;	  Wentzensen	  et	  al.,	  2002).	  	  The	  viral	  integration	  within	  the	  host	  genome	  is	  thought	  to	  happen	  in	  later	  stages	  of	  neoplastic	  progression	  and	  there	   is	   little	  evidence	  that	   integrants	  are	  present	  in	  the	  early	  stages	  of	  lesion	  formation.	  A	  recent	  study	  using	  the	  APOT	  method,	  in	  fact,	   identified	   that	   in	   85%	   of	   HSIL	   classified	   lesions,	   E7	   transcripts	   were	  produced	   from	   episomal	   virus	   forms	   only	   (Klaes	   et	   al.,	   1999).	   In	   contrast,	   E7	  transcripts	  were	  produced	  predominantly	   from	   integrated	  viral	   genomes	   in	   the	  majority	  of	   in-­‐situ	   carcinomas.	  Therefore	   it	   is	   recognized	   that	   the	   integration	  of	  E6	  and	  E7	  is	  likely	  to	  be	  a	  later	  event	  in	  the	  pathological	  process,	  and	  even	  more	  importantly	  in	  the	  final	  stages	  of	  cancer	  development.	  	  	  Previous	   investigations	   in	   our	   laboratory	   using	   NIKS	   cells	   transfected	  with	   the	  HPV16	  genome	  showed	  that	  they	  contained	  predominantly	  episomal	  forms	  of	  the	  HPV16	   virus.	   However,	   to	   confirm	   the	   validity	   of	   our	   model	   system	   it	   was	  necessary	   to	   show	   that	   these	   episomal	   lines	   maintain	   their	   integrity	   when	  passaged	  in	  culture.	  We	  performed	  the	  APOT	  assay	  to	  understand	  whether	  the	  E7	  expression	  came	  from	  episomal	  or	  integrated	  forms	  of	  the	  virus.	  	  The	  APOT	  method	  specifically	  involves	  RT-­‐PCR	  analysis	  of	  two	  primer	  sets,	  which	  are	   specific	   for	   the	   E7	   ORF	   and	   the	   early	   viral	   poly-­‐A	   region,	   which	   lies	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downstream	   of	   E7.	   In	   this	   method,	   if	   E7	   transcripts	   are	   created	   from	   a	   non-­‐disrupted	   episomal	   form	   of	   the	   HPV-­‐16	   genome,	   these	   primers	   will	   amplify	   a	  single	  1.1	  kb	  cDNA	  fragment,	  which	  contains	  part	  of	  the	  E4	  ORF.	  However,	   if	  E7	  transcripts	   are	   created	   from	   integrated	   transcripts,	   the	   E4	   ORF	   fragment	   is	  typically	  deleted,	  and	  a	  series	  of	  assorted	  E7	  fragments	  are	  generated	  (Klaes	  et	  al.,	  1999).	  	  To	   perform	   the	   APOT	   experiment	   we	   used	   RNA	   extracts	   from	   sub-­‐confluent	  cultures	   of	   each	   NIKS-­‐HPV16	   cell	   line.	   The	   APOT	   procedure	   resulted	   in	   the	  generation	  of	  a	  single	  1.1	  Kb	  band	  for	  all	  three	  LSIL	  and	  HSIL	  clones	  (Figure	  3.5A).	  We	  used	  a	  NIKS-­‐HPV16	  clone	  (Int.)	  as	  positive	  ‘integrant’	  control	  sample	  of	  which	  APOT	   products	   were	   compared	   alongside	   the	   NIKS-­‐HPV16	   cell	   lines.	   The	  integrant	  NIKS-­‐HPV16	  clone	  was	  prepared	  by	   culturing	   the	   cells	   for	  over	   thirty	  passages.	   NIKS-­‐HPV16	   negative	   cells	  were	   also	   used	   as	   APOT	   negative	   control.	  Southern	   blot	   using	   specific	   oligo-­‐primers	   to	   detect	   E4	   and	   E7	   were	   used	   to	  confirm	   that	   the	   sequences	   amplified	   contained	  both	   genes,	  when	  amplification	  occurred	  from	  episomal	  genomes	  (Figure	  3.5B).	  In	  contrast,	  the	  lack	  of	  E4	  in	  the	  integrant	  sample	  confirmed	  the	  validity	  of	  the	  method.	  These	   results	   confirm	   that	  E7	   transcripts	   are	  produced	   from	  episomal	   forms	  of	  the	  HPV-­‐16	  genome	  in	  both	  LSIL-­‐like	  and	  HSIL-­‐like	  cell	   lines.	  This	  also	  suggests	  that	  differences	  in	  promoter	  activity,	  early	  viral	  gene	  expression	  and	  differences	  in	  episomal	  copy	  number,	  rather	  than	  E6	  and	  E7	  integration,	  may	  be	  important	  to	  determine	  the	  cell	  phenotype	  in	  later	  stages	  of	  neoplastic	  progression.	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Figure	  3.5.	  APOT	  analysis	   of	   the	   viral	   transcripts	   from	  HPV-­‐16	  monolayer	  
cell	   lines	   (A)	   The	   agarose	   gel	   shows	   single	   amplified	   1.1	   kb	   PCR	   products	  containing	  E7	  and	  partially	  E4,	  in	  all	  LSIL	  and	  HSIL	  cell	  lines,	  which	  indicates	  that	  E7	   transcripts	  have	   come	   from	  an	   intact	   episome.	  For	   the	  DNA	  marker	   (M)	   the	  size	  of	  two	  bands	  is	  shown.	  Amplified	  cDNA	  obtained	  from	  mRNA	  extracted	  from	  cells	   containing	   integrated	   sequences	   of	   HPV16	   genome	   was	   used	   as	   internal	  ‘positive’	  control.	  This	  integrated	  control	  (Int.)	  contains	  several	  amplified	  bands,	  which	   represent	   E7	   transcripts	   that	   are	   produced	   from	   several	   E7	   integration	  sites	   in	   the	   host	   genome.	   	   HPV-­‐negative	   NIKS	   (N-­‐)	   were	   used	   as	   a	   negative	  control.	   All	   tested	  HPV-­‐16	   cell	   lines	   show	   only	   the	   1.1kb	   amplification	   product	  indicative	  of	  episomal	  forms	  of	  the	  viral	  genome.	  (B)	  Agarose	  gel	  of	  PCR	  amplified	  products	  was	  blotted	  against	   specific	   oligo-­‐probes	   for	  E7	  and	  E4.	  The	  Southern	  blot	  analysis	  showed	  that	  all	  amplified	  sequences	  were	  positive	  to	  E7	  probes,	  but	  evidenced	   the	   presence	   of	   E4	   transcripts	   in	   the	   1.1	   kb	   PCR	   product	   only.	   E7	  transcripts	  generated	  from	  integrants	  (Int.)	  were	  negative	  for	  E4	  confirming	  that	  the	  E4	  gene	  was	  deleted	  upon	  integration.	  	   	  
Chapter	  3	  	  	  
	   114	  
	  
	  
Chapter	  3	  	  	  
	   115	  
3.5	   NIKS-­‐HPV16	   cells	   lines	   cultured	   in	   monolayers	   at	   ‘low-­‐
density’	   resemble	   the	   differentiation	   state	   of	   epithelial	   basal	  
cells.	  
	  The	  wound	  healing	  like	  environment	  that	  I	  aim	  to	  recreate	  in	  vitro	  depends	  on	  the	  presence	   of	   monolayer	   cells	   that	   have	   the	   characteristics	   of	   basal	   cells	   upon	  plating,	  including	  the	  possibility	  to	  proliferate	  and	  migrate	  as	  happens	  during	  the	  wound	  healing	  process.	  In	  order	  to	  recreate	  such	  conditions,	  the	  NIKS	  cells	  used	  must	   be	   able	   to	   grow	  and	  be	  maintained	   in	   an	  undifferentiated	   steady	   state,	   at	  least	  until	  the	  space	  between	  cells	  has	  been	  filled.	  	  As	   mentioned	   earlier,	   NIKS-­‐HPV16	   cell	   lines	   were	   used	   to	   recreate	   in	   vitro	   a	  system	   able	   to	   support	   a	   productive	   HPV	   infection,	   similar	   to	   the	  cervical/mucosal	  epithelium	  during	  infection.	  In	  fact,	  as	  the	  activation	  of	  the	  viral	  late	  promoter	  is	  linked	  to	  the	  terminal	  differentiation	  program,	  it	  was	  important	  to	   show	   that	   our	   cutaneous	  NIKS	  model	   could	   follow	   a	   differentiation	   program	  that	   was	   similar	   to	   the	   one	   of	   cervical/mucosal	   epithelium.	   Although	   some	  architectural	  differences	   exist	   in	   cutaneous	   and	  mucosal	   epithelium,	   the	  overall	  process	  of	   terminal	  differentiation	   is	   a	  highly	   conserved	  process	  between	   these	  tissue	   types	   (Fuchs,	   1990),	   and	   similar	   patterns	  were	   reproduced	   in	  NIKS	   cells	  (Isaacson	  Wechsler	  et	  al.,	  2012;	  Middleton	  et	  al.,	  2003).	  	  Our	  scope	  was	  to	  confirm	  that	  NIKS-­‐HPV16	   cells	   cultured	   in	  monolayer	   show	  only	   limited	   differentiation,	  which	   is	  comparable	  with	  what	   is	  seen	   in	   the	  basal	  compartment	  of	   the	  normal	  epithelium.	  	  Two	  main	  strategies	  exist	   that	  can	  be	  useful	   for	  the	  study	  of	  the	  differentiation-­‐dependent	  life	  cycle	  of	  HPV	  using	  in	  vitro	  cultures	  of	  NIKS	  cells.	  The	  first	  method,	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known	   as	   organotypic	   raft	   culture	   (Figure	   3.2)	   (Isaacson	  Wechsler	   et	   al.,	   2012;	  Middleton	  et	  al.,	  2003),	  is	  used	  to	  induce	  terminal	  differentiation	  of	  keratinocytes	  epithelium	   and	   involves	   the	   production	   of	   a	   three-­‐dimensional	   epidermis.	   Such	  organotypic	  raft	  can	  support	  the	  entire	  life	  cycle	  of	  several	  viruses	  (Lambert	  et	  al.,	  2005;	  Nakahara	  et	   al.,	   2005;	  Wilson	  and	  Laimins,	  2005).	  The	  other	  method	   is	   a	  modification	  of	   the	  standard	  monolayer	  culture	  approach.	  The	  differentiation	  of	  cells	   cultured	   in	   monolayer	   can	   be	   triggered	   by	   cell-­‐to-­‐cell	   contact	   signals,	   for	  example	  when	   the	   cell	   density	   is	   too	   high	   and	   the	   cells	   remain	   confluent	   for	   a	  significant	  period	  of	  time	  (Studzinski,	  2007).	  In	  order	   to	  examine	   the	  extent	   to	  which	  monolayer	  cells	  have	  characteristics	  of	  the	   basal	   epithelium,	   we	   used	   specific	   antibodies	   targeted	   against	   proteins	  expressed	  during	   early	   keratinocyte	   differentiation,	   including	  Keratin-­‐10	   (K10),	  which	   is	   the	   first	   keratin	   to	   be	   produced	   at	   initial	   stages	   of	   terminal	  differentiation	   in	   cutaneous	   epithelia	   (Eckert	   et	   al.,	   1997).	   In	  normal	   cutaneous	  tissue,	   K10	   is	   first	   detected	   in	   cells	   immediately	   above	   the	   basal	   layer	   (i.e.	  parabasal	   and.	   spinous	   layer).	   Although	   K10	   is	   actively	   expressed	   only	   in	   the	  parabasal	   and	   spinous	   layers,	   it	   can	   still	   be	   detected	   in	   its	   cross-­‐linked	   forms	  throughout	  the	  granular	  and	  cornified	  layers.	  	  Previous	  studies	  using	  raft	  systems	  showed	  that	  basal-­‐like	  cells	  did	  not	  stain	  for	  K10	  antibodies,	  as	  expected	  given	  the	  undifferentiated	  status	  (Isaacson	  Wechsler	  et	  al.,	  2012;	  Middleton	  et	  al.,	  2003)	  (Figure	  3.6).	  In	   cultured	   keratinocytes	   K10	   antibodies	   were	   used	   to	   establish	   extent	   of	  differentiation	  (Figure	  3.7a;	  3.7b).	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The	   experiment	   was	   carried	   out	   using	   glass	   cover-­‐slips	   onto	   which	   fibroblasts	  had	  been	  previously	  seeded.	  Once	  the	  fibroblasts	  were	  completely	  attached	  to	  the	  wells,	  NIKS-­‐HPV16	  LSIL	  and	  HSIL	  cells	  were	  plated	  at	  very	  low	  density	  in	  order	  to	  allow	  the	  cells	  to	  proliferate	  for	  few	  days	  prior	  to	  reaching	  a	  confluent	  state.	  The	  glass	  cover-­‐slips	  were	  removed	  and	  fixed	  at	  seeding	  point	  (Day	  0),	  and	  at	  Day	  1,	  2,	  3,	   5	   and	  7.	   Immuno-­‐staining	  with	   specific	   antibodies	   showed	   that,	   in	   both	   cells	  lines,	  the	  percentage	  of	  K10	  positive	  cells	  was	  consistently	  below	  5%	  from	  Day	  1	  to	  Day	  5	  (Figure	  3.7a;	  3.7b).	  Interestingly,	  on	  Day	  0,	  7.4%	  of	  the	  keratinocytes	  on	  the	  HSIL	  cover	  slips	  and	  5.1%	  of	   the	  keratinocytes	  on	  the	  LSIL	  cover	  slips	  were	  found	  to	  be	  positive	  for	  K10,	  which	  may	  be	  the	  result	  of	  differentiated	  cells	  being	  carried	  over	  from	  the	  previous	  culture	  passage.	  Consequently,	   we	   conclude	   that	   cells	   cultured	   in	   monolayer	   show	   limited	  differentiation	  under	   the	  conditions	  used	  here,	  and	   in	   this	  respect	  resemble	   the	  basal	  cells	  of	  normal	  and	  infected	  epithelium.	  The	  comparison	  between	  the	  two	  cell	  lines	  showed	  that	  there	  were	  no	  significant	  differences	  in	  K10	  expression	  at	  any	  of	  the	  time	  points	  considered	  (Table	  3).	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Figure	  3.6	  Expression	  of	  K10	  and	  K13	  protein	   in	  raft	  cultures	  and	  HPV16-­‐
positive	  cervical	  tissue.	  Raft	  culture	  obtained	  from	  NIKS,	  NIKS-­‐HPV16	  HSIL	  and	  LSIL	  clones	  were	  stained	  using	  K10	  (Red)	  antibodies	  to	  show	  the	  extent	  of	  the	  cell	  early	  differentiation.	  A	  section	  of	  HPV16	  positive	  cervical	  tissue	  was	  stained	  with	  the	   differentiation	   marker	   K13	   (Red)	   antibody	   and	   used	   for	   comparison.	   All	  sections	   were	   counterstained	   with	   DAPI	   (Blue)	   and	   images	   were	   acquired	  digitally	   at	   x20	   magnification.	   The	   dotted	   lines	   indicate	   the	   location	   of	   the	  basement	   membrane.	   The	   immoistochemistry	   of	   the	   cervical	   tissue	   and	   raft	  cultures	  were	  carried	  out	  by	  Kate	  Middleton	  and	  Erin	   Isaacson	  (NIMR,	  London)	  respectively	  and	  used	  with	  permission.	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Figure	   3.7a.	   Differentiation	   state	   analysis	   of	   keratinocytes	   cultured	   in	  
monolayer.	  NIKS-­‐HPV16	  HSIL	  and	  LSIL	  cell	   lines	  were	  seeded	  at	  low	  density	  in	  on	  cover	  slips,	  cultured	  in	  standard	  medium	  for	  up	  to	  seven	  days	  and	  stained	  at	  each	   time	   point	   with	   anti-­‐keratin	   10	   specific	   antibodies	   (red).	   DAPI	   staining	  (blue)	   was	   used	   to	   help	   localize	   cell	   nuclei.	   Fluorescent	   light	   images	   were	  acquired	  digitally	  at	  10x	  magnification. 
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Figure	   3.7b.	   Differentiation	   state	   analysis	   of	   keratinocytes	   cultured	   in	  
monolayer.	  NIKS-­‐HPV16	  HSIL	  and	  LSIL	  cell	  lines	  were	  seeded	  at	  low	  density	  on	  cover-­‐slips,	  cultured	  in	  standard	  medium	  for	  up	  to	  seven	  days	  and	  and	  stained	  at	  each	   time	   point	   with	   anti-­‐keratin	   10	   specific	   antibodies	   (red).	   DAPI	   staining	  (blue)	   was	   used	   to	   help	   localize	   cell	   nuclei.	   Fluorescent	   light	   images	   were	  acquired	  digitally	  at	  10x	  magnification.	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Table	  3.1.	  Image-­‐J	  analysis	  of	  K10	  positive	  cells.	  Image-­‐j	  software	  was	  used	  
to	  count	  the	  number	  of	  DAPI	  (blue)	  and	  K10	  (red)	  positive	  cells	  present	  at	  
each	  time	  point.	  The	  number	  of	  K10	  positive	  cells	  is	  represented	  as	  percentage	  of	  the	  total	  number	  of	  keratinocytes	  staining	  positive	  for	  DAPI.	  Counting	  has	  been	  performed	   from	   three	   independent	   cover	   slips	   for	   each	   time	   point	   considered.	  The	  experiment	  was	  repeated	  three	  times.	  	  
























(≥10%) 	  	  
 	  	  
3.6	  Cloned	  NIKS	  cells	  have	  a	  consistent	  expression	  of	  p53	  and	  
pRb	  expression.	  	  Previous	   studies	   have	   indicated	   that	   NIKS	   are	   genetically	   stable	   and	   have	   a	  uniform	   genetic	   background.	   This	   was	   important	   for	   our	   experiments,	   as	   we	  wanted	  to	  avoid	  genetic	  variation	  in	  the	  cell	  population	  within	  our	  HPV	  cell	  lines.	  Moreover,	  in	  order	  to	  investigate	  the	  effects	  that	  exogenous	  growth	  factors	  have	  on	   transfected	   cells,	   it	  was	   fundamental	   to	   confirm	   that	  NIKS	  have	  no	  variation	  within	  their	  populations.	  NIKS	  are	  near-­‐diploid	  human	  keratinocytes	  containing	  a	  stable	  isochromosome,	  8q,	  which	  it	   is	  not	  known	  to	  affect	  the	  expression	  of	  p53	  and	  pRb	  (Allen-­‐Hoffmann	  et	  al.,	  2000).	  The	  NIKS	  used	   in	  our	  experiments	  were	  produced	   from	   a	   parental	   neonatal	   foreskin	   cell	   line	   that,	   after	   59	   culture	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passages,	  immortalized	  spontaneously	  (Allen-­‐Hoffmann	  et	  al.,	  2000).	  Despite	  the	  fact	   that	   foreskin	   keratinocytes	   can	   be	   a	   natural	   host	   cell	   for	   HPV	   viruses,	   the	  authors	   confirmed	   there	   were	   no	   detectable	   levels	   of	   HPV	   DNA.	   They	   also	  confirmed	  that	  the	  growth	  characteristics	  of	  NIKS	  cells	  were	  consistent	  between	  each	  passage.	  To	  further	  investigate	  this,	  the	  authors	  measured	  the	  mRNA	  levels	  of	   autocrine	   growth	   factors	   and	   markers	   such	   as	   Transforming	   growth	   factor	  (TGF),	  TGF-­‐ß1	  (a	  keratinocyte	  growth	  inhibitor),	  Epidermal	  growth	  factor	  (EGF),	  the	  oncogene	  c-­‐myc	  and	  keratin	  K14.	  Their	  results	  confirmed	  that	  there	  were	  no	  differences	   in	   the	   expression	   levels	   of	   these	   growth	   factors	   and	  markers	  when	  compared	  to	   the	  parental	  cell	   line	  (Allen-­‐Hoffmann	  et	  al.,	  2000).	  NIKS	  have	  also	  been	  shown	  to	  be	  non-­‐tumorigenic	  when	  injected	  into	  mice,	  which	  suggests	  that	  they	  are	  not	  a	  transformed	  cell	  line.	  More	  recently,	  NIKS	  cells	  have	  been	  used	  as	  dermo-­‐epidermal	  skin	  substitutes	   in	  subjects	  affected	  by	  serious	  burns	  (GIbson,	  2007;	  Schurr	  et	  al.,	  2009).	  The	  analysis	  of	  NIKS	   clones	  aimed	   to	  verify	   that	   any	   fluctuation	  between	  NIKS-­‐HPV16	   clones	   in	   the	  way	   they	   affect	   the	   expression	  of	  p53	  and	  pRb	  expression	  was	  associated	  primarily	  to	  HPV16	  E6	  and	  E7	  and	  not	  dependent	  by	  the	  NIKS	  cell	  background.	  	  	  Preliminary	  studies	  on	  HPV16-­‐LSIL	  and	  HPV16-­‐HSIL	  clones	  protein	  extract	  have	  demonstrated	   that	   p53	   and	   pRb	   levels	  may	   vary	   between	   clones	   (Figure	   3.8A).	  Upon	  several	  culture	  passages,	  however,	  these	  differences	  appear	  less	  evident	  as	  shown	   previously	   in	   Figure	   3.4.	  We	   hypothesise	   that	   the	   selective	   pressure	   on	  cells	   in	   culture	  might	   be	   the	   cause	   of	   the	   loss	   of	   p53	   and	   pRb	   expression	   over	  time.	  
Chapter	  3	  	  	  
	   123	  
Thus,	   in	  order	   to	  determine	   that	  NIKS	  expressed	  similar	   levels	  of	  p53	  and	  pRb,	  which	   are	   the	  main	   targets	   of	   the	   viral	   oncogenes	   E6	   and	   E7,	   we	   developed	   a	  specific	   cloning	   assay.	  To	  do	   this	   fifty	  NIKS	   clones	  were	   isolated	   from	   the	  NIKS	  population.	  NIKS	  cells	  were	  plated	  at	   low	  density	  so	  that	  the	  colonies	  generated	  from	  single	  cells	  were	  able	  to	  outgrow	  and	  be	  harvested	  as	  soon	  as	  they	  became	  visible.	  Clones	  obtained	  using	  this	  method	  were	  then	  transferred	  to	  independent	  plates	  and	  grown	   five	  days.	  Twenty-­‐five	  NIKS	  clones	  obtained	  with	   this	  method	  were	  unable	  to	  survive	  after	  plating.	  Fifteen	  out	  of	  25	  clones	  were	  grown	  to	  60-­‐70%	   confluence	   before	   being	   harvested	   and	   stored	   as	   cell	   pellets.	   The	   pellets	  obtained	  were	  used	   to	   carry	  out	  western	  blot	   analysis	   (Figure	  3.8B).	  The	   latter	  was	  performed	  using	  specific	  antibodies	  against	  p53	  and	  pRb,	  and	  revealed	  that	  only	  minimal	   differences	   in	   their	   expression	   levels	  were	   found	   between	   clones	  (Figure	  3.8B).	  This	  experiment	  demonstrated	  that	  the	  NIKS	  background,	  in	  terms	  of	  p53	  and	  pRb	  expression,	  was	  essentially	  comparable	  in	  all	  clones	  analyzed.	  The	  effects	  of	  E6	  and	  E7	  on	  p53	  and	  pRb	  respectively,	  can	  be	  related	  to	  a	  variation	  in	  oncogene	  expression	  within	  the	  NIKS-­‐HPV16	  population	  and	  was	  not	  dependent	  on	   internal	  variations	  between	   individual	  cells	   that	   lead	   to	   the	  NIKS	  cell	   clones.	  Furthermore,	  these	  assays	  validated	  the	  use	  of	  NIKS	  cells	  to	  build	  a	  model	  system	  for	  comparative	  analysis	  of	  multiple	  HPV	  types.	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Figure	   3.8.	   The	   NIKS	   cloning	   assay	   studies	   variation	   amongst	   NIKS	   cells	  
population	   prior	   to	   HPVs	   genome	   transfection.	   (A)	  Western	  blot	  analysis	  of	  pRb	  and	  p53	  protein	  expression	  in	  HPV16-­‐HSIL,	  HPV16-­‐LSIL	  clones	  and	  NIKS	  (N).	  (B)	  Western	  blot	   analysis	   of	   the	  pRb,	   p53	  obtained	   from	  protein	   extracts	   of	   15	  NIKS	   parental	   clones.	   GAPDH	   expression	   was	   used	   to	   determine	   the	   loading	  control.	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3.7	  Discussion	  
	  The	  main	   focus	  of	   this	  Chapter	  was	   to	   carry	  out	  a	  detailed	  analysis	  of	   the	  NIKS	  and	  NIKS-­‐HPV16	  cells	  cultured	  in	  monolayer	  in	  order	  to	  verify	  their	  suitability	  for	  the	  study	  of	  wound	  healing	  in	  vitro.	  In	  particular,	  we	  describe	  an	  analysis	  of	  the	  cell	  line	  background	  that	  we	  are	  using	  in	  our	   in	  vitro	  model	  system.	  We	  confirmed	  that	  NIKS-­‐HPV16	  HSIL	  and	  LSIL	  cell	  lines	   were	   producing	   a	   cell	   phenotype	   distinct	   from	   that	   of	   NIKS	   cells	   when	  propagated	   in	  monolayer	  culture	   (Figure	  3.1).	  Moreover,	  we	  show	  the	  ability	  of	  cells	  containing	  HPV16	  genome	  to	  proliferate	  faster	  than	  NIKS.	  Although	  HSIL	  and	  LSIL	   cell	   lines	   produce	   a	   different	   phenotype	   when	   propagated	   in	   monolayer	  cultures	  (Isaacson	  et	  al	  2012),	  we	  now	  show	  that	  these	  lines	  are	  indistinguishable	  in	   the	  early	  stages	  of	  monolayer	  proliferation.	  However,	   the	  difference	  between	  NIKS	  and	  NIKS-­‐HPV16	  cells	  doubling	  time	  was	  significant.	  These	  results	  suggest	  that	  HPV16	  genome	  containing	  cells	  might	  have	  a	  competitive	  advantage	  against	  cells	  not	  containing	  the	  virus.	  	  Following	   the	   study	   of	   the	   growth	   characteristics	   of	   the	  NIKS-­‐HPV16	  HSIL	   and	  LSIL	   cell	   lines	   we	   were	   intrigued	   by	   the	   possibility	   that	   the	   viral	   oncogene	  expression	   may	   vary	   during	   the	   early	   stages	   of	   cell	   proliferation.	   We,	   in	   fact,	  hypothesized	   that	   in	  NIKS-­‐HPV16	  HSIL	  and	  LSIL	  cell	   lines,	   changes	   in	  oncogene	  expression	  levels	  may	  explain	  the	  different	  cell	  phenotype	  at	  later	  stages	  (Figure	  3.3).	   Thus,	   to	   determine	   whether	   the	   viral	   oncogenes	   in	   these	   cell	   lines	   were	  functional	  we	  analysed	  the	  levels	  of	  the	  host	  p53	  and	  pRb	  proteins,	  which	  are	  the	  host	  cellular	   targets	  of	   the	  HPV16	  E6	  and	  E7	  proteins.	   Interestingly,	  we	  noticed	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from	  data	  presented	  here	   (and	   from	  data	  presented	  by	   Isaacson	  2012)	   that	   the	  presence	   of	   E6	   and	   E7	   proteins	  were	   related	   to	   the	   loss	   of	   p53	   and	   pRb	   at	   all	  stages	   of	   the	  monolayer	   proliferation	   (Figure	   3.4).	  We	   illustrated	   that	   in	   NIKS-­‐HPV16	  clones	  the	  levels	  of	  the	  viral	  oncoprotein	  targets	  are	  dramatically	  reduced.	  However,	  we	  were	   not	   able	   to	   determine	   oncogene	   variations	   across	   the	  NIKS-­‐HPV16	  clones	  analysed.	  No	  obvious	  differences	  were	  apparent	  however	  between	  the	   HSIL	   and	   LSIL	   clones	   at	   least	   at	   the	   level	   of	   E7	   expression.	   Recent	  investigations	  give	  evidence	  of	  the	  role	  of	  HPV16	  E7	  in	  the	  proliferation	  of	  HPV16	  containing	  cells.	  The	  studies	  suggest	  in	  fact	  that	  inhibiting	  the	  HPV16	  E7	  binding	  to	  Rb	  by	  using	  mRNA	  aptamers	  (small,	  single-­‐	  stranded	  oligonucleotides	  selected	  for	  high-­‐affinity	  binding),	  produce	  an	  apoptotic	  effect	  on	  cell	   lines	  derived	   from	  cervical	  carcinoma	  (Nicol	  et	  al.,	  2011;	  Nicol	  et	  al.,	  2013).	  	  	  Results	  led	  us	  to	  investigate	  the	  expression	  of	  viral	  oncogenes	  during	  the	  first	  few	  days	  after	  plating	  where	  no	  difference	   in	   cell	   growth	  was	  apparent.	  During	   this	  period	   the	   E6	   and	   E7	   proteins	   appear	   to	   have	   a	   role	   in	   increasing	   the	   cycling	  speed	   of	   the	   NIKS-­‐HPV16	   containing	   cells.	   A	   recent	   investigation	   suggests	   that	  inhibiting	   the	  HPV16	  E7	  binding	   to	  Rb	  by	  using	  mRNA	  aptamers	   (small,	   single-­‐	  stranded	   oligonucleotides	   selected	   for	   high-­‐affinity	   binding),	   produce	   an	  apoptotic	  effect	  on	  cell	  lines	  derived	  from	  cervical	  carcinoma	  (Nicol	  et	  al.,	  2013).	  This	   period	   of	   growth,	   when	   the	   HPV-­‐containing	   cells	   have	   space	   to	   grow,	  resembles	   in	   some	  ways,	   the	   situation	   that	  occurs	   following	   infection	  at	  wound	  sites.	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In	   order	   to	   model	   the	   early	   stages	   of	   infection,	   however,	   we	   also	   need	   to	   be	  certain	  that	  the	  HPV	  genomes	  are	  predominantly	  episomal.	  	  	  The	  modest	  increase	  of	  E7	  expression	  during	  the	  early	  phase	  of	  cell	  proliferation	  led	   the	   study	   of	   the	   integrity	   of	   viral	   genome	   state.	   In	   fact,	   we	   needed	   to	  understand	   whether	   the	   viral	   genome	   expression	   was	   promoted	   by	   the	   viral	  genome	  integration	  into	  the	  host	  DNA	  during	  the	  cell	  proliferation.	  	  Therefore,	  the	  analysis	  of	  the	  monolayer	  model	  system	  focused	  on	  proving	  that	  NIKS-­‐HPV16	  cell	  lines	  were	   exclusively	   episomal.	  We	   studied	   several	   NIKS-­‐HPV16	   cell	   lines	   and	  demonstrated	   that	   the	   genome	   was	   contained	   as	   episomal.	   Furthermore,	   by	  analysing	   specific	   sequences	  of	  E4	  and	  E7	   in	   the	  amplified	  episomal	   transcripts	  we	  confirmed	  that	  the	  viral	  expression	  originates	  exclusively	  from	  viral	  episomes.	  At	   present,	   data	   in	   this	   thesis	   suggest	   that	   the	   oncogene	   levels	   are	   exclusively	  regulated	   from	   non-­‐integrated	   viral	   genes.	   Thus,	   we	   excluded	   that	   viral	  expression	  coming	  from	  viral	  integrants	  are	  responsible	  of	  the	  modest	  increased	  in	  E7	  expression	  during	  the	  cell	  proliferation	  in	  monolayer.	  This	  however	  does	  not	  rule	  out	  that	  a	  level	  of	  heterogeneity	  in	  the	  host	  cell	   line	  could	   also	   contribute	   to	   these	   phenotypes	   in	   individual	   clonal	   cell	   lines.	   As	  mentioned	   earlier,	  NIKS	   arose	   as	   a	   spontaneously	   immortalized	   cell	   line	  with	   a	  near	  diploid	  genome,	  and	  they	  were	  shown	  to	  be	  maintained	  as	  an	   isogenic	  cell	  line	   (Allen-­‐Hoffmann	   et	   al.,	   2000).	   It	   was	   then	   necessary	   to	   verify	   that	   the	  parental	  NIKS	  is	  still	  a	  homogeneous	  cell	  line,	  and	  the	  cells	  did	  not	  acquire	  further	  genomic	   instability	   over	   time	   that	   might	   contribute	   to	   these	   phenotypes.	   We	  deemed	   useful	   to	   perform	   the	   analysis	   of	   the	  NIKS	   background	   in	   terms	   of	   the	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expression	   levels	   of	   the	   cellular	   counterparts	   of	   the	   HPV16	   oncoproteins.	   We	  found	   that	   NIKS	   clonal	   cells	   were	   steadily	   expressing	   p53	   and	   pRb,	   so	   we	  concluded	   that	   the	   NIKS	   clonal	   cells	   are	   analogous.	   Thus,	   we	   established	   that	  NIKS	  cells	  were	  suitable	  for	  further	  studies	  and	  transfection	  within	  our	  model.	  	  Although	  the	  expression	  of	  E6	  and	  E7	  genes	  was	  consistent	   in	  the	  early	  state	  of	  cell	  proliferation,	  we	  aimed	  to	  understand	  the	  differentiation	  state	  the	  transfected	  keratinocytes	   during	   monolayer	   proliferation.	   We	   raised	   the	   possibility	   that	  keratinocyte	  differentiation	  might	  differ	  between	  cell	  lines	  resulting	  in	  altering	  in	  the	   genome	   amplification	   and	   viral	   gene	   expression.	   We	   confirmed	   that	   the	  differentiation	   state	   of	   the	  HPV16	   cell	   lines,	   evidenced	   by	   K10	   expression,	  was	  comparable	   between	   the	   HSIL	   and	   LSIL	   cell	   lines	   (Figure	   3.7a;	   3.7b).	  Furthermore,	   we	   found	   that	   the	   cell	   differentiation	   in	   the	   early	   stages	   of	  monolayer	   proliferation	  was	   extremely	   low.	   These	   results	   indicate	   that,	   during	  the	   first	   three	   days,	   the	   proliferation	   of	   the	   cell	   lines	   in	   monolayer	   resembles	  closely	   the	   amplification	   of	   the	   epithelial	   basal	   cells	   in	   terms	   of	   cell	  differentiation.	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4.	  The	  use	  of	  NIKS	  monolayer	  system	  to	  study	  
wound	  healing	  in	  vitro	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4.1	  Introduction	  
	  Wound	   healing	   is	   a	   complex	   process	   that	   occurs	   in	   timely	   defined	   stages	   and	  involves	   many	   different	   cell	   types.	   It	   is	   referred	   to	   the	   repair	   process	   starting	  when	   the	   outer	   covering	   of	   the	   skin,	   the	   epidermis	   or	   the	   mucosal	   epithelia	  become	   injured	   (Singer	   and	  Clark,	   1999).	   This	   highly	   coordinated	  physiological	  process	   involves	   inflammation,	   wound	   cell	   proliferation	   and	   migration,	  neovascularization,	   and	   regeneration	  of	   the	   extracellular	  matrix	   (Martin,	   1997).	  The	  epidermal	  keratinocytes	  are	  the	  main	  cells	  of	  the	  epidermis	  and	  they	  retain	  a	  key	  role	  in	  the	  tissue	  repair	  process	  (Santoro	  and	  Gaudino,	  2005).	  	  The	  physical	  stimuli	  that	  result	  from	  the	  loss	  of	  cellular	  continuity	  trigger	  a	  range	  of	   tissue	   responses	   in	   order	   to	   repair	   the	   damage	   (Shaw	   TJ,	   2009).	   These	   are	  regulated	  by	  the	  local	  production	  of	  peptide	  growth	  factors,	  which	  influence	  cells	  in	   the	   wounded	   area	   through	   autocrine	   and	   paracrine	   mechanisms	   (Shirakata,	  2010;	  Werner	  and	  Grose,	  2003).	  Two	  structurally	  related	  peptide	  growth	  factors,	  the	  EGF	  and	  TGF-­‐alpha,	  play	  important	  roles	  in	  wound	  healing	  of	  tissues	  such	  as	  the	   skin,	   cornea,	   and	   gastrointestinal	   tract	   (Schultz	   et	   al.,	   1991).	  Many	   types	   of	  cells	   including	   skin	   keratinocytes,	   fibroblasts,	   vascular	   endothelial	   cells,	   and	  epithelial	  cells	  express	  EGF/TGF-­‐alpha	  receptors	  (Santoro	  and	  Gaudino,	  2005).	  In	  addition,	   several	   cells	   involved	   in	   wound	   healing	   including	   platelets,	  keratinocytes,	   and	   activated	   macrophages	   synthesize	   growth	   factors	   including	  EGF	  or	  TGF-­‐alpha	   (Schultz	   et	   al.,	   1991).	  Keratinocyte-­‐derived	  growth	   factors	   as	  well	   as	   cytokines	   and	   chemokines	   also	   contribute	   to	   the	   regulation	   of	   tissue	  renewal	   (Shirakata,	  2010).	  The	  role	  of	  EGF	  has	  been	  extensively	   investigated	   in	  normal	   and	   pathological	   wound	   healing.	   It	   is	   implicated	   in	   keratinocyte	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migration,	  fibroblast	  function	  and	  the	  formation	  of	  granulation	  tissue	  (Breuing	  et	  al.,	  1997).	  Several	  studies	  have	  demonstrated	  that	  healing	  of	  a	  variety	  of	  wounds	  in	   animals	   and	   patients	   was	   enhanced	   by	   treatment	   with	   EGF	   or	   TGF-­‐alpha	  (Breuing	   et	   al.,	   1997;	   Brown	   et	   al.,	   1986).	   Epidermal	   regeneration	   of	   partial	  thickness	  burns	  on	  pigs	  or	  dermatome	  wounds	  on	  patients	  was	  accelerated	  with	  topical	  application	  of	  EGF	  or	  TGF-­‐alpha,	  and	  EGF	  treatment	  accelerated	  healing	  of	  gastroduodenal	   ulcers	   (Breuing	   et	   al.,	   1997;	   Buckley	   et	   al.,	   1987).	   EGF	   also	  increased	  tensile	  strength	  of	  skin	  incisions	  in	  rats	  and	  corneal	  incisions	  in	  rabbits,	  cats,	  and	  primates	  (Grant	  et	  al.,	  1992;	  Kwon	  et	  al.,	  2006)	  	  The	  mechanisms	  of	  the	  wound	  healing	  have	  been	  previously	  studied	  using	  both	  in	  
vivo	   and	   in	   vitro	  model	   systems	   (Croft	   and	   Tarin,	   1970;	   Escamez	   et	   al.,	   2004;	  Werner	  and	  Grose,	  2003).	  The	  use	  of	  animal	  model	  systems	  allows	   the	  study	  of	  sequential	  phases	  of	  wound	  repair,	  from	  the	  moment	  of	  injury	  until	  the	  repair	  is	  accomplished.	   However,	   this	   method	   has	   a	   number	   of	   limitations.	   One	   of	   the	  major	  limitations	  in	  the	  study	  of	  wound	  healing	  and	  HPV	  in	  vivo	  is	  the	  absence	  of	  an	   animal	   model	   system	   that	   supports	   the	   viral	   life	   cycle	   of	   HPVs,	   as	   the	  permissive	   propagation	   of	   papillomaviruses	   outside	   their	   natural	   host	   is	   not	  possible.	  Several	  models	  however,	  have	  been	  described	  to	  permit	  the	  growth	  and	  propagation	  of	  HPV	  in	  subcutaneous	  and	  cutaneous	  human	  skin	  grafts	  implanted	  in	   the	   severe	   combined	   immunodeficiency	   (SCID)	   mouse	   (Bonnez,	   2005).	  	  	  However,	  animal	  models	  have	  been	  successfully	  employed	  to	  study	  other	  types	  of	  PVs,	   such	   as	   rabbit	   oral	   papillomavirus	   (ROPV)	   or	   cottontail	   rabbit	  papillomavirus	  (CRPV)	  (Christensen	  and	  Kreider,	  1991;	  Maglennon	  et	  al.,	  2011).	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Although	  such	  model	  systems	  are	  useful	  for	  the	  study	  of	  the	  formation,	  regression	  and	   reappearance	   of	   PVs	   lesions,	   their	   use	   to	   investigate	   the	   initial	   phases	   of	  lesion	  formation	  upon	  establishment	  of	  PV	  infections	  in	  the	  basal	  epithelia	  result	  laborious.	  	  In	  the	  recent	  years,	   it	  has	  been	  reported	  that	  transgenic	  mouse	   lines	  expressing	  the	  E6	  and	  E7	  oncogenes	  of	  HPV16	  in	  the	  skin	  have	  been	  used	  for	  wound	  healing	  studies	  (Escalante-­‐Alcalde	  et	  al.,	  2000).	  In	  these	  experiments,	  such	  mice	  showed	  a	  remarkable	  ability	  to	  regenerate	  an	  ear	  portion	  after	  a	  wound	  was	  created.	  Such	  effects	  appear	  to	  be	  primarily	  due	  to	  E6	  and	  E7	  expression,	  which	  plays	  an	  active	  role	   in	  re-­‐epithelization	  and	  epidermal	  growth	  (Davies	  et	  al.,	  1993).	   In	  addition,	  HPV16	   oncogenes	   have	   also	   been	   shown	   to	   increase	   the	   migratory	   ability	   of	  keratinocytes	  during	  wound	  healing	  scratch	  assay	  (Au	  Yeung	  et	  al.,	  2011).	  In	   the	   absence	   of	   an	   animal	   model	   system	   that	   allows	   the	   use	   of	   HPV,	   an	  alternative	   in	   vitro	   epithelial	   cell	   culture	   approach	   was	   attempted	   (Liang	   CC,	  2007).	  One	  of	   the	  major	  advantages	  of	  using	  such	  an	   in	  vitro	  approach	   is	   that	   it	  allows	  specific	  aspects	  or	   the	  behavior	  of	   ‘healing’	  cells	   to	  be	  examined	  without	  the	  extraneous	  influences	  of	  the	  body	  (Bentley,	  1936).	  As	  HPV	  infection	  would	  in	  many	  cases	  occur	   in	  a	  wounded	  epithelia,	   experiments	  were	  performed	  using	  a	  monolayer	   culture	   system	   in	   vitro	   that	   resemble	   some	   of	   the	   features	   of	   the	  epithelia	  healing	  cells.	  By	  using	  such	  a	  model	  system,	  we	  aimed	  to	  study	  the	  effect	  that	  the	  expression	  of	  HPVs	  may	  have	  on	  the	  wound	  healing	  process.	  In	  particular	  we	  make	  use	  of	  the	  wound	  healing	   scratch	   assay	   to	   examine	   cell	   colonization	  potential	   and	  make	   a	  close	  comparison	  between	  LR-­‐	  and	  HR-­‐HPV	  types.	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4.2	   NIKS	   cells	   harboring	   HPV16	   present	   a	   higher	   proliferative	  
ability	  in	  an	  in	  vitro	  scratch	  assay	  
	  Wound	   healing	   requires	   both	   migration	   and	   proliferation	   of	   many	   cell	   types	  including	  neutrophils,	  fibroblasts,	  endothelial	  cells,	  and	  keratinocytes.	  During	  the	  proliferative	  phase	  of	  wound	  healing,	  the	  keratinocytes	  respond	  to	  growth	  stimuli	  generated	   by	   fibroblasts	   and	   epithelial	   cells	   as	   a	   result	   of	   loss	   of	   cell-­‐to-­‐cell	  contact	   (Martin,	   1997;	   Santoro	   and	   Gaudino,	   2005).	   These	   stimuli	   cause	   re-­‐organization	   of	   the	   keratin	   network	   in	   cells	   in	   the	   wounded	   epidermis	   in	  preparation	   for	   their	   efficient	  migration	   (Wojcik	   et	   al.,	   2000).	   Keratinocyte	   cell	  migration	   is	  a	  complex	  process	   that	   involves	  a	  coordinated	  sequence	  of	  distinct	  functions	  including	  the	  formation	  of	  lamellipodia	  protrusions	  at	  the	  leading	  edge	  of	   the	   cell,	   formation	   of	   cell-­‐substrate	   adhesion	   at	   the	   tips	   of	   lamellipodia,	  actomyosin-­‐powered	  contraction	  of	  the	  cell	  body,	  and	  detachment	  of	  the	  cell	  rear	  (Kirfel	  et	  al.,	  2004;	  Sheetz,	  1994).	  Cell	  migration	  during	  wound	  healing	   involves	  also	   the	   expression	   of	   a	   number	   of	   growth	   factors	   and	   cytokines.	   One	   of	   these	  factors,	   the	   transforming	   growth	   factor-­‐beta	   (TGF-­‐β),	   controls	  many	   aspects	   of	  normal	   and	   pathological	   cell	   behaviour	   (Joo	   and	   Seomun,	   2008),	   including	   the	  migration	   of	   keratinocytes	   in	   wounded	   skin	   and	   epithelial	   cells	   in	   damaged	  cornea	  (Philipp	  et	  al.,	  2004).	  With	   regard	   to	  wound	  healing,	   the	   specific	   questions	   that	  we	   aimed	   to	   address	  were:	  firstly,	  whether	  the	  enhanced	  proliferation	  of	  NIKS-­‐HPV16	  might	  facilitate	  a	  more	   rapid	   wound	   repair	   in	   a	   competitive	   wound	   environment,	   and	   secondly,	  whether	   HPV16	   ‘infection’	   can	   have	   a	   positive	   impact	   on	   the	   migration	   of	   the	  NIKS	  infected	  cells.	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Previous	   investigations	  have	  shown	  that	   the	  expression	   in	   trophoblastic	  cells	  of	  the	   HR-­‐HPV	   E6	   and	   E7	   proteins	   under	   the	   control	   of	   the	   long-­‐control	   region	  endogenous	   promoter,	   in	   absence	   of	   normal	   E6/E7	   regulation,	   can	   cause	   a	  growth	   advantage	   and	   an	   increase	   in	   motility	   and	   invasivity	   compared	   to	  uninfected	   cells	   (Boulenouar	   et	   al.,	   2010).	   Other	   studies	   have	   specifically	  evaluated	   HPV16	   the	   E6	   protein	   in	   enhancing	   the	  migration	   ability	   of	   infected	  keratinocytes	  (Au	  Yeung	  et	  al.,	  2011),	  and	  when	  taken	  together,	  suggest	  that	  the	  early	  proteins	  of	  HR-­‐HPVs	  can	  modulate	  migration	  and	  proliferation.	  	  It	  remains	  to	  be	  established	  to	  what	  extent	  these	  proteins	  exert	  this	  function	  on	  infected	  keratinocytes	  harboring	  viral	  episomes.	  	  	  In	  this	  thesis,	  the	  proliferative	  and	  migratory	  properties	  of	  human	  keratinocytes	  infected	  with	  HR-­‐HPVs	  were	  considered	  using	  an	  in	  vitro	  scratch	  assay.	  To	  do	  this,	  the	  NIKS	  episomal	  cell	  lines	  were	  used.	  The	  in	  vitro	  scratch	  assay	  is	  a	  well-­‐developed	  method	  to	  measure	  cell	  migration	  in	  
vitro	  (Liang	  CC,	  2007),	  and	  involves	  the	  generation	  of	  a	  "scratch"	  in	  a	  monolayer	  culture	   in	   order	   to	   generate	   the	   wound-­‐like	   situation.	   As	   a	   mechanistic	   level	  scratching	   the	   cell	  monolayer	   relieves	   contact	   inhibition,	   and	   induces	   surviving	  cells	  near	  the	  wound	  edge	  to	  move	  and	  proliferate.	  The	  movement	  of	  the	  cells	  can	  then	  be	  monitored	   through	  a	   time-­‐lapse	  microscope	  by	  capturing	   the	   images	  at	  the	  start	  of	   the	  scratch	  and	  at	  defined	   intervals	  as	   the	  scratch-­‐area	   is	  colonized.	  The	  acquired	  images	  can	  then	  be	  compared	  to	  quantify	  the	  cell	  migration	  rates.	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To	  perform	  the	  scratch	  assay	  we	  have	  cultured	  the	  NIKS	  and	  NIKS-­‐HPV16	  cells	  to	  confluence	  in	  order	  to	  obtain	  an	  even	  tissue-­‐like	  monolayer.	  Once	  the	  cells	  were	  confluent,	   they	   were	   physically	   scratched	   with	   the	   use	   of	   a	   pipette	   tip.	   The	  scratches	  were	  performed	  as	  accurately	  and	  consistently	  as	  possible	   in	  order	  to	  create	  a	   regular	  gap	  size	  across	   the	  various	  experiments.	  Scratched	  plates	  were	  washed	  twice	  using	  pre-­‐warmed	  culture	  medium	  in	  order	   to	  remove	  cell	  debris	  and	  the	  plates	  were	  immediately	  positioned	  in	  a	  time-­‐lapse	  microscope	  equipped	  with	  a	  37	  °C	  chamber	  with	  5%	  CO2	   to	  support	  cell	  growth.	  Two	  hours	   from	  the	  time	  when	  cells	  were	  placed	  on	   the	  microscope	  define	   the	   starting	  point	  of	  our	  measurements	  (Figure	  4.1A).	  The	  scratched	  section	  images	  were	  acquired	  every	  fifteen	  minutes	   as	   the	   scratched	   area	  was	   colonized.	   Three	   selected	   image	   area	  for	   each	   set	   of	   cells	   were	   visualized	   in	   each	   experiment,	   which	   was	   replicated	  three	   times.	   To	   determine	   how	   cells	   were	   recovering	   from	   the	   scratch	   we	  measured	  the	  area	  of	  the	  dish	  unoccupied	  by	  cells	  at	  each	  time	  point	  using	  Image-­‐J®	   software.	  We	   averaged	   the	  measurements,	   which	   describe	   the	   ability	   of	   the	  edge	   cells	   to	   proliferate	   and	   move	   towards	   the	   empty	   space	   created	   by	   the	  scratch	  and	  plotted	  this	  in	  a	  chart	  (Figure	  4.1	  B). The	  results	  obtained	  demonstrate	   that	   the	  NIKS	  cell	   lines	  containing	  the	  HPV16	  genome	  are	  able	  to	  recover	  the	  artificial	  wound	  in	  a	  shorter	  time	  than	  the	  NIKS	  control	  cells.	  We	  report	  a	  significantly	  different	  re-­‐epithelization	  rate	  at	  8	  hours	  from	   scratch	   formation,	   with	   NIKS-­‐HPV16	   cells	   covering	   an	   area	   three	   times	  larger	   than	   the	   area	   covered	   by	   the	   NIKS	   in	   the	   same	   time	   frame.	   The	  measurement	   reveals	   that	   the	   LSIL-­‐like	   cell	   line	   recovers	   the	   free	   cell	   area	   in	  about	  16	  hours	  whereas	  the	  NIKS	  cells	  take	  up	  to	  24	  hours	  to	  completely	  heal	  the	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wound	   (Figure	   4.1B).	   Interestingly,	   these	   data	   are	   in	   accordance	   with	   the	  proliferation	  rate	  studies	  shown	  in	  the	  previous	  chapter.	  In	  fact,	  the	  proliferation	  advantage	  presented	  previously	   in	   the	  HSIL-­‐like	  and	  LSIL-­‐like	   cell	   growth	   rates	  (see	   Chapter	   3)	   appears	   aligned	   with	   the	   LSIL-­‐like	   cells	   ability	   to	   recover	   a	  scratched	  area	  in	  vitro.	  The	  HSIL-­‐like	  NIKS-­‐HPV16	  cells	  were	  not	  employed	  in	  this	  study	  as	  their	  proliferation	  rate	  resulted	  comparable	  with	  the	  proliferation	  rate	  of	  LSIL-­‐like	  NIKSHPV16	  cells	   in	  the	  early	  stage	  of	  monolayer	  proliferation	  (Section	  3.2).	  This	   experiment	   shows	   that	   keratinocyte	   cell	   lines	   containing	  HPV16	   episomes	  have	   a	   ‘healing’	   advantage	   over	   the	   control	   cells	   as	   they	   recover	   a	   scratch	   in	   a	  shorter	  time.	  We	  hypothesize	   that	   in	  a	  competitive	  environment,	   such	  as	   it	  would	  be	  present	  during	  wound	  healing,	  HR-­‐HPV	  infected	  cells	  gain	  a	  growth	  advantage	  that	  allows	  them	  to	  prevail	  over	  surrounding	  ‘uninfected’	  cells.	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Figure	  4.1.	  Wound	  healing	  scratch	  assay.	  (A)	  NIKS	  and	  NIKS-­‐HPV16	  containing	  clone	   (LSIL-­‐like)	   were	   grown	   to	   confluence	   in	   glass	   bottom	   dishes	   and	   then	  scratched	  with	  a	  P200	   tip.	  The	  wound	  closure	  was	  observed	  using	  a	   time-­‐lapse	  microscope	  and	  pictures	  analyses	  was	  carried	  out	  using	  Image	  J	  software.	  The	  bar	  sale	   represent	   100	   µm.	   (B)	   The	   chart	   represents	   the	   average	   of	   twelve	  measurements	   of	   the	   recovered	   free	   cell	   area	   of	   the	   wounds.	   The	   error	   bars	  represent	   the	   standard	   deviation	   of	   the	   mean	   values.	   The	   experiment	   was	  repeated	  three	  times.	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4.3	  Mitomycin	  C	  treatment	  impede	  the	  proliferation	  of	  both	  NIKS	  
and	  NIKS	  HPV16	  containing	  cells	  
	  The	  results	  presented	  in	  the	  previous	  section	  support	  the	  hypothesis	  that	  HPV16	  containing	   cells	   have	   a	   proliferative	   advantage,	   which	   is	   demonstrated	   by	   the	  increased	   speed	   at	   which	   the	   scratch	   is	   colonized.	   Because	   wounding	   of	   the	  epithelia	   is	   necessary	   for	   HPV	   infection	   at	  many	   sites,	   our	   results	   suggest	   that	  during	  the	  proliferative	  phase	  of	  wound	  healing,	  HPV16	   infected	  cells	  may	  have	  the	  potential	  to	  proliferate	  faster	  than	  infected	  cells	  in	  order	  to	  colonize	  the	  space	  available	   around	   them.	   During	   this	   proliferative	   phase,	   keratinocytes	   are	  stimulated	  by	  growth	  factors	  in	  order	  to	  both	  proliferate	  and	  to	  migrate	  towards	  the	   wounded	   site.	   In	   the	   experiments	   described	   previously	   (Section	   4.2),	   the	  migration	  rate	  of	  the	  keratinocytes	  could	  not	  properly	  be	  assessed	  because	  both	  cell	   proliferation	   and	   migration	   were	   occurring	   simultaneously.	   In	   order	   to	  evaluate	   the	   migration	   ability	   of	   the	   HPV-­‐containing	   keratinocytes,	   the	  proliferation	  rate	  must	  therefore	  be	  controlled.	  This	  was	  achieved	  by	  treating	  NIKS	  and	  NIKS-­‐HPV16	  cell	  lines	  with	  Mitomycin	  C.	  Mitomycin	  C	   is	   a	  well-­‐established	   chemotherapeutic	   agent	   that	   is	   used	   to	  block	  the	   proliferation	   of	   tumour	   cells.	   The	   use	   of	  Mitomycin	   C	   in	   a	   pilot	   experiment	  was	   first	   required	   to	   assess	   its	   ability	   to	   inhibit	   NIKS	   and	   NIKS-­‐HPV16	   cell	  proliferation.	  Growth	  rate	  experiments	  were	  performed	  in	  presence	  of	  0.5	  ug/mL	  Mitomycin	   C	   and	   compared	  with	   their	   relative	   untreated	   controls	   (Figure	   4.2).	  The	  use	  of	  this	  agent	  in	  both	  NIKS	  and	  NIKS-­‐HPV16	  containing	  cells	  showed	  that	  the	   proliferation	   was	   impeded.	   In	   fact,	   following	   Mitomycin	   C	   treatment	   the	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average	   number	   of	   cells	   counted	   at	   24-­‐,	   48-­‐,	   and	   72-­‐hours	   never	   exceeded	   the	  number	  of	  cells	  plated	  (Figure	  4.2	  –A,	  -­‐B).	  Moreover,	   we	   observed	   that	   the	   use	   of	   Mitomycin	   C	   did	   not	   cause	   any	   visible	  change	  in	  the	  cell	  morphology	  suggesting	  that	  the	  drug	  affected	  only	  their	  mitotic	  activity.	  The	  ability	  to	  selectively	  stop	  the	  proliferation	  of	  keratinocytes	  was	  subsequently	  used	  to	  assess	  the	  migratory	  activity	  during	  the	  scratch	  assay.	  	  	  	  
Figure	  4.2.	  Growth	  rate	  analysis	  +/-­‐	  Mitomycin	  C.	  (A)	  NIKS	  cells	  were	  cultured	  in	   triplicate	   in	   monolayer	   using	   6	   well	   plates.	   Cells	   were	   seeded	   at	   the	   same	  number	  and	  stimulated	  with	   complete	  medium	  and	  complete	  medium	   to	  which	  was	  added	  0.5	  µg/mL	  of	  Mitomycin-­‐C.	  The	  blue	  bars	   represent	   the	  average	   cell	  numbers	  of	  the	  untreated	  cells.	  The	  Bars	  in	  red	  represent	  the	  average	  number	  of	  cells	   in	   the	   treated	  samples.	  The	  error	  bars	   represent	   the	  standard	  deviation	  of	  the	   triplicate	   values.	   (B)	   NIKS-­‐HPV16	   cells	   were	   used	   in	   this	   experiment	   as	  described	   in	   (A).	   The	   blue	   bars	   represent	   the	   average	   cell	   numbers	   of	   the	  untreated	   cells.	   The	   green	   bars	   represent	   the	   average	   number	   of	   cells	   in	   the	  Mitomycin	  C	  treated	  samples.	  The	  error	  bars	  represent	  the	  standard	  deviation	  of	  the	   triplicate	  values.	  There	  was	  significant	  difference	  between	  the	  Mitomycin	  C-­‐treated	   and	   untreated	   samples	   (p	   <	   0.05).	   The	   experiment	  was	   repeated	   three	  times.	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4.3.1	   Mitomycin-­‐C	   treated	   monolayers	   show	   limited	   Histone	   H3	  
phosphorylation	  	  An	   additional	   complementary	   experiment	  was	  performed	  using	  Mitomycin	  C	   to	  directly	   evaluate	   the	   effect	   of	  Mitomycin	   C	   treatment	   on	   the	  mitotic	   activity	   of	  NIKS	   and	   NIKS-­‐HPV16	   populations	   in	   monolayer.	   To	   do	   this,	   the	   cells	   for	   the	  growth	   rate	   experiment	  were	   also	   employed	   in	   cover-­‐slip	   staining	   experiments	  using	  antibodies	  against	  a	  specific	  mitotic	  marker,	  the	  phosphorylated	  form	  of	  the	  Histone	  H3	  (H3P)	  (Hans	  and	  Dimitrov,	  2001).	  During	  mitosis,	  H3	  phosphorylation	  is	  involved	  in	  two	  processes:	  transcriptional	  activation	   requiring	   chromatin	   fiber	   de-­‐condensation,	   and	   chromosome	  compaction	  during	  cell	  division	  (de	  la	  Barre	  et	  al.,	  2000;	  Nowak	  and	  Corces,	  2000;	  Thomson	  et	  al.,	  1999).	  As	  the	  detection	  of	  H3P	  necessarily	  indicates	  that	  cells	  are	  going	  through	  mitosis,	  H3P	  levels	  were	  measured	  in	  the	  presence	  of	  Mitomycin	  C	  in	  order	   to	  establish	   the	  extent	  of	   cellular	  mitotic	   activity.	  To	  do	   this,	  NIKS	  and	  NIKS-­‐HPV16	  populations	  were	  grown	  for	  72	  hours	  on	  cover	  slips,	  and	  then	  lifted	  every	   24	   hours	   to	   perform	  H3P	   immuno-­‐staining	   (Figure	   4.3).	   NIKS	   cells	  were	  grown	  under	  standard	  conditions	  as	  control.	  	  The	   results	   show	   that	   the	   Mitomycin	   C	   treatment	   significantly	   decreases	   the	  number	  of	  H3P	  positive	   cells	   for	  both	  NIKS	  and	  NIKS-­‐HPV16	  cells	   (Figure	  4.3A,	  B).	  The	  data	  are	  collected	  in	  Table	  4.1.	  These	   data	   support	   the	   growth	   rate	   experiment	   shown	   in	   Fig.	   4.2,	   and	   confirm	  that	  Mitomycin	  C	  treatment	  is	  effective	  in	  limiting	  the	  mitotic	  activity	  of	  NIKS	  and	  NIKS-­‐HPV16	  cells.	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Figure	   4.3	  H3P	   expression	   in	   NIKS	   and	  NIKS-­‐HPV16	   populations.	   (A)	  NIKS	  cells	  grown	  on	  cover	  slips	  were	  immuno-­‐stained	  for	  H3P	  (red)	  and	  DAPI	  (blue)	  at	  24-­‐,	   48-­‐,	   and	   72-­‐hours	   post	   plating.	   The	   samples	   treated	  with	  Mitomycin	   C	   are	  shown	  on	   the	   right	  hand	   side	   column.	   (B)	  NIKS-­‐HPV16	   cells	  were	   cultured	   and	  stained	  as	  above.	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Table	  4.1	  Percentages	  of	  H3P	  positive	  cells.	  The	  number	  of	  H3P	  positive	  cells	  is	   represented	   as	   a	   percentage	   of	   the	   total	   number	   of	   keratinocytes	   staining	  positive	  for	  DAPI.	  Counting	  was	  performed	  from	  three	  independent	  experiments	  for	  each	  time	  point	  considered.	  
	  
	   24h	   48h	   72h	  
NIKS	   19/302	  (6.2%)	   21/461	  (4.5%)	   46/978	  (4.7%)	  
NIKS-­‐HPV16	   28/469	  (5.9%)	   31/567	  (5.4%)	   62/1342	  (4.6%)	  
NIKS+MMC	   0/335	  (<0.1%)	   0/328	  (<0.1%)	   0/225	  (<0.1%)	  
NIKS-­‐HPV16+MMC	   3/437	  (0.68%)	   1/389	  (0.25%)	   0/247	  (<0.1%)	  
Chapter	  4	  	  	  
	   144	  
4.4	  NIKS-­‐HPV16	  cells	  migrate	  faster	  than	  NIKS	  HPV	  negative	  cells	  
in	  a	  wound	  healing	  scratch	  assay	  	  During	  wound	  healing	  cells	  are	  stimulated	  to	  proliferate	  and	  to	  move	  towards	  the	  region	   of	   injury	   in	   order	   to	   reconstitute	   the	   cellular	   continuity	   of	   the	   tissue	  (Singer	  and	  Clark,	  1999).	  The	  ability	  of	  keratinocytes	  to	  migrate	  is	  also	  important	  in	   other	   processes	   such	   as	   cell	   invasion	   during	   tumour	   progression	   and	  metastasis	   (Friedl	   and	   Wolf,	   2003).	   The	   capability	   of	   infected	   cells	   to	   migrate	  towards	  the	  region	  of	  injury	  during	  wound	  healing	  is	  a	  key	  aspect	  of	  the	  HPV	  life	  cycle	  that	  needs	  to	  be	  investigated.	  	  One	   strategy	   to	   evaluate	   cell	   migration	   ability	   in	   a	   wound-­‐healing	   assay	   is	   to	  control	   cell	   proliferation.	   As	   shown	   in	   section	   4.2	   and	   4.3	   this	   can	   be	   achieved	  with	  the	  use	  of	  Mitomycin	  C	  as	  anti-­‐mitotic	  agent	  (Tomasz,	  1995).	   Interestingly,	  the	   effect	   of	   Mitomycin	   C	   on	   cell	   migration	   was	   previously	   investigated	  (Carragher,	  2009),	  and	  although	  high	  concentrations	  of	  Mitomycin	  C	  were	  shown	  to	  inhibit	  the	  migration	  of	  cancer	  cells	  lines,	  0.5	  ug/ml	  Mitomycin	  C	  was	  found	  to	  have	  no	  significant	  effect	  on	  migration	  capability	  (Carragher,	  2009).	  Following	  the	  inhibition	  of	  cell	  proliferation	  with	  Mitomycin	  C,	  the	  movement	  of	  the	  cells	  was	  examined	  (Figure	  4.4).	  As	   described	   in	   section	   4.1,	   the	   cells	   were	   grown	   to	   confluence	   before	   the	  monolayer	   was	   mechanically	   scratched	   in	   order	   to	   monitor	   over	   time	   the	   cell	  response	  to	  the	  ‘wound’	  and	  the	  migration	  of	  cells	  into	  the	  empty	  space	  created	  in	  the	  dish.	  	  After	  the	  scratch	  was	  applied	  the	  plates	  were	  washed	  in	  Mitomycin	  C	  containing	  medium	  to	  remove	  floating	  cell	  debris.	  The	  scratched	  plates	  were	  then	  incubated	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in	   a	   culture	   medium	   containing	   0.5	   µg/mL	   of	   Mitomycin	   C	   placed	   in	   a	  temperature-­‐controlled	  chamber	  of	  a	  time-­‐lapse	  microscope.	  A	  time-­‐lapse	  digital	  camera	   was	   used	   to	   follow	   the	   development	   of	   the	   scratch	   ‘healing’	   and	   to	  monitor	  the	  movement	  of	  the	  keratinocytes	  into	  the	  empty	  space	  of	  the	  dish.	  	  The	  wound	   site	  was	   photographed	   digitally	   at	   two-­‐hour	   intervals	   and	   images	  were	  analysed	  with	  Image-­‐J® Software	  (Figure	  4.4A).	  The	  repopulation	  of	  the	  free	  cell	  area	  was	   calculated	   as	   the	   difference	   between	   the	   repopulated	   free-­‐cell	   area	   at	  any	  given	  time	  compared	  with	  the	  dimension	  of	  the	  free-­‐cell	  area	  at	  2-­‐hour	  time	  point.	  The	   results	   show	   that	   although	   the	   infected	   cells	   were	   treated	   with	   the	   anti-­‐proliferative	  agent	  Mitomycin	  C,	  they	  were	  efficiently	  recovering	  the	  scratch	  area	  (Figure	   4.4B).	   The	   analysis	   of	   the	   images	   demonstrates	   that	   the	   NIKS	   cells	  containing	  HPV16	  genome	  were	  able	  to	  migrate	  significantly	   faster	   than	  control	  cells	  (Figure	  4.4B).	  	  We	  measured	   essentially	   the	  migration	   of	   the	   entire	   front	  moving	   towards	   the	  empty	   space.	   The	  movement	   of	   single	   cells	   leaving	   the	  wound	   edge	  was	   in	   fact	  very	   rare.	  The	  methodology	  used	   to	   create	   the	   scratch	  cause	   the	  detachment	  of	  the	   fibroblasts,	  however	  these	  are	  used	  by	  keratinocytes	  as	  a	  source	  of	  collagen	  and	  as	  a	  physical	  support,	  and	  their	   loss	  could	  feasibly	   limit	  the	  ability	  of	  single	  keratinocytes	   to	   detach	   from	   the	   wound	   edge.	   However,	   such	   a	   scenario	   was	  difficult	  to	  properly	  investigate	  using	  the	  available	  methodologies.	  	  Nevertheless,	  the	  results	  obtained	  indicate	  that	  the	  HPV16	  containing	  cells	  were	  more	   efficient	   in	   undergoing	   wound	   healing-­‐like	   repopulation	   of	   the	   scratched	  area	  than	  respective	  control	  cells,	  even	  in	  the	  presence	  of	  Mitomycin	  C.	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The	   migratory	   ability	   apparent	   in	   NIKS-­‐HPV16	   containing	   cells	   suggest	   that	  keratinocytes	   infected	   with	   HR-­‐HPVs	   acquire	   several	   important	   features	   that	  result	  in	  an	  increase	  of	  both	  migration	  and	  proliferation	  rates.	  The	  enhanced	  migration	  rate	  of	  the	  infected	  cells	  is	  likely	  to	  be	  important	  during	  wound	  healing	  and	  lesion	  formation,	  as	  these	  cells	  have	  the	  possibility	  to	  expand	  into	   a	   relatively	   large	   area	   and	   to	   possibly	   able	   to	   out-­‐compete	   the	   un-­‐infected	  cells	  in	  terms	  of	  their	  growth	  rate.	  Interestingly,	   these	   characteristics	   were	   evidenced	   in	   both	   NIKS-­‐HPV16	   clones	  and	   populations,	   suggesting	   that	   the	   expression	   of	   the	   viral	   genome	   is	  contributing	  to	  the	  establishment	  of	  this	  phenotype	  from	  the	  initial	  stages.	  	  The	  comparison	  of	  the	  migration	  rates	  obtained	  from	  treated	  and	  un-­‐treated	  cells	  suggested	  that	  the	  NIKS-­‐HPV16	  cells	  were	  indeed	  migrating	  at	  a	  similar	  rate	  than	  those	  untreated.	  The	  contribution	  of	  the	  increased	  proliferation	  rate	  (Section	  3.2;	  4.2)	  is	  however	  important	  in	  the	  repopulation	  of	  the	  scratched	  area.	  The	  results	  obtained	  using	  the	  NIKS-­‐HPV16	  model	  system	  are	  in	  accordance	  with	  what	   has	   been	   suggested	   previously	   in	   other	   systems	   (Au	   Yeung	   et	   al.,	   2011;	  Boulenouar	  et	  al.,	  2010).	  The	  presence	  of	  HPV16	  in	  both	  clones	  and	  populations	  is	  apparent,	  with	  cell	  migration	  likely	  to	  be	  an	  important	  feature	  that	  keratinocytes	  acquire	  during	  HPV	  infection.	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Figure	   4.4	   Wound	   healing	   scratch	   assay	   performed	   with	   Mitomycin	   C	  
treated	  samples.	   	  (A)	  Scratched	  monolayers	  in	  Mitomycin	  C	  containing	  medium	  were	  observed	  by	  time-­‐lapse	  microscopy	  and	  measurements	  of	  the	  free	  cell	  area	  taken	   using	   Image-­‐J	   software.	   A	   reproducibility	   test	   showed	   that	   repeated	  annotation	  of	  the	  same	  image	  produced	  an	  average	  difference	  of	  1.4%	  of	  the	  total	  image	  area	  between	  replicates	  and	  that	  the	  difference	  never	  exceeded	  3.5%.	  (B)	  Migration	  rate	  of	  the	  Mitomycin	  C	  treated	  samples.	  The	  chart	  shows	  the	  average	  of	   the	   measurements	   from	   three	   independent	   experiments.	   The	   error	   bars	  represent	  the	  standard	  deviation	  of	  the	  triplicate	  values..	  The	  cell	  migration	  rate	  is	  measured	  as	  cell-­‐movement	  in	  the	  free	  cell	  area.	  The	  dimension	  of	  the	  free-­‐cell	  area	  at	  2-­‐hour	  time	  point	  is	  used	  as	  comparative	  starting-­‐value	  for	  each	  sample.	  The	   error	   bars	   represent	   the	   standard	   deviation	   of	   the	   triplicate	   values.	   The	  experiment	  was	  repeated	  three	  times.	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4.5	   Comparative	   analysis	   of	   NIKS-­‐HPV	   16	   and	   NIKS-­‐HPV	   11	  
genome	  containing	  cells	  during	  monolayer	  proliferation	  in	  vitro	  
	  The	  data	  obtained	  so	  far	  suggest	  that	  the	  wound	  healing-­‐environment	  may	  favour	  the	   proliferation	   and	  migration	   of	   cells	   infected	  with	   high-­‐risk	  HPVs,	  with	   both	  HSIL-­‐	   and	   LSIL-­‐like	   cell	   lines	   showing	   an	   increased	   proliferation	   rate	   when	  compared	   to	   untransfected	   cells.	   The	   reduction	   in	   cell	   doubling	   time	   was	  apparent	  both	  before	  and	  after	  cell	  confluence	  was	  achieved,	  and	  is	  likely	  to	  be	  a	  consequence	  of	  viral	  gene	  expression	  from	  HPV	  episomes.	  In	   order	   to	   understand	  whether	   this	   characteristic	   is	   also	   seen	  with	   to	   LR-­‐HPV	  types	  we	   next	  went	   on	   to	   perform	   a	   comparative	   study	  with	  NIKS	   populations	  containing	  either	  HR-­‐	  or	  LR-­‐HPV	  types.	  A	   key	   aim	  was	   to	   address	   the	   question	   of	   how	   lesions	   form	   and	   to	   further	   our	  understanding	  of	  the	  differences	  these	  broad	  groups	  of	  papillomaviruses.	  	  	  	  
4.5.1	   NIKS	   cells	   containing	   HPV11	   genome	   have	   lower	   proliferation	   rate	  
than	  NIKS-­‐HPV16	  and	  NIKS-­‐HPV	  negative	  cells	  
	  HPV11	  causes	  benign	  papillomas	  and	  is	  a	  prototype	  for	  non-­‐malignant,	   low-­‐risk	  papillomaviruses	  from	  the	  Alpha	  genera.	  To	   determine	   whether	   NIKS	   cells	   containing	   the	   HPV11	   genome	   are	   able	   to	  proliferate	   as	   well	   as	   NIKS-­‐HPV16	   cells,	   we	   performed	   a	   comparative	  proliferation	  assay	  using	  the	  approaches	  described	  in	  section	  3.2	  (Figure	  4.5).	  Growth	   assays	   were	   performed	   in	   triplicate	   in	   order	   to	   demonstrate	   the	  statistical	  significance,	  with	  cells	  being	  plated	  at	  the	  same	  density	  at	  the	  start	  of	  each	  experiment.	  Two	  internal	  controls	  were	  added	  to	  the	  assay;	  NIKS	  cells	  were	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used	   to	  assess	   the	  growth	   rate	   in	  absence	  of	  HPV,	  while	   the	  NIKS-­‐HPV16	  HSIL-­‐like	  clone	  was	  used	  as	  a	  positive	  ‘hyper-­‐proliferative’	  control.	  NIKS	   cells	   transfected	   with	   HPV16	   and	   HPV11	   genomes	   showed	   significantly	  different	   growth	   patterns.	   NIKS-­‐HPV16	   populations	   grow	   quicker	   than	   NIKS	  (HPV-­‐negative)	   cells,	   proliferating	   beyond	   confluence	   (80-­‐90%	   confluence	   is	  reached	  with	  a	  number	  of	   cells	  of	   approximately	  1x106/well).	  The	  NIKS-­‐HPV11	  transfected	  cells	  shoved	  a	  rather	  slow	  growth,	  more	  like	  the	  untransfected	  NIKS	  (Figure	  4.5).	  The	  failure	  of	  the	  NIKS-­‐HPV11	  populations	  to	  recreate	  a	  phenotype	  similar	  to	  the	  NIKS-­‐HPV16	   is	   in	   accordance	   with	   recent	   data	   showing	   that	   HPV11	   genomes	  when	   transfected	   in	   immortal	   human	   keratinocyte	   line	   (HaCaT)	   cells	   are	  inefficient	   in	  promoting	  cell	  proliferation	  when	  transfected	   in	  vitro	  (Kaczkowski	  et	  al.,	  2012).	  The	   inability	  of	   the	  HPV11	  genome	   to	   increase	  cell	  proliferation	   is	  also	   suggested	   from	   the	   analysis	   of	   clinical	   biopsies,	   where	   the	   differential	  proliferation	  of	  basal	  cells	  in	  HPV16-­‐	  and	  HPV11-­‐induced	  lesions	  was	  highlighted	  (see	  Chapter	  1).	  Given	  this	  apparent	  inability	  to	  stimulate	  enhanced	  proliferation	  it	  is	  not	  clear	  how	  cells	  infected	  with	  LR-­‐HPV	  types	  expand	  to	  form	  a	  lesion.	  From	  previous	  studies	   it	  has	  been	  suggested	   that	  LR-­‐HPVs	  stimulate	   lesion	   formation	  only	   after	   successfully	   infection	   of	   stem	   or	   stem	   cell-­‐like	   cells	   in	   the	   basal	  compartment	   (Doorbar	   et	   al.,	   2012;	   Stanley	   et	   al.,	   2007).	   It	   has	   also	   been	  proposed	  that	  the	  highly	  proliferative	  situation	  created	  during	  the	  wound	  healing	  environment	   provide	   the	   primary	   stimulation	   for	   the	   proliferation	   of	   cells	  containing	  LR-­‐HPV	  genomes	  (Doorbar	  et	  al.,	  2012).	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The	  contribution	  of	  wound	  healing	  responses,	  and	  in	  particular	  the	  role	  of	  growth	  factors	  will	  be	  discussed	  later	  in	  the	  thesis.	  We	   conclude	   that	   in	   our	  model	   system,	   the	  HPV11	   genome	   does	   not	   drive	   cell	  proliferation.	  	  	  
	  	  
Figure	  4.5.	  NIKS-­‐HPV16/11	  and	  NIKS	  growth	  assay.	  NIKS,	  NIKS-­‐HPV16	  clone	  and	  populations	  (pool)	  and	  NIKS-­‐HPV11	  populations	  were	  grown	  for	  7	  days	  and	  the	   cells	  were	   counted	  each	  day	  after	  plating.	  The	   chart	   represents	   the	  average	  number	  of	   cells	  per	  well	  obtained	   from	  three	   independent	  experiments	  and	   the	  error	  bars	  show	  the	  standard	  deviation	  of	  the	  triplicate	  values.	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4.5.2	  HPV11	  genome	  does	  no	  stably	  persist	  in	  NIKS	  cells	  after	  transfection	  	  During	   the	   studies	   on	   NIKS	   HPV11	   populations	   we	   also	   tested	   the	   ability	   of	  HPV11	  genome	  to	  be	  maintained,	  and	  assessed	  the	  average	  copy	  number	  per	  cell	  immediately	   following	   transfection,	   selection	   and	   as	   the	   cells	   were	   cultured.	  HPV11	   inability	   to	  drive	   cell	  proliferation,	  does	  not	   allow	  of	   to	  positively	   select	  for	  fast	  cycling	  cell	  populations	  or	  clones	  after	  transfection.	  Thus,	  the	  presence	  of	  the	  HPV11	  genome	  in	   the	  cell	  populations	  used	  had	  to	  be	  regularly	   tested	   in	  all	  experiments.	  	  The	  cells	  were	  transfected	  and	  plated	  in	  flasks	  to	  acclimatize	  them	  to	  their	  culture	  conditions.	   After	   recovery	   from	   transfection	   stress,	   the	   cultures	   were	   typically	  subdivided	  into	  three	  flasks	  that	  were	  subsequently	  passaged.	  	  To	   determine	   the	   existence	   of	   viral	   genomes	   in	   the	   transfected	   cells,	   the	   cell	  cultures	  were	   grown	   to	   confluence	   at	   each	   passage	   prior	   to	   being	   harvested	   in	  order	   to	   perform	   real	   time	   quantitative	   PCR	   analysis	   on	   the	   extracted	   genomic	  DNA.	  	  The	   qPCR	   analysis	   revealed	   that	   the	   average	   level	   of	   the	   HPV11	   genomes	  contained	  in	  the	  transfected	  NIKS	  populations	  never	  exceeded	  90	  copies	  per	  cell	  at	   first	   culture	   passage	   (Figure	   4.6).	   	   Furthermore,	   we	   observed	   a	   direct	  correlation	   between	   viral	   copy	   number	   and	   the	   amount	   of	   transfected	   genome	  that	  was	  used	  to	  transfect	  the	  NIKS	  cells	  (Figure	  4.6).	  Interestingly,	  the	  amount	  of	  genome	   used	   during	   transfection	   had	   no	   effect	   on	   the	   ability	   of	   HPV11	   to	   be	  maintained	  in	  cultured	  cells	  after	  few	  passages.	  We	  observed	  that	  the	  number	  of	  HPV11	  copies	  per	  cell	  was	  reduced	  by	  about	  80%	  of	  the	  initial	  copy	  number	  post-­‐transfection	  over	  the	  period	  of	  four	  culture	  passages	  (Figure	  4.6).	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We	   believe	   that	   the	   loss	   of	   the	   HPV11	   genome	   was	   not	   dependent	   on	   the	  transfection	  efficiency,	  which	  was	  consistent	  between	  experiments	  when	  control	  plasmid	   was	   used.	   With	   ZsGreen1	   Fluorescent	   Protein	   transforming	   vectors	   a	  reproducible	  transfection	  rate	  of	  about	  70%	  of	  cells	  was	  routinely	  observed	  using	  the	  electroporation	  system.	  This	  was	  also	  seen	  when	  GFP	  plasmids	  were	  used	  to	  spike	  transfection	  with	  HPV11	  and	  HPV16	  DNA	  (Figure	  2.1).	  To	  assess	  further	  the	  transfection	  efficiency	  of	  HPV11	  genome,	  the	  cells	  were	  co-­‐transfected	   with	   the	   viral	   genomes	   and	   the	   pcDNA6	   plasmid	   (which	   carries	   a	  blasticidin-­‐resistance	   gene),	   and	   DNA	  was	   extracted	   from	   them	   48	   hours	   post-­‐transfection.	   The	  DNA	  was	   then	   analysed	   by	   qPCR	   to	   determine	   the	   number	   of	  HPV	  copies	  per	  cell.	  In	  this	  assay,	  the	  cells	  were	  first	  trypsinised	  and	  passed	  onto	  new	   plates	   24	   hours	   prior	   to	   the	   DNA	   extraction,	   to	   minimize	   the	   chances	   of	  having	   any	   exogenous-­‐DNA	   complexes	   attached	   on	   the	   outside	   of	   the	   cells	   and	  interfering	  with	  the	  results.	  The	  trypsinisation	  process	  of	  these	  cells	  involved	  one	  quick	   wash	   with	   trypsin-­‐versene,	   a	   2	   minute	   incubation	   to	   remove	   the	   feeder	  cells	   and	   a	   5-­‐10	   minute	   incubation	   to	   remove	   the	   NIKS	   cells,	   followed	   by	  neutralization	   of	   the	   trypsin	   and	   centrifugation	   of	   the	   detached	   cells.	   The	   copy	  numbers	  for	  the	  transfection	  of	  the	  HPV16	  and	  HPV18	  genomes	  were	  normalized	  to	   those	   for	   the	   transfection	   of	   the	   HPV11	   genome,	   for	   three	   independent	  experiments	   (Fig.	   4.6).	   The	   transfection	   efficiencies	   of	   the	   three	   genomes	  were	  found	  to	  be	  comparable.	  	  We	  suspect	  that	  the	  inability	  of	  HPV11	  to	  increase	  cell	  proliferation	  and	  enhance	  cycling	   speed	   means	   that	   HPV11	   transfected	   cells	   do	   not	   have	   any	   growth	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advantage	  when	  present	  as	  part	  of	  a	  mixed	  population.	  This	  may	  explain	  the	  short	  life	  span	  of	  the	  viral	  genome	  within	  the	  cell	  populations	  transfected	  with	  HPV11	  genomes.	  To	  compensate	  for	  this	  deficiency,	  in	  all	  our	  experiments	  employing	  NIKS-­‐HPV11	  populations,	   we	   used	   newly	   transfected	   cells	   in	   which	   the	   presence	   of	   HPV11	  genome	   was	   routinely	   assessed	   by	   qPCR	   methods.	   Only	   when	   the	   presence	   of	  HPV11	   genome	   within	   the	   NIKS	   population	   was	   satisfactorily	   established,	   by	  comparing	  the	  number	  of	  copies	  at	  48	  hours	  from	  transfection	  with	  the	  number	  of	   HPV11	   copies	   contained	   in	   the	   NIKS	   after	   the	   first	   culture	   passage,	   did	   we	  proceed	  to	  the	  use	  of	  NIKS-­‐HPV11	  cells	  to	  perform	  comparative	  studies	  in	  vitro.	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4.5.3	   Comparative	   analysis	   of	   the	   colonization	   ability	   of	   NIKS-­‐HPV16	   cells	  
and	  NIKS-­‐HPV11	  cell	  populations	  
	  Our	  model	  system	  suggests	  that	  NIKS-­‐HPV16	  cells	  might	  outgrow	  NIKS-­‐negative	  cells	  because	  of	  their	  ability	  to	  proliferate	  faster	  and	  to	  overcome	  normal	  cell-­‐to-­‐cell	   contact	   inhibition	   signals.	   Additionally,	   the	   scratch	   assay	   experiments	  performed	   in	   the	   presence	   of	   Mitomycin	   C	   suggest	   a	   possible	   ability	   of	   NIKS-­‐HPV16	  genome	  containing	  cells	  to	  repopulate	  a	  wound	  quicker	  than	  control	  cells.	  Thus,	   a	   higher	   rate	   of	   proliferation	   and	   a	   faster	   migration	   characterize	   NIKS-­‐HPV16	  containing	  cells.	  	  Contrarily	   to	   HR-­‐HPV-­‐containing	   cells	   cells,	   NIKS	   cells	   transfected	   with	   the	  HPV11	   genome	   have	   a	   slow	   cycling	   phenotype	   as	   shown	   in	   the	   growth	   rate	  analysis	  (Section	  4.5.1)	  suggesting	  that	  the	  LR-­‐HPV	  genomes	  have	  no	  capacity	  to	  increase	  proliferation.	  The	   differences	   between	   NIKS-­‐HPV16	   and	   NIKS-­‐HPV11	   cells	   revealed	   by	   the	  monolayer	   culture	   system	   suggest	   that	   these	   two	   types	   of	   cells	   may	   behave	  differently	  in	  an	  environment	  crowded	  by	  NIKS-­‐HPV	  negative	  cells.	  In	  fact,	  we	  hypothesize	  that	  following	  HPV	  infection	  the	  cells	  containing	  the	  HR-­‐HPV	  genome	  may	  outcompete	  neighbouring	  cells	  that	  are	  not	  ‘infected’.	  To	  determine	  whether	  NIKS-­‐HPV16	  cells	  can	  indeed	  outgrow	  NIKS	  cells	  we	  have	  developed	   an	   in	   vitro	   ‘colonization	   assay’.	   The	   colonization	   assay	   involves	   the	  plating	  of	  NIKS-­‐HPV16	  positive	   cells	   transfected	  with	  a	  GFP-­‐expressing	  plasmid	  in	  dishes	  containing	  NIKS	  cells.	  The	  expression	  of	  the	  GFP-­‐positive	  cells,	  which	  is	  monitored	   by	   fluorescent	  microscopy,	   is	   used	   to	   track	   the	   proliferating	   HPV16	  genome-­‐containing	  colonies	  as	  they	  increase	  in	  size.	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In	   this	   assay,	   we	   used	   NIKS-­‐HPV16	   LSIL-­‐like	   clones	   and	   NIKS-­‐HPV16	   cell	  populations,	   which	  were	   transfected	  with	   GFP	   expressing	   plasmids	   in	   order	   to	  help	   visualize	   the	   cells	   containing	   the	   viral	   genome.	   Cells	   expressing	   GFP	  were	  then	   plated	   into	   the	   midst	   of	   un-­‐transfected	   NIKS	   cells,	   which	   were	   used	   as	   a	  normal	   growth	   reference	   in	   comparison	  with	  NIKS-­‐HPV16	  GFP	   expressing	   cells	  (Figure	   4.7).	   The	   analysis	   of	   the	   colonies	   formed	   by	   the	   different	   types	   of	   cells	  shows	   that	   cells	   containing	   the	   HPV16	   genome	   and	   a	   GFP	   plasmid	   form	   large	  clusters	   of	   cells	   over	   a	   period	   of	   96	   hours.	   In	   particular,	   they	   were	   able	   to	  outgrow	   the	   neighbouring	   NIKS-­‐HPV	   negative	   keratinocytes	   as	   expected	   as	   a	  result	   of	   their	   increased	   growth	   rate	   (Section	   3.1	   and	   4.5.1).	   The	   control	  experiment,	   which	   involved	   the	   analysis	   of	   NIKS	   cells	   transfected	   with	   GFP	  expressing	   plasmids	   plated	   onto	   untransfected	   NIKS	   cells,	   showed	   the	   typical	  NIKS	   HPV-­‐negative	   cell	   proliferation	   rate,	   with	   colonies	   formed	   by	   NIKS-­‐GFP	  expressing	   cells	   being	   small	   in	   size.	  A	   comparative	   analysis	   of	   the	   colonies	   size	  was	  carried	  out	  by	  measuring	  the	  area	  covered	  by	  GFP	  expressing	  cells	   in	  three	  different	   plating	   experiments.	   For	   each	   experiment	   three	   images	   for	   each	   time	  point	  were	  analysed	  and	  the	  size	  of	  the	  GFP	  colonies	  present	  in	  the	  field	  of	  view	  were	   measured	   using	   Image-­‐J®	   software.	   The	   results	   show	   that	   cells	   lines	  containing	   the	   HPV16	   genome	   produce	   large	   colonies	   96	   hours	   post	   plating,	  whereas	  the	  keratinocytes	  containing	  only	  GFP	  expressing	  plasmids	  produce	  only	  small	  colonies	  and	  do	  not	  outgrow	  their	  neighbour	  cells	  (Figure	  4.7).	  The	  ability	  of	  both	  NIKS	  HPV16	  LSIL-­‐like	  clones	  and	  NIKS	  –HPV16	  populations	  to	  overgrow	   NIKS	   cells	   confirms	   the	   hypothesis	   that	   HPV16	   containing	   cells	  outcompete	  the	  un-­‐infected	  neighbours.	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Furthermore,	   the	   analysis	   of	   the	   colony	   size	   is	   in	   accordance	  with	   the	  doubling	  time	  analysis	  and	  the	  growth	  rate	  analysis	  showed	  previously	  (see	  Chapter	  3).	  This	  experiment	  shows	  the	  ability	  of	  keratinocytes	  containing	  HPV16	  genomes	  to	  form	  colonies	   that	  may	  resemble	   the	  early	  phases	  of	  cell	  proliferation	   following	  HPV16	  infection	  in	  the	  basal	  layer	  of	  the	  epithelium.	  	  	  	  	  	  
Figure	  4.7	  GFP	  expressing	  cells	  colonization	  assay.	  (A)	  NIKS-­‐HPV16	  cells	  were	  transfected	   with	   GFP-­‐expressing	   plasmid,	   and	   plated	   onto	   NIKS.	   NIKS-­‐HPV16	  green	  fluorescent	  cell	  proliferation	  was	  estimated	  during	  96	  hours	  time	  course.	  A	  control	   experiment	   using	   NIKS-­‐GFP	   cells	   plated	   onto	   NIKS	   was	   carried	   out	   to	  compare	   the	   colonization	   rate	   of	  HPV16-­‐negative	   cells.	   The	   scale	   bars	  measure	  100	  µm.	  (B)	  The	  chart	  shows	  the	  number	  of	  fluorescent	  cells	  of	  each	  type	  (NIKS,	  NIKS-­‐HPV16	   clone	   LSIL-­‐like	   and	  NIKS-­‐HPV16	   populations)	   at	   24-­‐,	   48-­‐,	   and	   72-­‐hours	   post	   plating.	   The	   bar	   graphs	   show	   the	   average	   of	   three	   independent	  experiments	  and	  the	  error	  bars	  show	  the	  range.	  There	  was	  significant	  difference	  between	  the	  colony	  size	  formed	  by	  NIKS-­‐HPV16	  (Pool	  and	  L-­‐SIL)	  and	  NIKS	  at	  96h	  time	  point	  (p	  <	  0.05).	  The	  experiment	  was	  repeated	  three	  times.	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4.5.4	  NIKS-­‐HPV11	   cells	   expressing	  GFP	   are	   not	   able	   to	   outgrow	  NIKS-­‐HPV	  
negative	  cells	  
	  The	  colonization	  assay	  performed	  with	  NIKS	  and	  NIKS-­‐HPV16	  cells	  showed	  that	  HPV16	   genome-­‐containing	   keratinocytes	   were	   able	   to	   outgrow	   NIKS	   HPV-­‐negative	   cells	   in	   a	   competitive	   growth	   environment.	   	   This	   experiment	   provides	  insight	   as	   to	  what	  might	   occur	   in	   the	   basal	   compartment	   of	   the	   epithelia	   soon	  after	   the	  HR-­‐HPV	   infection.	   It	   is	   not	   clear	   however,	  whether	   this	  mechanism	   is	  also	   a	   feature	   of	   low-­‐risk	   HPV	   types	   which	   show	   limited	   levels	   of	   basal	   layer	  proliferation	  in	  clinical	  samples.	  	  The	   study	   of	   the	   NIKS-­‐HPV11	   containing	   cells	   has	   already	   demonstrated	   that	  HPV11-­‐containing	   keratinocytes	   do	   not	   proliferate	   as	   fast	   as	   HPV16	   genome	  containing	   cells.	   To	   determine	   the	   ability	   of	   HPV11	   and	   HPV16	   genome-­‐containing	  NIKS	  to	  form	  colonies	  in	  a	  competitive	  growth	  environment	  we	  made	  use	  of	  the	  comparative	  colonization	  assay	  outlined	  in	  Section	  4.5.3.	  NIKS-­‐HPV11	  and	  NIKS-­‐HPV16	  cell	  populations	  were	  transiently	  transfected	  with	  GFP	  plasmid	  and	  plated	  onto	  NIKS	  (HPV-­‐negative)	  cells	  as	  described	  earlier.	  NIKS	  cells	   were	   also	   transfected	   with	   GFP	   expressing	   plasmid	   and	   used	   in	   control	  experiments.	   The	   NIKS-­‐HPV11	   and	   NIKS-­‐HPV16	   GFP-­‐transfected	   cells	   were	  subdivided	   in	   three	   vials.	   One	   vial	   of	   NIKS-­‐HPV16	   and	   one	   of	   NIKS-­‐HPV11	  populations	  was	  used	  to	  check	  for	  viral	  genome	  maintenance	  before	  starting	  the	  experiment.	  A	  second	  vial	  was	  used	  in	  the	  experiment	  and	  a	  third	  stored	  at	  -­‐80˚	  C.	  In	  dishes	  containing	  cover	  slips,	  the	  GFP-­‐NIKS-­‐HPV11/16	  cells	  were	  plated	  so	  as	  to	   obtain	   an	   approximately	   20:1	   ratio	   between	   NIKS	   and	   NIKS-­‐HPV	   cells.	   Cells	  were	  subsequently	  grown	  for	  seven	  days	  and	  cover	  slips	  were	  lifted	  at	  each	  day	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over	  a	  period	  of	  seven	  days.	  Cover	  slips	  were	  then	  fixed	  and	  stained	  with	  DAPI	  to	  visualize	   the	   cell	   nuclei	   (Figure	   4.8).	   Green	   fluorescent	   colonies	  were	   observed	  using	  a	  Zeiss	  inverted	  microscope	  equipped	  with	  a	  fluorescence	  lamp	  and	  picture	  acquired	   digitally	   using	   Axion™	   Digital	   Imager	   Software.	   The	   sizes	   of	   the	   GFP	  positive	  colonies	  were	  assessed	  using	  Image-­‐J®	  software.	  	  Data	   gathered	   for	   each	   day	   from	   two	   independent	   experiments	  were	   averaged	  and	   values	   obtained	   at	   day	   2	   and	   day	   7	   compared.	   The	   result	   showed	   that	   the	  sizes	   of	   the	   colonies	   of	   the	   NIKS-­‐HPV16	   GFP-­‐positive	   cells	   were	   significantly	  larger	   than	   those	   that	   arose	   from	   the	   NIKS-­‐GFP	   cells	   and	   NIKS-­‐HPV11	   GFP-­‐positive	  cells	  (Figure	  4.8	  B).	  Furthermore,	   the	   number	   of	   GFP	   positive	   colonies	   was	   different	   between	   the	  HPV11	   and	   HPV16	   genome	   containing	   populations	   (Table	   4.2).	   A	   colony	   was	  defined	  as	  a	  cluster	  of	  minimum	  three	  contiguous	  cells.	  We	  conclude	  that	  the	  formation	  of	  colonies	  from	  HPV11	  genome	  containing	  cells	  was	  not	  as	  efficient	  as	  for	  NIKS-­‐HPV16	  cells.	  We	  hypothesize	  that	  as	  NIKS-­‐HPV11	  cells	  do	  not	  show	  enhanced	  cell	  proliferation	  or	  any	  ability	  to	  outgrow	  their	   ‘uninfected’	  neighbours,	  thus	  they	  are	  unlikely	  to	  compete	   successfully	   in	   a	   wound	   healing	   like	   environment.	   It	   is	   plausible	   to	  hypothesize	   that	   a	   long-­‐lived	   recipient	   with	   slow	   cycling	   characteristics	   may	  favour	  the	  proliferation	  of	  LR-­‐HPV	  genotypes.	   In	  order	  to	  successfully	   infect	   the	  basal	   epithelia	   therefore,	   LR-­‐HPVs	   may	   need	   to	   enter	   keratinocytes	   with	   stem	  cell-­‐like	   characteristics.	   The	   comparative	   analysis	   of	   LR-­‐	   and	   HR-­‐HPV	   types	  provides	  evidence	  of	  differences	  of	  HPV	  types	  belonging	  to	  different	  groups.	  The	  analysis	   of	   colony	   size	   performed	   in	   the	   monolayer	   model	   system	   may	   in	   the	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future	   be	   exploited	   in	   a	   raft	  model	   or	   in	   an	   in	  vivo	   system	   if	   GFP-­‐HPV	   genome	  hybrids	  can	  be	  prepared.	  	  	  	  	  	   	  
Figure	   4.8:	   Colonization	   assays	   of	   NIKS,	   NIKS-­‐HPV16	   and	   NIKS-­‐HPV11	  
populations.	  (A)	  Colony	  formation	  at	  day	  1	  to	  7	  of	  NIKS,	  NIKS-­‐HPV16	  and	  NIKS-­‐HPV11	  GFP	  cells	  onto	  NIKS	  cells.	  The	  cells	  expressing	  GFP	  were	  visualized	  using	  a	  fluorescence	   microscope	   and	   pictures	   were	   acquired	   digitally.	   DAPI	   staining	  (blue)	  was	  used	  to	  help	  visualize	  all	  keratinocytes	  present	  in	  the	  field	  of	  view	  and	  to	  reveal	   the	  cells	   that	  were	  GFP	  negative.	  Scale	  bars	  measure	  100	  µm.	  (B)	  Two	  time	  points	  were	  chosen	   for	   comparison	  of	   the	   sizes	  of	   colonies	  between	  NIKS-­‐HPV11	  and	  NIKS-­‐HPV16	  GFP	  cells.	  (C)	  The	  colony	  measurements	  from	  six	  images	  of	   two	   independent	  experiments	  were	  averaged	  and	  plotted	   in	  a	   chart.	  The	  bar	  graphs	   show	   the	   average	   of	   three	   independent	   experiments	   and	   the	   error	   bars	  show	  the	  range	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  In	  this	  chapter	  we	  have	  shown	  that	  HPV16	  genome	  containing	  NIKS	  cells	  have	  the	  ability	  to	  recover	  a	  scratched	  monolayer	  in	  a	  shorter	  time	  than	  NIKS	  cells.	  More	  specifically	  we	  have	  shown	  that	  the	  cells	  containing	  the	  viral	  genome	  migrate	  and	  proliferate	   faster	   than	   NIKS	   in	   an	   in	   vitro	   scratch	   assay.	   This	   suggests	   that	   the	  HPV16	  genome	  is	  likely	  to	  confer	  an	  advantage	  to	  an	  infected	  cell	  with	  regard	  to	  competitive	   proliferation	   in	   a	   wounded	   epithelium.	   This	   characteristic	   was	  common	  to	  both	  NIKS-­‐HPV16	  clonal	  cell	  lines	  and	  NIKS-­‐HPV16	  newly	  transfected	  population.	  Furthermore,	  according	  to	  previous	  experiments	  	  (see	  Chapter	  3),	  we	  suggest	   that	   ‘infected’	   HPV16	   cells	   may	   acquire	   such	   a	   proliferative	   advantage	  during	  the	  very	  early	  phase	  of	  virus	  genome-­‐establishment	  in	  the	  host	  cells.	  The	   contribution	  of	   the	  migration	   rate	  as	  opposed	   to	   the	  proliferation	   rate	  was	  evaluated	  in	  a	  separate	  monolayer	  scratch	  assay.	  The	  results	  of	  this	  investigation,	  suggested	   an	   additional	   ability	   of	   the	   infected	   cells	   to	   migrate	   into	   the	   empty	  space	  created	  by	  the	  newly	  formed	   ‘wound’.	  Other	  studies	  support	  the	   idea	  that	  
	   NIKS	   NIKS-­‐HPV11	   NIKS-­‐HPV16	  
Day	  2	   21	  colonies	   23	  colonies	   27	  colonies	  
Day	  7	   18	  colonies	   12	  colonies	   26	  colonies	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cells	   containing	   HPV16	   E6	   and	   E7	   may	   increase	   their	   migration	   rate	   when	  propagated	  in	  monolayer	  (Boulenouar	  et	  al.,	  2010).	  Although	   we	   observed	   a	   substantial	   increase	   in	   the	   migration	   rate	   we	   are	  conscious	  of	  the	  limitations	  of	  the	  migration	  assay.	  Surprisingly,	   the	  movements	  of	   free	   cells	   into	   the	   scratched	   region	   from	   the	   wound	   edges	   of	   the	   scratched	  monolayer	  were	  not	   observed.	   In	   this	   case,	   the	   removal	   of	   the	   fibroblasts	   layer	  during	  the	  formation	  of	  the	  scratch	  might	  have	  compromised	  the	  ability	  of	  single	  cells	  to	  migrate	  into	  the	  unoccupied	  space.	  Nevertheless,	  NIKS-­‐HPV16	  cells	  were	  consistently	  quicker	  than	  NIKS	  in	  performing	  the	  scratch	  repair.	  We	  hypothesize	  that	   the	   scratch	   is	   occupied	   as	   a	   result	   of	   an	   increase	   in	   size	   of	   the	   cells	   at	   the	  periphery	   of	   the	   scratch	   and	   also	   by	   the	   continued	   growth	   of	   cells	   that	   were	  previously	  contact	  inhibited	  within	  the	  dish.	  These	  features	  are	  common	  to	  NIKS	  cells	  independently	  of	  whether	  they	  contain	  HPV.	  According	  with	  data	  obtained	  here,	  we	  can	  speculate	  that	  the	  presence	  of	  the	  HR-­‐HPV	   viral	   genome	   is	   likely	   to	   confer	   to	   the	   infected	   basal	   cells	   an	   ability	   to	  contribute	  to	  rapid	  wound	  repair.	  Both	  cell	  proliferation	  and	  cell	  migration	  were	  greater	   in	   the	   NIKS-­‐HPV16	   cells,	   suggesting	   the	   possibility	   that	   infected	   cells	  prevail	   under	   the	   selective	   pressure	   of	   a	   proliferative	   wound	   healing	  environment.	  Recent	  studies	  using	  cervical	  cancer	  cell	  lines	  have	  also	  shown	  that	  HPV16	  containing	  cells	  confer	  a	  substantial	  advantage	  to	   the	  repairing	  cells	  (Au	  Yeung	  et	  al.,	  2011).	  It	  was	  reported	  also	  that	  in	  transgenic	  mice	  (Tg(bK6-­‐E6/E7)),	  the	   expression	   of	   the	   HPV16	   	   E6	   and	   E7	   oncogenes,	   under	   the	   control	   of	   the	  bovine	   keratin	   6	   promoter,	   markedly	   improves	   the	   mouse's	   capacity	   to	   repair	  portions	  of	  the	  ear	  after	  being	  wounded	  (Valencia	  et	  al.,	  2008).	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Our	   results	   suggest	   that	   NIKS-­‐HPV16	   containing	   cells	   may	   outgrow	   the	   cells	  lacking	   the	   viral	   genome.	   Interestingly,	  we	   found	   that	   both	  NIKS-­‐HPV16	   clones	  and	  NIKS-­‐HPV16	  populations	   could	   efficiently	   outgrow	   their	   neighbouring	   cells	  when	   propagated	   together.	   During	   wound	   healing	   therefore,	   an	   infected	   cell	  would	  be	  able	  to	  establish	  a	  colony	  by	  exploiting	  its	  increased	  cycling	  speed	  and	  proliferation	   efficiency.	   Interestingly,	   a	   comparison	   between	   the	   LR-­‐HPVs	   and	  HR-­‐HPVs	   genome	   containing	   cells	   showed	   that	   the	   LR-­‐HPVs	  were	   inefficient	   in	  forming	  large	  colonies	  and	  were	  not	  outgrowing	  the	  parental	  NIKS	  cells.	  Although	  we	   suppose	   that	  NIKS	   cells	  may	  not	  be	   an	   ideal	  host	   environment	   to	   study	  LR-­‐HPVs	  due	  to	  their	  inefficient	  genome	  establishment,	  it	  was	  interesting	  to	  note	  that	  the	   LR-­‐HPV	   cells	  were	   not	   able	   to	   support	   efficient	   proliferation,	   and	  were	   not	  able	   to	   outgrow	   the	   NIKS	   cells.	  We	   can	   therefore	   raise	   the	   possibility	   that	   LR-­‐HPVs	   infections	   occur	   in	   basal	   cells	   with	   particular	   characteristics.	   We	   also	  believe	  that	  the	  cycling	  speed	  of	  the	  NIKS	  cells	  used,	  as	  our	  LR-­‐HPV	  host	  may	  be	  not	   ideal	   for	   efficiently	   establishing	   the	   viral	   genome.	   Although	   recent	   studies	  suggest	   the	   ability	   to	   culture	   HPV11	   cell	   lines	   for	   an	   extended	   length	   of	   time	  (Fang	   et	   al.,	   2006),	   our	   current	   thinking	   suggest	   that	  we	   should	   perhaps	   select	  slow-­‐cycling	  NIKS	  cells	   (the	  more	   stem	  cell-­‐like)	   to	  perform	   further	  analysis	  on	  HPV11	  genome	  maintenance	  in	  NIKS.	  	  The	   comparison	   between	   NIKS-­‐HPV11	   and	   NIKS-­‐HPV16	   containing	   cells,	   as	  shown	   in	   this	   study,	   suggest	   that	   HR-­‐HPV	   containing	   cells	   acquire	   a	   selective	  advantage	   over	   against	   the	   uninfected	   cells.	   LR-­‐HPVs	   appear	   not	   to	   have	   this	  characteristic,	   as	   NIKS-­‐HPV11	   containing	   cells	   did	   not	   proliferate	   as	   fast	   as	  
Chapter	  4	  	  	  
	   168	  
parental	  NIKS	  cells.	  We	  speculate	  that	  LR-­‐HPVs	  infections	  occur	  in	  basal	  cells	  with	  characteristics	   similar	   to	   stem	  cells,	   in	  which	   the	   viral	   genome	   is	  preserved	   for	  long	  period	  through	  slow	  cellular	  replication.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  
Chapter	  5	  	  	  
	   169	  
5.	  Study	  of	  wound	  healing	  responses	  in	  an	  in	  vitro	  
model	  system	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5.1	  Introduction	  
	  The	  events	  during	  papillomavirus	   lesion-­‐formation	  are	  not	  well	  understood,	  but	  are	   likely	   to	   differ	   between	   high	   and	   low	   risk	   HPV	   types,	  which	   have	   different	  effects	   on	   the	   infected	   basal	   layer.	   These	   differences	   most	   likely	   reflect	  differences	  in	  protein	  function	  and	  gene	  expression	  patterns	  that	  have	  evolved	  to	  support	  the	  different	  biology	  of	  the	  two	  virus	  groups.	  While	  high-­‐risk	  HPV	  types	  such	   as	   HPV	   16	   or	   18	   can	   drive	   cell	   proliferation	   in	   the	   basal	   and	   suprabasal	  layers,	   low-­‐risk	   types	  such	  as	  HPV	  6	  and	  11	  appear	  not	   to	  possess	   this	   function	  (Doorbar	  et	  al.,	  2012).	  In	  order	  to	  compare	  the	  two	  virus	  groups,	  we	  have	  introduced	  the	  HPV	  genomes	  into	   genetically	   identical	   keratinocyte	  background	  and	  examined	   their	   effect	   on	  functions	  required	  for	  lesion	  formation	  following	  epithelial	  trauma.	  In	  this	  model,	  high-­‐risk	  HPV	  types	  increase	  cell	  growth	  and	  migration	  rate	  when	  cells	  have	  space	  to	  grow,	  such	  as	  would	  occur	  during	  wound	  healing.	  Such	  viruses	  can	  also	  overcome	  normal	  cell-­‐to-­‐cell	  contact	  inhibition	  as	  the	  cells	  pack-­‐up,	  and	  this	   is	   manifest	   in	   organotypic	   rafts	   as	   an	   increase	   in	   basal	   and	   parabasal	   cell	  division	  similar	  to	  that	  seen	  in	  neoplasia	  (Isaacson	  Wechsler	  et	  al.,	  2012;	  Doorbar	  et	  al.,	  2012).	  This	  growth	  advantage	  would	  allow	  a	  single	  infected	  cell	  to	  outgrow	  its	   uninfected	   neighbours	   following	   infection	   or	   during	   lesion	   expansion	   after	  wounding.	  Interestingly,	  the	  low-­‐risk	  HPV	  types	  appear	  to	  have	  a	  negative	  effect	  on	  the	  cell	  growth	  rate,	  allowing	  the	  uninfected	  cells	  to	  predominate	  as	  a	  result	  of	  their	   more	   rapid	   cell	   division.	   These	   observations	   suggest	   a	   fundamental	  difference	  in	  the	  biology	  of	  the	  two	  HPV	  group,	  and	  support	  the	  idea	  that	  low-­‐risk	  types	  may	  reside	  in	  a	  long-­‐lived,	  slow-­‐cycling	  cell	  such	  as	  a	  stem	  cell.	  For	  the	  high-­‐
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risk	  HPV	  types	  this	  model	  may	  not	  hold	  true,	  with	  lesion-­‐formation	  being	  directed	  actively	  through	  functional	  changes	  in	  the	  infected	  basal	  layer.	  In	  this	  chapter	  we	  aim	  to	  consider	  the	  effects	  that	  wound	  healing	  responses	  may	  have	  on	  lesion-­‐formation	  following	  epithelial	  trauma.	  We	  hypothesize	  that	  due	  to	  the	  presence	  of	  growth	  factors	  during	  wound	  healing,	  infected	  cells	  may	  receive	  a	  proliferative	  ‘boost’	  allowing	  them	  to	  expand	  into	  the	  injured	  region.	  The	   contribution	   of	   wound	   healing	   responses	   to	   the	   development	   of	   a	   HPV–related	  lesion	  is	  not	  well	  understood.	  It	  is	  supposed	  that	  the	  abundance	  of	  growth	  factors	  during	  wound–healing	  may	  favour	  the	  expansion	  of	  infected	  basal	  cells.	  In	  fact,	   the	   presence	   of	   proliferative	   growth	   factors	   increases	   immediately	   after	  epithelial	   trauma	   (Sheardown	   and	   Cheng,	   1996;	  Wilson	   et	   al.,	   1999).	   Thus,	   the	  area	  of	  injury	  is	  infiltrated	  by	  growth	  factors	  and	  cytokines,	  which	  act	  to	  stimulate	  keratinocytes	  in	  an	  autocrine	  and	  paracrine	  manner.	  The	  growth	  of	  keratinocytes	  is	   stimulated	   by	   the	   members	   of	   the	   epidermal	   growth	   factor	   family	   (EGF),	  fibroblast	   growth	   factor	   (FGF),	   nerve	   growth	   factor	   (NGF),	   and	   insulin-­‐like	  growth	   factor	   (IGF)	   families,	   as	   well	   as	   hepatocyte	   growth	   factor	   (HGF),	  granulocyte-­‐macrophage	   colony-­‐stimulating	   factor	   (GM-­‐CSF),	   and	   endothelin-­‐1;	  their	  growth	  is	  suppressed	  by	  the	  transforming	  growth	  factor-­‐β,	  vitamin	  D3,	  and	  interferon-­‐γ	   (Shirakata,	   2010).	   Keratinocyte-­‐derived	   growth	   factors,	   cytokines,	  and	   chemokines	   contribute	   to	   the	   skin’s	   cytokine	   network.	   These	   components	  play	  important	  roles	  during	  inflammation,	  immune	  responses	  and	  wound	  healing	  (Nickoloff	   et	   al.,	   2007;	   Werner	   and	   Grose,	   2003).	   During	   the	   re-­‐epithelization	  phase	  of	  wound	  healing,	  the	  concentration	  of	  growth	  factors	  increases	  in	  order	  to	  stimulate	  the	  cells	  to	  proliferate	  and	  migrate	  (Sheardown	  and	  Cheng,	  1996;	  Zhang	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et	  al.,	  1999).	  EGF	  level	  content	  in	  tears	  showed	  a	  significant	  increase	  after	  corneal	  injury	  (Brightwell	  et	  al.,	  1985).	  The	  variation	  of	  the	  EGF	  protein	  and	  EGF	  mRNA	  during	   corneal	   wounding	   is	   estimated	   to	   increase	   several	   about	   70	   fold	  immediately	   after	   trauma	   and	   to	   return	   to	   a	   basal	   level	   within	   24-­‐72	   hours	  (Wilson	  et	  al.,	  1999).	  EGF	  is	  known	  to	  be	  an	  important	  proliferative	  agent	  and	  is	  used	  in	  tissue	  culture	  to	  stimulate	  the	  proliferation	  of	  NIKS	  cells.	  Thus,	  in	  order	  to	  understand	  whether	  the	  variation	  of	  the	  growth	  factor	  concentration	  produces	  a	  stimulating	  effect	  on	  infected	  cells	  we	  first	  aimed	  to	  recreate	  wound	  healing-­‐like	  conditions	  by	  varying	  its	  concentration	  in	  the	  culture	  medium.	  Our	  studies	  aimed	  to	  establish	  whether	  a	  wound-­‐healing	   environment	   might	   affect	   the	   establishment	   of	   a	   HPV-­‐induced	  lesion.	  As	  part	  of	  this,	  we	  hypothesized	  that	  changing	  the	  EGF	  levels	  may	  simulate	  to	  some	  extent,	  the	  changes	  that	  occur	  upon	  wound	  healing	  in	  vivo	  when	  cells	  are	  infected	  with	  either	  low	  or	  high	  risk	  HPVs.	  	  
5.2	   Increasing	   EGF	   concentration	   results	   in	   increased	   HPV16	  
viral	  copy	  number	  in	  monolayer	  cultures.	  
	  A	  series	  of	  experimental	  and	  clinical	  studies	  have	  demonstrated	  a	  positive	  effect	  of	   EGF,	   TGF-­‐α	   and	   heparin	   binding-­‐EGF	   (HB-­‐EGF)	   on	  wound	   repair,	   suggesting	  that	   the	   endogenous	   growth	   factors	   are	   also	   involved	   in	   the	   healing	   process	  (Martin,	  1997;	  Schultz	  et	  al.,	  1987).	  In	  particular,	  such	  growth	  factors	  are	  released	  in	  abundance	  (mainly	  by	  eosinophils	  and	  macrophages)	  and	  are	  key	  regulators	  of	  keratinocyte	   proliferation	   at	   the	   wound	   site.	   Furthermore,	   epidermal	  keratinocytes	  at	   the	  wound	  edge	  were	   identified	  as	  a	  source	  of	  EGF	  and	  TGF-­‐	  α	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(Yu	   et	   al.,	   1994).	   HB-­‐EGF	  was	   also	   localized	   in	   the	   advancing	   epithelial	  margin	  and	  also	  at	  the	  marginal	  surface	  of	  keratinocytes	  in	  murine	  burn	  wounds	  (Cribbs	  et	  al.,	  2002).	  EGF,	   TGF-­‐α	   and	   HB-­‐EGF	   bind	   the	   Epidermal	   Growth	   Factor	   Receptor	   (EGFR),	  which	   is	   a	   trans-­‐membrane	   receptor	   tyrosine	  kinase	   that	   is	   expressed	  on	  many	  different	   cell	   types	   (Yarden,	   2001).	   The	   binding	   of	   ligands	   to	   the	   EGF	   receptor	  results	   in	   a	   proliferative	   signalling	   response	   at	   wound	   sites	   during	   re-­‐epithelisation	  (Santoro	  and	  Gaudino,	  2005).	  Thus,	  the	  environment	  is	  enriched	  with	  growth	  factors	  that	  may	  contribute	  to	  the	  expansion	  of	  HPV	  infected	  cells	  during	  the	  wound	  healing	  response.	  Moreover,	  it	  has	  been	   suggested	   that	   the	   concentration	  of	  EGF	   in	  monolayer	   cancer	   cell	   line	  cultures	   is	   able	   to	   alter	   the	   expression	  of	   early	   viral	   genes	   (Collins	   et	   al.,	   2005;	  Rosenberger	  et	  al.,	  2010).	  We	   hypothesise	   that	   papillomaviruses	   may	   have	   evolved	   to	   profit	   from	   the	  environmental	  condition	  found	  during	  wound	  healing	  and	  that	  the	  presence	  of	  an	  increased	   amount	   of	   EGF	   may	   favour	   a	   pattern	   of	   viral	   gene	   expression	   that	  allows	   the	   proliferation	   and	   the	   establishment	   of	   HPV-­‐infected	   cells	   in	   the	  epithelial	  basal	  layer.	  To	   determine	  whether	   an	   increased	   EGF	   concentration	   can	   alter	   the	   viral	   copy	  number	  in	  monolayer	  culture	  we	  have	  augmented	  up	  to	  50	  fold	  the	  concentration	  of	  EGF	  normally	  contained	  in	  the	  culture	  medium,	  during	  the	  proliferative	  phase	  of	   sub-­‐confluent	  NIKS-­‐HPV16	   cultures,	   to	  mimic	   the	   post-­‐wounding	   increase	   in	  EGF	  concentration	   found	   in	  vivo	   (Brightwell	  et	  al.,	  1985;	  Wilson	  et	  al.,	  1999).	   In	  order	   to	   avoid	   the	   variations	   in	   the	   viral	   copy	   number	   that	   might	   occur	   as	   a	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consequence	   of	   keratinocyte	   differentiation,	   we	   performed	   the	   experiment	   in	  strictly	  sub-­‐confluent	  conditions	  (NIKS	  cells	  differentiation	  was	  discussed	  Section	  3.5).	  NIKS-­‐HPV16	  cells	  were	  cultured	  in	  standard	  medium	  to	  confluence	  and	  re-­‐plated	  in	   at	   three	   different	   EGF	   concentrations.	   We	   have	   chosen	   to	   use	   the	   standard	  10ng/ml	   EGF	   concentration	   alongside	   two	   altered	   concentrations	   of	   100ng/ml	  and	   500ng/ml,	   which	   are	   comparable	   with	   the	   post-­‐wounding	   EGF	   increases	  described	   in	   vivo.	   We	   observed	   that	   increasing	   the	   EGF	   concentration	   had	   no	  significant	  effects	  on	  the	  morphology	  of	  the	  keratinocytes	  in	  culture	  (Figure	  5.1).	  The	   NIKS-­‐HPVs	   were	   grown	   for	   72	   hours	   and	   cell	   pellets	   were	   harvested	   for	  protein,	  DNA	  and	  RNA	  analysis.	  An	   analysis	   of	   the	   viral	   copy	   number	   in	   pellets	   was	   carried	   out	   using	   a	   qPCR	  approach.	  The	  results	  showed	  that	  the	  number	  of	  the	  HPV16	  viral	  genome	  copies	  increased	  at	  when	  using	  500ng/ml	  EGF	  in	  the	  culture	  medium	  (Figure	  5.2).	  The	  highest	   concentration	   of	   EGF	   induces	   increase	   of	   viral	   copy	   number	   72	   hours	  after	  EGF	  addition.	  These	  data	  suggest	  that	  the	  presence	  of	  growth	  factors	  at	  the	  site	  of	   infection	  is	  able	   to	   enhance	   viral	   genome	   replication.	   The	   imitation	   of	   such	   effects	   in	   vivo	  would	   be	   advantageous	   for	   the	   virus	   as	   keratinocytes	   containing	   high	   copy	  number	   are	   more	   likely	   to	   persist	   and	   proliferate	   in	   latter	   phases	   of	   lesion	  formation.	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Figure	  5.1	  Bright-­‐filed	  Images	  of	  monolayer	  cultures	  at	  24,	  48	  and	  72	  hours	  
post-­‐plating.	  (A)	  NIKS	  cells	  were	  seeded	  in	  equal	  number	  and	  cultured	  72	  hours	  using	   three	   concentrations	   of	   EGF.	   Pictures	   show	   the	   morphology	   of	   the	   NIKS	  cells	   cultured	   with	   10ng/ml	   EGF,	   which	   corresponds	   to	   the	   standard	  concentration	   used	   in	   monolayer	   cultures.	   (B)	   Images	   of	   NIKS-­‐HPV16	   cells	  cultured	   72h	   using	   standard	   and	   wound	   healing-­‐like	   EGF	   concentrations	   were	  also	  acquired.	  Images	  were	  acquired	  digitally	  using	  a	  10x	  magnification	  objective.	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Figure	   5.2.	   NIKS-­‐HPV16	   genome	   copy	   number	   at	   72	   hours	   compared	   to	  
HPV16	   genome	   copy	   number	   at	   plating	   (0h).	  NIKS-­‐HPV16	  populations	  were	  harvested	   at	   72	   hours	   post-­‐plating	   and	  DNA	   extracted	   from	   cell	   pellets.	  During	  the	   72	   hours	   time	   period	   the	   NIKS-­‐HPV16	   cells	   were	   treated	   with	   10ng/ml,	  100ng/ml	  and	  500ng/ml	  EGF.	  Quantitative	  PCR	  analysis	  was	  used	   to	  determine	  the	  absolute	  copies	  of	  HPV16	  genome	  and	  GAPDH	  house	  keeping	  genes	  at	  plating	  time	   and	   72	   hours	   post-­‐plating.	   The	   GAPDH	   copies	   were	   used	   to	   estimate	   the	  number	   of	   NIKS-­‐HPV16	   cells.	   The	   bar	   graphs	   show	   the	   average	   of	   three	  experiments	  and	  the	  error	  bars	  show	  the	  range.	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5.2.1	  EGF-­‐rich	  medium	  treatment	  has	  a	  long-­‐term	  effect	  on	  the	  increase	  the	  
HPV16	  genome	  copy	  number	  	  During	   wound	   healing	   it	   has	   been	   suggested	   that	   the	   concentration	   of	   growth	  factors	  rises	  locally	  in	  the	  area	  of	  the	  injury	  in	  order	  to	  stimulate	  the	  proliferation	  of	  keratinocytes.	  Corneal	  wound	  studies	  have	  measured	  the	  concentration	  of	  EGF	  in	  the	  tears	  and	  demonstrated	  that	  the	  EGF	  concentration	  varies	  during	  the	  days	  following	  corneal	   trauma	  (Wilson	  et	  al.,	  1999).	  EGF	   levels	  rise	  up	  to	  10	   fold	   the	  standard	   concentration	   immediately	   following	   wound	   creation	   with	   its	  concentration	  in	  tears	  returning	  to	  the	  basal	  level	  within	  24	  hours	  of	  the	  onset	  of	  the	   trauma.	   A	   second	   significant	   peak	   in	   the	   EGF	   concentration	  was	  noted	   at	   3	  days	  post-­‐wounding,	  suggesting	  that	  EGF	  rich	  environment	  persists	  for	  few	  days	  from	  wound	  creation	  (Wilson	  et	  al.,	  1999).	  A	   highly	   concentrated	   EGF	   medium	   was	   used	   in	   our	   monolayer	   culture	  experiment	   to	   determine	   the	   effect	   of	   the	   wound	   healing	   response	   on	   the	  amplification	   of	   the	   viral	   genome	   and	   on	   pattern	   of	   viral	   gene	   expression.	   As	  showed	   earlier,	   using	   an	   EGF	   supplemented	  medium	   resulted	   in	   an	   increase	   in	  HPV16	  viral	  copy	  number	  by	  72h.	  In	  order	   to	  determine	   the	  possible	   long-­‐term	  effect	  of	  EGF	  treatment	  on	  HPV16	  copy	  number	  we	  evaluated	  the	  number	  of	  viral	  genome	  copies	  96	  hours	  after	  EGF	  treatment.	  The	  experiment	  aimed	  to	  establish	  whether	  changes	  in	  the	  number	  of	  genome	   copies	   were	   sustained	   when	   the	   lower	   concentration	   of	   10ng/ml	   EGF	  was	  re-­‐established	  in	  the	  culture,	  as	  would	  happen	  in	  the	  days	  following	  epithelial	  wound.	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To	  do	   this,	  NIKS-­‐HPV16	   cell	   populations	  were	   seeded	  at	   equal	  density	   in	  7	   six-­‐well	  plates	  in	  order	  to	  obtain	  triplicate	  wells	  for	  each	  time	  point.	  The	  NIKS-­‐HPV16	  cells	  were	  cultured	  using	  three	  concentration	  of	  EGF,	  corresponding	  to	  10-­‐,	  100-­‐,	  and	   500-­‐ng/ml.	   The	   monolayer	   cultures	   (6	   plates)	   were	   left	   in	   EGF	   enriched	  medium	  for	  72	  hours.	  A	  separate	  monolayer	  culture	  of	  NIKS-­‐HPV16	  cells	  grown	  in	  a	  10ng/ml	  EGF	  Medium	  was	  used	  as	  control.	  After	  72	  hours,	  the	  first	  set	  of	  cells	  contained	  in	  three	  plates	  was	  harvested	  and	  DNA	  extracted	  for	  quantitative	  PCR	  analysis.	  In	  order	  to	  simulate	  the	  restoration	  of	  normal/steady-­‐state	  of	  EGF	  after	  epithelial	   trauma,	   the	   remaining	   three	   plates	   of	   NIKS-­‐HPV16	   populations	  were	  kept	   in	   culture	   for	   further	   96	   hours	   in	   standard	   complete	   medium	   (10	   ng/ml	  EGF),	  prior	  to	  harvesting	  and	  DNA	  extraction	  for	  quantitative	  PCR	  analysis.	  	  The	  comparison	  of	  viral	  copy	  number	  obtained	  with	  the	  first	  and	  the	  second	  set	  of	  cells	  showed	  no	  significant	  variation.	  In	  fact,	  the	  cells	  cultured	  in	  the	  highest	  EGF	  concentrations	  maintained	   the	   viral	   copy	   number	   at	   unvaried	   levels	  when	   EGF	  had	  returned	  to	  basal	  levels	  (Figure	  5.3).	  This	   suggests	   that	   even	   short	   exposures	   to	   high	   concentration	   of	   EGF	   might	  trigger	  a	  mechanism	  that	  elevates	  the	  viral	  copy	  number	  in	  the	  infected	  cell.	  We	  hypothesize	   that	   such	   a	   mechanism	   would	   be	   advantageous	   during	   the	   early	  phases	  of	   viral	   infection	  when	   the	  number	  of	   viral	   copies	   in	   the	  newly	   infected	  basal	  cells	  is	  believed	  to	  be	  very	  low.	  The	  virus	  might	  have	  evolved	  a	  mechanism	  that	   exploits	   the	   particular	   environment	   that	   the	   infected	   cell	   finds	   itself	   in	   a	  wound	  situation	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Figure	   5.3	   Evaluation	   of	   the	   copy	   number	   change	   in	   NIKS-­‐HPV16	  
populations.	   NIKS-­‐HPV16	   cells	   were	   plated	   in	   equal	   number	   and	   cultured	   in	  complete	  medium	  supplemented	  with	  10	  ng/ml,	  100	  ng/ml	  or	  500	  ng/ml	  EGF	  in	  each	  plate.	  After	  72	  hours	  the	  monolayers	  were	  cultured	  for	  a	  further	  96	  hours	  in	  10	  ng/ml	  EGF	  only.	  The	  copy	  number	  estimated	  at	  72	  hours	  post	  plating	  and	  the	  copy	   number	   evaluated	   at	   96	   hours	   post-­‐treatment	   were	   normalized	   with	   the	  copy	   number	   measured	   at	   plating	   point.	   The	   bar	   graphs	   show	   the	   average	   of	  three	   experiments	   and	   the	   error	   bars	   show	   the	   range.	   The	   experiment	   was	  repeated	  three	  times.	  
	  	  	  
5.3	  EGF	  treatment	  increases	  the	  HPV11	  genome	  copy	  number	  but	  
the	  effect	  is	  not	  maintained	  over	  time	  	  
	  As	   wounding	   of	   epithelia	   is	   necessary	   for	   HPV	   infection	   at	   some	   sites,	   virus	  establishment	   in	   the	   basal	   layers	   is	   thought	   to	   occur	   concurrently	   with	   tissue	  repair	   (Joyce	   et	   al.,	   1999;	   Kines	   et	   al.,	   2009).	   Thus,	   wound-­‐healing	   responses	  might	  influence	  the	  establishment	  of	  viral	  infection.	  Moreover,	  it	  is	  plausible	  that	  the	  expansion	  of	   infected	  cells	   is	  essentially	  driven	  by	  proliferative	  stimuli	   from	  repairing	   cells	   during	   the	   early	   phases	   of	   wound	   healing.	   This	   would	   be	  particularly	  useful	  when	  low-­‐risk	  HPV	  types	  infect	  the	  epithelium	  as	  we	  reported	  
Chapter	  5	  	  	  
	   181	  
that	  they	  are	  unable	  to	  drive	  proliferation	  of	  basal	  cells	  (Section	  4.5.1).	  As	  shown	  previously	  in	  section	  5.2,	  environmental	  changes	  such	  as	  changes	  in	  growth	  factor	  concentration	   are	   able	   to	   influence	   the	   levels	   of	   the	   viral	   genome	   contained	   in	  NIKS	  cells.	  To	  determine	  whether	  the	  concentration	  of	  EGF	  may	  interfere	  with	  the	  replication	   of	   HPV11	   viral	   episomes,	  we	   performed	   a	   similar	   experiment	   using	  NISK-­‐HPV11	  populations.	  NIKS-­‐HPV11	  populations	  were	  obtained	  by	   transfection	  of	  NIKS	  with	   full-­‐length	  HPV11	  genomes.	  The	  NIKS	  were	  harvested	  and	  plated	  on	  60	  mm	  6-­‐well	  plates	  at	  a	   density	   of	   5x105	   cells	   per	   well	   on	   a	   layer	   of	   1x105	   feeders	   and	   left	   to	   grow	  overnight	  in	  FC	  medium.	  Transfections	  were	  carried	  out	  using	  the	  Nucleofector®	  Transfection	  Equipment	  (Lonza)	  following	  the	  manufacturer’s	   instructions.	  Cells	  were	   transfected	   with	   up	   to	   a	   total	   of	   1	   μg	   of	   circular	   DNA	   together	   with	   a	  blasticidin	   resistance	   plasmid,	   which	   were	   purified	   from	   bacterial	   cultures.	   Six	  hours	   after	   transfection	   cells	  were	   given	   fresh	   FC	   selective	  medium.	   Cells	  were	  cultured	  to	  confluence	  and	  HPV11	  content	  was	  assessed	  using	  a	  quantitative	  PCR	  approach.	   The	   NIKS-­‐HPV11	   populations	   were	   harvested	   at	   confluence	   and	   re-­‐seeded	   in	   (12)	   60mm	   6-­‐well	   plates.	   The	   cultures	  were	   treated	  with	   increasing	  EGF	   concentrations	   as	   described	   in	   Section	   5.2.	   Cells	   grown	   in	   a	   10ng/ml	   EGF	  containing	   medium	   were	   used	   as	   control.	   Half	   of	   the	   cultured	   plates	   were	  harvested	  at	  day	  1,	  3,	  5	  and	  7.	  These	  cultures,	  which	  were	  cultured	   in	  10ng/ml	  EGF	  medium	   showed	   a	   constant	   level	   of	   viral	   genome	   copies	   (≅80	   copies/cell)	  throughout	  the	  duration	  of	  the	  experiment	  (Figure	  5.4A).	  The	  number	  of	  HPV11	  copies	  contained	  at	  the	  plating	  time	  was	  used	  as	  reference.	  Results	  showed	  that	  HPV11	  viral	  copy	  number	  remained	  unchanged.	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The	  second	  set	  of	  NIKS-­‐HPV11	  populations	  was	  cultured	  in	  EGF	  enriched	  medium	  (500	   ng/ml)	   (Figure	   5.4B).	   The	   EGF	   treatment	   was	  maintained	   for	   7	   days	   and	  cells	  harvested	  at	  day	  1	  and	  every	  other	  day.	  DNA	  was	  extracted	  from	  cell	  pellets	  and	  HPV11	  copies	  estimated	  with	  the	  use	  of	  the	  q-­‐PCR.	  The	  data	  obtained	  showed	  that	  high	  concentration	  of	  EGF	  produce	  a	  stimulative	  effect	   in	   the	  replication	  of	  the	  HPV11	  genome,	  similar	  to	  what	  showed	  in	  Section	  5.2.1	  for	  HPV16.	  Contrary	  to	  what	  was	  seen	  with	  NIKS-­‐HPV16,	  the	  viral	  genome	  copies	  in	  NIKS-­‐HPV11	  cells	  were	   not	  maintained	   over	   time.	   The	  HPV11	   copy	   number	   increased	   during	   the	  first	  three	  days	  of	  treatment	  but	  had	  returned	  to	  pre-­‐treatment	  level	  by	  day	  7.	  We	   believe	   that	   the	   mechanisms	   underlying	   the	   decrease	   in	   the	   viral	   copy	  number	  in	  cells	  transfected	  with	  HPV11	  genome	  are	  worth	  investigating.	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5.4	   EGF	   concentration	   correlates	   with	   NIKS-­‐HPV11	   and	   NIKS-­‐
HPV16	  copy	  number	  increase	  
	  During	  the	  proliferative	  phase	  of	  wound	  healing,	  keratinocytes	  are	  stimulated	  by	  a	   variety	   of	   growth	   factors,	   cytokines	   and	   chemokines.	   It	   is	   plausible	   that	   the	  duration	   of	   such	   stimuli	   varies	   depending	   on	   the	   tissue	   and	   the	   severity	   of	   the	  injury.	  To	  look	  at	  this,	  we	  have	  reproduced	  in	  vitro	  such	  conditions	  by	  altering	  the	  concentration	  of	  EGF	  in	  the	  culture	  medium.	  This	  was	  increased	  up	  to	  500	  ng/ml	  and	  cells	  were	  analysed	  for	  HPV	  genome	  content.	  As	  shown	  previously	  for	  HPV16	  the	  EGF	  treatment	  also	  stimulated	  the	  replication	  of	  HPV11	  viral	  genomes.	  In	  order	  to	  compare	  the	  effects	  of	  EGF	  concentration	  on	  the	  low-­‐risk	  and	  high-­‐risk	  HPV	  types,	  we	  went	  on	  to	  reproduce	  the	  experiment	  using	  NIKS	  transfected	  with	  HPV11	  and	  HPV16	  genomes.	  NIKS	  cells	  were	  transfected	  in	  parallel	  and	  once	  the	  presence	  of	  viral	  genome	  had	  been	  established	  the	  cells	  were	  cultured	  to	  50-­‐60%	  confluence	  and	   then	  re-­‐plated	   in	   triplicate	  culture	  plates.	  The	  medium	  added	  to	  the	   culture	   plates	   was	   equal	   except	   for	   the	   content	   of	   diluted	   EGF.	   Three	  concentrations	  were	  used	  to	  culture	  the	  cell	  populations:	  10	  ng/ml,	  50	  ng/ml	  and	  500ng/ml.	  The	   cells	  were	   cultured	   72	   hours	   and	   viral	   copy	   number	  was	   analysed	  with	   q-­‐PCR.	  Both	   cell	   populations	   displayed	   a	   similar	   increase	   in	   the	   viral	   copy	   number	  (Figure	  5.5).	  Interestingly,	  the	  number	  of	  genome	  copies	  was	  not	  similar	  between	  the	   two	   cell	   populations,	   with	   the	   HPV16	   genome-­‐containing	   NIKS	   having	   a	  greater	  number	  of	  copies.	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In	  conclusion,	  an	  EGF-­‐rich	  medium	  stimulates	  HPV-­‐containing	  cells,	   resulting	   in	  an	  increase	  in	  the	  quantity	  of	  genome	  copies.	  This	  effect	  is	  common	  to	  both	  low-­‐risk	  and	  high-­‐risk	  HPV	  types	  analysed	  during	  the	  proliferative	  time	  frame	  (0-­‐72	  hours)	  (Figure	  5.5).	  However,	  as	  shown	  earlier,	  the	  NIKS-­‐HPV11	  cells	  are	  not	  likely	  to	  maintain	  a	  high	  virus	   copy	   number	   and	   return	   to	   basal	   level	   when	   cells	   are	   confluent.	  Furthermore,	  the	  number	  of	  established	  HPV11	  copies	  in	  the	  transfected	  NIKS	  is	  always	  lower	  than	  that	  observed	  for	  NIKS-­‐HPV16,	  suggesting	  that	  low-­‐risk	  HPVs	  may	  ideally	  establish	  in	  slow-­‐cycling	  cells	  or	  cells	  with	  a	  specific	  phenotype.	  The	   significant	   effect	   on	   the	  viral	   copy	  number	  obtained	  with	   a	   temporary	  EGF	  treatment	   show	   that	   HPVs	   have	   evolved	   to	   exploit	   the	   transitory	   conditions	  created	  during	  wound	  healing.	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Figure	   5.5.	   Absolute	   viral	   genome	   copies	   measured	   in	   NIKS-­‐HPV16	   and	  
NIKS-­‐HPV11	  populations.	   (A)	  Average	  from	  three	   independent	  experiments	  of	  the	   absolute	   viral	   genome	   copies	   measured	   in	   NIKS	   cells	   after	   genome	  transfection.	   (B-­‐C)	   HPV16/11	   copies	   in	   NIKS	   cultured	   with	   different	  concentrations	  of	  EGF.	  The	  bar	  graphs	  show	  the	  average	  of	  three	  experiments	  and	  the	  error	  bars	  show	  the	  range.	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5.5	   Increasing	   EGF	   concentration	   does	   not	   produce	   a	  
proliferative	  effect	  in	  monolayer	  cultures	  	  
	  Treating	  NIKS-­‐HPV11	  and	  NIKS-­‐HPV16	  populations	  with	  increased	  concentration	  of	  EGF	  lead	  to	  an	  increase	  in	  the	  of	  genome	  copy	  number	  in	  the	  transfected	  NIKS.	  The	   effect	   is	   particularly	   noticeable	   in	   NIKS-­‐HPV16	   cells,	   which	   maintain	   the	  elevated	  copy	  number	  for	  an	  extended	  period	  of	  time,	  once	  the	  EGF	  stimulus	  was	  removed.	   NIKS-­‐HPV11	   cells	   were	   also	   stimulated	   by	   the	   high-­‐EGF	   medium	   to	  increase	  copy	  number,	  but	  the	  copy	  number	  rise	  was	  only	  transient.	  EGF	  has	  well-­‐established	   growth-­‐stimulative	   properties,	   and	   thus	   we	   aimed	   to	   determine	  whether	  the	  high	  EGF	  concentration	  could	  also	  lead	  to	  an	  increase	  in	  cell	  number	  during	  monolayer	  growth.	  In	   order	   to	   understand	   whether	   the	   EGF	   concentration	   used	   in	   the	   latter	  experiment	  could	  also	  lead	  to	  enhanced	  cell	  proliferation	  in	  monolayer,	  we	  went	  onto	   develop	   a	   specific	   growth	   assay.	   This	   proliferation	   assay	   was	   carried	   out	  using	  both	  NIKS-­‐HPV11	  and	  NIKS-­‐HPV16	  cell	  populations.	  Cells	  were	   seeded	   for	  measurement	   of	   proliferation	   rate,	  which	  was	   conducted	  without	   blasticidin	   selection.	   Cultures	   were	   harvested	   for	   proliferation	  measurement	  every	  at	  day	  1	  and	  every	  48	  hours	  for	  a	  total	  of	  7	  days.	  Triplicate	  wells	  were	  set-­‐up	  for	  each	  cell	  type	  and	  time-­‐point.	  	  The	  results	  show	  NIKS-­‐HPV16	  cells	  cultured	  at	  high	  EGF	  concentration	  (50	  ng/ml	  and	  500	  ng/ml)	  produce	  a	  greater	  number	  of	  cells	  by	  day	  5	  and	  day	  7	  than	  NIKS-­‐HPV16	   cultured	   in	   standard	  medium	   (10	   ng/ml)	   (Figure	   5.6).	   Interestingly	   the	  number	  of	  NIKS-­‐HPV16	  cells	  counted	  at	  day	  3	  was	  lower	  than	  NIKS-­‐HPV16	  cells	  cultured	  in	  standard	  EGF	  medium.	  Although	  the	  cell	  number	  increase	  was	  modest	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we	  believe	  that	  the	  medium	  rich	  of	  growth	  factors	  allowed	  the	  NIKS-­‐HPV16	  cells	  to	  proliferate	  more	   efficiently	  post-­‐confluence.	  Contrary	   to	   this,	   culturing	  NIKS-­‐HPV11	   cells	   in	  EGF	   rich	  medium	  did	  not	  produce	   any	   appreciable	   effect	   on	   the	  number	  of	  the	  cells	  counted	  at	  any	  time-­‐point.	  	  Thus,	   we	   conclude	   that	   NIKS-­‐HPV16	   and	   NIKS-­‐HPV11	   populations	   contain	  elevated	  copies	  of	  the	  viral	  genome	  when	  exposed	  to	  high	  concentrations	  of	  EGF	  (Figure	   5.5),	   but	   do	   not	   necessarily	   show	   a	   concomitant	   elevation	   in	   cell	  proliferation.	  We	  hypothesise	  however,	  that	  cells	  containing	  a	  greater	  number	  of	  viral	  genome	  copies	  may	  have	   limited	  proliferative	  ability	  due	  to	  a	  more	  robust	  activation	   of	   cellular	   mechanisms	   of	   DNA	   replication	   control	   (DDR),	   or	   other	  inhibitions	  signals	   in	  response	  to	  the	  replication	  of	   foreign	  viral	  DNA	  within	  the	  cell.	   It	   is	   plausible	   that	  NIKS	   cells	   containing	  HPV16	  may	  have	   a	  more	   effective	  ability	   to	   overcome	   the	  DDR	   check	  points,	  whereas	  NIKS-­‐HPV11	   cells	   are	  more	  susceptible	   of	   being	   inhibited,	   given	   that	   HPV11	   genomes	   appear	   not	   to	   be	  maintained	  long-­‐term	  in	  rapidly	  dividing	  cells	  in	  vivo.	  	  We	   believe	   that	   the	   role	   of	   the	   DNA	   damage	   response	   pathways	   in	   NIKS-­‐HPVs	  cells	  is	  worth	  investigating	  to	  examine	  these	  hypotheses.	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Figure	   5.6.	   NIKS-­‐HPV11	   and	  NIKS-­‐HPV16	   growth	   assay.	  Cells	  were	  cultured	  seven	  days	  in	  Medium	  containing	  different	  concentration	  of	  EGF	  (norm=10ng/ml;	  +10=100ng/ml;	   +50=	   500ng/ml).	   The	   cell	   number	   of	   six	   different	   wells/time	  points	  was	  obtained	  using	  a	  coulter	  counter.	  Cell	  numbers	  were	  averaged	  for	  each	  time	  point	  and	  plotted	  in	  a	  chart.	  The	  error	  bars	  represent	  the	  standard	  error	  of	  the	  measured	  values.	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5.6	  NIKS-­‐HPV16	  cells	  exposed	  to	  high	  concentration	  of	  EGF	  show	  
variations	  in	  the	  splicing	  pattern	  of	  E6/E6*	  mRNA	  
	  As	  mentioned	  in	  the	  introduction,	  two	  main	  promoters,	  the	  early	  p97	  and	  the	  late	  p670	   promoter	   regulate	   HPV16	   gene	   transcription.	   The	   activation	   and	  suppression	   of	   these	   promoters	   is	   differentiation	   dependent,	   and	   results	   in	   the	  production	   of	   a	   number	   of	   polycistronic	   mRNAs	   (Figure	   1.10).	   Differential	  splicing	  can	  further	  regulate	  the	  polycistronic	  mRNAs	  (Jia	  et	  al.,	  2009;	  Schwartz,	  2008).	  Alternative	   splicing	  of	   the	   early	  pre-­‐mRNAs	   leads	   to	   the	   translation	  of	   a	  number	   of	   functional	   proteins	   such	   as	   E6,	   E6*	   and	   E7,	   which	   have	   specific	  biological	  functions	  (Grassmann	  et	  al.,	  1996;	  zur	  Hausen,	  2002).	  Alternative	  splicing	  can	  also	  be	  regulated	  by	  extracellular	  stimuli	  as	  a	  number	  of	  pathways	   and	   splicing	   factors	   have	   been	   discovered	   that	   regulate	   this	   process	  (Blaustein	   et	   al.,	   2007).	   Amongst	   these	   exogenous	   stimuli,	   growth	   factors	  activated	   signal	   pathways	   are	   known	   to	   influence	   the	   splicing	   patterns	   of	   a	  number	  of	  genes,	  including	  CD44v5	  and	  fibronectin.	  The	  mechanism	  by	  which	  the	  growth	   factors	   exert	   these	   functions	   includes	   activation	   and	   suppression	   of	  different	  splicing	  factors	  leading	  enhanced	  exon	  exclusion	  (Blaustein	  et	  al.,	  2007).	  With	  regard	  to	  HPVs,	  splicing	  of	  the	  polycistronic	  E6/E7	  mRNA	  produces	  a	  new	  ORF	  termed	  E6*,	  where	  the	  first	  5’	  exon	  is	  excluded.	  The	  E6*	  mRNAs	  have	  been	  described	  only	   in	  high-­‐risk	  HPVs	  (Zheng	  and	  Baker,	  2006).	   In	  particular,	   the	  E6	  gene	   of	   HPV16	   has	   the	   potential	   to	   encode	   full-­‐length	   as	   well	   as	   truncated	   E6	  proteins	  (E6*I	  and	  E6*II)	  by	  alternative	  splicings.	  HPV16	  E6*I	  alternative	  splicing	  is	  produced	  via	  exclusion	  of	  a	  183-­‐bp	   fragment	  of	   the	  E6	  ORF,	  which	   leads	   to	  a	  premature	   termination	   codon.	   Interestingly,	   only	   full-­‐length	   E6	   demonstrate	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transforming	   capacity.	   E6*	   ORF	   species	   are	   the	   most	   abundant	   transcripts	   in	  HPV16	   caused	   lesions,	   cervical	   carcinoma	   biopsies	   and	   in	   explanted	   carcinoma	  cell	  lines	  (Bohm	  et	  al.,	  1993).	  E6*	  protein	  functions	  include	  the	  modulation	  of	  E6	  in	  HPV18	  by	  rescuing	  the	  p53	  levels	  in	  vivo	  and,	  in	  HPV16,	  the	  8-­‐kDa	  E6*	  protein	  can	  induce	  apoptosis	  by	  stabilizing	  procaspase-­‐8	  which	  is	  otherwise	  targeted	  by	  E6	  (Filippova	  et	  al.,	  2007;	  Pim	  and	  Banks,	  2010).	  	  Although	  some	  biochemical	  differences	  regarding	  the	  different	  E6	  isoforms	  have	  been	  examined,	  less	  information	  exists	  about	  the	  regulation	  of	  alternate	  splicing	  
in	   vivo	   and	   its	   biological	   function	   within	   the	   epithelia	   (Schwartz,	   2008).	  Additionally,	  the	  in	  vivo	  regulation	  of	  E6/E6*	  splicing	  is	  not	  yet	  fully	  understood.	  Interestingly,	   a	   recent	   study	   has	   suggested	   that	   HPV16	   E6	   alternate	   splicing	   is	  dependent	  on	  the	  presence	  of	  EGF,	  and	  that	  the	  MEK1/2-­‐Erk1/2	  MAP	  kinases	  act	  as	   key	   regulatory	   components	   in	   promoting	   or	   inhibiting	   the	   exon	   exclusion	  (Rosenberger	  et	  al.,	  2010).	  This	  study	  suggests	  a	  model	  for	  HPV16	  viral	  oncogene	  regulation	   during	   cell	   differentiation,	   as	   the	   concentration	   of	   EGF	   is	   known	   to	  vary	  in	  the	  differentiating	  epithelia	  (Collins	  et	  al.,	  2005).	  Because	   EGF	   concentration	   also	   varies	   during	   wound	   healing	   we	   aimed	   to	  monitor	  HPV16	  oncogene	  alternative	  splicing	  in	  our	  monolayer	  model	  system.	  	  To	   determine	   the	   E6/E6*	   ratios	   produced	   from	   the	   viral	   episomes,	   we	   used	  specific	  primers	  covering	  the	  complete	  first	  alternative	  exon	  (Figure	  5.7A).	  When	  NIKS	  containing	  the	  HPV16	  genome	  were	  exposed	  to	  a	  high	  concentration	  of	  EGF	  (100	  ng/ml	  or	  500	  ng/ml)	  we	  detected	  an	  increased	  level	  of	  E6	  full-­‐length	  mRNA	  compared	  with	  the	  untreated	  samples	  (Figure	  5.7B).	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These	   data	   suggest	   that	   EGF	   concentration	   is	   capable	   of	   interfering	   with	   the	  regulation	   of	   HPV16	   viral	   oncogene	   regulation.	   We	   hypothesize	   that	   during	  wound	  healing,	  the	  virus	  may	  require	  high	  levels	  of	  E6	  to	  prevent	  apoptosis	  and	  to	   elevate	   copy	   number	   by	   creating	   a	   more	   sustained	   replication	   competent	  environment.	   Such	   a	   mechanism	   might	   be	   brought	   about	   by	   the	   high	  concentration	   of	   growth	   factors	   at	   the	   site	   of	   infection.	   When	   the	   wound	   is	  repaired	  the	  concentration	  of	  EGF	  would	  be	  expected	  to	  return	  to	  basal	  level	  and	  the	  virus	  may	  require	  an	  alternate	  splicing	  pattern	  in	  order	  to	  properly	  regulate	  basal	   cell	   proliferation	   and	   to	   maintain	   or	   increase	   E7	   production,	   which	   is	  beneficial	   to	   the	   virus	   as	   it	   can	   enhance	   the	   proliferation	   rate	   of	   the	   basal	   and	  parabasal	  cells.	  We	   have	   shown	   that	   EGF	   levels	   are	   involved	   in	   the	   mechanism	   of	   E6/E6*	  alternate	   splicing	   regulation	   in	   cells	   harbouring	   viral	   episomes	   in	  vitro.	   Further	  investigation	   will	   be	   necessary	   to	   assess	   the	   mechanism	   by	   which	   the	   E6/E6*	  splicing	   regulation	   is	   achieved	   and	   to	   understand	   whether	   splicing	   patterns	   of	  other	  ORFs	  are	  also	  altered	  by	  the	  concentration	  of	  growth	  factors.	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Figure	  5.7	  Analysis	  of	  splicing	  patterns	  in	  NIKS-­‐HPV16	  cells.	  (A)	  Organization	  of	  HPV16	  E6/E7	  and	  E6*/E7	  early	  mRNA;	  base	  pair	  numbers	  are	  given	  relative	  to	  HPV	  genome	   localization.	  Exclusion	  of	   the	  exon	  226-­‐409	  results	   in	   formation	  of	  E6*	   ORF,	   which	   contains	   a	   premature	   stop-­‐codon.	   Arrows	   indicate	   primer	  localisation	   for	   semi-­‐quantitative	  RT-­‐PCR.	   (B)	  Analysis	   of	  E6	   splicing	  pattern	   in	  NIKS-­‐HPV16	   populations	   treated	   72h	   with	   Medium	   containing	   different	  concentration	  of	  EGF	   (10	  ng/ml;	   100	  ng/ml;	   500	  ng/ml).	  GAPDH	  primers	  were	  used	  as	  control.	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5.7	   Exogenous	   EGF	   treatment	   affects	   EGFR	   expression	   and	   its	  
related	  molecular	  targets	  in	  NIKS-­‐HPV	  cells	  
	  It	  is	  known	  from	  a	  number	  of	  studies	  that	  EGF	  is	  a	  mitogen	  for	  oestrogen	  receptor	  (ER).	   It	  has	  been	  shown	  that	  EGF	  mimics	  the	  oestrogen	  functions	  and	  cross-­‐talk	  with	  ER-­‐α	  to	  exert	  its	  activity	  (Clark	  et	  al.,	  2001).	  The	  EGFR	  is	  highly	  expressed	  in	  breast	   and	   ovarian	   cancers	   (Arteaga,	   2002;	   Yokota	   et	   al.,	   1986).	   As	  mentioned	  earlier,	  the	  EGFR	  half-­‐life	   is	   influenced	  by	  the	  expression	  of	  the	  HPV	  protein	  E5,	  which	  prevents	  the	  recycling	  of	  the	  receptor	  (Venuti	  et	  al.,	  2010).	  Recent	  studies	  performed	  on	  HPV-­‐positive	  cervical	  cancer	  cell	  lines	  have	  demonstrated	  that	  the	  treatment	  with	  exogenous	  EGF	  stimulated	  the	  expression	  of	  EGFR	  (Narayanan	  et	  al.,	   2012).	   According	   to	   what	   has	   been	   reported	   in	   previous	   studies,	   the	  mechanism	  by	  which	  EGF	  stimulates	  the	  cell	  proliferation	  of	  cervical	  cancer	  cells	  upon	  exogenous	  treatment	  might	  be	  dependent	  on	  the	  activation	  of	  the	  EGFR	  and	  Cyclin	  D1	  (Narayanan	  et	  al.,	  2012).	  EGF	  also	  stimulates	  NIKS	  cellular	  proliferation	  via	  the	  EGF	  signaling	  pathway	  (Roy	  and	  King,	  2013).	  We	  hypothesize	   that	   in	   our	  wound	  healing	  model	   system	   the	   expression	   of	   the	  EGF	   receptor	   might	   be	   influenced	   by	   the	   extensive	   and/or	   prolonged	   EGF	  administration.	  To	  determine	  whether	  the	  amount	  of	  EGF	  contained	  in	  the	  culture	  medium	  has	  an	  effect	  on	  EGFR	  expression	  we	  decided	  to	  estimate	  the	  EGFR	  level	  using	  a	  western	  blotting	  approach.	  NIKS	  HPV-­‐negative	  and	  NIKS-­‐HPV16	  cell	  lines	  were	  initially	  cultured	  in	  standard	  medium	  for	  a	  period	  of	  seven	  days	  and	  cell	  pellets	  harvested	  for	  protein	  analysis.	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This	   preliminary	   analysis	   was	   carried	   out	   in	   order	   to	   understand	   whether	   the	  confluence	  state	  of	  the	  monolayer	  culture	  had	  an	  effect	  on	  EGFR	  expression.	  	  The	   western	   blot	   analysis	   showed	   that	   in	   the	   samples	   containing	   the	   HPV16	  genome,	   the	   expression	   of	   EGFR	   increased	   compared	   to	   the	   samples	   not	  containing	  the	  virus	  when	  confluence	  was	  reached	  (Figure	  5.8A).	  Thus,	  in	  order	  to	  counter	  the	  possibility	  that	  the	  expression	  of	  EGFR	  was	  altered	  by	  the	  confluence	  state	  of	  the	  cells	  we	  decided	  to	  successively	  culture	  the	  NIKS-­‐HPV16	  genome	  containing	  cells	  up	  to	  72	  hours.	  The	  culture	  media	  used	  in	  these	  experiment	  was	  supplemented	  with	  EGF	  in	  order	  to	  reach	  the	  concentration	  used	  in	   the	  previous	  experiments.	  The	  EGF	  concentrations	  employed	  were	  10	  ng/ml,	  100	  ng/ml	   and	  500	  ng/ml.	  The	   cells	   cultured	   for	  72	  hours	  were	  harvested	   and	  protein	  levels	  assessed	  using	  specific	  EGFR	  antibodies.	  The	  western	  blot	  showed	  an	  increase	  in	  EGFR	  expression	  in	  the	  NIKS-­‐HPV16	  cells	  cultured	  with	  100	  and	  500	  ng/ml	  of	  EGF	  (Figure	  5.8B).	  These	   data	   suggest	   that	   exogenous	   EGF	   is	   able	   to	   alter	   the	   number	   of	   the	   EGF	  receptor	  present	  on	  the	  cell	  surface.	  	  We	  hypothesise	  that	  the	  number	  of	  the	  receptors	  may	  be	  increased	  in	  response	  to	  the	  EGF	  treatment	  and	  that	  their	  half-­‐life	  may	  be	  elongated	  by	  the	  expression	  of	  viral	  proteins	  such	  as	  E5.	  	  	  The	  increased	  EGFR	  expression	  levels	  and	  the	  change	  in	  viral	  copy	  number	  led	  us	  to	   investigate	   the	   effects	   of	   exogenous	  EGF	   treatment	   on	   the	   various	  molecular	  targets	  of	  EGFR.	  To	  do	  this,	  we	  examined	  the	  transcription	  levels	  of	  EGFR,	  Akt-­‐1,	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Cyclin	   D1	   p21,	   p53,	   Caspase-­‐3	   and	   GAPDH.	   The	   RNA	  was	   extracted	   from	   EGF-­‐stimulated	  cells	  and	  a	  quantitative	  RT-­‐PCR	  was	  performed.	  Although	   we	   have	   not	   examined	   EGFR	   expression	   increase	   in	   NIKS-­‐HPV11	  samples,	   we	   also	   performed	   the	   RT-­‐PCR	   analysis	   on	   NIKS-­‐HPV11	   populations	  cultured	   72	   hours	   in	   culture	   medium	   containing	   10ng/ml,	   100ng/ml	   and	  500ng/ml	  EGF.	  Using	  qPCR,	  we	  found	  on	  average	  a	  	  >2.0-­‐3.0-­‐fold	  increase	  in	  p21,	  Caspase-­‐3,	  and	  p53	  transcripts	   levels	   in	  the	  samples	  treated	  with	  100ng/ml	  and	  500ng/ml	  EGF	  when	   compared	   to	   cells	   grown	   at	   ‘normal’	   EGF	   levels	   	   (Figure	   5.9).	   Exogenous	  EGF	   did	   not	   significantly	   alter	   the	   transcript	   levels	   of	   Cyclin	   D1	   and	   EGFR,	  suggesting	  that	  cell	  proliferation	  at	  the	  G0èG1èS	  boundary	  was	  not	  stimulated.	  A	  decrease	  of	  >2.0-­‐3.0-­‐fold	  of	  the	  steady	  state	  level	  of	  Akt	  mRNA	  in	  the	  samples	  stimulated	  with	  100ng/ml	  and	  500ng/ml	  was	  also	  measured	  (Figure	  5.9).	  Collectively,	   these	   data	   suggest	   that	   culturing	   NIKS-­‐HPV11	   cells	   with	   high	  concentration	   of	   EGF	   does	   not	   produce	   a	   stimulatory	   effect	   in	   terms	   of	   cell	  proliferation	  as	   the	  mRNA	   level	  of	  EGFR	  and	  MAP	  kinase	   (Akt-­‐1)	  and	  Cyclin	  D1	  were	  not	  significantly	  altered.	  Contrarily,	   the	   level	   of	   EGFR,	   Akt,	   Cyclin	   D1,	   and	   p53	   transcripts	   were	  significantly	   increased	   by	   EGF	   stimulation	   in	   NIKS-­‐HPV16	   treated	   cells	   (Figure	  5.10).	   A	   greater	   stimulatory	   effect	  was	   obtained	   by	   culturing	  NIKS-­‐HPV16	   cells	  with	   medium	   containing	   100ng/ml	   and	   500ng/ml	   EGF.	   Although	   we	   did	   not	  observe	  a	  significant	  difference	  in	  the	  level	  of	  mRNA	  expression	  for	  p53	  following	  EGF	   stimulation,	   the	   steady	   state	   level	   of	   mRNA	   of	   p21	   and	   Capsase-­‐3	   were	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decreased	   by	   EGF	   treatment,	   suggesting	   a	   negative	   regulation	   of	   the	   tumour	  suppressor	  genes.	  We	  also	  have	  observed	  an	  increased	  p97	  promoter	  activity	  as	  consequence	  of	  EGF	  stimulation	  (Figure	  5.11).	  However,	  such	  effect	  might	  not	  be	  common	  to	  low-­‐risk	  HPVs,	   as	   two	   independent	   promoters	   regulate	   the	   transcription	   messages	   that	  contain	  the	  E7	  ORF	  (DiLorenzo	  and	  Steinberg,	  1995).	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Figure	   5.8	   Expression	   level	   of	   EGFR	   in	   NIKS	   and	   NIKS-­‐HPV16	   clones	   and	  
populations.	   (A)	   Expression	   level	   of	   EGFR	   was	   determined	   by	   western	   blot	  analysis	   on	   protein	   extracts	   from	  NIKS	   and	  NIKS-­‐HPV16-­‐HSIL	   and	   -­‐LSIL	   clones	  cultured	  over	  a	  period	  of	  6	  days	  in	  monolayer.	  The	  A-­‐431	  cell	  extract	  was	  used	  as	  comparative	  positive	  EGFR	  control.	  (B)	  Western	  blot	  analysis	  of	  EGFR	  indicating	  a	  specific	  stimulatory	  effect	  by	  exogenous	  EGF	  administration	  (10ng/ml,	  100ng/ml	  and	  500ng/ml)	  to	  the	  culture	  medium.	  NIKS-­‐HPV16	  populations	  were	  cultured	  in	  monolayer	   for	   72	   hours.	   NIKS	   (EGF	   500ng/ml)	   and	   NIKS-­‐HPV16	   LSIL	   (EGF	  10ng/ml)	   samples	   were	   used	   for	   comparative	   analysis.
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Figure	   5.9	   Quantitative	   real-­‐time	   RT-­‐PCR	   analysis	   of	   EGF-­‐modulated	  
molecular	  targets	   in	  NIKS-­‐HPV11	  populations.	  The	  mRNA	  expression	  level	  of	  EGFR,	   Akt,	   Cyclin	   D1,	   p53,	   p21	   and	   Caspase-­‐3	   was	   determined	   by	   performing	  quantitative	  RT-­‐PCR	  analysis	  with	   the	   total	  RNA	  extracted	   from	  EGF-­‐stimulated	  NIKS-­‐HPV11	  cells	  cultured	  in	  monolayer	  for	  72	  hours	  using	  10ng/ml,	  100ng/ml	  and	  500ng/ml	  of	  EGF.	  The	  fold	  increase	  in	  the	  expression	  level	  was	  normalized	  to	  the	  expression	   level	  measured	  at	  seeding	  point.	  GAPDH	  expression	  was	  used	  as	  reference	   gene.	   Expression	   levels	   of	   Akt	   indicate	   >2.0-­‐3.0-­‐fold	   decrease	   in	   the	  100ng/ml	   and	   500ng/ml	   samples	   respectively.	   The	   data	   presented	   generated	  from	   the	   mean	   values	   of	   three	   independent	   experiments	   and	   the	   standard	  deviation	  (±)	  is	  presented	  as	  error	  bars.	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Figure	   5.10	   Quantitative	   real-­‐time	   RT-­‐PCR	   analysis	   of	   EGF-­‐modulated	  
molecular	  targets	   in	  NIKS-­‐HPV16	  populations.	  The	  mRNA	  expression	  level	  of	  EGFR,	   Akt,	   Cyclin	   D1,	   p53,	   p21	   and	   Caspase-­‐3	   was	   determined	   by	   performing	  quantitative	   RT-­‐PCR	   analysis	   with	   total	   RNA	   extracted	   from	   EGF-­‐stimulated	  NIKS-­‐HPV16	  cells	  cultured	  in	  monolayer	  for	  72	  hours,	  using	  10ng/ml,	  100ng/ml	  and	  500ng/ml	  of	  EGF.	  The	  fold	  increase	  in	  the	  expression	  level	  was	  normalized	  to	  the	  expression	   level	  measured	  at	  seeding	  point.	  GAPDH	  expression	  was	  used	  as	  reference	   gene.	   Expression	   levels	   of	   p21	   and	   Caspase-­‐3	   indicate	   >2.0-­‐4.5-­‐fold	  decrease	   in	   the	   100ng/ml	   and	   500ng/ml	   samples	   respectively.	   The	   data	  presented	  generated	  from	  the	  mean	  values	  of	  three	  independent	  experiments	  and	  the	  standard	  deviation	  (±)	  is	  presented	  as	  error	  bars.	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Figure	   5.11	   Quantitative	   real-­‐time	   RT-­‐PCR	   analysis	   of	   E6	   transcripts	   in	  
NIKS-­‐HPV16	   populations.	   The	   mRNA	   expression	   level	   of	   E6	   mRNAs	   was	  determined	  by	  performing	  quantitative	  RT-­‐PCR	  analysis	  with	  total	  RNA	  extracted	  from	  EGF-­‐stimulated	  NIKS-­‐HPV16	  cells	   cultured	   in	  monolayer	   for	  3	  and	  5	  days,	  using	   10ng/ml,	   100ng/ml	   and	   500ng/ml	   of	   EGF.	   The	   fold	   increase	   in	   the	  expression	   level	   was	   normalized	   to	   the	   expression	   level	   measured	   at	   seeding	  point.	   GAPDH	   expression	   was	   used	   as	   reference	   gene.	   Expression	   levels	   of	   E6	  indicate	  >2.0-­‐3.0-­‐fold	   increase	  at	  day	  5	   in	   the	  100ng/ml	  and	  500ng/ml	  samples	  respectively.	   The	   data	   presented	   generated	   from	   the	   mean	   values	   of	   three	  independent	   experiments	   and	   the	   standard	   deviation	   (±)	   is	   presented	   as	   error	  bars.	  	  	  	  
5.8	  Discussion	   	  	  In	   Chapter	   5	  we	   have	   shown	   that	   exogenous	   growth	   factors	   interfere	  with	   the	  production	  of	  HPV	  viral	   genome	   in	   the	  NIKS	   transfected	   cells.	  More	   specifically	  the	   experiments	   have	   shown	   that	   by	   increasing	   the	   amount	   of	   available	  EGF	   in	  the	  culture	  medium,	  an	   increased	  number	  of	   the	  viral	   copies	  could	  be	  detected.	  We	   have	   also	   observed	   that	   such	   increase	   in	   the	   EGF	   administration	   was	   well	  tolerated	  by	  the	  keratinocytes	  in	  culture.	  Thus,	  we	  speculate	  that	   in	  an	  EGF	  rich	  environment,	  the	  presence	  of	  the	  growth	  factors	  may	  have	  a	  significant	  effect	  on	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viral	  copy	  number.	  Overall	  the	  amount	  of	  viral	  copies	  in	  HR-­‐HPV	  transfected	  cells	  increased	   significantly,	   suggesting	   that	   such	   HPV	   types	   are	   particularly	  susceptible	   to	   changes	   in	   the	   external	   environment.	   Interestingly,	   we	   reported	  that	  although	  the	  LR-­‐HPV	  types	  showed	  a	  similar	  copy	  number	  increase,	  the	  copy	  number	  per	  cell	  was	  lower	  than	  HR-­‐HPV	  transfected	  cells.	  We	  therefore	  raise	  the	  possibility	  that	  NIKS	  cells	  may	  tolerate	  HPV16	  viral	  episomes	  better	  than	  HPV11	  genomes,	  where	  the	  viral	  copy	  number	  was	  found	  to	  decline.	  	  In	   NIKS-­‐HPV16	   cells	   after	   EGF	   treatment	   the	   elevated	   copy	   number	   was	  maintained	   long-­‐term	  at	   the	  higher	   levels.	   In	   contrast,	   in	  NIKS-­‐HPV11	   cells,	   the	  copy	   number	   increase	   caused	   by	   the	   administration	   of	   increased	   exogenous	  growth	   factors	   was	   not	   maintained	   upon	   continued	   growth.	   We	   therefore	  hypothesise	   that	   during	   the	   initial	   phases	   of	   PVs	   infection,	   infected	   cells	  containing	  LR-­‐HPV	  types	  would	  benefit	  from	  the	  presence	  of	  high	  concentrations	  of	  growth	   factors	  as	   this	  could	  stimulate	  an	   initial	  rise	   in	  genome	  copy	  number.	  The	  inability	  of	  NIKS-­‐HPV11	  to	  maintain	  a	  high	  number	  of	  genome	  copies	  might	  be	  related	  to	  the	  inefficiency	  of	  HPV11	  in	  counteracting	  the	  host	  cell	  mechanisms	  that	  control	  the	  replication	  of	  exogenous	  DNA.	  The	   spontaneous	   rise	   in	   HPV	   episomal	   levels	   after	   EGF	   administration	   was	   a	  recent	  finding	  with	  the	  NIKS	  monolayer	  system.	  Previous	  studies	  have	  shown	  that	  the	   levels	   in	  growth	   factors	   increase	  during	  wound	  healing	   (Cribbs	  et	  al.,	   2002;	  Schultz	  et	  al.,	  1991).	  Therefore	  we	  speculate	  that	  during	  viral	  infection,	  the	  basal	  cell	   environment	  enriched	   ingrowth	   factors	  may	  play	  a	   fundamental	   role	   in	   the	  establishment	  of	  a	  successful	  HPV	  infection.	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We	   have	   also	  made	   an	   interesting	   correlation	   between	   the	   levels	   of	   exogenous	  EGF	  and	  HPV16	  viral	  genome	  expression.	   In	   this	  case,	  we	   found	  that	  when	  high	  concentrations	  of	  EGF	  were	  added	   to	  NIKS-­‐HPV16	  cell	   cultures,	   the	   levels	  of	  E6	  and	  E6*	   transcripts	  were	  altered.	   In	  particular	  we	   found	  that	  high	   levels	  of	  EGF	  increase	   the	   expression	   of	   HPV16	   E6	   full-­‐length	   mRNAs.	   Therefore,	   it	   is	  reasonable	  to	  assume	  that	  during	  initial	  phases	  of	  viral	  infection	  HR-­‐HPVs	  might	  require	   high	   levels	   of	   full-­‐length	   E6	   to	   prevent	   apoptosis.	   	   Interestingly,	   recent	  studies	  using	  cervical	  cancer	  cell	  lines	  have	  also	  shown	  that	  changes	  in	  EGF	  levels	  in	  the	  culture	  medium	  can	  modulate	  E6/E6*	  splicing	  patterns	  (Collins	  et	  al.,	  2005;	  Rosenberger	  et	  al.,	  2010).	  When	  we	  studied	  the	  effects	  of	  exogenous	  EGF	  we	  also	  found	  that	  this	  produced	  an	   increased	   expression	   level	   of	   the	   EGF	   receptor.	   The	   downstream	   effects	   of	  EGFR	  activation	  may	  contribute	  to	  cell	  proliferation	  and	  the	  enhancement	  of	  viral	  genome	   amplification.	   Thus,	   we	   decided	   to	   look	   at	   the	   EGFR	  molecular	   targets	  that	  may	  be	  altered	  by	  the	  presence	  of	  exogenous	  EGF.	  Preliminary	  data	  suggest	  in	   fact,	   that	   in	   the	   NIKS-­‐HPV16	   cell	   populations,	   the	   activation	   of	   EGFR	  contributes	   to	   the	   proliferative	   response	   when	   monolayer	   cells	   reach	   the	  confluence	   state.	   I	   found	   also	   that	   at	   this	   stage	   the	   HPV16	   E6	   transcripts	  increased,	  which	  might	  be	  as	   a	   result	   of	   the	  activation	  of	   the	  p97	  promoter.	  By	  contrast,	  the	  EGFR	  targets	  analysed	  in	  NIKS-­‐HPV11	  cells	  showed	  that	  exogenous	  EGF	  did	  not	  produce	  a	  proliferative	  stimulus	  as	  seen	  in	  NIKS-­‐HPV16	  cells.	  These	  observations	  suggest	  that	  different	  mechanisms	  might	  control	  cell	  proliferation	  in	  NIKS-­‐HPV11	   and	   NIKS-­‐HPV16	   cell	   populations.	   	   Further	   investigations	   are	  necessary	  to	  elucidate	  the	  molecular	  pathways	  involved.	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Although	  these	  data	  suggested	  that	  NIKS-­‐HPV16	  cells	  might	  have	  a	  proliferative	  advantage	   when	   EGF	   is	   administrated	   at	   high	   concentration,	   we	   observed	   a	  modest	   increase	   in	   the	   number	   of	   cells	   produced	   during	   a	   seven-­‐day	   growth	  period.	   As	   EGF	   treatment	   had	   no	   significant	   effect	   on	   the	   cell	   proliferation	   of	  NIKS-­‐HPV11,	   we	   hypothesize	   that	   host	   cellular	   mechanisms	   that	   control	   the	  replication	   of	   exogenous	   DNA	   may	   be	   activated	   in	   response	   to	   the	   increased	  copies	  of	  viral	  genome	  contained	  in	  the	  cells.	  These	  responses	  limit	  our	  ability	  to	  study	  HPV11	   in	   cell	   culture	  models	   at	   the	  moment.	   In	   vivo,	   this	   limitation	  may	  control	   the	   expansion	   of	   the	   LR-­‐HPV	   infections;	   perhaps	   to	   restrict	   immune	  system	   intervention	   that	  would	  otherwise	  eliminate	   infected	  cells.	  This	  strategy	  might	  differ	  between	  low-­‐	  and	  high-­‐risk	  types.	  We	  also	  hypothesise	  that	  in	  NIKS-­‐HPV16	  cell	  populations	  the	  activation	  of	  the	  DNA	  Damage	  Responses	  (Edwards	  et	  al.,	  2013)	  might	  be	  better	  tolerated	  as	  a	  modest	  increase	  in	  the	  cell	  proliferation	  was	  measured	  in	  the	  growth	  assay.	  Future	  work	  will	  be	  aimed	  at	  understanding	  the	  role	  of	  these	  pathways	  in	  HPV	  lesion	  formation.	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6.	  	  Final	  discussion	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6.1	  General	  Discussion	  
	  Despite	   the	   recent	   introduction	  of	  prophylactic	  vaccines	   for	   cervical	   cancer	  and	  other	  HPV-­‐associated	  diseases,	  it	  is	  estimated	  that	  this	  will	  not	  dramatically	  affect	  the	   burden	   of	   cervical	   cancer	   for	   30-­‐50	   years	   (Stanley,	   2012).	   Although	   most	  work	  so	   far	  has	   focused	  out	  on	  the	  study	  of	  high-­‐risk	  HPV	  types	  such	  as	  HPV16	  and	  HPV18,	   it	   is	   necessary	   to	   increase	   the	   understanding	   of	   the	   different	   risks	  associated	   with	   different	   HPV	   types,	   pursuing	   also	   the	   understanding	   of	   the	  molecular	  pathways	  that	   these	  viruses	  destabilise.	  Advancements	   in	  these	  areas	  are	  likely	  to	  yield	  better	  strategies	  for	  disease	  treatments,	  which	  are	  necessary	  to	  complement	   current	   methods	   of	   disease	   management	   and	   disease	   prevention.	  Furthermore,	   it	  will	   also	  be	  necessary	   to	  extend	   the	  knowledge	  of	   the	  high-­‐risk	  associated	  disease	  occurring	  not	  only	  at	  cervical	  sites,	  but	  at	  other	  important	  sites	  as	   well,	   such	   as	   the	   oropharynx	   and	   oesophageal	   squamocolumnar	   junction.	   A	  final	  important	  area	  of	  study	  focuses	  on	  the	  mechanisms	  by	  which	  low-­‐risk	  HPV	  types	   produce	   benign	   lesions,	   such	   as	   laryngeal-­‐papillomatosis,	   which	   in	   some	  rare	  cases	  can	  progress	  to	  cancer.	  In	   this	   thesis	  we	  have	  examined	   the	  mechanisms	  of	   lesion	   formation	   caused	  by	  HPV.	   To	   accomplish	   this,	   we	   have	   developed	   a	  model	   system	   in	  which	  we	   can	  mimic	   in	   the	  most	   reasonable	  way,	   the	   environment	   in	  which	   a	  HPV	   lesion	   are	  thought	  to	  develop.	  	  Initially,	   I	   characterised	   the	   model	   system	   that	   has	   been	   used	   in	   this	   study.	  	  Experiments	  were	  performed	  to	  understand	  the	  dynamics	  of	  the	  infected	  cell,	   in	  the	   way	   that	   they	   proliferate	   and	   migrate,	   as	   would	   happen	   during	   the	   initial	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phases	   of	   HPV	   infection	   following	   a	   micro	   wound.	   The	   work	   presented	   in	   this	  thesis	   also	   focuses	   on	   the	   comparison	   of	   different	   HPV	   types	   using	   this	  model	  system.	  Comparison	  of	  HPV11	  and	  HPV16	  episome-­‐containing	  NIKS	  revealed	  that	  cells	   containing	   low-­‐risk	   HPV	   genomes	   (unlike	   those	   containing	   the	   high-­‐risk	  HPV)	  lacked	  the	  ability	  to	  enhance	  cell	  proliferation	  rate.	  The	  inability	  of	  low-­‐risk	  HPV	  containing	  cells	  to	  form	  large	  colonies	  in	  a	  competitive	  growth	  environment	  suggest	  such	  HPV	  types	  lack	  an	  important	  characteristic	  that	  high-­‐risk	  HPV	  types	  can	  impart	  on	  NIKS	  cells.	  These	  observations	  support	  the	  hypothesis	  that	  HPV11-­‐containing	  cells,	  and	  maybe	  also	  other	  low-­‐risk	  HPV	  types	  cannot	  impart	  a	  highly	  proliferative	   phenotype	   onto	   the	   cells	   that	   they	   infect.	   This	   hypothesis	   is	  compatible	   with	   observations	   made	   on	   clinical	   lesions	   caused	   by	   HPV11	   and	  HPV16,	  as	  discussed	  in	  Section	  1.6.	  This	  comparative	  study	  is	  also	  in	  accordance	  with	   recent	   reports	   in	  which	   the	   authors	   suggest	   a	   disadvantageous	   growth	   of	  HPV11	   containing	   cells	   in	   culture	   (Kaczkowski	   et	   al.,	   2012;	   Klingelhutz	   and	  Roman,	  2012).	  In	  this	  study,	  I	  have	  made	  use	  of	  exclusively	  of	  episomal	  cell	  lines,	  which	  are	  grown	  in	  an	  undifferentiated	  basal-­‐like	  environment,	  which	  we	  believe	  provides	   us	   with	   key	   insight	   into	   the	   differential	   biologies	   of	   the	   LR-­‐	   and	   HR-­‐HPVs.	  	  The	   role	   of	   the	   basal-­‐cell	   environment	   in	   the	   formation	   of	   an	   HPV	   lesion	   was	  evaluated,	   considering	   in	   particular	   the	   hypothesis	   that	   many	   infections	   occur	  following	  creation	  of	  epithelial	  trauma	  that	  exposes	  the	  basement	  membrane	  and	  allows	  the	  attachment	  of	  the	  virus	  (Kines	  et	  al.,	  2009).	  Following	  this	  hypothesis,	  we	  aimed	  to	  recreate	   in	  vitro	   the	  conditions	   that	  would	  be	  comparable	   to	   those	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created	   during	   wound	   healing.	   We	   focused	   initially	   on	   understanding	   the	  dynamics	  of	  repopulation	  of	  the	  HR-­‐HPV	  containing	  NIKS	  in	  a	  scratched	  area	  of	  a	  keratinocyte	   monolayer	   culture	   in	   vitro.	   The	   data	   obtained	   showed	   that	   the	  ‘infected’	   cells	   (in	   this	   case	   cells	   transfected	   with	   recircularised	   HPV	   episome)	  have	   the	   ability	   to	   proliferate	   and	  migrate	   at	   a	   greater	   speed	   than	   ‘uninfected’	  cells.	   It	   is	   plausible	   to	   hypothesize	   that	   such	   a	   phenotype	   would	   confer	   a	  competitive	   advantage	   to	   the	   infected	   cells	   during	   wound	   healing.	   Thus,	   in	  accordance	   with	   previous	   investigations	   that	   employed	   cancer	   cell	   lines	  expressing	  HR-­‐HPV	  oncogenes	  (Au	  Yeung	  et	  al.,	  2011;	  Valencia	  et	  al.,	  2008),	  we	  report	   for	   the	   first	   time	   that	   in	  an	   in	  vitro	   system	  the	  presence	  of	  HR-­‐HPV	  viral	  episomes	   can	   similarly	   induce	   a	   highly	   proliferative	   phenotype	   to	   the	   ‘infected’	  cells	  in	  a	  wound	  like	  environment.	  This	  study	  was	  extended	  to	  look	  at	  the	  additional	  effects	  that	  a	  growth	  factor-­‐rich	  environment	  might	  produce	  on	  the	  behaviour	  of	  the	  infected	  cells.	  In	  fact,	  during	  normal	  wound	  healing	  the	  cells	  not	  only	  have	  increased	  space	  to	  proliferate,	  but	  they	   are	   also	   actively	   stimulated	   by	   the	   presence	   of	   higher	   concentration	   of	  growth	   factors	   than	   they	   would	   be	   in	   unwounded	   epithelium	   (Sheardown	   and	  Cheng,	  1996).	  Under	  normal	  circumstances,	  the	  presence	  of	  such	  growth	  factors	  is	   necessary	   to	   increase	   the	   proliferation	   of	   cells	   at	   the	   wound	   site.	   We	   have	  tested	  the	  effect	  that	  an	  increased	  concentration	  of	  EGF	  has	  on	  episomal	  genome	  replication	  and	  viral	  gene	  expression	  from	  viral	  episomes.	  Interestingly,	  the	  rise	  in	  EGF	  concentration	  corresponds	  to	  an	  increase	  in	  viral	  genome	  copy	  number	  in	  both	  HPV16	  and	  HPV11	  genome-­‐containing	  cells.	  The	  effect	  on	  HR-­‐HPV	  genome	  replication	  was	  however	  greater,	  and	  was	  more	  prolonged.	  Although	  I	  report	  here	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that	   NIKS	   cells	   containing	   either	   HPV16	   or	   HPV11	   are	   responsive	   to	   EGF	  stimulation,	   our	   observations	   are	   in	   contrast	   to	   previously	   inhibitory	   reported	  effects	   of	   EGF	   on	   HPV16	   E6/E7	   gene	   expression	   (Yasumoto	   et	   al.,	   1991).	   The	  sustained	   effect	   of	   EGF	   on	   genome	   replication	   seen	   in	   the	   NIKS	   HPV16	   cells	  suggest	  an	  important	  role	  for	  external	  signalling	  in	  the	  establishment	  of	  HR	  HPV	  types.	   	  If	  we	  are	  correct	  that	  HPV11	  persists	  long-­‐term	  in	  slow	  cycling	  stem-­‐like	  cells	  without	  an	  elevation	   in	  cell	  proliferation	  rate,	   then	  it	  may	  be	  that	  EGF	  also	  contributes	   to	   an	   elevation	   in	   copy	   number	   soon	   after	   infection	   here	   as	   well.	  Having	   made	   observations	   on	   EGF-­‐mediated	   copy	   number	   regulation,	   we	   next	  evaluated	  the	  effect	  of	  increasing	  concentrations	  of	  EGF	  on	  viral	  gene	  expression.	  Recent	  work	  has	  suggested	  that	  an	  epithelial	  EGF	  gradient	  can	  control	  the	  splicing	  of	   E6/E7	   transcripts	   (Rosenberger	   et	   al.,	   2010).	   Although	   such	   studies	   were	  carried	   out	   using	   cancer	   cell	   lines	   that	   contain	   integrated	   HPV	   sequences,	   and	  which	   express	   high	   level	   of	   viral	   oncogenes,	   we	   wondered	   whether	   wound	  healing-­‐like	   changes	   in	   EGF	   levels	   may	   exert	   similar	   effects	   on	   NIKS-­‐HPV16	  episomal	   lines.	   Indeed,	   when	   high	   concentrations	   of	   EGF	   were	   added	   to	   the	  culture	   medium,	   HPV16	   E6	   mRNA	   were	   found	   to	   become	   more	   abundant.	   We	  hypothesize	   that	   the	   activation	   of	   EGFR	   is	   necessary	   to	   modify	   the	   balance	  between	  E6*	  and	  E6	  after	  infection	  and	  to	  elevate	  the	  level	  of	  the	  E6	  protein.	  In	  normal	   epithelium,	   the	   expression	   of	   the	   EGFR	   can	   be	   detected	   throughout	   the	  epidermis,	  with	  elevated	   levels	   in	   the	  basal	  and	  parabasal	   layers	   (Nanney	  et	  al.,	  1984).	  Thus,	  EGFR	  activation	  and	  alternative	  splicing	  of	  the	  HPV	  early	  gene	  may	  be	   linked,	   especially	   during	   the	   early	   phases	   of	   infection	   and	   lesion	   formation.	  	  Such	   mechanisms	   might	   counteract	   apoptotic	   stimuli	   in	   newly	   infected	   basal	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keratinocytes	   or	   enhance	   their	   growth	   potential.	   We	   also	   reported	   that	   an	  increased	  expression	  of	  EGFR	  was	  mediated	  by	  high	  levels	  of	  EGF	  in	  the	  culture	  medium	   in	   NIKS-­‐HPV16	   genome-­‐containing	   cell	   populations.	   Such	   increases	   in	  EGFR	  expression	  seem	  however	  to	  correlate	  with	  increased	  cell	  proliferation	  only	  in	  NIKS-­‐HPV16	  cells.	  In	  fact,	  when	  we	  assessed	  whether	  the	  stimulative	  effect	  of	  EGF	   might	   correspond	   with	   an	   increase	   in	   cell	   proliferation,	   we	   found	   to	   our	  surprise	  that	  the	  proliferation	  of	  NIKS-­‐HPV11	  was	  not	  significantly	  altered	  by	  the	  increasing	  concentration	  of	  EGF.	  NIKS-­‐HPV16	  by	  contrast,	  showed	  an	  increase	  in	  cell	   number	   after	   the	   cells	   reached	   confluence,	   with	   the	   continuous	   stimulus	  appearing	   to	   push	   the	   cells	   to	   even	   a	   more	   extreme	   highly	   proliferative	  phenotype.	  In	  the	  context	  of	  HPV-­‐mediated	  immortalization	  and	  transformation,	  it	  is	  plausible	  to	  hypothesize	  that	  the	  increased	  concentration	  of	  EGF	  could	  favour	  the	   production	   of	   full-­‐length	   E6	   protein	   expression,	   which	   is	   necessary	   for	  efficient	  p53	  degradation.	  When	  the	  EGF	  concentration	  returns	  to	  resting	  levels,	  as	   when	   for	   example	   microwounds	   are	   repaired,	   the	   preferential	   E6	   exon	  exclusion	  would	   result	   in	   a	   higher	   expression	   of	   E7,	   that	  would	   be	   expected	   to	  give	  to	  the	  infected	  cells	  a	  selective	  growth	  advantage	  during	  proliferation..	  This	  might	  also	  explain	  the	  prevalence	  of	  E6*	  mRNA	  in	  most	  cervical	  carcinomas	  cells	  lines	   and	   high-­‐grade	   cervical	   lesions	   in	   vivo	   (Bohm	   et	   al.,	   1993;	   Hafner	   et	   al.,	  2008).	   	   We	   also	   report	   an	   apparent	   increase	   in	   p97	   promoter	   activity	   as	   a	  consequence	   of	   increasing	   EGF	   level	   in	   tissue	   culture	   (as	   evidenced	   by	   the	  increase	   in	   transcripts	   spanning	   E6/E7	   region	   (Fig.	   5.11)).	   However,	   such	  mechanism	  is	  not	  likely	  to	  be	  preserved	  in	  low-­‐risk	  HPVs	  such	  as	  HPV11,	  as	  two	  independent	  promoters	  regulate	  the	  transcription	  of	  mRNAs	  that	  encode	  the	  E6	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and	  E7	  gene	  products	   (DiLorenzo	  and	  Steinberg,	  1995).	  We	  have	  not	  measured	  the	  level	  of	  the	  HPV11	  E7	  proteins	  	  or	  compared	  them	  with	  the	  expression	  levels	  of	   the	   high-­‐risk	   E7	   proteins	   in	   HPV16	   NIKS	   cells.	   However,	   my	   data	   indicates	  clearly	   that	   HPV11	   has	   no	   obvious	   proliferative	   effect	   on	   the	   phenotype	   of	   the	  NIKS	   cells	   following	   transfection.	   Furthermore,	   the	   administration	   of	   high	  concentrations	   of	   EGF	   to	   the	   culture	   medium	   produced	   only	   a	   temporary	  fluctuation	   in	   the	   HPV11	   copy	   number,	   with	   no	   significant	   growth	   advantage	  apparent	  when	  elevated	  concentration	  of	  EGF	  were	  added	  to	  the	  culture	  medium.	  Upon	  extended	  passage	  of	  cells	  in	  culture,	  I	  also	  observed	  that	  the	  levels	  of	  HPV11	  genomes	  decreased.	  The	  study	  of	  episomal	  maintenance	  in	  the	  HPV11	  transfected	  cells	  is	  complicated	  by	  the	  lack	  of	  immortalizing	  ability	  of	  the	  low-­‐risk	  HPV	  types.	  We	  believe	  that	  the	  inability	  of	  HPV11	  genomes	  to	  be	  stably	  maintained	  in	  NIKS	  might	   be	   linked	   to	   the	   fact	   that	   HPV11	   is	   not	   normally	   maintained	   in	   rapidly	  dividing	  cells	  in	  vivo.	  We	  therefore	  hypothesize	  that	  HPV11	  genome	  may	  be	  better	  maintained	   in	   cells	   that	  more	   closely	   resemble	   the	   slow-­‐cycling	   epithelial	   stem	  cell.	  Although	  the	  use	  of	  a	  different	  type	  of	  recipient	  cell	  was	  considered,	  previous	  investigations	   reported	   variation	   in	   episomal	   maintenance	   levels	   when	   HPV11	  genomes	   were	   transfected	   into	   primary	   keratinocytes	   derived	   from	   diverse	  donors	   (Oh	  et	   al.,	   2004).	  We	   suspect	   that	   a	   slow-­‐cycling	   clonal	   cell	   line	  derived	  from	  NIKS	  might	   be	   helpful	   in	   understanding	   the	  maintenance	   of	   low-­‐risk	  HPV	  genomes	  however,	  and	  such	  slow	  cycling	  variant	  cell	  lines	  have	  now	  been	  isolated	  in	  the	  lab.	  	  Alternatively,	  host	  cell	  lines	  with	  compromised	  p53	  expression	  may	  be	  used	  to	  examine	  the	  efficiency	  of	  long-­‐term	  episomal	  maintenance	  and	  replication	  of	   low-­‐risk	   HPV	   genome	   following	   transfection.	   Recent	   studies	   using	   in	   HPV18	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transfected	  human	  primary	   keratinocytes,	   suggest	   that	   p53	   and	   additional	   host	  proteins	   are	   involved	   in	   regulating	   viral	   DNA	   amplification	   (Kho	   et	   al.,	   2013).	  	  Such	  cells	  might	  also	  be	  useful	  in	  better	  understanding	  the	  biology	  of	  the	  low-­‐risk	  E6	   proteins,	   which	   do	   not	   inactivate	   p53	   as	   efficiently	   as	   the	   high-­‐risk	   E6	  proteins,	   and	   show	   a	   weaker	   p53	   binding	   and	   degradation	   ability	   (Klingelhutz	  and	  Roman,	  2012).	  Another	   difference	   between	   NIKS-­‐HPV11	   and	   NIKS-­‐HPV16	   cell	   populations	  noticed	  during	  our	   investigations	   lies	   in	   their	  ability	   to	   stimulate	  Cyclin	  D1	  and	  EGFR	   transcription.	   Recent	   studies	   have	   suggested	   that	   exogenous	   EGF	  stimulation	   may	   enhance	   HPV-­‐mediated	   proliferation	   as	   consequence	   of	   EGFR	  and	  Cyclin	  D1	  activation	   (Narayanan	  et	  al.,	  2012).	   I	   report	  here	   that	   there	   is	  an	  increase	  in	  EGFR	  protein	  levels	  in	  NIKS-­‐HPV16	  cells	  when	  high	  concentrations	  of	  EGF	  are	  added	  to	  the	  monolayer	  culture.	  This	  change	  appears	  to	  coincide	  with	  an	  increase	  in	  EGFR	  and	  Cyclin	  D1	  mRNA	  levels	  in	  these	  cells.	  In	  contrast,	  NIKS	  cells,	  and	  NIKS	  cells	   transfected	  with	  HPV11	  do	  not	  produce	  high	   levels	  of	  EGFR	  and	  Cyclin	  D1	   transcripts	   on	   EGF	   stimulation,	   suggesting	   a	   differential	   activation	   of	  promoter	   activity	   across	   the	   cell	   populations	   analysed.	   The	   presence	   of	   high	  levels	   of	   EGFR	   and	   Cyclin	   D1	   transcripts,	   and	   the	   loss	   of	   p53	   protein	   in	   NIKS-­‐HPV16	  cells	  may	  contribute	  to	  their	  characteristic	  more	  proliferative	  phenotype.	  Further	   analysis	   of	   the	   protein	   levels	   between	   low-­‐	   and	   high-­‐risk	   HPV	   cell	  populations	  will	  be	  needed	  to	  fully	  understand	  how	  the	  various	  functions	  of	  both	  E6	   and	   E7	  work	   together	   to	   drive	   neoplasia.	   In	   NIKS-­‐HPV11	   cells	   the	   levels	   of	  EGFR	  and	  Cyclin	  D1	  transcripts	  did	  not	  increase	  suggesting	  a	  negative	  regulation	  of	  the	  cell	  cycle,	  as	  the	  transcript	  levels	  of	  Akt-­‐1	  decreased	  upon	  EGF	  treatment.	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Although	  the	  analysis	  of	  EGFR	  molecular	  targets	  carried	  out	  here	  was	  limited	  only	  to	   the	   analysis	   of	   transcript	   levels,	   important	  differences	  were	   clearly	   apparent	  between	   the	   HPV11	   and	   HPV16	   genome-­‐containing	   cells.	   My	   findings	   are	  consistent	   with	   the	   reports	   from	   other	   studies,	   which	   suggest	   that	   Cyclin	   D1	  expression	   is	   dependent	   on	   autocrine	   stimulation	   through	   EGFR	   (Robles	   et	   al.,	  1998).	  One	   mechanism	   that	   may	   be	   important	   in	   regulating	   the	   proliferation	   rate	   of	  NIKS-­‐HPV11	   cells	   could	   be	   their	   sensitivity	   to	   growth	   arrest	   resulting	   from	   the	  detection	  of	  extra	  chromosomal	  DNA	  by	  the	  cell.	  The	  presence	  of	  HPV	  episomes	  (i.e.	   extra	   chromosomal	   DNA)	   is	   in	   fact	   likely	   to	   be	   sensed	   as	   a	   DNA	   damage	  stimulus.	  The	  ability	  of	  HPV	   to	   interfere	  with	   the	   control	  mechanisms	  has	  been	  suggested	  to	  be	  crucial	  to	  allow	  the	  persistence	  of	  the	  viral	  episomes	  (Moody	  and	  Laimins,	  2009).	  It	  is	  plausible	  that	  an	  increasing	  number	  of	  HPV	  copies	  may	  lead	  to	   activation	   of	   such	   cellular	   checkpoint	   responses,	   with	   the	   host	   cell	   being	  inclined	   to	  progress	   towards	  apoptosis	  unless	   the	  virus	  expresses	  proteins	   that	  are	  able	  to	  efficiently	  counteract	  these	  defence	  mechanisms.	  The	  inability	  of	  low-­‐risk	  HPVs	   to	   immortalise	   primary	   keratinocytes	   (Woodworth	   et	   al.,	   1989)	  may	  explain	   why	   the	   cells	   transfected	   with	   HPV11	   genomes	   are	   not	   efficient	   in	  maintaining	  the	  viral	  episomes	  in	  culture	  (Oh	  et	  al.,	  2004).	  Further	  studies	  on	  the	  DNA	   damage	   pathway	   in	   low-­‐	   and	   high-­‐risk	   HPV-­‐infected	   cells	   may	   better	  elucidate	  the	  fundamental	  differences	  between	  these	  two	  HPV	  groups.	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6.2	   The	   further	   evaluation	   of	   the	   biology	   of	   low-­‐risk	   and	   high-­‐
risk	  HPV	   types	  using	  a	  monolayer	   culture	   system	  as	   laboratory	  
model	  for	  comparison	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